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Abstract 
 Pulmonary arterial hypertension is an incurable vasculopathy, which affects 
significantly more women than men. Hence, female sex hormones may be intimately 
involved in the initiation and progression of disease pathogenesis. Indeed, current evidence 
suggests dysregulated oestrogen biosynthesis and metabolism, result in microenvironment 
favouring excessive proliferation of pulmonary artery smooth muscle cells, leading to 
significant vascular remodelling. Impairment of signalling via the bone morphogenetic 
protein receptor II (BMPRII) signalling pathway might also be partially accountable for 
increased cellular proliferation, and the sex dimorphism associated with the disease. Much 
of the currently available evidence regarding the pathophysiological mechanism of this 
vasculopathy was gained using experimental animal models of pulmonary hypertension, we 
aimed to develop and employ in situ and in vitro models to investigate the role of oestrogen 
and its metabolism in pulmonary arterial hypertension. 
Signalling through aryl hydrocarbon receptor results in altered expression of Phase I and II 
metabolising enzymes, including oestrogen metabolising enzymes. Using an in-silico 
approach, we demonstrated that the importance of aryl hydrocarbon receptor in experimental 
animal model of pulmonary hypertension induced by exposure to Sugen 5416 and chronic 
hypoxia. Initial quantitative real-time polymerase chain reaction analysis revealed that 
expression of CYP1A1 gene might be decreased in cultured pulmonary arterial smooth 
muscle cells from female patients, rats exposed to chronic hypoxia and Smad1 heterozygous 
mice. CYP1A1 gene expression was, however, greatly increased in the Sugen 5416/hypoxic 
experimental animal model. We further demonstrated that in this specific model several 
genes under the transcriptional activation of the aryl hydrocarbon receptor, such as 
NAD(P)H quinone dehydrogenase 1 and aryl hydrocarbon receptor repressor, are increased. 
In vitro stimulation of human pulmonary arterial smooth muscle cells with Sugen 5416, 
which is a potent agonist of the aryl hydrocarbon receptor, resulted in increased expression 
of CYP1A1 and 1B1. We further demonstrated by employing R.E.A.P. fractionation 
protocol, that stimulation of smooth muscle cells with Sugen 5416 resulted in the 
translocation of the aryl hydrocarbon receptor from the cytoplasm to the nucleus, where it 
was able to exert its transcriptional activity. The blockade of the aryl hydrocarbon receptor 
pathway by CH223191, resulted in attenuated expression of these oestrogen metabolising 
enzymes only in smooth muscle cells derived from pulmonary arteries of control subjects. 
In human pulmonary microvascular endothelial cells, simulation with Sugen 5416 and aryl 
  
hydrocarbon receptor inhibitor, FICZ, increased apoptosis of these cells as assessed via 
reduced cell number and increased cleavage of Caspase 3. Hence, Sugen 5416 may induce 
vascular injury, leading to initiation of pathophysiological mechanisms of experimental PH. 
Even though the aryl hydrocarbon receptor pathway interacts with hypoxia-inducible factor 
signalling, we showed that stimulation of pulmonary artery smooth muscle cells does not 
alter mediators involved in the latter pathway. Furthermore, we showed that sex dimorphism 
might exist in the basal expression of mediators involved in the hypoxia-inducible factors 
signalling pathway (HIFs). In smooth muscle cells derived from pulmonary arteries of 
female PAH patients, the expression of HIF1α was significantly increased, while the 
regulators of HIF1α proteasomal degradation were significantly decreased. Equally, in 
smooth muscle cells derived from pulmonary arteries of male PAH patients, protein 
expression regulators of HIF1α proteasomal degradation were significantly decreased. In 
vitro, we demonstrated that there a possible synergy exists between the aryl hydrocarbon 
receptor and hypoxia-inducible factor signalling pathways, where co-stimulation with Sugen 
5416 and hypoxia resulted in increased proliferation of smooth muscle cells derived from 
pulmonary arteries of female PAH. 
We also aimed to develop and employ an in vitro model to investigate the role of oestrogen 
and its metabolism in the pathophysiological mechanism of pulmonary arterial hypertension, 
and to quantitatively assess oestrogen metabolism in this model. We showed that stimulation 
with 2-methoxyoestrogens increased expression of prostacyclin synthase in pulmonary 
microvascular endothelial cells from female control subject. Using immunoblotting 
technique, we further demonstrated that in smooth muscle cells derived from pulmonary 
arteries of male control subjects 2-methoxyoestradiol increased protein expression of Id3 
and had no significant effect in smooth muscle cells derived from pulmonary arteries of 
female control subjects. It appears that in female pulmonary artery smooth muscle cells 2-
methoxyoestradiol increased the expression of p27/Kip1 in a concentration-dependent 
manner. In fact, in vitro stimulation with 2-methoxyoestradiol attenuated serum-induced 
proliferation in smooth muscle cells derived from pulmonary arteries of control subjects of 
both sexes. In smooth muscle cells derived from pulmonary arteries of PAH patients, 2-
methoxyoestradiol only reduced cellular proliferation in female cells, while having no effect 
in male cells. We have also examined the effects of 2- and 4-hydroxyoestradiol on serum-
induced proliferation in pulmonary artery smooth muscle cells from male control subjects. 
Here we found both metabolites mediated attenuation of cellular proliferation, with 2-
hydroxyoestradiol mediating its effects through its biotransformation into 2-
  
methoxyoestradiol, as catechol-O-methyl transferase inhibition restored cellular 
proliferation. Inhibition of catechol-O-methyl transferase did not have an effect on 4-
hydroxyoestradiol-mediated reduction of serum-induced proliferation. 
Using the in vitro model of pulmonary arterial hypertension employing pulmonary artery 
smooth muscle cells, we have assessed the effects of treprostinil on oestrogen metabolism 
in these cells using high performance liquid chromatography/flux analysis. We demonstrated 
that pulmonary artery smooth muscle cells derived from female and male PAH patients 
might metabolise 17β-oestradiol differently than those derived from control subjects. 
Moreover, treprostinil might affect the metabolism of 17β-oestradiol to oestrone, probably 
by affecting the activity of 17β-hydroxysteroid dehydrogenase type 2. Basal protein 
expression level as assessed by immunoblotting technique indicated that the latter enzyme 
might be increased in pulmonary artery smooth muscle cells derived from male PAH 
patients. To overcome certain shortcomings of high performance liquid 
chromatography/flux analysis for investigation of oestrogen metabolism, we aimed to 
develop and optimise a liquid chromatography tandem mass spectrometry approach. We 
have established the technique, and optimised separation of methoxyoestrogens and wash 
steps. The novel approach was used to assess oestrogen metabolism in in vitro model of 
pulmonary arterial hypertension, showing that smooth muscle cells derived from female 
PAH patients produce significantly more oestrone and 17α-isomer of oestradiol. Moreover, 
smooth muscle cells derived from male PAH patients metabolised the least 17β-oestradiol 
in comparison with female patient cells. Although the technique is now established, further 
optimisation is required to achieve reliable quantification of oestrogen metabolites in 
reasonable concentration ranges, as currently the method appears unreliable at concentration 
ranges for some oestrogen metabolites. 
Using a hypothesis-free metabolomic screen we also demonstrated that certain metabolic 
pathways associated with energy reactive oxygen species and L-tryptophan metabolism 
might be affected in pulmonary artery smooth muscle cells. 
Using in situ model we showed that induction of the aryl hydrocarbon receptor by Sugen 
5416 leads to alterations in the expression of oestrogen metabolising enzymes, such as 
CYP1B1 and CYP1A1. Thereby possibly affecting the pathogenic mechanisms by 
introducing an imbalance of oestrogen metabolism. By using in vitro model of pulmonary 
arterial hypertension, we also showed methoxyoestrogen the role of methoxyoestrogens, 2- 
  
and 4-hydroxyoestrogens in the attenuation of cellular proliferation in pulmonary artery 
smooth muscle cells. Furthermore, we established oestrogen metabolic profile in pulmonary 
artery smooth muscle cells derived from controls and patients of both sexes and quantified 
these metabolites. We have therefore successfully applied in situ and in vitro approaches to 
investigate the role of oestrogen and oestrogen metabolism in the pathogenesis of pulmonary 
arterial hypertension. 
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Chapter I 
1 Introduction 
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Oxygen is one of the most fundamental requirements of life for most organisms, as the 
aerobic cellular respiration provides the energy required for the maintenance of elementary 
life functions. 
1.1 Pulmonary Circulation 
The cardiovascular system (CVS) is an intricate system of organs enabling normal 
circulation of the blood throughout the body. An important part of the CVS is the pulmonary 
circulation, which receives deoxygenated blood from the heart through the right atrium and 
ventricle, and pulmonary arteries leading to the lung. In the lung, the pulmonary arteries 
(PAs) divide into numerous small arterioles and capillaries forming capillary beds, which 
encapsulate the alveoli. Pulmonary respiration or gaseous exchange of carbon dioxide and 
oxygen takes place in small PAs and successive capillaries, which are often named 
functional pulmonary capillaries (Levitzky, 2013). The oxygenated blood then drains form 
the lung via pulmonary veins to the left atrium and is circulated from the left ventricle 
throughout the body. 
 The Structural and Functional Organisation of the 
Pulmonary Circulation 
The structure and architecture of the pulmonary circulation greatly reflect its physiological 
function, which is to provide a high flow, high capacitance, low pressure and low resistance 
system of delivering deoxygenated blood from the heart to the lung’s microcirculation for 
efficient gaseous exchange.  
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The pulmonary circulation is a closed system and is separated from the systemic circulation. Within 
the pulmonary circulation, the blood vessel organisation closely follows the organisation of airways, 
meaning the branching of pulmonary arteries, which deliver deoxygenated blood from the right heart 
to the lung, is branched in close association with the airways. The branching pattern of the main 
pulmonary artery extending from the heart to small arterioles reaching alveoli, where gaseous 
exchange occurs, equates to 15 orders of vessel branching. Adapted from (Powell et al., 2016). The 
numbers in the diagram indicate the order of airways and pulmonary circulation branching. 
 
 
 
 
 
 
The structure of the vascular wall is shared by systemic and pulmonary circulation. The innermost 
layer, termed tunica intima, is composed mainly from endothelial cells and sub-endothelial 
connective tissue. The function of the middle layer, tunica media, composed mainly from vascular 
smooth muscle cells and elastin, is to regulate the vascular tone and thereby associated vascular 
pressure. The outermost layer, tunica adventitia, is composed of fibroblasts and extracellular matrix, 
which is rich in collagen fibres, and conveys structural integrity of vessels exposed to high pressures.  
Figure 1–1: The branching of the airways and pulmonary circulation in a human body. 
Tunica Intima‒
Endothelial cells 
Tunica Media‒Smooth 
muscle cells and elastin 
Tunica Adventitia‒
Fibroblasts and 
extracellular matrix rich 
in collagen fibres 
Figure 1–2: The structure of vessel wall. 
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All the vessels in the vascular system share the same composition of the vessel wall, which 
generally consists of three histologically distinct layers: i) intima, ii) media and iii) 
adventitia, which are separated with basement membrane, as shown in Figure 1–2. In 
arteries, the outermost layer, the tunica adventitia, is composed of myofibroblasts, which 
deposit extracellular matrix rich in collagen fibres, giving arteries their elastic character and 
maintain their structural integrity in high-pressure physiological environment. The tunica 
media, is composed of vascular smooth muscle cells (VSMCs), exhibiting contractile 
phenotype, and elastin. While this layer regulates the vascular tone, the innermost layer, 
tunica intima, consisting of a single layer of endothelial cells (ECs), is imperative for the 
maintenance of vascular homeostasis. 
To accommodate the changing function of these vessel, the structure and size of the 
pulmonary arteries changes following the vessel branching within the lung (Elliott and Reid, 
1965). The main PA which extends from the right ventricle and branches into PAs supplying 
deoxygenated blood to the left and right lung, is characterised by its utmost elastic properties, 
due to high content of elastic and collagen fibres forming the numerous elastic laminae 
contained within the medial layer. The elastic character of this large artery, due to the 
presence of 7 elastic laminae, allows it to act as a buffer, reducing the pulsating effects in 
the PAs further away from the heart. PA branching pattern is, as previously described, in 
close association with the branching pattern of the airways, with the character of the 
transitional arteries becoming less elastic further away from the heart, meaning the vessel 
wall contains fewer elastic laminae (Jones and Capen, 2011). The PAs in the lung exhibit 
the elastic and transitional character up to 9th airway branching generation (Elliott and Reid, 
1965;Jones and Capen, 2011). The character of PAs alters further in the very distal part of 
the lung, first becoming muscular, then transitioning to partially-muscular or non-muscular 
arteries, as shown in Figure 1–1. These pulmonary vessels are characterised by a medial 
layer consisting of smooth muscle cells (SMCs). The medial layer becomes progressively 
thinner and/or contains very few SMCs (De Mello and Reid, 1997;Jones and Capen, 2011). 
Similarly, with the branching of the PAs, the diameter of the vessel changes, becoming 
progressively smaller, with the diameter of large elastic PAs being greater than 3,200µm. In 
transitional PAs, the diameter reduces to 3,200–2,000µm, and becomes smaller in muscular 
and non-muscular PAs, which have the diameter of more than 150µm and less than 130µm, 
respectively (Jones and Capen, 2011). Most of the non-muscular PAs, leading to the alveoli, 
have the diameter of less than 50µm, with the average diameter of pulmonary capillaries, 
reaching the alveoli, being only approximately 6μm (Jones and Capen, 2011). 
5 
 
 The Development of the Pulmonary Circulation 
The development of the lung and pulmonary vasculature begins early during the embryonic 
development. The simultaneous development of both organ systems reflects the imperative 
for role of vascularisation for normal lung organogenesis (Joshi and Kotecha, 2007). The 
organogenesis of the lung and the development of pulmonary circulation are poorly 
understood, with limited understanding of the early stages of development and the regulation 
of the lung’s vascularization (deMello et al., 1997;Steinhorn, 2010). Pereda and colleagues 
recently published novel findings on the morphogenesis of pulmonary circulation in humans 
(Pereda et al., 2013). Currently, three theories explaining the morphogenesis of pulmonary 
vasculature exist: i) vasculogenesis, ii) combination of central angiogenesis accompanied 
with peripheral vasculogenesis, and ii) distal angiogenesis accompanied with vascular 
remodelling (Figure 1–3), with the last two theories being most widely accepted. 
Diagram adapted from (Parera et al., 2005). 
Generally, lung morphogenesis can be characterised by four developmental stages: i) 
pseudoglandular, ii) canicular, iii) saccular and iv) alveolar. During the pseudoglandural 
stage, the lung appears as two primitive lung buds and primitive proximal forms of airways, 
whose development and budding are driven by growth signals from the mesenchyme 
(Rosenthal and Bush, 2002). According to the theory of pulmonary circulation forming 
through a combination of central angiogenesis accompanied by peripheral vasculogenesis, 
the development of the hierarchical pulmonary vasculature begins with the formation of the 
truncus arteriosus. The latter represents the origin from which the proximal macro-vessels, 
Figure 1–3: Schematic representation of theories explaining the morphogenesis of 
pulmonary vasculature. 
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the aorta and the main PA are formed (Gao and Raj, 2010). As PA and pulmonary veins are 
extending from aortic arches and vessel outgrowths from the heart, respectively (Rosenthal 
and Bush, 2002), the morphogenesis of pulmonary vasculature is also closely related to that 
of the heart (Peng et al., 2013b). Simultaneously, the PAs and veins up to the 7th branching 
generation are developing independently from the microvasculature, through process of 
central sprouting or angiogenesis (deMello et al., 1997). During canicular phase, the distal 
airways and pulmonary vessels are formed. Irregular vessel plexus in association with the 
airways are formed by vasculogenesis, during which capillary vessels are formed by the 
transformation of mesenchymal cells into vessel-forming endothelial cells (Pereda et al., 
2013). After the irregular vascular beds are established, these vessels undergo extensive 
remodelling, whereby the character of these vessels is altered (Pereda et al., 2013). The 
branched structure of airways is formed during the process of branching morphogenesis with 
the last generation of the airways ending in saccules formed during the saccular phase (Gao 
and Raj, 2010;Pereda et al., 2013;Metzger et al., 2008). During this developmental stage, the 
distal vascular bed undergoes extensive modification, where the density of small vessels and 
capillaries is increased, and the capillaries are reorganised (Jones et al., 2014). The lung’s 
segmentation organisation is finalised at the end of the embryonic period (Pereda et al., 
2013). The theory of central angiogenesis with peripheral vasculogenesis speaks in favour 
of parallel, yet independent, development of the central and peripheral vascular systems 
within the lung. DeMello and colleagues have reported that in Swiss-Weber mouse foetuses 
few connections between the central and peripheral pulmonary vessels, forming a complete 
functional pulmonary vascular system, are established during pseudoglandural phase The 
extent of these connections becoming exceedingly more significant by the end of gestation 
period (deMello et al., 1997;deMello and Reid, 2000). The proposed primary mechanism of 
fusion of pulmonary macro- and micro-vessels is vasculogenesis (Hall and Haworth, 
1987;Hall et al., 2000). The theory of distal angiogenesis proposes that the capillaries 
encapsulating the terminus of the airways in the distal lung are formed by the extension from 
pre-existing vessels, synchronous with the growth of lung buds (Parera et al., 2005). The 
distal capillary network expands by sprouting and nonsprouting angiogenesis, where the 
expansion of vessel network is supported by pre-existing capillaries or the mesenchyme, 
respectively (Risau, 1997;Risau and Flamme, 1995). Dynamic vascular remodelling is 
essential in distal angiogenesis, resulting in the gradual muscularisation of proximal vessels, 
the growth and fusion or degeneration of certain pulmonary vessels (Parera et al., 2005). 
During the embryonic development, the pulmonary vasculature is prepared to assume its role 
of blood oxygenation, which occurs immediately upon birth. During alveolarisation stage, 
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which begins in the late gestation period and lasts until adulthood in humans, mature alveoli 
are formed from saccules. Additionally, the number of alveoli is increased during this phase 
(Jones et al., 2014), the capillaries encapsulating the terminal airways buds begin to mature 
and the surface area for gas exchange of micro-vessels is significantly increased (Gao and 
Raj, 2010;Burri, 2006;Hislop, 2005). The maturation of pulmonary vasculature continues 
birth for several years after (Perl and Whitsett, 1999;Papamatheakis et al., 2013). 
The growth and development of the pulmonary vessel bed is vigorously regulated at every 
developmental stage to achieve the appropriate branching pattern of the vessels with the 
correct size and vessel wall characteristics (Jones and Capen, 2011). The most important 
vascular growth factor in the formation of the vascular plexus within the lung is the vascular 
endothelial growth factor-A (VEGF-A), whose spatial and temporal isoform expression, 
stimulates and directs angiogenesis and vasculogeneis, resulting in vascular development 
and increased vascular density (Tirziu and Simons, 2009;Voelkel et al., 2006;Healy et al., 
2000). Other signalling molecules and pathways, such as the bone morphogenetic protein 
(BMP) belonging to the transforming growth factor β superfamily, have also been implicated 
in the regulation of pulmonary vascular development (Chen et al., 2004). 
 The Physiological Changes in the Pulmonary 
Circulation at Transition at Birth 
Prior to birth, the foetal lung is hyperexpanded and filled with liquid, which is produced 
within the lung. Therefore, the placenta is serving as the main organ for gaseous exchange 
during gestation. Most of the oxygenated blood from the placenta circulates from the right 
to the left atrium via the foramen ovale and bypasses the lung circulation completely via the 
ductus arteriosus. Hence, the proportion of the combined cardiac output to the lung is low 
in utero (Rasanen et al., 1996;Gao and Raj, 2017). During this period, the pulmonary 
vasculature is relatively insensitive to vasoactive stimuli (Lewis et al., 1976;Rasanen et al., 
1998). Additionally, the pulmonary vascular resistance is high due to low number of 
pulmonary vessels and the thickness of the vessel wall in the developing lung 
(Lakshminrusimha, 2012). As gestation advances, the growth of the lung and pulmonary 
vasculature results in increased proportion of the blood flow to the lung and decreased 
pulmonary vascular resistance (Rasanen et al., 1996). At the end of gestation, the pulmonary 
vessels become more sensitive to vasoactive stimuli and the presence of oxygen, resulting 
in actively sustained vasoconstriction in hypoxic conditions, contributing to a significant 
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increase in vascular resistance (Lewis et al., 1976;Heymann et al., 1977). Within moments 
after birth, with the first breath, the lung assumes its primary role of gaseous exchange. The 
increased partial pressure of oxygen (pO2) within the lungs, due to initiation of ventilation, 
results in stimulation of reflex vasodilation. This leads to significant decrease in pulmonary 
vascular resistance and an increase in pulmonary blood flow. The physical expansion of the 
lung with the first breath is associated with the release of vasoactive factors, resulting in 
increased pulmonary blood flow (Fineman et al., 1995). The mechanisms contributing to 
sudden changes within the pulmonary circulation also include: i) rapid reorganisation of 
SMCs within the pulmonary vessel wall, resulting in remodelled vessels having larger 
luminal cross-section (Haworth et al., 1987), ii) recruitment of intra-acinar arteries, iii) the 
release of vasodilatory mediators, and iv) gradual vascular remodelling (Haworth et al., 
1987). Increased blood flow to the lung helps with the closing of foetal shunts, resulting in 
established normal circulation of blood from the right ventricle to PAs. 
 The Regulation of Vascular Tone and Blood Flow in 
the Pulmonary Circulation 
Vascular tone is defined as the level of constriction of blood vessels, regulating the vascular 
resistance and blood flow through these vessels. The vascular tone and blood flow of the 
pulmonary circulation, which both partially depend on the structure of artery wall, are 
closely regulated to ensure efficient blood oxygenation in a high-flow, low pressure and low 
resistance system. Nonetheless, a certain degree of vascular tone is always maintained in the 
pulmonary vasculature in basal conditions (Bergofsky et al., 1963). Several mechanisms are 
employed to maintain the low pulmonary vascular resistance, with numerous factors 
affecting the vascular tone, ranging from passive (changes in cardiac output and left atrial 
pressure) to active (vasoactive factors and pO2) (Carden et al., 2005). 
The resting vascular tone is partially regulated by i) local production of nitric oxide (NO), 
produced in the endothelium (Cooper et al., 1996) and ii) regulation of the membrane 
potential of PASMCs, where local activity of potassium channels, leads to membrane 
depolarisation and activation of voltage-gated calcium channels (Nelson and Quayle, 1995), 
as shown in Figure 1–4. In VSMCs, there are at least five different types of potassium 
channels expressed (Mandegar and Yuan, 2002), with voltage-gated potassium channels 
(Kv) being associated with the maintenance of vascular tone in PASMCs in resting 
(Mandegar and Yuan, 2002;Evans et al., 1996). Sustained vasoconstriction and proliferation 
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of SMCs were associated with impaired function of Kv in PAH (Yuan et al., 1998). Although 
less than in the systemic vasculature, the sympathetic nervous system may also significantly 
contribute to the maintenance of basal vascular tone in the lung, mainly through inhibition 
of α2-adrenoreceptors according to (Duke and Stedeford, 1960). 
 
Figure 1–4: The maintenance of vascular tone in pulmonary arterial smooth muscle cells. 
In vascular smooth muscle cells, vasoconstriction (and vasodilation) is mediated through changes in 
the activity of voltage-dependent K+channels, leading to changed activity of voltage-gated Ca2+ 
channels. The subsequent depolarisation of the membrane potential, and activation of voltage-
dependent Ca2+ channels, result in increased intracellular levels of Ca2+, thereby activating calcium-
calmodulin, which in turn activates the myosin light-chain kinase. The latter phosphorylates the head 
of the myosin light chain, activating the contraction of smooth muscle, and resulting in vessel 
constriction. 
Vm=Membrane potential, Ca-CAM=Calcium-calmodulin, MLC-K=Myosin light-chain kinase 
After birth, the vascular tone in pulmonary circulation is mainly regulated by the ECs, which 
produce and respond to stimuli such as hormones, neurotransmitters and vasoactive factors 
(Sandoo et al., 2010). The vascular tone is regulated through the paracrine effects these 
vasoactive compounds exert on SMCs. The local balance of circulating prostaglandins 
(PGD2, PGF2, PGE1, PGE2 and prostacyclin), thromboxane A2, serotonin (5-HT), and 
endothelin-1 (ET-1) modulates vascular tone (Gao and Raj, 2017), with the vasoactive 
compounds having varying effects on the vascular resistance, depending on the 
concentration, initial pulmonary vascular tone, absence of endothelium, etc. (Hughes and 
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Morrell, 2001). Interestingly, factors mediating vasodilation have only slight effect on 
pulmonary circulation when oxygen is abundant (Mazza Jr. and Taichman, 2006). 5-HT and 
ET-1 partially mediate their effects of increased vascular resistance through activation of 
protein kinase C (PKC), resulting in release of calcium ions from intracellular storage and 
inhibition of adenylate cyclase (Jackson, 2000). The mechanisms of vasoconstriction 
induced by 5-HT and ET-1 are shown in Figure 1–5. 
 
Figure 1–5: Mechanism of vasoconstriction mediated by endothelin-1 and serotonin in 
vascular smooth muscle cells. 
The binding of endothelin-1 or serotonin to corresponding receptors, results in the activation of Gq 
and/or Gi subunit of G-protein coupled receptors, respectively. The activation of Gq subunit results 
in the activation of phospholipase C, which hydrolyses phosphatidylinositol 4,5-bisphosphate, 
forming cellular membrane, resulting in the formation of diacyl glycerol (Rich et al.) and inositol 
trisphosphate. The latter mediators act on inositol triphosphate receptors in the sarcoplasmic 
reticulum and protein kinase C, leading to increased intracellular levels of Ca2+ and vasoconstriction, 
respectively. The activation of Gi subunit leads to inhibition of membrane-bound adenosine cyclase, 
resulting in decreased levels of cyclic adenosine monophosphate, which mediates vasodilation. 
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Diagram adapted from (Hughes and Morrell, 2001). Vasodilation of smooth muscle cells is mediated 
by the production of cAMP by adenylate cyclase, which activates PKA, which is followed 
downstream by increased ATP release. ATP then binds to endothelial purinergic receptors on 
endothelial cells and activates endothelial NOS to stimulate NO-dependent vasodilation. 
AC=Adenosine cyclase, ATP=Adenosine triphosphate, cAMP=Cyclic adenosine monophosphate, 
DAG=Diacyl glycerol, eNOS=Endothelial nitic oxide synthase, InsP3R=Inositol-activated 
receptors, IP3=Inositol trisphosphate, NO=Nitric oxide, PCL-β/δ=Phospholipase C, PKA= Protein 
kinase A, PKC=Protein kinase C, P2y=Endothelial purinergic receptors 2y. 
1.2  Pulmonary Hypertension 
Sufficient blood oxygenation is essential for the execution of normal physiological 
functions, which closely depend on undisturbed energy metabolism. In pulmonary 
hypertension (PH), a class of severe and progressive vasculopathies, the pulmonary vascular 
network is altered due to narrowing, obstruction or loss of PAs, resulting in diminished 
capacity of gaseous exchange within the lung. The pathological changes within the PA 
network are a consequence of deregulated vasoconstrictive processes and progressive 
remodelling, forcing a naturally low-pressure, low-resistance system to become a high-
pressure, high-resistance system. The persistently increased pulmonary arterial pressure 
(PAP) and resistance, resulting in prolonged excessive strain on the right heart, ultimately 
lead to right-sided heart hypertrophy and right heart failure. 
 Clinical Definition 
As the pulmonary circulation is a low-pressure system, the PAP at rest is normally 
considerably lower than that measured in systemic arteries, and is in the range of 
14±3mmgHg, with PAP of 20mmHg still considered as normal (Galiè et al., 2016). 
Clinically, the haemodynamic definition of PH is given as mean PAP (mPAP) of >25mmHg 
in rest, with pulmonary capillary wedge pressure (PCWP) ≤15mmHg (Hoeper, 2009;Galie 
et al., 2004b). Although additional criteria of mPAP >30mmHg during physical was also 
used in the past, it was recently shown in a comprehensive literature review by Kovacs and 
colleagues  that mPAP during physical exertion is greatly dependent on the level of exercise 
and age, and should therefore not be used for clinical diagnosis (Kovacs et al., 2009). 
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 Classification of Pulmonary Hypertension 
Due to the complexity and diversity of PH aetiology, the therapeutic management and 
prediction of patient prognosis were historically difficult. The World Health Organisation 
introduced the Evian clinical classification system in 1998, which categorised 
vasculopathies according to exhibited common histological features, pathophysiological 
mechanisms, clinical presentation and available therapeutic options, in an effort to improve 
the management of the diseases (Simonneau et al., 2013). The classification was amended 
several times; with the latest updated clinical classification introduced in 2013 (Barst et al., 
2006) shown in Table 1-1.  
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Table 1-1: Updated World Health Organisation Classification of Pulmonary Arterial 
Hypertension (2013). 
1 Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic PAH (IPAH) 
1.2 Hereditable PAH (HPAH) 
1.2.1 BMPR-II 
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin-induced 
1.4 Associated PAH (APAH) 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension (PPHTN) 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.4.6 Chronic haemolytic anaemia 
1’ Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
hemangiomatosis (PCH) 
1’’ Persistent pulmonary hypertension of the newborn (PPHN) 
2 Pulmonary hypertension associated with left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and 
congenital cardiomyopathies 
3 Pulmonary hypertension associated with lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease (COPD) 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung disease 
4 Chronic thromboembolic pulmonary hypertension (CTEPH) 
5 Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anaemia, myeloproliferative 
disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disorder, Gaucher disease, thyroid 
disorders 
5.4 Other: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, 
segmental PH 
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In a clinical setting, however, the severity of symptoms in PH is often assessed using the 
New York Heart Association (NYHA) functional classification system. The system details 
the severity of clinical symptoms and the limitations of patient’s physical ability (Table 1-2). 
Both classifications are used in clinical setting to assist medical professionals in the selection 
of the best available therapeutic options for the management of the disease and aid the 
accurate prediction of patient prognosis. 
Table 1-2: New York Heart Association Classification of Functional Status of Patients 
with Pulmonary Hypertension. 
Class I Patients with pulmonary hypertension. No resulting limitation of physical activity. 
Ordinary physical activity does not result in undue dyspnoea or fatigue, chest pain 
or near syncope. 
Class II Patients with pulmonary hypertension with a slight limitation of physical activity. 
Comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, 
chest pain or near syncope. 
Class III Patients with pulmonary hypertension with marked limitation of physical activity. 
Comfortable at rest. Less than ordinary activity causes undue dyspnoea or fatigue, 
chest pain or near syncope. 
Class IV Patients with pulmonary hypertension with inability to carry out any physical 
activity without symptoms. Patients manifest signs of right heart failure. Dyspnoea 
and/or fatigue may even be present at rest. Discomfort is increased by any physical 
activity. 
 
1.2.2.1 An Overview of Underlying Aetiologies of Pulmonary Arterial 
Hypertension 
The first class of PAH according to the WHO classification, is represented by idiopathic 
PAH, previously also named primary PH, and describes the condition where no apparent 
cause for increased PAP and pulmonary arterial resistance is identified. The second class of 
PAH aetiology is termed heritable PAH, describing the vasculopathy with an underlying 
genetic cause, where the individuals with clinical presentation of the disease harbour a 
mutation associated with the disease phenotype or increased disease risk. The third class of 
PAH aetiology is described as drug or toxin-induced. Gurtner was the first to published a 
review on the possible association of the use of appetite depressing drug aminorex fumarate 
and the sudden epidemic of PAH in the late 1960s, which disappeared when this anorexic 
medication was withdrawn from the market (Gurtner, 1985). Almost three decades later, 
further association of appetite depressing drugs was observed in France, where the number 
of PAH diagnosis was increased in female population regularly taking dexfenfluamine 
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and/or fenfluramine (Brenot et al., 1993). A direct consequential relationship between 
increased risk of PAH and appetite-suppressant drugs, based on a case-control study, was 
reported in (Abenhaim  et al., 1996), followed by an editorial suggesting these medications 
cause an increased in extracellular levels of 5-HT (Voelkel, 1997) resulting in pulmonary 
vasoconstriction (McGoon and Vanhoutte, 1984), and hyperplasia as well as hypertrophy of 
pulmonary artery SMCs (PASMCs) (Lee et al., 1994). Since, the catalogue of drugs and 
toxins related to PH greatly increased, with amphetamine derivatives, L-tryptophan, cocaine 
and serotonin reuptake inhibitors named as likely or possible risk factors (Price et al., 2012). 
The fourth and final class of PAH aetiology is considered as PH developed due to the 
presence of several primary underlying conditions, such as autoimmune diseases or diseases 
affecting the immune system, or cardiovascular conditions affecting the systemic circulation 
or the heart. 
Several pulmonary diseases, leading to increased pressure within the lung circulation, 
clinically manifest as PH, although their aetiology is mainly associated with progressive 
narrowing of the small pulmonary veins, rather than arteries, the proliferation of alveolar 
capillaries or the failure of pulmonary circulation transition at birth, respectively. 
 Diagnosis of Pulmonary Hypertension 
The difficulty with early diagnosis of PH is that at the onset of the disease patients do not 
experience significant symptoms. The first symptoms arise during progressed stages of PH 
and are associated with difficult breathing, such dyspnoea, during moderate everyday 
physical activity. With disease progression, other symptoms such as fatigue, weakness, 
angina, dizziness and syncope may also appear. These symptoms, however, can be mild in 
nature, and are non-specific (Galiè et al., 2016;ActelionPharmaceuticalsLtd). In more 
advanced stages, symptoms associated with insufficient oxygenation are triggered by 
minimal physical activity and are accompanied by symptoms associated with right-side heart 
failure. Due to initial non-specific symptoms, the time taken from disease onset to diagnosis 
was estimated to be on average of more than 2 years (Humbert et al., 2006;Badesch et al., 
2010), meaning that at the time of diagnosis patients are usually exhibiting progressive 
stages of the disease (Gaine and Rubin, 1998;Humbert et al., 2006). 
The diagnosis of PAH is demanding, usually requiring invasive procedures to confirm the 
clinical condition. The indication suggestive of PH in an individual is first evaluated using 
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non-invasive methods, as per clinical practice guidelines for the diagnosis of PAH in Europe. 
If the initial physical examination and electrocardiogram demonstrate elevated probability 
of PAH, further examinations, such as echocardiography, pulmonary function tests, arterial 
blood gas analysis, chest radiography and high-resolution computed tomography of the lungs 
are required to determine whether the symptoms are caused by a secondary left heart disease 
or lung disease (Schannwell et al., 2007). If no secondary diagnosis is made, then the patient 
must undergo a ventilation and perfusion lung scan to evaluate the circulation of air and 
blood within the lung. These procedures are used to determine whether the symptoms may 
be caused by chronic thromboembolic pulmonary hypertension. In case no changes in the 
lung’s perfusion are detected, the diagnosis of PAH is considered (Gaine and Rubin, 
1998;Humbert et al., 2006). Once the diagnosis of PAH is made, cardiac magnetic resonance 
imaging, blood tests and immunology tests, abdominal ultrasound and right heart 
catheterization are performed to confirm the diagnosis, determine the aetiology of the disease 
and assess the functional and haemodynamic impairment of the patient (Gaine and Rubin, 
1998). Following PAH diagnosis, vasoreactivity assessment is used to determine patient’s 
response to calcium channel blockers (CCBs), which can be used for treatment of certain 
forms of PAH. 
Parameters such as functional class of the disease, right ventricular function, pulmonary 
haemodynamics, together with walking distance and peak oxygen uptake can be utilised to 
make a reliable prediction of patients prognosis (Schannwell et al., 2007). 
 Epidemiology of Pulmonary Arterial Hypertension 
Longitudinal observational studies and national registries provided much of the information 
on the clinical and haemodynamic characteristics exhibited by the patients, as well as 
invaluable data on the PAH patient population demographics (Hoeper and Gibbs, 2014). 
Most recently gathered epidemiological data indicates there are between 1–3.2 newly 
diagnosed PAH cases annually, per million of population (Ling et al., 2012;Escribano-
Subias et al., 2012). There is between 6.6–16 individuals per million of adult population 
currently affected by PAH (Ling et al., 2012;Escribano-Subias et al., 2012), with the overall 
population prevalence 52 cases per million population in Scotland (Peacock et al., 2007). 
The demographics of PAH patients changed significantly over the years, since the clinical 
data from the fist compiled registry by the National Institutes of Health registry on PAH was 
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published (Rich et al., 1987), with current reported median age at the time of diagnosis for 
PAH being 50 years (Ling et al., 2012). According to Hoeper and colleagues, patients 
diagnosed with IPAH are even older at the time of diagnosis (Hoeper et al., 2013). Contrary, 
most recent registry demonstrated that patients with IPAH are younger at diagnosis 
compared to patients presenting with PAH of a different aetiology (Gall et al., 2017). Due 
to initial non-specific symptoms and late diagnosis, it was reported that approximately 70–
80% of patients at the time of diagnosis had impairment associated with Class III and IV 
according to the NYHA classification (McGoon et al., 2008;Badesch et al., 2010;Ling et al., 
2012). Impairment associated with Class III and VI according to the NYHA reported in the 
most recent Giessen Pulmonary Hypertension Registry was 82% (Gall et al., 2017). 
Since the availability and approval of novel therapeutic strategies for PAH, the survival of 
appropriately treated PAH patients has greatly improved. Nonetheless, less than two thirds 
of patients survive 3 years once the PAH diagnosis was made (Humbert et al., 2010a;Benza 
et al., 2012), and the average survival time from diagnosis has been estimated to be 5–7 years 
(Gomberg-Maitland et al., 2011;Kane et al., 2011;Benza et al., 2012). The registries carried 
out in the UK and Spain, revealed that the 5-year mortality rate decreased significantly and 
was between 30–40% (Ling et al., 2012;Escribano-Subias et al., 2012). The 5-year survival 
of PAH patients with exhibiting functional classes of impairment according to NYHA 
Classes I/II, III and IV is approximately 80%, 60% and 40%, respectively (Gall et al., 2017). 
The survival of patients is closely associated with the underlying aetiology of the disease, 
with the poorest survival observed for PAH associated with underlying medical conditions 
(Gall et al., 2017). According to the latest registry, the elderly population of PAH patients 
exhibits significantly more impairment as per the NYHA functional classification compared 
to the Aspire registry (Hurdman et al., 2012), which is in accordance with (Ling et al., 2012), 
who proposed that patients with PAH aged 50 or less, exhibit better survival despite more 
severe haemodynamic impairment. 
The NIH registry first reported a significantly higher proportion of women developed the 
clinical disease compared to men (Rich et al., 1987). Modern registries suggest the gender 
bias observed in PAH is even more pronounced, with women being between 2.3 and 4.3-
times more likely to develop PAH than males (Escribano-Subias et al., 2012;Humbert et al., 
2006;Badesch et al., 2010;Hoeper et al., 2013;Peacock et al., 2007;Walker et al., 2006). The 
latest registry on PH, published in 2017, reports an almost two-fold higher ratio of female 
patients presenting the clinical disease compared to male patients (Gall et al., 2017). The 
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proportion of female patients with clinical PAH in recent registries is shown in Figure 1–
6A, and the percentage of females diagnosed with IPAH is presented in Figure 1–6B. 
 
 
Figure 1–6: Proportion of females with clinically diagnosed pulmonary arterial 
hypertension in epidemiological studies and registries. 
The diagram (A) depicts the proportion of female patients with pulmonary arterial hypertension, 
while the diagram (B) depicts the proportion of females diagnosed with idiopathic form of pulmonary 
arterial hypertension, as recorded by epidemiological registries carried out in Europe and United 
States. Adapted from (McGoon and Humbert, 2014). 
Recent data suggests that certain classifications of PAH exhibit even stronger female to male 
predominance (Roberts et al., 2009;Kawut et al., 2008), probably due to the epidemiological 
features of the predisposing conditions (i.e. connective tissue disease, systemic sclerosis, 
certain congenital cardiac anomalies leading to congenital heart disease and systemic lupus 
A 
B 
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erythematosus), which affect more females (Manes et al., 2012). Nonetheless, it was 
suggested that correcting for the sex bias of the underlying condition still preserves sex bias 
in APAH (Kawut et al., 2008). The sex bias in PAH was recently shown to diminish with 
the onset of menopause in women, indicating oestrogen metabolic pathways might be vital 
in the onset and progression of PAH (Hoeper et al., 2013). Although initially the survival 
data suggested that post-menopausal female patients have a slightly better survival rate 
compared to male patients despite similar treatment (Shapiro et al., 2012), newer data 
indicates that female patients in general seem to have significantly better survival compared 
to males (Gall et al., 2017). 
 Pathobiology of Pulmonary Arterial Hypertension 
The development and progression of PAH were shown to involve a complex interaction 
between genetic and endogenous/exogenous factors. While the presence of underlying 
genetic mutation might predispose individuals to PAH, other factors such as an underlying 
disease, exposure to drugs or toxins are usually required for the clinical disease to arise. The 
interaction of the pathophysiological processes contributing to the onset and progression of 
clinical PAH is depicted in Figure 1–7. 
The vascular endothelial lining is the site of the production of vasoactive compounds (Figure 
1–8), which regulate the vascular tone and resistance in systemic and pulmonary vessels 
through paracrine regulation of SMCs. Hypoxia (Hx) and inflammation were both shown to 
play a notable role in endothelial damage and/or dysfunction, which is essential in the 
pathobiology of PH (Budhiraja et al., 2004). Numerous studies reported that the removal of 
endothelium resulted in a rapid and spontaneous onset of vasoconstriction in PAs (Aaronson 
et al., 2002). Hence, in PAH, the initial pathological insult causing endothelial dysfunction, 
first results in an imbalance in the production and/or secretion of vasoactive mediators. The 
prolonged paracrine effects of vasoactive mediators lead to sustained vasoconstriction of 
small PAs and arterioles in otherwise low pressure, low resistance system (Filipe et al., 
2008;Novella and Hermenegildo, 2011). Although in the systemic circulation, the 
physiological response to hypoxia results in vasorelaxation, in pulmonary vasculature 
vasoconstriction is observed to preserve ventilation/perfusion matching and the maximal 
possible oxygenation of the blood. The disruption of the vascular endothelium leads to 
increased vascular tone and vasoconstriction in small PAs. The resulting Hx conditions 
influence further disease development. 
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Figure 1–7: Pathophysiological processes contributing to the onset and progression of 
pulmonary arterial hypertension. 
The onset of clinical pulmonary arterial hypertension is believed to be caused by the presence of at 
least two interrelating genetic and/or endogenous/exogenous factors. The pathophysiological disease 
process first entitles vascular injury, causing the apoptosis of endothelial cells. The disruption of the 
vascular endothelium leads to increased vascular tone and vasoconstriction in small pulmonary 
arteries. The resulting hypoxic conditions influence further disease development. Dysregulation in 
the production of vasoactive and growth factors leads to increased pulmonary artery smooth muscle 
cells proliferation and dysfunction, resulting in the thickening of the medial layer. The recruitment 
of inflammatory/progenitor cells causes degradation of extracellular matrix, which in turn enables 
migration of fibroblasts, smooth muscle, endothelial and progenitor cells to adventitial layer. Here, 
the abovementioned cell types contribute to development of fibrosis. Monoclonal endothelial cell 
proliferation is associated with the establishment of apoptosis-resistant cell population, following 
vascular injury, and leads to the formation of plexiform lesions. Trans-differentiation of endothelial 
cells to mesenchymal or smooth muscular cells, alongside transition of contractile smooth muscle 
cells phenotype to synthetic phenotype, leads to increased synthesis and degradation of extracellular 
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matrix, contributing to the development of neointima. Diagram adapted from (Mandegar et al., 2004) 
and (Montani et al., 2013). 
BMPR-II= Bone morphogenetic protein receptor II, 5-HTT= Serotonin transporter, EC= Endothelial 
Cells, SMC= Smooth Muscle Cells, ROS= Reactive oxygen species. 
While the circulating concentrations of endogenous vasoconstrictors thromboxane A2 
(TXA2) and ET-1 are elevated in PAH, the levels of prostacyclin (PGI2), a potent 
endogenous vasodilator in systemic and pulmonary vasculature (Moncada and Vane, 
1978;Badesch et al., 2004;Barst et al., 2009), are reduced in PAH patients, as shown by the 
reduced concentration of its stable metabolites in patients’ urine samples (Christman et al., 
1992). Sustained vasoconstriction of small PAs and arterioles converts the pulmonary 
circulation, which is normally a low pressure, low resistance system into a high pressure, 
high resistance system (Filipe et al., 2008; Novella and Hermenegildo, 2011). Gene 
expression of prostacyclin synthase (PGIS), the enzyme converting prostaglandin H2 to 
PGI2, was detected in endothelial and SMCs of proximal and distal PAs, with greater 
production in the latter (Badesch et al., 1989). Hypoxia was shown to have a direct effect on 
the PGI2 signalling, where animals exposed to hypoxia exhibited significant pathological 
changes in the pulmonary vascular plexus, reminiscent to those observed in PAH 
(Hoshikawa et al., 2001b;Faller, 1999;Herget et al., 2000). Furthermore, the production of 
ET-1, 5-HT and other vasoconstrictors is also transcriptionally regulated by low oxygen 
tension (Kourembanas and Bernfield, 1994). Nonetheless, PGI2 was shown to oppose the 
onset of hypoxia- and monocrotaline-induced PAH in animal models (Geraci et al., 
1999;Tahara et al., 2004), indicating the importance of PGI2 metabolic pathways in PAH 
pathogenesis. The bioavailability of another potent vasodilatory, NO, is also decreased in 
disease setting (Klinger et al., 2013), possibly due to decreased expression of endothelial 
NO synthase (eNOS) in the lungs of patients with PH (Giaid and Saleh, 1995). 
The initial endothelial dysfunction additionally affects PA remodelling through the 
imbalance of vasoactive compounds, favouring extensive vascular remodelling through 
increased production of vasoconstrictors, such as ET-1 and 5-HT, exhibiting mitogenic/pro-
proliferative properties (Clapp et al., 2002). Vascular injury affects the phenotype of vascular 
PASMCs, leading to the transition SMCs with contractile character to synthetic/proliferative 
character (Tajsic and Morrell, 2011). SMCs having synthetic and/or proliferative phenotype, 
exhibit increased deposition of extracellular matrix, primarily in the adventitial layer 
(Stenmark et al., 2006b;Durmowicz et al., 1994). Dysregulation of metabolic pathways 
regulating PASMCs proliferation, migration and apoptosis, e.g. RhoA/ROCK (Barst et al., 
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2011;Chan and Loscalzo, 2008;Sheikh et al., 2014), results in extensive muscularisation and 
thickening of the non-muscular distal vessels (Barst et al., 2011), leading to a significant 
reduction of the luminal area. Sheikh and colleagues reported significant increase in 
muscularisation of non-muscularised distal vessels and proliferation of SMCs in response to 
hypoxia (Sheikh et al., 2014). The disequilibrium in the production of vasoactive compounds 
having pro- and anti-mitogenic properties, also significantly contributes the thickening of 
the medial layer. 
 
 
Figure 1–8: The equilibrium of vasoactive mediators in pulmonary arterial hypertension 
favours vasoconstriction. 
Increased production of vasoconstrictors, and decreased production of vasodilators, results in 
sustained vasoconstriction, leading to increased mean pulmonary arterial pressure. Moreover, the 
mitogenic properties of these mediators have a significant impact on the remodelling of the 
pulmonary vasculature. 
Histological abnormalities in the distal medium and small PAs observed in PAH progress 
from endothelial dysfunction and sustained vasoconstriction, to structural changes in the 
vascular wall. The ultimate morphological hallmarks of the disease include remodelling of 
pulmonary vasculature by extensive muscularisation of non-muscular vessels, neointima 
formation and obstruction of these vessels. Distinct remodelling of the adventitial layer was 
described to occur early in hypoxia, with significant proliferation of fibroblasts (Belknap et 
al., 1997). The initial recruitment of inflammatory/progenitor cells to vessel wall causes the 
degradation of extracellular matrix, which in turn enables migration of fibroblasts, SMCs, 
endothelial and progenitor cells to adventitial layer. Equally, trans-differentiation of ECs to 
Vasodilation Vasoconstriction
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mesenchymal or SMCs, with transition of contractile SMCs phenotype to synthetic 
phenotype, leads to increased degradation and/or synthesis of extracellular matrix. The 
differentiation of fibroblasts into myofibroblast might also result in augmented production 
of extracellular matrix, and the remodelling of the adventitial layer (Stenmark et al., 2006a), 
which was also reported by (Durmowicz et al., 1994). The authors suggested that the 
expression of extracellular matrix proteins occurs in response to chronic hypoxia, therefore 
it appeared to be an adaptive mechanism to alterations in haemodynamic parameters and pO2 
(Durmowicz et al., 1994). Importantly, certain components of the extracellular matrix, 
shown to be increased in lung tissue form IPAH patients (Papakonstantinou et al., 2008), are 
associated with promoting the migration and proliferation of PASMCs, possibly contributing 
to the pathophysiological changes in the adventitial and medial layers, associated with 
muscularisation of otherwise non-muscularised vessels. The latter are mostly attributed to 
the differentiation of pericytes and/or other cell types, such as stem cells and fibroblasts, into 
SMCs and their subsequent proliferation and hypertrophy (Tuder et al., 2007;Rabinovitch, 
2012). Importantly, migration of fibroblasts to the intimal and medial layers in hypoxic 
conditions and subsequent expansion was reported (Stenmark et al., 2002;Das et al., 2002). 
This resulted in increased production of extracellular matrix, and contributed to the reduction 
of vessel lumen through the formation of neointima (Tuder et al., 2007). The formation of 
neointima may be worsened by increased pressure within pulmonary vessels (Okada et al., 
1997). A distinct absence of apoptosis described in SMCs and endothelial cells (ECs) was 
described in plexiform lesions in the lung samples of primary PH patients (Tuder et al., 
2001b), with significant implication in complication of severe PAH with the formation of 
plexiform lesions. Specifically, following vascular injury, monoclonal EC proliferation was 
associated with the establishment of apoptosis-resistant cell population and formation of 
plexiform lesions. The latter are disorganised vascular formations composed of proliferating 
ECs, SMCs and infiltrated circulating immune and progenitor cells (Abe et al., 2010;Lee et 
al., 1998;Tuder et al., 1994), complicating the disease and leading to complete obliteration 
of distal PAs (Malenfant et al., 2013). The ECs in the plexiform lesions express markers of 
angiogenesis, therefore these lesions could be formed through a process of disorganised 
angiogenesis (Tuder et al., 2001a). The progression of vascular remodelling and the 
formation of plexiform lesions, albeit in experimental animal model, is shown in Figure 1–
9. The distinct reduction of the vascular lumen in distal PAs and the obliteration of small 
vessels, result in significant reduction in the blood flow within the distal part of the lung. 
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Figure 1–9: Gradual advancement of pulmonary arterial hypertension as per 
histopathological changes in the distal pulmonary arteries and lesions in Su5416/Hx rats.  
The vascular remodelling in Su5416/Hx animals closely resembles that observed in humans. Initially, 
only medial hypertrophy is observed, followed by proliferation and hypertrophy in the media intima. 
In the progressive stages of the disease, neointimal and plexiform lesions occur. Adapted from (Abe 
et al., 2010). 
1.2.5.1 Serotonin in Pulmonary Arterial Hypertension 
5-HT is derived from L-tryptophan by tryptophan hydroxylase (TPH), which converts L-
tryptophan to 5-hydroxytryptophan in a rate-limiting reaction. The latter then serves as a 
precursor for L-aromatic acid decarboxylase, producing 5-hydroxytryptamine (5-HT) also 
known as serotonin. 5-HT serves as a neurotransmitter in central and peripheral tissues, with 
its production reported in the gastrointestinal tract and central nervous system. Moreover, in 
lung samples and pulmonary microvascular ECs (PMECs), the expression of tph1 isoform 
is significantly increased and localised mainly in ECs (Eddahibi et al., 2006). The deletion 
of tph1 gene in mice resulted in attenuation of pulmonary haemodynamics and vascular 
remodelling (Morecroft et al., 2007). Upon its synthesis, 5-HT is released into the 
bloodstream, from where it is actively taken up by platelets via the serotonin transporter (5-
HTT or SERT). Activated platelets release 5-HT, which then, locally present in high 
concentrations, mediates vasoconstriction. Indeed, the exposure of isolated lungs from 
normoxic rats to lower concentrations of 5-HT induced a concentration-dependent 
vasodilation, while higher concentrations elicited vasoconstriction (Eddahibi et al., 1997). 
The especially potent vasoconstriction response to stimulation with 5-HT was reported in 
the resistance PAs, where vasoconstriction was mediated via 5-HT1B receptor (MacLean et 
al., 1996). The production of 5-HT in the peripheral arteries, specifically thoracic aorta and 
superior mesenteric artery, was proposed by (Ni et al., 2008). Conditioning of PASMCs with 
medium collected from PMECs, which were stimulated with tryptophan, induced 
hyperplasia of SMCs (Eddahibi et al., 2006). Interestingly, these effects were potentiated in 
cells derived from IPAH patients (Eddahibi et al., 2006). 5-HT induced cellular proliferation 
was further exacerbated in hypoxia (Eddahibi et al., 1999). The observed mitogenic effects 
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of 5-HT are associated with increased expression of SERT in hypoxia (Eddahibi et al., 1999). 
In HPAH, a set of polymorphism within the promoter of SERT gene was described, which 
are associated with earlier onset of the disease (Willers et al., 2006). Overexpression of the 
SERT gene in experimental model of PH was associated with the onset of PH phenotype in 
these animals and will be discussed in detail below (MacLean et al., 2004;White et al., 
2011a). 
1.2.5.2 Reactive Oxygen Species in Pulmonary Arterial Hypertension 
The implication of reactive oxygen species (ROS) in the pathophysiology of PAH was 
proposed due to the ability of these reactive compounds to interfere with cellular processes 
via irreversible oxidative post-translational modifications and damage of proteins, enzymes 
and DNA. Indeed, there is increased generation of ROS in hypoxic models of PH 
(Hoshikawa et al., 2001a), and patients with clinical PAH (Reis et al., 2013), indicating that 
the imbalance in the production/removal of these compounds might result in 
pathophysiological changes in the pulmonary vasculature, including vascular remodelling. 
ROS are primarily produced by the nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH oxidase, Nox) family of enzymes, which are involved in the respiratory electron 
transport chain (Fulton et al., 2017). Seven isoforms of NADPH oxidases were described, 
including Nox1–4 and Duox1–2 (Bedard and Krause, 2007). The activation of Nox usually 
entails coordinated assembly of cytoplasmic proteins, which following post-translational 
modifications, form a functional unit (Bedard and Krause, 2007). Increased levels of Nox4 
mRNA were observed in murine hypoxic model of PH, monocrotaline-induced model of PH 
in rats, and IPAH patients (Mittal et al., 2007;Dorfmuller et al., 2011). Equally, increased 
levels of Nox1 mRNA were reported in PASMCs derived from monocrotaline-treated rats 
(Veit et al., 2013). Most recently it was reported that the basal expression of Nox1/Nox4 is 
increased in PASMCs from PAH patients (Hood et al., 2016). Interestingly, stimulation of 
these cells with oestradiol and 16α-hydroxyoestrone (16αOHE1) resulted in increased ROS-
dependent proliferation, sustained production of ROS and increased expression of Nox1, 
respectively (Hood et al., 2016). Generally, the introduction of small interfering RNA 
(siRNA) to silence the gene expression of Nox1/Nox4 results in decreased proliferation of 
PASMCs, increased apoptosis, and attenuated PH phenotype (Mittal et al., 2007;Dorfmuller 
et al., 2011;Veit et al., 2013). 
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1.2.5.3 Prostacyclin Synthase in Pulmonary Arterial Hypertension 
PGI2 is a lipid mediator with potent vasodilatory effects, primarily produced in the ECs. It 
is derived from arachidonic acid (AA) in a three-phase reaction, where cyclooxygenase 
enzymes (COX), produce the prostaglandin PGG2, which is rapidly converted into PGH2, 
and the latter then serves as a precursor for the PGIS, a specific prostanoid synthase. In 
vascular tissue, PGI2 is the main metabolite formed from AA (Bunting et al., 1976). The 
enzyme is expressed in all vascular cells of proximal and distal PAs, with greater expression 
in the ECs (Badesch et al., 1989). While numerous human lung cancer cell line exhibit 
decreased expression of PGIS, the importance of this enzyme in lung cancer was shown by 
a transgenic murine model over-expressing this enzyme, which exhibited protection against 
lung tumour formation (Stearman et al., 2007). Equally, the expression of PGIS in 
pulmonary circulation of PAH patients is decreased compared to normal subjects (Tuder et 
al., 1999). A comprehensive set of PGIS promoter variants exists, resulting in heterogenous 
transcription of this gene (Stearman et al., 2014). Furthermore, in patients with clinical PAH 
the transcriptional activity of the PGIS gene is less compared to healthy individuals, which 
might underline the previously described low circulating levels of PGI2 in PAH patients. Hx 
increased the expression of PGIS and release of PGI2 in VSMC and ECs (Camacho et al., 
2011). Alterations of PGIS expression and activity might be an adaptive response to hypoxic 
stress (Camacho et al., 2011).  
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Phospholipase A2 catalyses the hydrolysis of membrane lipids to liberate arachidonic acid, which is 
further metabolised by COX-1 and/or COX-2 to the unstable PGH2. Individual prostaglandin 
synthase enzyme then uses the precursor prostaglandin PGH2 to form distinct prostaglandins. TXAS, 
PGDS, PGES, PGIS and PGFS respectively generate, TxA2, PHD2, PGE2, PGI2 and PGF2α.  
Figure 1–10: Prostaglandin biosynthesis. 
 
28 
 
The beneficial effects of prostacyclin and its therapeutic analogues are attributed to the 
activation of the prostacyclin receptors (IP, DP, EP2 and EP4). These are located in the 
plasma membrane, leading to IP receptor coupling with Gs type of GPCR and resulting in 
production of cAMP, leading to vasodilation/vasorelaxation (Narumiya et al., 1999;Wise, 
2003). Inhibitory prostacyclin receptors (EP3) and contractile receptors (EP1, FP and TP) 
couple Gi or Gq type of GPCR receptors, respectively. This results in i) inhibition of AC 
activity, and therewith associated restricted vasorelaxation, or ii) activation of PCL-β/γ, 
leading to increased production of DAG and IP3, which ultimately result in mobilisation of 
intracellular Ca2+ and PKC activation, associated with vasoconstriction. 
The protective effects of PGI2 in the vasculature far surpasses those mediated through 
vasodilation alone, suggesting anti-proliferative effect. In the heart, PGI2 modulated the 
expression of collagen, an important ECM component (Yu et al., 1997), therefore it might 
also be associated with reduced fibrosis and remodelling. Genetic deletion of prostacyclin 
receptor resulted in aggravated intimal hyperplasia, associated with the absence of inhibitory 
effects on SMC proliferation and migration (Fetalvero et al., 2007). Vascular remodelling is 
associated with the de-differentiation of SMCs, whereby the contractile phenotype of these 
cells is substituted with synthetic, resulting in substantial increase in ECM component 
deposition and increase in proliferation and migration. The authors also observed that PGI2 
also opposes de-differentiation of SMCs by upregulating the expression of contractile 
proteins, thereby promoting enhanced contractile phenotype in human myometrial tissue 
(Fetalvero et al., 2008). The biosynthesis and PGI2 signalling pathway in SMCs are depicted 
in Figure 1–11. 
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Figure 1–11: Prostacyclin biosynthesis and signalling pathway. 
Prostacyclin is produced in endothelial cells from arachidonic acid, through a three-step reaction 
catalysed by cyclooxygenase and prostacyclin synthase enzymes, respectively. Prostacyclin then, in 
paracrine or autocrine manner, exerts its actions on smooth muscle cells, where it binds to 
prostacyclin receptors, resulting in activation of signalling pathways associated with the activation 
of G-protein coupled receptors (GPCR), leading to vasodilation or vasoconstriction, depending on 
the type of GPCR prostacyclin receptor is coupled with. Replicated from (Ivey et al., 2008). 
EC= Endothelial cells, SMC= Smooth muscle cells, PGI2=Prostacyclin, IP=Relaxant prostacyclin 
IP receptor, AC=Adenylate cyclase, cAMP=Cyclin adenosine monophosphate; PKA=Protein kinase 
A, PLC-β/δ= Phospholipase C β/δ, DAG= Diacylglycerol, IP3= Inositol trisphosphate, PKC=Protein 
kinase C. 
1.2.5.4 Interaction of Prostacyclin and the Peroxisome Proliferator-
Activated Receptor Signalling 
Many different ligands were shown to activate peroxisome proliferator-activated receptors 
(PPARs), which are ligand-inducible transcription factors, forming a subfamily of nuclear 
receptors comprising of PPARα, PPARγ and PPARβ/δ isoforms. The compounds that 
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activate PPARs include peroxisome proliferators, hypolipidaemic and anti-inflammatory 
drugs, and endogenous ligands such as fatty acids, eicosanoids and their derivatives (Berger 
and Moller, 2002). Several metabolites of AA were shown to activate PPARs (Forman et al., 
1995;Yu et al., 1995). A screen for PPAR activators revealed that different PPARs isoforms 
are activated by prostaglandins to varying degrees (Yu et al., 1995), indicating the receptors 
possess differential affinities for these molecules. PGA1, PGD1 and PGD2, and PGJ2 increase 
the activation of PPARs for several ten-folds. Although, PGI2 and its more stable metabolite 
PGF1α, were shown to only have a more marginal effect on PPAR activation (Yu et al., 
1995), probably due to the very short half-life, PGI2 was described as an endogenous ligand 
for PPARβ/δ and γ isoforms (Forman et al., 1995;Nemenoff et al., 2008). There is evidence 
that PGI2 can activate PPARs directly (Forman et al., 1997) or indirectly, though the IP 
receptor (Falcetti et al., 2007), indicating it is PPAR endogenous ligand (Forman et al., 
1997;Hertz et al., 1996). In addition to endogenous PGI2, stable derivatives, such as iloprost 
and treprostinil, were also shown to activate PPAR isoforms (Forman et al., 1997;Ali et al., 
2006). Therefore, it is plausible that some protective effects of these prostacyclin analogues 
are partly mediated through the PPAR signalling pathways. Ligand-activated PPARs form 
heterodimers with retinoid X receptors (RXR), and regulate gene expression by binding to 
the peroxisome proliferator response elements in promoter regions of target genes (Berger 
and Moller, 2002), mostly involved in glucose and lipid metabolism (Wang, 2010), 
inflammation (Becker et al., 2006), and cell survival (KEGG PPAR signalling pathway). 
Several functions were attributed to the isoforms activated by PGI2, from modulating lipid 
and glucose metabolism, to inflammation, cell growth, and differentiation (Genini et al., 
2012), as well as cardioprotective effects (Langenfeld et al., 2005). Specifically, in the CVS, 
prostacyclin receptor agonist beraprost, enhanced the expression of PPARγ and inducible 
NO synthase (iNOS), leading to diminished proliferation of aortic SMCs (Lin et al., 2008). 
Additionally, through the activation of PPARα/δ PGI2 might also oppose the shift from 
contractile to synthetic phenotype, induced by increased pressure and/or shear stress, in 
vascular SMCs (Tsai et al., 2009). 
Exposure of rats to certain peroxisome proliferator chemicals (e.g. phthalates) caused a 
marked reduction in oestrogen levels, leading to physiological irregularities in the animal 
reproductive systems (Davis et al., 1994). Therefore, it was postulated that PPARs could act 
to modulate oestrogen signalling pathways and metabolism. The RXRs were shown to be 
able to bind to ERE in the promoter region of oestrogen regulated genes and modulate their 
expression (Segars et al., 1993;Keller et al., 1995), indicating the existence of a cross-talk 
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between PPAR and oestrogen signalling pathways. By binding to ERE, PPARs act as 
competitive inhibitors (Keller et al., 1995), e.g. PPARγ mediates reduced transcription of 
aromatase gene and increased protein turnover (Yanase et al., 2001;Fan et al., 2005). 
Moreover, PPAR signalling led to increased degradation of ERα (Qin et al., 2003), resulting 
in altered oestrogen signalling. PPARα, which is constitutively expressed in the mouse lung 
(Becker et al., 2008b), increased the expression of 17βHSD type 1, leading to increased 
oestrone (E1) production (Corton et al., 1997;Davis et al., 1994). The treatment with 
peroxisome proliferator completely abolished CYP2C11 gene expression, an enzyme which 
metabolises oestradiol to 2OHE1/2 and 16αOHE1/2 in males (Corton et al., 1997), indicating 
PPAR activity could modulate the expression of oestrogen metabolising enzymes. 
Interestingly, the expression of CYP1B1 was shown to be induced through the activation of 
PPARα activation (Lovekamp-Swan et al., 2003;Murray et al., 2001). Equally, deletion of 
the CYP1B1 gene in mice resulted in suppressed expression of PPARα, and the genes 
regulated by this receptor (Larsen et al., 2015). 
 Right Ventricular Hypertrophy in Pulmonary Arterial 
Hypertension 
In the foetus, the thickness of the left and right ventricles is the same. Following the immense 
change in the pressure of the pulmonary vasculature upon the first breath and the maturation 
of pulmonary vessels during the first years of life, the anatomy of both ventricles’ changes. 
Namely, the wall of the right ventricle (RV) remains thin (approximately 4mm) and the 
thickness of the left ventricle (LV) increases to be able to withstand greater afterload, closely 
related to the higher systemic pressure in the aorta compared to mPAP. In a healthy 
individual, the pulmonary circulation can, in times of increased oxygen requirements, accept 
several-fold higher stroke volume from RV with no change in pulmonary pressure 
(Matthews and McLaughlin, 2008). However, persistently increased pressure overload due 
to chronically increased mPAP results in increased wall thickness of RV (Bristow et al., 
1998). The authors described additional changes in the RV geometrical character and 
chamber volume (Bristow et al., 1998). The compensatory RV hypertrophy with preserved 
cardiac output, in absence of proper therapeutic options due to late diagnosis and the focus 
of current treatments of PAH, progresses to maladaptive hypertrophy with contractile 
dysfunction, resulting in RV failure affecting the adequate perfusion of the pulmonary 
circulation (Ryan and Archer, 2014). Although most of the available therapeutic options for 
PAH are focused on vasoconstriction, the results of a dynamic cohort conducted by Sandoval 
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and colleagues, showed that the survival of PAH patients is significantly dependent on the 
RV function (Sandoval et al., 1994). Furthermore, the reduction in PVR does not necessarily 
result in improved RV function or has prognostic significance in treated patients (van de 
Veerdonk et al., 2011). The authors showed that the patients’ survival is only significantly 
affected by the RV ejection fraction (van de Veerdonk et al., 2011). 
Despite lower prevalence and incidence of PAH in men, they generally have worse survival 
compared to females (Humbert et al., 2010a;Ling et al., 2012;Escribano-Subias et al., 2012). 
The results of Multi-Ethnic Study of Atherosclerosis (MESA) indicated that the RV mass, 
volume and ejection fraction greatly depend on sex, age and race (Kawut et al., 2011). A 
study of cardiac volumetric measurements in a population of IPAH patients revealed that 
men have generally lower values of RV ejection fraction and stroke volume (Swift et al., 
2015), possibly explaining the poor survival of men diagnosed with PAH. 
 Current Treatment Options for Pulmonary Arterial 
Hypertension 
Currently, PAH is still considered as an incurable disease, even though, data from current 
PAH registries indicates that the 5-year survival of PAH patient post-diagnosis improved in 
comparison to the first published survival data by Rich and colleagues (Rich et al., 1987;Ling 
et al., 2012). Initially, it was reported that less than two thirds of patients survive 3 years 
once the PAH diagnosis was made (Humbert et al., 2010a;Benza et al., 2012). The average 
survival time from diagnosis was estimated to be 5–7 years (Gomberg-Maitland et al., 
2011;Kane et al., 2011;Benza et al., 2012). The 5-year mortality rate reported in UK and 
Spanish registries was between 30–40% (Ling et al., 2012;Escribano-Subias et al., 2012). 
Recent data indicates that 5-year survival of PAH patients with exhibiting functional classes 
of impairment according to NYHA Classes I/II, III and IV is approximately 80%, 60% and 
40%, respectively (Gall et al., 2017). Importantly, only estimated 19% of patients included 
in the NIH registry were treated for the disease long term (Medarov and Judson, 2015), 
while, according to the National Audit of Pulmonary Hypertension 2017, 99% of patients 
with PH diagnosis are on active therapy and referral (Digital, 2017). 
The first therapeutic approaches were based on the use of vasodilators CCBs, providing 
alleviation of symptoms experienced by the patients, and non-specific therapies, such as 
anticoagulation therapy, diuretics and therapy with supplemental oxygen. Although there is 
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no direct evidence that the non-specific therapies have a beneficial effect in PAH, the use of 
diuretics is recommended to reduce the load on the right heart, reducing heart failure 
symptoms in these patients. Camerini and colleagues reported the beneficial effect of 
nifedipine, a CCB, on haemodynamic parameters within the lung of PAH patients. 
Moreover, prolonged administration of nifedipine resulted in improvement of symptoms and 
reduced signs of right heart failure (Camerini et al., 1980). Rich and colleagues reported the 
beneficial effects of therapy with high-dose CCBs in IPAH patients on heamodynamic 
parameters such as mPAP and PVR, right ventricular hypertrophy and the overall survival 
(Rich  et al., 1992). The therapy using CCBs is particularly effective in approximately 12% 
of the patient population, who exhibit significant response to vasodilators, as per the 
vasoreactivity assessment carried out during the diagnostic procedures (Sitbon et al., 2005). 
Unfortunately, prolonged treatment with CCBs is effective in an extremely small proportion 
of PAH patients (Sitbon et al., 2005). Therefore, prolonged treatment with CCBs is not 
recommended by the WHO, especially for patients with more severe impairments according 
to the NYHA classification. 
Currently, the recommendation for the treatment of PAH is to use one of the regulatory-
approved treatments, including prostacyclin analogues, endothelin-1 receptor antagonists 
(ETRA) and phosphodiesterase-5 inhibitors (PDE5I). The approved therapeutic options are 
intended to improve the patient’s symptoms and decrease the mortality rate. The choice of 
the most suitable therapeutic option is based on the disease severity, including 
haemodynamic parameters, functional limitations, and presence of right heart failure, route 
of administration, side effects and possible drug interactions with other concurrent therapies. 
Initially, the patients receive a monotherapy, and their response to the therapy is regularly 
monitored. Should the monotherapy not be sufficiently effective, then a combination 
therapy, using medications belonging to different treatment classes, is utilised (Galie et al., 
2009;Badesch et al., 2007). 
The first approved class of therapeutics for the treatment of PAH was prostacyclin and its 
analogues, which are derivatives of the endogenous molecule with prolonged half-life. The 
beneficial effects of prostacyclin analogues in SMCs were attributed to its effects through: 
i) the binding to the G-protein coupled receptors (GPCRs), leading to activation of PKA and 
increased production of cAMP, resulting in SMCs relaxation and vasodilation (Narumiya et 
al., 1999;Wise, 2003), and ii) the inhibition of SMC proliferation (Clapp et al., 2002). The 
anti-proliferative properties of prostacyclin analogues are not entirely understood, with 
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Clapp and colleagues having reported the anti-proliferative effects might be mediated in a 
cAMP-dependent manner (Clapp et al., 2002), while others have demonstrated prostacyclin 
analogues might activate the DNA-binding protein inhibitors Id1/Id3 through the bone 
morphogenetic protein receptor II (BMPRII) signalling pathway (Yang et al., 2010). Three 
prostacyclin analogues (epoprostenol, treprostinil and iloprost) are currently approved for 
the treatment of PAH and are used to manage moderate to severe PAH. Previously associated 
with intravenous administration, new generation prostacyclin exhibit improved 
pharmacokinetic properties and stability at room temperature, enabling improved routes of 
administration. 
 
 
Figure 1–12: Diagram depicting signalling pathways targeted by current and emerging 
therapies in pulmonary arterial hypertension. 
Currently approved therapeutic strategies in pulmonary arterial hypertension target three major 
signalling pathways involved in the regulation of vascular tone in pulmonary arteries: i) Endothelin, 
ii) Prostacyclin and iii) Nitric Oxide. Endothelial dysfunction and/or injury results in decreased 
production of endogenous vasodilatory mediators, i.e. prostacyclin and nitric oxide, while the 
expression of endothelin-1, promoting vasoconstriction and smooth muscle cell proliferation, is 
upregulated. Therefore, current therapeutic approaches focus on i) inhibiting the endothelin-1 
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signalling pathway through endothelin-1 receptor antagonists, or ii) administration of prostacyclin 
analogues to activate prostacyclin IP receptors, and iii) inhibition of phosphodiesterase 5, resulting 
in decreased decomposition of cyclic glucanosyl monophosphate, leading to vasodilation and arrest 
of proliferation. Adapted from (Humbert et al., 2014). 
ETA= Endothelin A receptor, ETB= Endothelin B receptor, BMPRII= Bone-morphogenetic protein 
receptor II, Id1/Id3= DNA-binding protein inhibitor ID-1/3, cAMP= Cyclin adenosine 
monophosphate, sGC= Soluble guanylyl cyclase, GTP= Guanosine triphosphate, cGMP= Cyclic 
guanosine monophosphate, GMP= Guanosyl monophosphate, PDE5= Phosphodiesterase 5. 
The vasoconstrictor properties of ET-1 and its importance in the maintenance of vascular 
tone were recognised, due to high amounts of ET-1 being produced by the lung. ET-1 is 
rapidly produced in direct response to the presence of specific stimuli, including hypoxia 
and low levels of oestrogens (Galie et al., 2004a). Increased levels of ET-1 in the plasma of 
PH patients were observed (Stewart et al., 1991), which might be a direct response to 
pulmonary vascular injury (Olave et al., 2012). The levels of ET-1 appear to be indicative 
of the disease severity, as assessed by PVR, mPAP and exercise capacity (Giaid et al., 
1993;Rubens et al., 2001). Activation of ET-1 production was also reported in the rat 
monocrotaline and other models of PH (Miyauchi et al., 1993;Galie et al., 2004a). ET-1 acts 
through two endothelin-type receptors, ETA and ETB, where the former receptor is 
implicated in mediating vasoconstriction through Gi/Gq receptors and activation of protein 
kinase C, respectively (Vázquez-Prado et al., 1997;Warner et al., 1993), and the latter 
receptor is associated with the release of endogenous vasodilators (Hirata et al., 1993). While 
PASMCs express both receptor types constitutively, only ETB is expressed in PAECs. 
Moreover, both types of receptors are differentially distributed in pulmonary vasculature, 
with greater expression of ETA in proximal vessels, and greater expression of ETB in distal 
vessels (Davie et al., 2002;Soma et al., 1999;MacLean et al., 1994). A marked up-regulation 
of ET receptors was reported in pre-clinical animal models (Li et al., 1994), and in PAs from 
PH patients (Galie et al., 2004a), with PAs also exhibiting increased ET-1 binding capacity 
(Davie et al., 2002), corroborating the importance of ET-1 signalling in the pathogenesis of 
the disease first proposed by MacLean and colleagues. Several studies to date indicated that 
the activity of ETB receptor, involved in the clearance of ET-1, might be reduced (Langleben 
et al., 2006;Dupuis et al., 2000). A sex disparity was observed in the levels of ET-1, with 
male rats having higher levels of the endogenous molecule and more pronounced ETA-
mediated signalling in the kidney (Kittikulsuth et al., 2013), which could translate into 
increased vascular tone in this population compared to age-matched females (Stauffer et al., 
2010). Hence, it is surprising that a meta study of patient data from six randomized placebo-
controlled trials of ET-1 receptor antagonists (ERAs) revealed that, the differences in ET-1 
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expression led to greater response to ERAs in women compared to men (Gabler et al., 2012). 
A direct link between the levels of ET-1 and sex hormones was suggested, with oestrogens 
decreasing the gene expression of ET-1 in ECs (Bilsel et al., 2000). Currently available 
endothelin receptor antagonists can be divided into two classes: i) dual antagonists 
(ambrisentan), and ii) selective antagonists (bosentan, macitentan), where the dual 
antagonists target both ET-1 receptors, and the selective antagonists are selectively blocking 
ETA receptor in SMCs. The selective antagonists have the advantage of decreasing ET-1-
mediated vasoconstriction and proliferation, while the beneficial effects of ETB remain 
unaltered. 
The last class of approved therapeutics for PAH are phosphodiesterase 5 inhibitors (PDE5I), 
which target the cyclic guanosine monophosphate (cGMP)-specific PDE5 enzyme. The NO 
signalling pathway is involved in the regulation of vascular tone by mediating vasodilation 
of small vessels. Produced in ECs, the NO mediates relaxation of the underlying SMCs 
through the activation of soluble guanylyl cyclase (sGC) enzyme, resulting in the production 
of cGMP, a secondary messenger mediating vasodilation either by: i) affecting intracellular 
levels of Ca2+, ii) activation of Ca2+-sensitive K+ channels thereby increasing K+ influx 
(Archer et al., 1994), or iii) by stimulation of de-phosphorylation of myosine fibres 
(Nakamura et al., 2007). The PDE enzyme catalyses the degradation of cGMP, leading to 
termination of signal transduction. Several PDE isoforms (PDE1‒6) exist, with PDE5 being 
abundantly expressed in the pulmonary vasculature (Corbin et al., 2005). Increased 
expression of PDE3 and PDE5 isoforms in vitro and in vivo were associated with PH 
phenotype (Murray et al., 2002), indicating that increased degradation of cGMP might be 
affecting vascular reactivity. Sildenafil and tadalafil are currently approved for the treatment 
of moderate to severe PAH. PDE5I were also shown to inhibit proliferation, although the 
exact mechanism is not yet fully understood (Li et al., 2007). Another class of therapeutics, 
associated with the NO pathway, directly stimulates sGC resulting in cGMP production, and 
stabilising the activation of this enzyme by NO (Stasch and Evgenov, 2013). Concurrent use 
of PDE5I and sGC stimulators is not recommended due to the risk of provoking systemic 
hypotension (Humbert and Ghofrani, 2016). 
Patients who do not respond to available therapies or exhibit a significant decline in their 
clinical condition, and are deemed to be eligible for lung transplantation, are referred to a 
transplantation centre (George et al., 2011). 
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As available therapeutic approaches do not offer reversal of haemodynamic changes, the 
need for novel treatments, tackling the extensive vascular remodelling, is apparent, 
especially, as most of the described therapies demonstrate only marginal improvement in 
survival (Stenmark and Rabinovitch, 2010). Pullamsetti and colleagues produced a 
comprehensive review of the novel therapeutic concepts, currently still in experimental or 
clinical stages, including novel approaches to vasodilation using prostacyclin receptor 
agonists, and prospective i) anti-proliferative treatment strategies targeting tyrosine kinases, 
ii) transcription factor-based strategies targeting PPARγ, Notch, and Wnt/β signalling 
pathways, iii) inflammation-targeting strategies, iv) epigenetic modulation-based therapies 
utilising miRNA mimics, histone deacetylase inhibitors and DNA methyltransferase 
inhibitors, v) BMPRII modulation strategies focused on restoration of BMPRII expression 
and signalling, and vi) regenerative approaches aimed at targeting vascular pruning by 
induction of angiogenesis by early endothelial progenitor cells (Pullamsetti et al., 2014). 
1.3  Underlying Genetic Causes of Pulmonary 
Arterial Hypertension 
The occurrence of HPAH, previously termed primary PH, within families was first reported 
more than 65 years ago. Since, immense advances were made in terms of understanding the 
disease inheritance pattern, which is consistent with autosomal dominant mode (Loyd et al., 
1984), and the genetic factors contributing to the disease onset. The transmission pattern 
indicated the possible X-chromosome linkage (Loyd et al., 1984). The hereditary form of 
the PAH only accounts for approximately 5% of entire PAH patient population (Thenappan 
et al., 2007). Nonetheless, the presence of mutations was linked with earlier onset of the 
disease, more severe haemodynamic impairment and poorer survival (Sztrymf et al., 
2008;Girerd et al., 2010a). While the mutations in the BMPRII are the most characterised in 
PAH, numerous rare mutations in novel genes were connected with the onset of the 
hereditary form, including ALK-1, KCNK3, ENG, ACVRL1, CAV1, SMAD9, EIF2AK4 and 
BMPRIB, causing 1‒3% of HPAH cases (Austin et al., 2002).  
 Mutations in BMPRII Gene 
The BMPRII is a constitutively active serine/threonine receptor kinase, belonging to the 
transforming growth factor-β (TGF-β) superfamily, found to be an important component of 
38 
 
PAH pathogenesis. The presence of mutations in the gene encoding various regions of the 
BMPRII are present in more than 70% of patients with HPAH (Lane et al., 2000;Deng et al., 
2000;Trembath et al., 2001), and approximately 25% of IPAH patients (Thomson et al., 
2000). Austin and colleagues reported that the risk of developing PAH in BMPRII mutation 
carriers is 14% and 42%, in males and females respectively (Austin et al., 2002). The 
mutations in the BMPRII gene seem to affect the expression levels, with BMPRII expression 
being decreased in patients with different forms of PAH (Atkinson et al., 2002), inferring 
that mutations occurring in the gene encoding the BMPRII receptor lead to diminished 
signalling though this pathway. Evidence indicates that the BMPRII signalling is 
significantly reduced in the PAECs derived from patients with IPAH and HPAH (Richter et 
al., 2004;Yang et al., 2005). The presence of a mutation in the BMPRII gene can generally 
be described as detrimental, as individuals with these mutations present clinical PAH more 
than 10 years earlier than patients that are not harbouring this defect (Girerd et al., 2010b), 
and exhibit higher mPAP and lower cardiac output (Evans et al., 2016). Moreover, studies 
showed that the presence of mutations in the BMPRII gene is closely associated with the 
severity of haemodynamic impairment of the pulmonary circulation, meaning these patients 
might require surgical intervention sooner than non-carriers (Sztrymf et al., 2008). 
Nonetheless, approximately 80% of individuals who are carriers of mutation in the BMPRII 
gene will never develop PAH (Hamid et al., 2009). Extremely low penetrance of the disease 
despite the presence of a mutation, strongly suggests more than one insult/injury is required 
for the disease to be presented clinically. 
1.3.1.1 BMPRII Signalling Pathway 
The binding of a BMP ligand or growth factor induces hetero-dimerization of type I and type 
II BMPR, results in the formation of an active receptor complex, which phosphorylates 
mothers against decapentaplegic homologs (Smad) 1/5/8. Phosphorylated Smad complex 
can then bind with Smad4, resulting in its translocation to the nucleus, and modification of 
gene expression through: i) direct interaction of Smad proteins with DNA or ii) indirect 
interaction through recruitment of co-activators, co-repressors and transcription factors 
(Massague et al., 2005). One of major downstream mediators of the BMPRII signalling 
pathway is the family of inhibitor of the DNA-binding (Id) proteins, which are involved in 
regulation of cellular differentiation and proliferation (Miyazono et al., 2010). The BMPRII 
signalling pathway can interact with other signalling pathways, such as extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein 
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(MAP) kinase pathways (Guo and Wang, 2009). Signalling through the BMPRII pathway 
was shown to promote survival in PAECs and inhibition of proliferation in PASMCs, while 
modulating the response of vascular cells to growth factors (Perez et al., 2011;Nakaoka et 
al., 1997;Teichert-Kuliszewska et al., 2006;Zhang et al., 2003). 
 
 
Figure 1–13: Bone morphogenetic protein receptor II (BMPRII) signalling pathway. 
The binding of bone morphogenetic protein 4 or a suitable growth factors results in 
heterodimerisation of BMPRII with BMPRI, forming an active receptor complex, which leads to 
phosphorylation of Smad-1, -5 and -8. Phosphorylated Smad proteins then dimerise with Smad-4, 
and the complex is translocated into the nucleus, where it regulates the transcription of genes 
involved in cell growth, proliferation and apoptosis. The active extracellular signal–regulated kinases 
(ERK) and/or mitogen activated protein kinases inhibit the BMPRII signalling pathway, resulting in 
dysregulated cellular proliferation. 
BMP4=Bone morphogenetic protein 4, BMPRII=Bone morphogenetic protein receptor type II, 
BMPRI=Bone morphogenetic protein receptor type I, Smad-1/5/8=Mothers against decapentaplegic 
homologs, P=Phosphorylation, ERK=Extracellular signal–regulated kinases, Id1/3=DNA-binding 
protein inhibitor Id1/3 
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In a healthy cell, the binding of a ligand to the BMPRII leads to the activation of PPARγ, 
which can block the Smad-independent signalling through the phosphorylation of the 
extracellular signal-regulated kinase1/2 (pErk1/2), leading the induction of genes p27 and 
p21, resulting in the senescence of the cell (Morrison and Farmer, 1999). However, when 
the BMPRII signalling is impaired by a mutation in the corresponding gene, then the binding 
of a growth factor to the receptors, causes the activation of Smad-independent signalling, 
resulting in VSMC proliferation in vitro (Sarjeant et al., 2003). 
Stimulation of PAECs with oestrogen under hypoxic conditions resulted in decreased 
expression of proteins involved in the BMPRII signalling pathway (Ichimori et al., 2013). 
Under basal conditions, significantly less BMPRII receptor, phospho-Smad1/5/8 (p-
Smad1/5/8), Id1 and Id3 proteins were expressed in the PASMCs derived from females 
compared to males (Mair et al., 2015), with similar observations made by Austin and 
colleagues in lymphocytes (Austin et al., 2009). In vitro experiments showed that oestrogen 
treatment leads to a reduction in the BMPRII signalling pathway through the activity of 
hypoxia-inducible factor 1α (HIF1α) and oestrogen receptor α (ERα) (Ichimori et al., 
2013;Fessel et al., 2013), with the effects of oestrogen potentiated by five-fold in the 
presence of other pro-proliferative signals (Fessel et al., 2013). Hence, not surprisingly, 
disease penetrance in BMPRII mutation carriers is increased by altered oestrogen 
metabolism (Austin et al., 2009), with female gender reported as significantly affecting 
disease penetrance (Austin et al., 2009;Badesch et al., 2010). It was recently shown that the 
inhibition of the key enzyme in the local production of oestrogen in the pulmonary 
circulation, increases the BMPRII signalling pathway (Mair et al., 2014). Significantly, 
oestrogen regulates lysosomal activity through non-genomic signalling (Burlando et al., 
2002), which has also regulating the BMPRII signalling pathway (Durrington et al., 2010). 
 Mutations in ALK-1 Gene 
The activin A receptor type II-like kinase-1 (ALK-1) is a serine/threonine-protein kinase 
receptor in the TGF-β signalling pathway, which induces the phosphorylation of Smad1/5/8. 
Mutations in ALK-1 gene was linked with the onset of HPAH and extremely poor patient 
prognosis in individuals harbouring this mutation compared to carriers of BMPRII mutation 
(Girerd et al., 2010a). 
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1.4  Animal Models of Pulmonary Arterial 
Hypertension 
The survival of PAH patients’ post-diagnosis remains poor (Humbert et al., 2010a;Benza et 
al., 2012), with the average survival time estimated to be 5–7 years (Benza et al., 
2012;Gomberg-Maitland et al., 2011;Kane et al., 2011). Poor survival prognosis indicates 
that due to the complexity of PAH pathogenesis, most significant pathogenic signalling 
mechanisms are still unidentified, and consequently not therapeutically targeted. Animal 
models of the disease offer the opportunity to gain new insights into PAH pathogenesis and 
therewith associated effective pharmacological approaches. Numerous animal models were 
developed to assist the research of PAH. The features of some experimental animal models 
of PH are summarised in Table 1-3. 
 Hypoxia-Induced Pulmonary Hypertension 
Most frequently, in research setting, PH in numerous animal species is induced by exposure 
to chronic hypoxia (cHx). The advantage of cHx models is the simplicity of model 
implementation and the range of species it can be used in. The exposure of rats to cHx 
induces remodelling of the pulmonary vascular plexus, including the muscularisation of 
small non-muscular PAs and increased muscularisation of pre-capillary arteries (Stenmark 
et al., 2009), associated with migration, proliferation and hypertrophy of SMCs (Stenmark 
et al., 2006b;Meyrick and Perkett, 1989). In cHx, thickening and fibrosis of large proximal 
PAs, leading to severe stiffening of these vessels, were documented (Drexler et al., 2008). 
The described progressive structural changes within the lung lead to an increase in the mean 
PAP. Although these animals developed increased mPAP, resulting in the onset of RV 
hypertrophy (RVH), this does not lead to RV failure (RVF), as seen in humans (Stenmark et 
al., 2009). In mice, exposure to cHx results in the muscularisation and thickening of distal 
and proximal PAs, although to a lesser extent compared to rats (Frank et al., 2008). The 
differences in response to cHx in mice are due to differential gene expression induced by Hx 
(Tada et al., 2008). Although this model was shown to exhibit highly reproducible and 
predictable response within a strain of animals, it is hindered by exceeding variability in the 
response to Hx between animal species, strain and animal’s age (Stenmark et al., 2006b). 
The model is, however, additionally limited by relatively modest increases in mPAP and the 
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absence of plexiform lesions, which are characteristic for human PAH. Therefore, cHx 
animal models can only be regarded as models of less severe PH, and not PAH. 
The cHx, although a classical animal model of PAH, does not completely recapitulate the 
human disease. Moreover, the extent of involvement of Hx-induced signalling pathways is 
not completely understood in human disease. In animals, prolonged exposure to cHx was 
associated with activation of hypoxia-induced signalling pathways, whereas intermittent 
cHx also resulted in altered oestrogen signalling through ERα (Wu et al., 2008). In this 
classical experimental model of PH, males develop more severe disease phenotype, and 
ovariectomy in female animals severely exacerbates the disease (Tofovic et al., 2006). 
 Monocrotaline-Induced Pulmonary Hypertension 
In this classical animal model of PH, established in the late 1960s, the disease is induced by 
repetitive oral administration of a pyrrolizidine alkaloid found in the Crotalaria Spectabilis 
seeds, termed monocrotaline (MCT) (Kay et al., 1967). For MCT to be activated, the alkaloid 
is required to undergo transformation into a dehydrogenated pyrrole metabolite, through 
reactions catalysed by cytochrome P450 3A4 enzyme and oxidases (Lafranconi and 
Huxtable, 1984;Yao et al., 2014;Reid et al., 1998;Wilson et al., 1992). This results in an 
active bifunctional cross-linked MCT pyrrole. The MCT model is described as highly 
variable, as the establishment of the animal model heavily depended on liver metabolism, 
which exhibited great variance between animals, strains and species (Stenmark et al., 2009). 
MCT is metabolised more rapidly in livers from male rats compared to female rats 
(Lafranconi and Huxtable, 1984). Nowadays, the model is easily established in numerous 
species by a single injection of MCT or the active pyrrole. However, even the administration 
of the active compound does not result in reducing variability in this model, representing a 
significant limitation of this model. 
The MCT-induced PH model is characterised by gradual alterations in the haemodynamic 
parameters, vascular remodelling and RV hypertrophy over a period of several weeks after 
initial induction, which is preceded by lung dysfunction (Lai et al., 1991;Gomez-Arroyo et 
al., 2012). Histological changes in the lungs of MCT-induced PH included intimal 
hyperplasia and medial hypertrophy, resulting in extensive thickening and remodelling of 
the vessel wall (Stenmark et al., 2009;Ryan et al., 2011) while distinctive plexiform 
pathophysiological lesions observed in other models of PH were not present (Gomez-Arroyo 
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et al., 2012). Exposure of MCT-treated animals to a second insult, resulted in development 
of plexiform lesions, vessel obliteration and severe RV hypertrophy (Okada et al., 1997). In 
addition to significant vasoconstrictor aspect of MCT-induced PH, the pathophysiological 
changes in this model are alleviated or reversed by most experimental treatments (Maarman 
et al., 2013), limiting its use to study severe PH in humans (Gomez-Arroyo et al., 2012). 
Proposed mechanisms of MCT-induced PH involve: i) direct induction of endothelial injury 
(Kay et al., 1967;Rosenberg and Rabinovitch, 1988), and ii) dysregulation of survival and 
proliferative pathways, and NO signalling in PAECs (Huang et al., 2010). MCT induces 
rapid sustained expression of phosphorylated Smad1, which accumulated in the nucleus, in 
cultured PAECs (Ramos et al., 2007). A decrease in BMPRII and increase in Smad6 were 
also observed (Ramos et al., 2007). 
MCT model of PH, as one of the classical and well-established models, was extensively used 
in the research of PAH. More than two decades ago, Farhat and colleagues investigated the 
effects of oestrogens in male rats administered with MCT, demonstrating that treatment with 
17β-oestradiol (17βE2) attenuated muscularisation of small PAs and RV hypertrophy 
(Farhat et al., 1993). As in cHx experimental model, also males treated with MCT develop 
more a severe disease phenotype compared to females. The protective effects of exogenous 
17βE2 will be discussed later. 
Early observations in so-called classic models of PH, such as cHx and MCT-induced PH, 
indicated that females exhibited less frequent and less severe PH than males (Rabinovitch et 
al., 1981;Rafikova et al., 2015). RVH and remodelling were observed in both of these animal 
models. However, significant dysfunction associated with RV maladaptive hypertrophy, and 
therewith associated higher mortality rate, is typically only seen in the MCT model (Gomez-
Arroyo et al., 2012;Kato et al., 2003). To overcome these limitations of PAH animal models, 
novel models were developed more recently, that are thought to replicate the human 
phenotype more closely. 
 Pulmonary Artery Banding 
The technique of pulmonary artery banding (PAB) is known since 1952, when the technique 
was developed to aid patients with congenital heart disease with secondary PAH due to 
increased blood flow to the lungs (Muller and Danimann, 1952). The surgical technique was 
adapted by Dias and colleagues to induce PH in animals, characterised by progressive 
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narrowing of PA and RVH (Maarman et al., 2013;Dias et al., 2002). PH is induced by 
physically constricting the PA by tightly tying a silk suture around an 18-gauge needle 
positioned alongside PA, which is then removed, and the animal is left to recover. The suture 
causes further constriction of the vessel in the growing animal, resulting in pressure-
overload-induced RVH (Maarman et al., 2013;Dias et al., 2002). This model is mostly 
employed to investigate the molecular physiology and pathophysiological mechanisms 
involved in RVH and RV failure, which is the main cause of death in PAH. The PAB model 
is not employed frequently, as the initiation of this model requires highly technically skilled 
researchers and is also associated with significant mortality of animals. 
 Serotonin Transporter Overexpressing Mice 
The MacLean research group reported the existence of a transgenic mouse model of PH, 
where the overexpression of the 5-HT transporter in mice (termed SERT+ mice) results in 
the development of PH in the absence of any other insults (MacLean et al., 2004). Instead, 
the group later showed that the disease phenotype is spontaneously developed in female 
SERT+ mice (White et al., 2012), characterised by PA remodelling, increased RV systolic 
pressure and RV hypertrophy, at 5–6 months of age. Male animals do not exhibit any PH 
phenotype at any age (White et al., 2011a). Moreover, in this model, exposure of transgenic 
female mice to hypoxia, results in the development of severe PH (White et al., 2011a) 
 S100 Ca2+ Binding Protein A4 Overexpressing Mice 
Mice overexpressing the S100Ca2+-binding protein A4 (S100A4/Mts1) represent another 
class of transgenic animal model of PH, established by (Ambartsumian et al., 1998). The 
overexpressed gene encoding the S100A4/Mts1 is associated with the regulation of cell 
proliferation, differentiation and apoptosis (Ambartsumian et al., 1998;Greenway et al., 
2004). A small population of female mice with this transgenic modification developed PA 
remodelling with vascular lesions, with no apparent pathological changes in the right heart 
(Greenway et al., 2004;Dempsie et al., 2011). S100A4/Mts1 is upregulated in PAH 
(Greenway et al., 2004). In this model, animals develop histological changes in PAs, which 
resemble human neointimal lesions leading to occlusion of the vessel lumen (Greenway et 
al., 2004). The mechanism of action in PAH is associated with 5-HT, where the latter induces 
the release of S100A4/Mts1, which affected PASMC proliferation and migration (Lawrie et 
al., 2005). 
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 BMPRII Mouse Model of Pulmonary Arterial 
Hypertension 
The presence of mutations in the BMPRII coding gene in most HPAH population, also 
present in a significant proportion of IPAH patients, plays an important role in the 
pathophysiology of PAH. The impact of BMPRII mutations on the pathophysiology of the 
disease was extensively studied in mice heterozygous for the BMPRII allele (BMPRII +/−). 
Beppu and colleagues were first to generate a mouse model carrying a mutant BMPRII allele 
(Beppu et al., 2000). Although authors later reported these mice had altered haemodynamic 
parameters and remodelled PAs compared to their wild-type littermates (Beppu  et al., 
2004;Song et al., 2005), pulmonary haemodynamics, PA wall thickness and index of 
muscularisation were not significantly different from wild-type littermates under normoxic 
(Nx) or Hx conditions (Long et al., 2006). Nonetheless, mice carrying the specific R899X 
mutation in the BMPRII gene, develop significant pulmonary vascular remodelling, 
characterised by increased right ventricular systolic pressure (RVSP), muscularisation of 
small pulmonary vessels and vaso-occlusive lesions, but only with a second insult, in this 
case with 16α-hydroxyoestrone (16 αOHE1) (West et al., 2008b). Specifically, these animals 
exhibit changes in angiogenesis, vasoreactivity, and injury response (West et al., 2008b). 
Chronic treatment of BMPRII deficient mice with 5-HT resulted in increased PA systolic 
pressure, RVH, and vascular remodelling (Long et al., 2006). The experimental PH 
phenotype in mice heterozygous for the BMPRII allele is exaggerated in cHx (Long et al., 
2006). In the BMPRII model, however, no intimal and plexiform lesions are observed. 
 Smad1 Conditional Knock-Out Mice Model of 
Pulmonary Arterial Hypertension 
Although the mutations in the gene encoding for the BMPRII receptor were described as the 
main genetic cause of HPAH, the role of the BMP signalling in the disease setting remained 
elusive. Smad1 protein is activated directly by the BMP receptors, as one of the down-stream 
signalling proteins of the BMP and the TGF-β signalling pathways. The conditional Smad1 
knock-out model was developed to observe by Huang and colleagues, who aimed to 
determine the role of Smad1 in adult animals (Huang et al., 2002). Smad1 conditional knock-
out animals exhibit altered haemodynamic parameters and vascular remodelling of the 
pulmonary circulation similar to animals harbouring the specific R899X mutation in the 
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BMPRII gene (Long et al., 2011). Cross-breeding of both genetically engineered models 
results in animals with significantly increased RV systolic pressure compared to single 
heterozygous mice. Hence, it appears that the effect of both gene knock-outs is synergistic 
and increases susceptibility of animals for developing PAH. Female Smad1 heterozygous 
mice develop PAH phenotype spontaneously at 5‒6 months of age, characterised by 
haemodynamic alterations and pulmonary vascular remodelling, while male animals never 
developed the disease (Mair et al., 2015). In these female animals, ovariectomy results in 
decreased haemodynamic parameters and vascular remodelling, respectively (Mair et al., 
2015). Nonetheless, in this model, despite established PAH phenotype, female animals do 
not develop RVH (Mair et al., 2015). Interestingly, the expression of phosphorylated Smad1 
is decreased in the medial and intimal layers of the vessel wall compared to normal subjects, 
where Smad1 was mostly localised within the nucleus of the ECs (Yang et al., 2005).  
Although transgenic models of PAH are useful to investigate the role of a specific pathway 
in the development and progression of the disease, they are possibly limited by not 
representing all the complex features of PAH pathogenies. Table 1-3 summarises the features 
of commonly used experimental models of PH. 
Table 1-3: Summary of Features of Animal Models of Pulmonary Arterial Hypertension. 
CH= Chronic hypoxia, MCT= Monocrotaline, PAB= Pulmonary arterial binding, 5-HTT= 
Serotonin transporter, BMPRII= Bone morphogenetic protein receptor II, R= Rat, M= 
Mouse 
Model Species Pulmonary 
Hypertension 
Medial 
Hypertrophy 
Intimal 
Lesions 
Plexiform 
Lesions 
CH R, M Low Yes No No 
MCT R, M High Yes No No 
PAB R,M Low No No No 
5-HTT M Yes Yes No No 
S100A4/Mts4 M Low Yes Yes No 
BMPRII M Low Yes No No 
Smad1 M Low Yes No No 
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None of the models described above develops pathophysiological changes in the pulmonary 
vasculature that exactly mimic all the hallmarks of the human disease. White and colleagues 
reported the development of plexiform-like lesions and severe vascular pruning in their 
animal model, where rats, which underwent left pneumonectomy and were additionally 
treated with MCT (White et al., 2007). 
 Sugen 5416 and Hypoxia-Induced Pulmonary Arterial 
Hypertension 
A novel alternative model of PH was recently developed by Taraseviciene-Stewart and 
colleagues, where rats are given one dose of Sugen 5416 (Su5416), a VEGF receptor 
inhibitor (see Figure 1–14), and then exposed to cHx (Taraseviciene-Stewart et al., 2001). 
The protocol for model establishment differs in rats and mice, where the former is given a 
single dose of Su5416, and the latter receive several injections (Ciuclan et al., 2011). 
Although a single dose of Su5416 in Nx causes mild PH characterised by moderate PA 
remodelling in rats, only coupling of Su5416 with cHx results in the development of severe 
persistent PH (Taraseviciene-Stewart et al., 2001). Ciuclan and colleagues reported that upon 
return of the mice from hypobaric chambers, the disease phenotype was reversed, unlike 
with rats where the disease persisted and progressed even after the animals were removed 
from Hx (Ciuclan et al., 2011). These observations were somewhat similar to the disease 
onset and progression occurring in humans. For instance, in Su5416/Hx model of PH medial 
wall hypertrophy and neointimal thickening occur 3–5 weeks after model initiation (Abe, 
2017). Additionally, complex plexiform lesions are formed approximately 13–14 weeks 
following model initiation (Abe et al., 2010). The mechanism by which the disease 
phenotype is induced in animals is not well understood. However, it is believed that exposure 
to Su5416 and Hx results in endothelial dysfunction, leading to vasoconstriction and vascular 
remodelling. Additionally, in diseased animals a population of apoptosis-resistant PAECs is 
believed to be detrimental in establishing the disease phenotype with angio-obliterative 
lesions (Stenmark et al., 2009;Jurasz et al., 2010). In terms of molecular mechanism of 
Su546/Hx model, a dysregulation of TGF-β and BMPRII signalling pathways was also 
observed, with considerable induction of HIF1α in these animals (Ciuclan et al., 2011). 
Tofovic and colleagues were the first to report that female sex in Su5416/Hx model is 
associated with the onset of more severe PAH complicated by plexiform lesions, as observed 
in humans, while males only developed occlusion of vessels. However, plexiform lesions 
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are not always present (Tofovic et al., 2012;Dean et al., 2016), which would suggest an 
advantage of this model over other known PH models. Moreover, in this model oestrogens 
appear to be detrimental to the disease development, and even worsened the disease 
phenotype, featuring complex vascular lesions and exceedingly elevated mPAP (Tofovic et 
al., 2012). Ovariectomy and/or inhibition of endogenous oestrogen production in this model 
are associated with lessened and delayed disease phenotype (Bilan et al., 2013;Tofovic and 
Rafikova, 2009). Albeit female animals develop a more severe disease phenotype as 
characterised by vascular remodelling and the presence of complex vascular lesions in this 
model, they exhibit a lesser change in the RV mass and hypertrophy (Tofovic et al., 
2012;Tofovic and Rafikova, 2009), which closely recapitulates the observations of 
epidemiological studies in humans. Su5416/Hx model is furthermore characterised by 
relative ineffectiveness of available therapeutic options in the reversal of disease phenotype. 
Due to extensive similarities of Su5416/Hx model with PAH observed in humans, this is the 
model of choice for numerous researchers. Notably, the murine Su5416/Hx model is not 
frequently used, as mice do not develop severe PAH with plexiform lesions (Abe, 2017). 
 
Figure 1–14: Effects of vascular endothelial growth factor receptor inhibition by Sugen 
5416. 
A schematic representation of possible pathways through which Sugen 5416 affects angiogenesis. 
As discussed above, it appears that sex plays an exceedingly important role in the onset of 
clinical and experimental PAH phenotypes, in humans and animals, respectively. Therefore, 
49 
 
the understanding of biosynthesis of steroidal sex hormones and their metabolism is vital in 
the understanding of the mechanisms behind the observed sex disparity in PAH. 
1.5 Steroidogenesis 
The term steroid hormone is used to describe all hormones exhibiting steroidal character, 
with their functions throughout the body being mediated through nuclear receptors, 
regulating genomic mechanisms, and/or membrane-bound receptors, regulating rapid-
response intracellular signalling pathways. Biologically active steroidal hormones are 
synthesised from cholesterol in a complex multi-step, multi-enzyme biological process 
termed steroidogenesis. Steroid hormones, depending on the class of the hormone being 
generated, are biosynthesised at different locations within the body, with most of sex 
hormones produced in the gonads and corpus luteum, adrenal gland, and placenta, with low 
levels also being produced in peripheral tissues such as liver, heart, skin, adipose tissue and 
brain (Cui et al., 2013). Although sex hormones are primarily responsible for the 
development and regulation of primary and secondary sex characteristics, they are also 
critical for the functional regulation of peripheral tissues (Cui et al., 2013). 
In the first step of steroidogenesis (simplified scheme is provided in Figure 1–15), the 
cholesterol, transported to mitochondria, is metabolised by various cytochrome P450 
enzyme to pregnenolone, which serves as an immediate precursor molecule for the synthesis 
of all steroid hormones. In the subsequent reactions, catalysed by several cytochrome P450 
enzymes, pregnenolone is bio-transformed to dehydroepiandrosterone (DHEA), which is the 
most abundant steroid hormone found in humans. Even though, the main function of DHEA 
is to serve as an intermediate in the biosynthesis of oestrogen and androgen hormones, it was 
shown that DHEA possesses some biological activity. In the cHx and MCT models, DHEA 
prevented and reversed the experimental PH phenotype as assessed by haemodynamic and 
remodelling parameters (Bonnet et al., 2003;Meloche et al., 2010). The protective character 
of DHEA in PAH might be due to increased expression of sGC and vasodilation associated 
with improved responsiveness to NO (Oka et al., 2007). Additionally, DHEA was shown to 
increase the expression of BMPRII, leading to increased apoptosis in hPASMCs from PAH 
patients (Meloche et al., 2010). In Su5416/Hx model, chronic treatment with DHEA resulted 
in improved cardiac function due to: i) antioxidant properties, ii) decreased RV systolic 
pressure and iii) preserved contractile function of RV (Alzoubi et al., 2013). Indeed, 
decreased plasma levels of DHEA are associated with the onset of PAH in men (Ventetuolo 
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et al., 2016). Following successful completion of phase II clinical trials involving the use of 
DHEA for treatment of PAH, phase III clinical trials have now commenced (Meloche et al., 
2010). 
The DHEA can be bio-transformed to DHEA-sulphate (DHEA-S) by DHEA 
sulfotransferase, which circulates tightly bound to albumin, exhibiting prolonged half-life 
(White and Portfield, 2013). 3β Hydroxysteroid dehydrogenase (3βHSD) catalyses the 
reaction of biotransformation of DHEA to androstenedione, which serves as the precursor 
molecule for the synthesis of oestrogens and androgens. Two 3βHSD were identified in 
humans (Mason, 1993), while five different isoforms are known in mice (Payne et al., 1997). 
Androstenedione can be directly converted to testosterone by 17β hydroxysteroid 
dehydrogenase type 3 (17βHSD type 3), whereas the reverse reaction is catalysed by the 17β 
hydroxysteroid dehydrogenase type 2 (17βHSD type 2). Both precursors, androstenedione 
and testosterone, can be converted to 17βE2 and oestrone, respectively, in the reaction of 
aromatisation catalysed by aromatase. Aromatase is the key enzyme in the generation of 
oestrogens, also termed cytochrome P450 19A1, and is expressed in numerous tissues 
throughout the body, from the gonads, brain, adipose tissue, placenta, and blood vessels, 
including pulmonary arteries, meaning there is localised production of oestrogens in 
peripheral tissues. 
 Female Steroid Sex Hormones – Oestrogens 
There are three main oestrogens in a human body, oestrone (E1), 17βE2, and oestriol (E3), 
where biological potency of oestrogens is E2>E1>E3. Oestradiol exists in two different 
isomers, 17β-oestradiol (17βE2) and 17α-oestradiol (17αE2), where the former possesses 
greater biological activity. The levels of oestrogens change during the life time of a female. 
During pregnancy, E3 is the dominating circulating oestrogen, with high levels of this 
hormone being produced by the placenta. In women of child-bearing age, E3 is formed from 
E1 and E2 through reaction of 16α-hydroxylation. Prior to menopause, the circulation 
concentration of 17βE2 depends greatly on the stage of the oestrous cycle, with normal range 
of 15–350pg/mL (0.06–1.3nM), and the levels increasing approximately 2-fold during 
ovulation. In peri-menopausal women, the levels of 17βE2 begin to fall, and the circulating 
levels of 17βE2 in post-menopausal women are usually less than 10pg/mL (<0.04nM) 
(Laboratories), with E1 assuming the role of the main circulating oestrogen in terms of 
concentration. Prior to menopause, 17βE2 is mostly produced in the ovaries and adrenal 
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gland, and acts in a paracrine way to regulate distal target tissues. In post-menopausal 
women and men, however, the oestrogens are primarily formed from androgens in the 
peripheral tissues, such as the adipose tissue, skin, etc. (Grodin et al., 1973;MacDonald et 
al., 1979), with 17βE2 acting in a paracrine or intracrine manner (Simpson, 2003). In post-
menopausal women, E1 is synthesised mainly in the adipose tissue, with DHEA serving as 
the precursor molecule (Cui et al., 2013). Due to their steroidal character, most of circulating 
oestrogens in the vascular system are transported bound to the sex hormone-binding globulin 
(SHBG), and to lesser extent serum albumin. Only a small proportion of oestrogens exist in 
the circulation is unbound, and therefore biologically active.  
52 
 
 
Figure 1–15: Biosynthesis of oestrogen steroid hormones form the precursor molecule, 
cholesterol. 
Cholesterol is the precursor molecule for the biosynthesis of all major steroid hormone classes. It is 
converted into pregnenolone in a biotransformation reaction catalysed by CYP11A. Pregnenolone is 
then further converted by either CYP17A1 to DHEA or 3β-hydroxysteroid dehydrogenase to 
progesterone. Both intermediates are then bio-transformed into androstenedione, which can be either 
converted into testosterone in a biotransformation reaction catalysed by 17β-hydroxysteroid 
dehydrogenase type 3, or into 16α-hydroxy-androstenedione by the activity of CYP2C11. 
Testosterone, as the primary male sex hormone, can be converted into 17β-oestradiol by the activity 
of aromatase. 17β-oestradiol, as the primary female sex hormone, can be bio-transformed into 
oestrone or oestriol by the activity of 17β-hydroxysteroid dehydrogenase type 2 and CYP enzymes, 
respectively. Green colour indicates the intermediates involved in the production of both, androgens 
and oestrogens, while oestrogens are coloured pink and androgens are blue. 
HSD3β=3β-Hydroxysteroid dehydrogenase, 17βHSD3=17β-Hydroxysteroid dehydrogenase type 3, 
DHEA=Dehydroepiandrosterone, 17βHSD2=17β-Hydroxysteroid dehydrogenase type 2, 
17βHSD1=17β-Hydroxysteroid dehydrogenase type 1, CYP19A1=Aromatase, CYP=Cytochrome 
P450 enzyme.  
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 Aromatase 
Aromatase belongs to the cytochrome P450 enzyme (CYP) superfamily, catalysing the rate-
limiting final-step reaction in the biosynthesis of 17βE2 (Simpson and Santen, 2015), 
consisting of three consecutive oxidation reactions. Therefore, for its normal function 
aromatase requires the availability of oxygen and the nicotinamide adenine dinucleotide 
phosphate (NADPH) cofactor. The functional form of aromatase is associated with NADPH 
cytochrome P450 reductase (Amarneh et al., 1993). The aromatase catalytic activity is 
specific to aromatisation of androgen hormones, specifically androstenedione and 
testosterone. Evidence indicated that the enzymes’ activity in tissues is regulated through 
stringent tissue-specific expression of aromatase, depending on tissue-specific gene 
promoters (Simpson et al., 1994;Simpson, 2003). Ten different tissue-specific gene 
promoters regulating the expression of aromatase, were described so far by Bulun and 
colleagues, all activated by specific activators (hormones, cytokines, and signalling 
molecules) under physiological or pathophysiological conditions (Bulun et al., 2005). For 
example, the expression of aromatase in the ovaries is regulated by the follicle-stimulating 
hormone (FSH), while cytokines and tumour necrosis factor α (TNFα) regulate its expression 
in the adipose tissue (Cui et al., 2013). Prostaglandin PGE2 was shown to stimulate 
aromatase expression in the adipose tissue, while aromatase expression was correlated with 
cyclooxygenase 1 and 2 expressions in breast cancer (Brueggemeier et al., 1999). The 
structure of the gene encoding aromatase enables that regardless whichever of the promoters 
is used for gene transcription, alternative splicing of the mature mRNA results in the 
formation of identical enzyme in all aromatase-expressing tissues (Zhao et al., 2016). 
Interestingly the expression level of aromatase in the adipose tissue of post-menopausal 
women is higher than that of pre-menopausal women (Misso et al., 2005). Authors therefore 
concluded that the capacity of the adipose tissue to produce oestrogens increases with age. 
Additionally, aromatase activity in humans is regulated by a rapid 
phosphorylation/dephosphorylation mechanism (Charlier et al., 2011). 
The association of obesity, increased aromatase expression, and oestrogen production in 
PAH disease setting was long recognised (Grodin et al., 1973;Key et al., 2003). The local 
oestrogen biosynthesis describes the production of oestrogens in the extragonadal tissues, 
where the newly synthesised hormones act locally (Labrie et al., 1998). Local production of 
oestrogens, although small in comparison to circulating levels, results in high localised 
concentrations, exerting biological functions (Simpson and Davis, 2001). For example, the 
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local production of oestrogens is considerably higher in cancerous breast tissue than in 
plasma (de Jong et al., 1997). Indeed, Mair and colleagues demonstrated that aromatase is 
expressed in hPASMCs and vascular lesions from patients with PAH (Mair et al., 2014). In 
men and post-menopausal women, the levels of circulating oestrogens reflect the local 
production of these hormones in the peripheral tissue (Simpson, 2003). The use of aromatase 
inhibitors for treatment of oestrogen-dependent cancers has long been recognised. More 
recently, aromatase inhibitors have also been considered in PAH, where a recently published 
results of the phase 2 clinical trial to determine the safety and efficacy of anastrazole, showed 
there was a significant reduction in E2 levels with no change in RV ejection fraction (Kawut 
et al., 2017). 
 Metabolism of Oestrogens 
Oestrogen activity in the body is regulated by deactivation of highly potent 17βE2, including 
its conversion to a less-active forms such as E1 or E3. Moreover, oestrogens can also be 
biotransformed into oestrogen derivatives, which cannot interact with oestrogen receptors 
(Kotov et al., 1999). Oestrogens are primarily metabolised by the CYPs, which are Phase I 
drug-metabolising enzymes, catalysing oxidative biotransformation of oestrogens and other 
steroids, most frequently at positions C2, C4, and C16 (Zhu and Conney, 1998), although 
numerous other hydroxylated metabolites were characterised (Lee et al., 2002;Lee et al., 
2001). As the liver is the primary site of steroid metabolism, most of P450 enzymes are 
abundantly expressed here. Nonetheless, numerous inducible isoforms of CYPs were found 
to be expressed in the extrahepatic tissue, such as lung tissue (Hukkanen et al., 2001), 
indicating the lung is also a site of significant oestrogen metabolism (see Figure 1–16). The 
resulting oestrogen metabolites possess a more polar, and therefore hydrophilic character, 
and serve as precursor molecules for Phase II drug-metabolising enzymes, which are 
typically transferases catalysing biotransformation reactions of conjugation. Hydroxylated 
oestrogens serve as precursors to oestrogen sulfotransferase enzymes (SULTs), which 
catalyse reaction of sulphurylation, resulting in sulphate oestrogen metabolites. The resulting 
conjugated metabolites are generally i) more easily excretable due to enhanced hydrophilic 
character, ii) metabolically inactive, or iii) pharmacologically inactive, meaning they are 
unable to interact with their respective receptors (Jancova et al., 2010). The most abundant 
oestrogen conjugates are sulphates and glucuronides (Raftogianis et al., 2000), where the 
former exhibit prolonged half-life (Coughtrie et al., 1998) and might therefore serve as an 
oestrogen reservoir with concentrations of E1-sulfate approximately 10-fold higher than 
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unconjugated oestrogen (Pasqualini et al., 1989). Oestrogen glucuronides, instead, are 
primarily excreted from the body. Glutathione (GSH) and methyl oestrogen conjugates are 
also well documented. 
In the process of oestrogen metabolism certain emerging compounds, such as metabolites 
containing hydroxyl groups at positions C2 or C4 is the steroidal backbone, can be further 
metabolised by CYP450 enzymes. The formation of catechol-oestrogens and quinones (CE-
Qs) or semiquinones, resulting from further oxidation of 2- and/or 4-hydroxylated 
oestrogens, where the latter can covalently bind to DNA to form depurinating adducts and 
induce mutations (Cavalieri et al., 1997). Additionally, catechol-oestrogens might also enter 
redox cycling, resulting in enhanced generation of hydrogen peroxide, hydroxyl radicals and 
other ROS (Yager and Liehr, 1996). These reactive catechol-oestrogens serve as precursor 
molecules for catechol-O-methyl transferases (COMT), enzymes catalysing methylation 
reaction. Although the most active pathway towards catechol-oestrogen excretion is 
methylation, to a lesser extent, reactive catechol-oestrogens might also be metabolised to 
glucuronides and sulphate oestrogen conjugates (Zhu and Conney, 1998;Raftogianis et al., 
2000). Soluble COMT (S-COMT) and membrane-bound COMT (M-COMT) enzymes exist, 
which differ in their relative affinity for their substrates, catalytic capacity and tissue 
expression (Raftogianis et al., 2000). 
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Figure 1–16: Metabolism of oestrogen hormones. 
Oestrone and 17β-oestradiol can be converted into one another by the activity of 17β-hydroxysteroid 
dehydrogenase, and both oestrogen hormones can be metabolised by CYP450 enzymes to numerous 
hydroxylated oestrogens. The principal hydroxylated oestrogen metabolites are 2- and 4-
hydroxyoestrogens, with only small proportion of 16α-hydroxy-oestrogens being formed. The 2- and 
4-hydroxylated oestrogens can be further metabolised by COMT, producing 2- and 4-
methoxyoestrogens, which have been shown to mediate protective effects in the cardiovascular 
system. Other reactions of biotransformation of hydroxylated oestrogens include the formation of 
oestrogen sulfate conjugates by the activity of UGT, which exhibit prolonged elimination half-lives 
and might therefore serve as an oestrogen reservoir, and the formation of oestrogen glucuronide 
conjugates, by the activity of UTG, which are primarily eliminated from the body. Oestrogens can 
also be further oxidised into catechol quinones and semi-quinones, which can form covalent bonds 
with DNA, resulting in depurinating adducts and therewith associated DNA damage. 
17βHSD2=17β-hydroxysteroid dehydrogenase type 2, 17βHSD1=17β-Hydroxysteroid 
dehydrogenase type 1, CYP=Cytochrome P450 enzyme, COMT=Catechol-O-methyl transferase, 
SLUT=Oestrogen sulfotransferase enzymes, UGT= Glucuronosyltransferase, GST= Glutathione S-
transferase  
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 Regulation of Oestrogen Signalling 
As discussed above, oestrogen signalling locally might be partly regulated by the 
biosynthesis of oestrogens via aromatase and transformation of oestrogens into sulphate 
conjugates, which are present in high concentrations but cannot bind to and activate 
oestrogen receptors. The oestrogen sulphates, however, serve as precursors for steroid 
sulfatase enzymes, hydrolysing E1/E2-sulfate to an active unconjugated from. Reportedly, 
the activity of E1 sulphatase in the breast tumour tissue was much higher than that of 
aromatase, indicating sulphate conjugates could also be the likely source of plasma 
oestrogens (Santen et al., 1986), specifically 17βE2 (MacIndoe, 1988), through 
interconversion of unconjugated E1 by 17βHSD type 1. Overexpression of 17βHSD 
isoforms 1 and 2 was associated with poorer prognosis and disease recurrence in breast 
cancer (Gunnarsson et al., 2001;Song et al., 2006). Steroid sulphatase is also capable of 
hydrolysing DHEA-S, which has little hormonal activity, but represents a large precursor 
reservoir for oestrogen biosynthesis. Nonetheless, biological effects in target tissues can only 
be mediated by hormonally active oestrogens, depending on their potency and receptor 
affinity through their interaction with oestrogen receptors (Kuiper et al., 1997). Oestrogen 
receptors (ER), belonging to the class I steroid hormone nuclear receptor superfamily, 
include receptor ERα and ERβ, with the latter receptor discovered approximately 20 years 
ago (Mosselman et al., 1996). ERs, as other nuclear receptors are comprised of six domains, 
where the N-terminal A/B domain is the regulatory domain also termed activation function 
1 (AF-1), followed by C domain, which is the DNA-binding domain. Domain D represents 
the hinge region, which is responsible for nuclear localisation of the receptor, followed by 
the hormone binding domain E and the C-terminal F domain, which is involved in regulation 
of receptor activity and conformation. 
The central DNA-binding domain and the N-terminal regulating domain represent the most 
and the least conserved regions of ERs, respectively. Both ER receptors have distinct roles 
in oestrogen signalling yet share a significant percentage of sequence homology. Due to their 
extensive homology, ERα and ERβ exhibit similar affinities for 17βE2. Additionally, E1 and 
E3, although possessing high receptor affinity, are weaker agonists of ERs compared to 
17βE2 (Heldring et al., 2007). The inactive ERs are present in the nucleus, and bound with 
heat-shock and other proteins, which disassociate upon the binding of oestrogen or 
oestrogen-like compound. The binding of a suitable ligand results in the activation of the 
receptors, forming dimers and interacting with specific segments of DNA, oestrogen-
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response elements (ERE), leading to transcription of target genes. Several splice variants 
were described for both receptors, and although it is not known whether all variants of ERα 
are translated and expressed as proteins, several variant isoforms of ERβ were characterised 
in tissues (Scobie et al., 2002;Palmieri et al., 2004), termed ERβ1–5 (Moore et al., 1998). 
Leung and colleagues reported that although the full-length ERβ, also termed ERβ1, is the 
only functional receptor isoform, the other variants can function as dimerising partners, 
thereby affecting the receptor activity (Leung et al., 2006). Conversely, there are functionally 
distinct ERβ isoform with greater transcriptional activity than ERβ1 (Wilkinson et al., 2002). 
Hence, it appears that the expression of variant ERβ isoforms may significantly modulate 
oestrogen signalling through affecting i) receptor activity, ii) target gene expression and iii) 
co-activator interaction, in a ligand-dependent manner (Ramsey et al., 2004). 
Both ER receptors were shown to be expressed within the lung, with ERβ levels being 
approximately two-fold higher compared to ERα in the primary lung tumours (Kuiper et al., 
1997). In tissues such as ovaries and the uterus both ER subtypes are present. However, there 
are significant differences in peripheral tissues, such as the liver, lung, etc. exist, with 
significantly more ERβ expressed within the lung compared to ERα (Kuiper et al., 1997). 
ERs were also shown to induce target gene transcription through interaction with DNA-
bound transcription factors, instead of ERE (Sukovich et al., 1994) and ligand-independent 
receptor activation through modulation of kinase/phosphatase activity in the absence of 
hormone (Weigel and Zhang, 1998). Alternatively, oestrogens were shown to mediate rapid 
non-genomic effects (Szego and Davis, 1967), possibly through cytoplasmic ER, which is 
tethered to the inner plasma membrane through protein interactions (Levin, 2005). Since, it 
was established that these effects are associated with activation of four signalling pathways: 
i) phospholipase C/protein kinase C (Morley et al., 1992;Bulotta et al., 2009), ii) 
Ras/Raf/MAPK (Klinge et al., 2005), iii) phosphoinositide-3-kinase (PI3K)/AKT (Lee et al., 
2005), and iv) cAMP/PKA (Farhat et al., 1996;Chen et al., 1998). Filardo and colleagues 
observed rapid transient activation of the GPER by oestrogen via an inhibitory signal 
mediated by cAMP (Filardo et al., 2002). 
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1.5.4.1 Classical Ligand-Dependent Direct Activation of Oestrogen 
Receptor 
The steroid properties of oestrogens and oestrogen-like compounds allow the molecules to 
freely diffuse through the cellular membrane into the cytoplasm and nucleus. Therefore, 
genomic oestrogenic effects are mediated through ligand-dependent direct activation of ERs, 
which bind to specific ERE sequences. Shortly, the binding of a suitable ligand to the 
hormone-dependent activation function 2 (AF-2) induces a transformational change in the 
receptor, leading to receptor activation and dissociation of the inhibitory multiprotein 
complex, which in absence of suitable ligands keeps ERs in their inactive form. The 
displacement of inhibitory complex also allows for i) the receptor to be translocated into the 
nucleus, ii) promotes dimerization of ERs, and iii) increases receptor affinity for ERE 
through induction of conformational changes exposing high affinity DNA binding site (Hall 
et al., 2001). DNA-bound homo-/hetero-dimers of ERs can interact with co-factors, which 
as co-regulators can either enhance or reduce the transcription of the target gene, thereby 
mediating ligand- and tissue-specific oestrogen signalling (Kase, 2003). The transcriptional 
activity of ERs is dependent on the AF-1 and AF-2, located in the C- and N-terminus, 
respectively. Out of the two transcriptionally active domains, the AF-2 possesses the 
strongest transactivation function. The maximal transcriptional activity of the receptors can 
only be achieved when both activation functions are engaged (Tzukerman et al., 
1994;Maggi, 2011). The duration and magnitude of biological response to oestrogen 
stimulation is tightly regulated by i) the dissociation of the ligand from the receptor, and ii) 
the degradation of the ER receptor bound to the DNA (Kase, 2003). As some of the ligands 
exhibit very small dissociation constants, main degradation mechanism is the ubiquitin-
proteasome pathway (Nawaz and O'Malley, 2004), where the degradation of the receptor is 
enhanced once it is bound to hormone. ERβ degradation is an oestrogen-dependent process, 
partially regulated by the conformational position of F domain, which in absence of a ligand 
protect the receptor from degradation (Tateishi et al., 2006). 
1.5.4.2 Ligand-Independent Activation of Oestrogen Receptor 
Many post-translational modifications, such as phosphorylation, acetylation, ubiquitination, 
methylation, sumoylation and palmitoylation have been identified, with approximately 22 
identified modification sites in ER (Faus and Haendler, 2006;Le Romancer et al., 2011). 
Less is known regarding post-translational modifications of ERβ. The latter isoform can be 
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glycosylated, leading to increased receptor stability (Cheng and Hart, 2001). 
Aforementioned modifications were shown to modulate numerous aspects of ER activity, 
from receptor stability, subcellular localisation, and dimerization to receptor’s ability to bind 
to DNA sequences and interact with co-regulators (Le Romancer et al., 2011). 
Phosphorylation at serine residues (S102, S104, S106 and S118) within ERα were associated 
with increased transcription activity, which may either be constitutive or induced by 
oestrogens (Medunjanin et al., 2005;Kato et al., 1995;Rogatsky et al., 1999). 
Phosphorylation at residue Y52 results in ligand-independent activation of transcription and 
enhanced receptor stability (He et al., 2010). 
1.5.4.3 Non-Classical Ligand-Dependent Activation of Oestrogen 
Receptor 
Ligand-bound ER can also interact with other transcription factors bound to their response 
elements, resulting in association of the ER with promoters, which may or may not include 
ERE-like sequences. The exact mechanism of this non-classical mechanism of oestrogen 
signalling is not well understood, however, it was shown that ERs can interact with 
transcription factors such as nuclear factor kappa-B (NF-κB), specificity protein 1 (SP1) and 
Jun/Fos/activator protein 1 (AP1) at corresponding DNA binding sites. The interaction of 
ERα with NF-κB and AP1, respectively, was shown to negatively affect the expression of 
several genes, including human interleukin 6 (IL-6) (Ray et al., 1997), TNFα (Srivastava et 
al., 1999), and quinone reductase (Montano and Katzenellenbogen, 1997). Agonists and 
antagonists of ERs, supress and stimulate gene transcription mediated through ER 
interaction with AP1, respectively (Jakacka et al., 2001) Although certain mutations might 
lead to abolishment of the classical oestrogen signalling, such ERs might still be able to their 
mediate effects through the non-classical pathways (Jakacka et al., 2001). Activation of both 
regulatory domains of ER is required for the activity of ERα, while only activation of the 
AP1 regulatory domain in the presence of selective oestrogen receptor modulators (SERMs) 
is required for ERβ activity (Webb et al., 1999). It was proposed that the binding of the 
Fos/Jun transcription factors at the AP1 binding site, leading to the recruitment of CPB/p300 
and associated proteins, including p160 co-activators, allows for the interaction of ERs 
through the non-classical signalling at the AP1 binding site (Kushner et al., 2000). 
Stimulation with BSA-bound 17βE2 induced transcription of genes without the involvement 
of ER classical signalling (Watters et al., 1997). 
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1.5.4.4 Non-Genomic Oestrogen Signalling 
Primarily, oestrogen signalling is characterised by a latency in the onset of effects, resulting 
in altered gene and protein expression, mediated by ERs localised within the nucleus (King 
and Greene, 1984). Multiple rapid actions of oestrogens have also been identified, indicating 
non-genomic signalling pathways may also be activated by oestrogens. Non-genomic 
oestrogen signalling pathways are activated by i) ERs tethered to the plasma membrane 
and/or ii) G-protein coupled receptor GPER1. A variant of the ERα is specifically targeted 
and localised to plasma membrane by post-translational modification of palmitoylation (Li 
et al., 2003). Moreover, some investigators reported that phosphorylation of ERs might also 
target these receptors to the inner plasma membrane (Balasenthil et al., 2004), while others 
observed that tethering of ERs to plasma membrane is dependent on the presence of specific 
adaptor proteins, such as Src-homology and collagen-homology (Shc) and insulin-like 
growth factor (IGF) protein (Evinger and Levin, 2005). Oestrogen stimulation increased the 
association of ERα with PI3K, leading to increased kinase activity, resulting in the activation 
of protein kinase B/Akt and cell survival pathways (Simoncini et al., 2000). Equally, 
stimulation of ECs with 17βE2 resulted in increased activity of eNOS, with MAPK and PI3K 
signalling pathways mediating these effects, depending on the concentration of the stimulant 
(Simoncini et al., 2000). Enhanced eNOS expression and activity are considered vaso-
protective, mediating vasodilation through relaxation of SMCs. 
The discovery of the G-protein coupled oestrogen receptor 1 (GPER1/gpr30) was prompted 
by reports of rapid activation of signalling pathways classically associated with growth 
factor and/or G protein-dependent signalling, leading to receptor cloning and 
characterisation in the late 1990s. Gpr30, previously described as an orphan receptor, is 
activated by 17βE2 in numerous breast cancer cell lines (Filardo et al., 2000). Gpr30 receptor 
is widely expressed throughout the body, and is also present the lung (Kvingedal and 
Smeland, 1997). Activation of gpr30 by 17βE2 results in the activation of Erk1/2 MAP 
kinases through EGFR transactivation (Filardo et al., 2000). Moreover, the same researchers 
later showed that gpr30 also activated adenylate cyclase (AC), leading to mobilisation of 
cAMP Activation of gpr30, localised at the endoplasmic reticulum, results in the 
mobilisation of intracellular Ca2+ storage through activation of PI3K, mediating rapid 
cellular response (Revanche et al., 2005). Interestingly, vascular SMCs of gpr30-deficient 
animals exhibited enhanced response to ET-1 mediated vasoconstriction, therefore the 
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authors concluded gpr30 might regulate vasoconstrictor activity of ECs, possibly leading to 
a reduction of blood pressure (Meyer et al., 2012). 
 Oestrogens in Disease 
Numerous diseases exhibit sex dimorphism, including some cancers and cardiovascular 
disease. The evidence of the implications of female sex hormones are discussed below. 
1.5.5.1 Oestrogens in Cancer 
To illustrate the role of oestrogens in lung disease, the importance of lung cancer is 
considered here. Recent statistical data indicates that lung cancer is the second most common 
cancer following breast cancer amongst women, accounting for 12% of all diagnosed cases 
(Siegel et al., 2017), with a documented 22% increase in incidence in women within the past 
30 years (Chakraborty et al., 2010). There is a direct association of lung cancer risk with 
hormone replacement therapy (Adami et al., 1989). Moreover, only a small proportion of 
lung cancers in females can be attributed directly to smoking (Chakraborty et al., 2010), 
indicating the majority of cases are directly related to female sex. Although, it was shown 
that females diagnosed with lung cancer have better survival than males (Cerfolio et al., 
2006), no conclusive evidence exists on the effects oestrogens and female gender might have 
on survival in lung cancer (Schwartz et al., 2007). Additionally, the mortality of female 
patients receiving anti-oestrogen treatment for breast cancer significantly reduces the 
mortality associated with lung cancer (Bouchardy et al., 2011). Nonetheless, akin to PAH, 
female sex was recognised as a risk factor for development of lung cancer, indicating the 
lung might be exceedingly sensitive to oestrogen, which might be directly associated with 
the pro-proliferative environment resulting in disease pathogenesis and onset. Inhibition of 
aromatase in the cHx and Su5416/Hx models of PAH resulted in the attenuation of the 
models, however only in female animals (Mair et al., 2014). 
1.5.5.2 Oestrogens in Cardiovascular Disease 
Cardiovascular disease (CVD) is one of the leading causes of death in the developed 
countries according to WHO. Female sex is associated with later onset of CVD, as well as 
reduced mortality of females compared to males. For example, females present with CVD 
7–10 years later than males (Mosca et al., 2011) and that coronary heart disease (CHD) in 
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pre-menopausal women is predominantly associated with smoking (Prescott et al., 1998). 
Interestingly, Women’s Ischemia Syndrome Evaluation (Wise) revealed that oestrogen 
deficiency in pre-menopausal women is associated with a significantly increased risk of 
coronary artery disease (CAD) (Bairey Merz et al., 2003). Moreover, the onset of menopause 
significantly increases the risk of CHD in women, and is associated with exacerbation of the 
disease (Matthews et al., 1989). Hence, it appears that endogenous oestrogens might be 
mediating protective effects within the cardiovascular system. 
Losordo and colleagues investigated the association of ER expression with significant CAD, 
showing reduced expression of receptors in samples derived from female individuals with 
CAD (Losordo et al., 1994). ERα and ERβ differentially regulate the expression of identical 
target genes within the same tissue (Lindberg et al., 2003). The relative expression of ER 
isoforms in cell types within the CVS might be an important aspect of oestrogen-mediated 
protective effect. Indeed, activation of ERβ in rat vascular SMCs led to enhanced expression 
of the iNOS, while activation of ERα resulted in negative regulation of the same gene 
(Tsutsumi et al., 2008). Interestingly, the expression of ERα in the vascular ECs varied in 
pre-menopausal women, depending on the stage of oestrous cycle and oestrogen levels. In 
post-menopausal women, the levels of ERα are significantly reduced compared to pre-
menopausal women during late follicular stage (Gavin et al., 2009). Indeed, the duration of 
oestrogen stimulation affects the expression of both ER isoforms in vascular endothelium, 
with chronic exposure resulting in enhanced expression of ERα and decreased expression of 
ERβ (Ihionkhan et al., 2002). Moreover, cHx led to increased expression of ERβ in ECs of 
PAs (Lahm et al., 2012). A genome-wide expression profiling study to characterise genes 
specifically involved in the pathogenesis of PAH demonstrated that ERα is upregulated in 
PAH patients of both sexes (Rajkumar et al., 2010). Numerous genes regulated by ERα, 
involved in TGFβ and NO signalling, are altered in PAH. Recently the relative expression 
of ER in PASMCs derived from control subjects and PAH patients subjects of both sexes 
was reported (Wright et al., 2015). There is significantly more ERβ expressed in PASMCs 
derived from male PAH patients compared to cells derived from control subjects, while there 
is significantly more ERα expressed in cells derived from female PAH patients compared to 
control subjects. Hence, it appeared that the changes in the expression of ERs might be 
associated with disease setting, having significant consequences for oestrogen signalling. 
Treatment of ovariectomised female mice with 17βE2 attenuated cardiac hypertrophy 
following transaortic constriction compared to matched male animals, which were treated 
with vehicle (van Eickels et al., 2001). These observations might be dependent on ERβ 
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isoform (Skavdahl et al., 2005). Interestingly, the ERβ isoform might also be responsible for 
normal lung development and physiology (Patrone et al., 2003). 
1.5.5.3 Androgens in Cardiovascular Disease 
Testosterone is the main male sex hormone, synthesised from cholesterol through the 
formation of pregnenolone, progesterone and androstenedione, which is then transformed to 
testosterone by the activity of 17β-hydroxysteroid dehydrogenase type 3. As significantly 
more men are affected by CVD, it was long perceived that female sex hormones are 
protective. Nonetheless, recent epidemiological data indicated that increased prevalence of 
atherosclerosis, coronary heart disease (CHD), metabolic syndrome and hypertension in men 
are associated with decreased plasma levels of testosterone (Jones;Jones, 2010). Moreover, 
lower testosterone levels are also correlated with increased mortality in CVD and cancer 
(Khaw et al., 2007;Ponikowska et al.), while higher levels were shown to reduce the risk of 
cardiovascular events (Ohlsson et al., 2011). Testosterone mediated vasodilation in 
numerous vascular plexus, including pulmonary vasculature (Smith et al., 2008). Indeed, in 
men with chronic heart failure (CHF), the administration of exogenous testosterone 
improved the afterload of the LV, probably through decreasing systemic vascular resistance 
and consequently increased cardiac output (Pugh et al., 2003). 
1.6  Cytochrome P450 Enzymes 
In humans, there are approximately 57 genes encoding functional enzymes belonging to the 
CYP superfamily, while the existence of additional 58 pseudogenes was also described 
(Nelson et al., 2004a). The members of CYP450 superfamily, constituting the principal 
assembly of enzymes involved in oxidative metabolism of endogenous and exogenous 
compounds, are divided into families and sub-families, according to the extent of sequence 
identity, with members of CYP450 families exhibiting extensively overlapping substrate 
specificities (Nebert and Russell, 2002). As discussed above, CYP450 enzymes catalyse a 
variety of oxidative biotransformation reactions, including hydroxylation, S-oxidation, N- 
and O-dealkylation, and epoxidation of numerous compounds: i) endogenous molecules, 
including steroid hormones, sterols, eicosanoids and retinoids, and ii) exogenous 
compounds, including numerous drugs and environmental pollutants playing an important 
role in the biosynthesis and detoxification of reactive compounds (Nebert and Russell, 
2002). The CYP450 enzymes were implicated in the bioactivation of inert toxins, possibly 
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leading to mutagenesis and carcinogenesis (Nebert and Russell, 2002). To illustrate the 
importance of CYP450 enzymes in the biosynthesis and metabolism of endogenous 
compounds, six enzymes participate (cholesterol desmolase, 11β-hydroxylase, aldosterone 
synthesizing enzyme, 17α-hydroxylase, aromatase and 21-hydroxylase) in the process of 
steroidogenesis, synthesis of oestrogens and interconversion of androgens into oestrogens 
(Nebert and Russell, 2002). Although generally, CYP450 enzymes are found in most tissues, 
due to their role in detoxification, it is believed that the majority of CYP450 enzymes are 
widely expressed in the liver. There is also significant, albeit lower, expression in other 
tissues which are regularly exposed to environmental pollutants, such as the lung, 
gastrointestinal tract and kidney (Nebert and Russell, 2002;Krishna and Klotz, 1994). 
According to a review by Lee and colleagues, numerous CYP450 enzymes are also present 
in target tissues for oestrogen (Lee et al., 2003). Most CYP450 enzymes exhibit tissue-
specific expression pattern (Nishimura et al., 2003). Interestingly, not all CYP isoforms are 
expressed in the liver. Certain isoforms, e.g. CYP1A1, were found to be extensively 
expressed in adult liver, while their expression in foetal liver was only marginal, albeit the 
most abundant expression of CYP1A1 was detected in the lung (Nishimura et al., 2003). 
Additionally, isoforms exhibiting region-specific catalytic selectivity, such as CYP1B1, are 
essentially only expressed in extrahepatic oestrogen-responsive tissues (Lee et al., 2003). 
CYP450 enzymes are haemoprotein monooxygenases, meaning the active site contains a 
protoporphyrin-IX haem with an iron(III) covalently linked to the protein by the sulphur 
atom of a proximal cysteine residue (Meunier et al., 2004). Moreover, the conjugated ring 
system of the haem is vital for enzyme’s catalytic activity. Generally, the reaction catalyse 
by CYP450 enzymes can be written as: 
𝑁𝐴𝐷(𝑃)𝐻 +  𝐻+ +  𝑂2 + 𝑅𝐻 → 𝑁𝐴𝐷𝑃
+ + 𝐻2𝑂 + 𝑅𝑂𝐻, 
where the required electrons for the reaction are provided by the cofactor NADPH from the 
associated P450 reductase enzyme (Meunier et al., 2004). The catalytic cycle of CYP450s 
enzymes is initiated upon the binding of a suitable molecule in the active site, resulting in 
altered arrangement of iron (III) ion. The electron transfer from associated P450 reductase 
to the iron (III) centre, resulting in its transition to ferrous state, produces a highly active 
reduced form of CYP450 enzyme, which can bind an oxygen molecule. Following the 
binding of oxygen molecule to the ferrous cytochrome, the second reduction step, which is 
the rate-limiting, occurs. The CYP450 enzyme catalytic cycle is terminated with two 
66 
 
protonation steps, resulting in the formation of a peroxide complex, ultimately leading to the 
release of a water molecule and oxidised substrate, and the decoupling of the reaction 
(Meunier et al., 2004). 
 NADPH-dependent Oxidative Metabolism of 
Oestrogens 
NADPH-dependent oxidative metabolism of oestrogens by CPY450 enzymes represents the 
first step in the body’s attempt towards inactivation of these steroid hormones, containing 
their biological effects in target tissues, leading to their eventual excretion. Recent evidence 
indicates, oestrogen metabolism might not be as straightforward, as numerous metabolites 
have been shown to exert biological effects, which are independent of their parental hormone 
(Lee et al., 2003;Zhu and Conney, 1998). See Figure 1–17 for a summary of the biological 
effects of oestrogens in pulmonary circulation. 
Generally, the expression CYP450 enzymes is induced by the presence of enzymes’ 
substrate, especially for the many inducible extrahepatic CYP450 isoforms. The induction 
of CYP450 enzymes is a closely regulated process, allowing cells to appropriately respond 
to exposure of environmental pollutants (Williams et al., 2005). CYP450 enzymes exhibit 
certain substrate specificity, also resulting in their preferential site of oxidation reaction 
within the substrate molecule. Hence, the expression pattern of CYP450 enzymes might 
affect the local production of oestrogen metabolites. Lee and colleagues have recently 
characterised oxidative metabolism of 17βE2 and E1 of 15 different CYP450 enzymes (Lee 
et al., 2003). 
Although numerous CYP450 isoforms metabolise 17βE2, some exhibit very little or no 
activity for oxidative metabolism of this hormone. The positions of hydroxylation for 
different cytochrome P450 enzymes are summarised in Table 1-4. Predominant 
hydroxylation positions in Table 1-4 are shown in bold. With 17βE2 as substrate, CYP1A1 
and CYP1A2, isoforms exhibit high catalytic activity for hydroxylation at position C2. Most 
CYP isoforms also exhibit catalytic activity for hydroxylation at position C4. Interestingly, 
numerous isoforms have also shown a detectable activity for the conversion of 17βE2 to E1, 
with CYP2A6 isoform having most substantial activity for this reaction. The catalytic 
activity of CYP1A2 for E1 being almost two-fold than that for 17βE2. Although CYP1B1 
catalyses hydroxylation at positions C2 and C4 with 17βE2 and E1 as substrates, with the 
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latter reaction being favoured. While CYP1A1 has only weak activity for hydroxylation of 
17βE2 at position C16α, and no activity for hydroxylation of E1 at the same position, 
CYP3A4 exhibits high activity for these two reactions. Moreover, the ratio of 
4OHE1/2OHE1 is almost two-fold compared to ratio 4OHE2/2OHE2 for this specific 
isoform. Out of all the isoforms investigated by Lee and colleagues, CYP1B1 possesses a 
predominant activity for hydroxylation at position C4, with the highest ratio of 
4OHE2/2OHE2 (Lee et al., 2003). Nevertheless, the absolute amount of these metabolites 
formed by CYP1B1 is still lower than that of CYP1A1 and CYP1A2 (Lee et al., 2003). 
Table 1-4: Positions of hydroxylation for different cytochrome P450 enzymes. 
Cytochrome P450 
Isoform 
Substrate Position of Hydroxylation 
CYP1A1/2 17βE2 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16β 
CYP1A1/2 E1 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16β 
CYP1B1 17βE2 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16α/C16β 
CYP1B1 E1 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16α/C16β 
CYP3A7 17βE2 / 
CYP3A7 E1 C2/C4 
CYP2C8 17βE2 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β//C16β 
CYP2C8 E1 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16α/C16β 
CYP3A4 17βE2 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16α/C16β 
CYP3A4 E1 C2/C4/C6α/C7α/C15α/C16α/C6β/C12β/C16α/C16β 
 
 Aryl Hydrocarbon Receptor Signalling Pathway 
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor, belonging to 
the superfamily of basic helix-loop-helix (bHLH)/Per-Arnt-Sim (PAS) transcription factors 
(Gu et al., 2000), and is associated with regulation of biological response to polycyclic 
aromatic hydrocarbons (PCAHs) and other environmental pollutants. AhR was shown to 
regulate the expression of xenobiotic-metabolising enzymes, including CYP450 enzymes. 
AhR has a role in development and physiological homeostasis. AhR knock-out mice 
demonstrated the is an association between AhR and the induction of target genes such as 
CYP1A1, CYP1A2, and CYP1B1 upon stimulation with a potent, selective AhR agonist, 
2,3,7,8-tetrachlorodibenzodioxin (TCDD) (Fernandez-Salguero et al., 1995). Moreover, 
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AhR knock-out animals exhibited numerous phenotypical abnormalities, including 
decreased number of immune cells in the periphery, observed in young animals, while 
mature animals also presented cardiac hypertrophy with fibrosis, abnormal blood vessel 
formation in the liver, and calcification of the uterus (Fernandez-Salguero et al., 1995). AhR-
deficient mice did not develop tumours following injection with a known carcinogen 
benzo[a]pyrene (B[a]P), indicating the possible role of AhR signalling pathway in 
carcinogenesis and tumour progression (Shimizu et al., 2000). This may be through 
induction of enzymes involved in the activation of inactive pro-carcinogenic compounds to 
active carcinogens. Equally, previously, an association between CYP1A1 induction and 
tumorigenesis in the lung was described (Shimada and Fujii-Kuriyama, 2004). 
The AhR is ubiquitously expressed in most tissues and cell types, with significant levels of 
cDNA present in the placenta, lung, kidney, and liver (Dolwick et al., 1993), and lower 
expression in the heart (Carver et al., 1994). The expression of AhR was mainly 
immunolocalized to epithelial cells in these organs. Although it was shown that AhR is 
expressed in ECs derived from pulmonary microvasculature (Zhang and Walker, 2007), 
comprehensive literature on basal (and pathological) expression and localisation of AhR in 
pulmonary vasculature was lacking. Most recently, immunohistochemistry technique was 
employed to determine the localisation of AhR expression in human lung tissue, showing 
the receptor is mainly present in ECs and SMCs of pulmonary veins and arteries, while it 
was also detected in bronchial and alveolar sac epithelia (Li et al., 2017). 
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Figure 1–17: Schematic representation of the role of oestrogen metabolites in the onset 
and progression of pulmonary arterial hypertension. 
Oestrogens are metabolised by cytochrome P450 enzymes, which catalyse the introduction of 
hydroxyl group at numerous positions within the steroidal backbone of these hormones, resulting in 
the formation of numerous oxidised oestrogen metabolites. Most commonly, 2- and 4-
hyroxyoestrogens are formed, with small proportion of 16α-hydroxy-oestrogens. The latter have 
been shown to stimulate proliferation of smooth muscle cells, resulting in extensive vascular 
remodelling. The 2-hydroxyoestrogens exhibit anti-proliferative properties, while the 4-
hydroxyoestrogens are mostly associated with the production of reactive oxygen species, associated 
with DNA damage. Moreover, 2- and 4-hyroxyoestrogens can be further metabolised to 2- and 4-
methoxyoestrogens, which were shown to possess anti-proliferative properties, and were suggested 
to oppose the onset of pulmonary arterial hypertension in animal models.  
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 Activation of Aryl Hydrocarbon Receptor 
The AhR signalling pathway (see Figure 1–18 for summary) is initiated by 
endogenous/exogenous ligand diffusion through the plasma membrane into the cell, and its 
consecutive binding with the cytosolic AhR protein, which is associated with heat shock 
protein 90 (Hsp90), prostaglandin E synthase 3 (P23) and AhR associated 9 (AIP/ARA9) 
(Pongratz et al., 1992;Kazlauskas et al., 2000;Carver et al., 1998;Carver and Bradfield, 
1997;Ma and Whitlock, 1997). The AhR-associated protein complex maintains the receptor 
in a conformation suitable for ligand binding and prevents the translocation of the receptor 
into the nucleus in the absence of a suitable ligand. The ligand binding activates AhR, 
leading to the dissociation of AIP and P23 proteins, while the ligand-receptor complex is 
then translocated into the nucleus, where the Hsp90 dissociates from AhR, enabling its 
heterodimerization with AhR nuclear translocator (ARNT or HIF1β) (Probst et al., 
1993;Hankinson, 1995). AhR-ARNT complex, yielding a functional transcription factor, is 
then able to bind to dioxin- and/or xenobiotic-response elements (DRE/XRE) in the DNA 
sequence, resulting in altered transcription of target genes, amongst which CYP1A1, 
CYP1A2, and CYP1B1 are the best characterised (Denison et al., 2011). The AhR target 
genes also include NAD(P)H dehydrogenase (quinone 1) (NQO1), UDP 
glucuronosyltransferase 1 family polypeptide A cluster (UGT1A), and glutathione S-
transferase alpha 1 (GSTA1) (Brauze et al., 2017). CBP/p300 is a co-activator of the AhR-
ARNT complex (Kobayashi et al., 1997). The AhR signalling is attenuated by: i) the binding 
of the ARNT with the aryl hydrocarbon receptor repressor (AhRR), which is under the 
transcriptional regulation of AhR, resulting in decreased availability of functionally active 
transcription factor (Mimura et al., 1999), or ii) ubiquitin/proteasome degradation of the 
ligand-bound AhR (Davarinos and Pollenz, 1999).  
 The Function of Aryl Hydrocarbon Receptor in the 
Cardiovascular System 
The role of AhR in the CVS was first suggested by studies in AhR-deficient mice. With age 
these developed cardiac hypertrophy with fibrosis, suggesting AhR pathway may be 
imperative in cardiac development (Carreira et al., 2015;Vasquez et al., 2003). The absence 
of AhR resulted in increased expression of HIF1α and consequently vascular endothelial 
growth factor (VEGF) (Thackaberry et al., 2002), leading to compensatory hypertrophy of 
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cardiomyocytes (Vasquez et al., 2003). AhR-deficient mice developed systemic 
hypertension associated with significantly increased levels of circulating and tissue 
vasoactive molecules, such as ET-1 (Lund et al., 2003). AhR deficient mice have a 
potentiated response to changes in pO2, leading to significant Hx-mediated increase in in 
ET-1 and systemic blood pressure (Lund et al., 2008). Activation of the AhR signalling 
pathway results in the induction of numerous Phase I drug metabolising enzymes, including 
CYP1A1, and leads to increased production of ROS, which in turn, may lead to endothelial 
dysfunction (Park et al., 1996). There is a correlation between endothelial dysfunction, 
characterised by disrupted integrity and increased permeability, and activation of AhR 
pathway (Toborek et al., 1995). Interestingly, there are neonatal vascular structures in AhR-
deficient mice, indicating this signalling pathway might be associated with maturation of the 
vessels, during which the neonatal vasculature is replaced by matured vessel plexus (Lahvis 
et al., 2000). Due to the presence of abnormal vascular architectures in AhR-deficient mice, 
it can be inferred this signalling pathway may be also imperative in normal vascular 
development (Lahvis et al., 2000).  
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Binding of a suitable ligand to AhR in the cytoplasm, causes the dissociation of accessory proteins, 
resulting in the translocation of the activated receptor into the nucleus. In the nucleus, the receptor 
heterodimerises with ARNT, and then binds to dioxin or xenobiotic response elements, resulting in 
altered transcription of target genes. 
AhR=Aryl hydrocarbon receptor, API (ARP9)= Aryl hydrocarbon receptor associated 9, 
Hsp90=Heat shock protein 90, p23=Prostaglandin E synthase 3, ARNT= AhR nuclear translocator, 
AhRR= AhR repressor. 
 
 
 
 
 
 
In hypoxia, the proteasomal degradation of HIF1α is diminished, as the activity of PHDs and vHL is 
reduced due to decreased partial pressure of oxygen. In such circumstances, HIF1α is translocated 
into the nucleus, where it competes with AhR for binding with ARNT, thereby reducing the 
availability of ARNT for signalling through the AhR pathway. 
HIF1α=Hypoxia inducible factor 1α, PHDs= Prolyl hydroxylase enzymes, vHL= von Hippel-Lindau 
tumour suppressor protein 
Figure 1–19: The interaction of hypoxia inducible factor signalling pathways and the aryl 
hydrocarbon receptor signalling pathway. 
Figure 1–18: Aryl hydrocarbon receptor signalling pathway. 
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 Interactions between the AhR Signalling Pathway and 
Hypoxia-Inducible Factor Signalling 
Figure 1–19 provides a summary of the interactions between the AhR signalling pathway 
and HIF signalling. Hypoxia-inducible factors (HIFs) belong to the same subfamily of 
transcription factors as AhR, the bHLH/PAS family. Six different HIFs exist, with members 
HIF1–3α denoting hypoxia-inducible factors, and members HIF1–3β denoting AhR nuclear 
translocators. While all HIFs are constitutively expressed, only the nuclear translocators are 
stable in Nx conditions. Unlike with AhR, activation of HIFs does not require the binding of 
a suitable endogenous/exogenous ligand, as the transcription factors respond directly to 
changes in the partial pressure of oxygen in the cellular environment. The regulation of 
HIF1α activity occurs by hydroxylation-dependent proteasome-mediated degradation of 
these transcription factors. In Nx conditions, prolyl hydroxylase enzymes (PHDs) catalyse 
hydroxylation of two conserved proline residues of HIF1α, for which the enzymes require 
molecular oxygen as a co-factor. Three different PHDs exist, with PHD2 exhibiting the 
highest affinity for HIF1α (Berra et al., 2003). A complex of the von Hippel-Lindau (vHL) 
tumour suppressor protein and a ubiquitin ligase E3 then binds to the hydroxylated HIF1α 
(Kamura et al., 2000), leading to poly-ubiquitination of and proteasomal degradation of 
HIF1α. Mitogen-activated protein kinases p42/p44 (Erk1/2) mediates phosphorylation of 
HIF1α in vitro, leading to increased HIF1α-dependent transcriptional activity (Richard et al., 
1999). In Hx, the activity of PHDs is greatly reduced or inactive due to the absence of a 
suitable co-factor. Therefore, the HIF1α is stabilised, as its proteasome-mediated 
degradation is greatly decreased. This leads to the translocation and accumulation of the 
transcription factor into the nucleus, where it heterodimerises with ARNT, also named 
HIF1β (Jiang et al., 1996). The heterodimer binds to Hx response enhancer elements within 
the DNA sequence (Liu et al.), resulting in transcription of target genes involved in 
angiogenesis, metabolism, apoptosis, etc. (Semenza, 2009). Equally, HIF2α, first 
characterised by Tian and colleagues, has approximately 50% of sequence homology with 
HIF1α (Tian et al., 1997), binds to HIF1β, resulting in the induction of specific target genes 
as shown by (Ema et al., 1997). HIF2α is abundantly expressed in the developing lung and 
might have an important role in the normal vascularisation of the lung (Ema et al., 1997). 
Hence, it appears that HIF1β, involved in AhR- and HIF1α-mediated signalling, is an 
important modulator of signalling pathways through its association with several transcription 
factors, forming active transcription complexes. Moreover, competitive recruitment of 
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ARNT (HIF1β) might result in repression of genes targeted by these two signalling pathways 
(Nie et al., 2001). A reciprocal repression of the AhR and HIF1α pathways exists in certain 
cell lines, with the degree of repression depending on the sequence of introduced stimuli 
(Nie et al., 2001). Interestingly, HIF1α possesses a very high affinity for ARNT, resulting in 
significant competition with the AhR (Gradin et al., 1996). Nonetheless, these two distinct 
signalling pathways may also be interacting through other co-activators (Kobayashi et al., 
1997;Ebert and Bunn, 1998). In some cell lines there is no reciprocal repression of the AhR 
and HIF1α pathways (Nie et al., 2001). Hence, the interaction between these signalling 
pathways may differ with respect to cell type, tissue and species (Chan et al., 1999). 
 Interaction of the AhR Signalling Pathway with other 
Signalling Pathways 
There might be cross-talk between the AhR and ER signalling pathways (see Figure 1–20), 
inferring AhR agonists might modulate the activity of ERs (Umbreit and Gallo, 1988). The 
anti-oestrogenic effects of TCDD, a potent AhR agonist, resulting in disturbed oestrogenic 
cycle in female mice were documented (Umbreit and Gallo, 1988). Additionally, 
administration of a single dose of TCDD results in significantly reduced ER levels in the 
liver and uterus (Romkes et al., 1987). TCDD administration abolishes 17βE2-induced cell 
proliferation due to interference with expression of several cyclins required for advancement 
through cell cycle (Buchanan et al., 2002). In breast and endometrial cancer cell lines, 
TCDD-stimulated CYP1A1 gene induction only occurred in ER-positive cell lines (Ricci et 
al., 1999). Moreover, TCDD treatment resulted in enhanced expression of TGFβ, was also 
implicated in the pathogenesis of PAH (Ricci et al., 1999). In rats the exposure to TCDD 
may lead to the onset of breast and ovarian cancer (Jenkins et al., 2007). In the absence of 
17βE2, activation of AhR receptor by 3-methylcholanthrene (3MC) resulted in induction of 
ERE-mediated transcription (Ohtake et al., 2003). Ligand-activated AhR, upon its 
translocation into the nucleus and heterodimerisation with ARNT, associates with either of 
the unliganded ERs, further recruiting the p300 co-activator (Ohtake et al., 2003). Evidence 
further suggested that in the absence of 17βE2, ligand-bound AhR might recruit ERα through 
specific protein interaction, resulting also in the induction of ERα-target genes (Ohtake et 
al., 2003;Matthews et al., 2005). Nonetheless, oestrogen concentrations, depending on 
numerous aspects such as age and type of tissue, might define whether AhR ligands have 
oestrogenic or anti-oestrogenic effects (Ohtake et al., 2003). ARNT might function as a co-
activator for both ER isoforms, through association with the ligand binding domain, in an 
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17βE2-dependent manner (Brunnberg et al., 2003). AhR-target genes are only induced in 
ER-positive breast cancer cell lines following treatment with TCDD, while no such response 
was noticeable in ER-negative cell lines (Vickers et al., 1989). Independently, several 
research groups observed the recruitment of ERα to XRE/DRE in the presence of ligand-
activated AhR (Beischlag and Perdew, 2005;Matthews et al., 2005). Matthews and 
colleagues further reported that knock-down of ERα expression resulted in significantly 
diminished induction of CYP1A1 gene in the presence of TCDD (Matthews et al., 2005). 
The interaction of ERα with the AhR signalling pathway may represent a negative regulation 
mechanism of oestrogen signalling (Matthews and Gustafsson, 2006). 
 
Figure 1–20: Schematic representation of interaction between oestrogen signalling 
pathway and aryl hydrocarbon receptor signalling pathway. 
The proposed mechanism of interaction between oestrogen and AhR signalling pathways is by i) 
direct inhibition of oestrogen signalling through the binding of AhR/ARNT heterodimer to inhibitory 
response elements within the oestrogen target genes, ii) through induction of oestrogen metabolising 
enzymes by the AhR signalling pathway, resulting in increased production of metabolites with lower 
affinity for oestrogen receptors, iii) competing for and/or squelching of coactivator proteins shared 
by both signalling pathways, iv) increased proteasomal degradation of oestrogen receptors through 
activation of AhR signalling pathway, or v) induction of gene encoding for an inhibitory protein 
through activation of AhR signalling pathway. Adapted from (Matthews and Gustafsson, 2006). 
XRE=Xenobiotic response element, ERE=Oestrogen response element, p300=Histone 
acetyltransferase p300, CBP= CREB-binding protein, p160= Nuclear Receptor Coactivator p160 
i) 
ii) 
iii) 
iv) 
v) 
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 CYP1B1 
Cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) isoform is generally 
considered as an extrahepatic CYP450 isoform, exhibiting constitutive as well as inducible 
expression (Eltom et al., 1999). Post-translational mechanisms may also be involved in the 
regulation of CYP1B1 expression, by showing the activation of AhR by 3MC had no effect 
on the CYP1B1 gene expression levels, while induction was still observed on protein level 
(McFadyen et al., 2003). This isoform is highly expressed in foetal brains and kidneys 
(Hakkola et al., 1997). The expression of CYP1B1 in the lung tissue was shown by Spivack 
and colleagues, who evaluated its role in lung carcinogenesis, showing significantly higher 
levels are displayed in tumours (Spivack et al., 2001). In the CVS, vascular SMCs display 
the highest expression of CYP1B1, while the expression in the ECs is much lower (Zhao et 
al., 1998a). Many single nucleotide polymorphisms were identified in the gene encoding 
CYP1B1, and numerous polymorphisms indeed were associated with carcinogenesis, 
including: i) cancers occurring in oestrogen-target tissues and lung cancer (De Vivo et al., 
2002;Wang et al., 2011;Goodman et al., 2001;Murray et al., 1997;Xu et al., 2012), or ii) 
increased activation of pro-carcinogens (Shimada et al., 1996). Interestingly, females who 
present specific CYP1B1 polymorphisms may have increased risk of lung cancer (Xu et al., 
2012). 
1.6.7.1 The Role of CYP1B1 in Cardiovascular Disease 
Studies showed that CYP450 enzymes might be involved in the pathogenesis of CVD 
through metabolism of AA, producing either potent vasoconstriction mediators such as i) 
20-hydroxyeicosatetraenoic acid (20-HETE) (Fleming, 2005), which exert their biological 
effects at relatively low concentrations in small arteries and arterioles (Harder et al., 1995), 
or ii) epoxyeicosatrienoic acids (EETs), which are potent vasodilators in small vessels 
(Harder et al., 1995). Therefore, it appears CYP450 enzymes can regulate the vascular tone, 
and these metabolites might also regulate pulmonary and cardiac functions by activation of 
ion channels (Ma et al., 1993;Harder et al., 1995). In addition to their vasoconstrictor 
properties, 20-HETE induce a significant concentration-dependent increase in cell 
proliferation of VSMCs, with the proliferation probably mediated through the MAPK 
signalling pathway (Uddin et al., 1998). Hence, CYP1B1 might play an important part in 
vascular remodelling of small resistance arteries (Ding et al., 2013). Inhibition of CYP1B1 
activity in spontaneously hypertensive rats by TMS reduced cardiovascular hypertrophy, 
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vascular reactivity, endothelial dysfunction and systemic blood pressure (Jennings et al., 
2014). Therefore, the research into the role of CYP1B1 in PAH pathogenesis has not been 
unmerited and has led to important findings regarding its role in the disease setting. 
1.6.7.2 The role of CYP1B1 in Pulmonary Arterial Hypertension 
Significant expression levels of CYP1B1, which primarily catalyses the hydroxylation of 
17βE2 and E1 to 4OHE2/E1, in the lung (Spivack et al., 2001;Zhao et al., 1998b) indicated 
local oestrogen metabolite production might have important implications in the pathology 
of lung cancer, CVD and PAH. Preliminary gene expression experiments indicated the 
expression of CYP1B1 gene may be sex-specific, with 10-fold decrease in expression levels 
in lymphocytes associated with PAH onset in female BMPRII mutation carriers, but not in 
males (West et al., 2008a). Recently, White and colleagues explored the differences in gene 
expression in SERT+ animal model of PAH, to identify genes which might be associated 
with the development and progression of PAH, showing that CYP1B1 gene is significantly 
upregulated (White et al., 2011b). The basal expression of CYP1B1, as assessed by in-situ 
immunolocalization and protein blotting techniques, is significantly higher in IPAH patients 
compared to control subjects, while the expression is further enhanced in the presence of 
17βE2 or 5-HT (White et al., 2012;White et al., 2011b). Additionally, in BMPRII mutation 
carriers, the presence of CYP1B1 polymorphisms is associated with significantly higher 
penetrance of PAH (Austin et al., 2009). The absence or inhibition of CYP1B1 appeared to 
attenuate some of the pathophysiological characteristics of PAH to various degrees. Namely, 
CYP1B1 inhibition significantly reduced pulmonary vascular remodelling, RVH, RV 
systolic pressure and the appearance of occlusive lesions in small PAs in cHx/SU5416 model 
of PAH (White et al., 2012). 16αOHE1, a metabolite produced by CYP1B1, whose increased 
circulating levels are associated with increased risk of breast cancer in humans and mice 
(Bradlow et al., 1986;Bradlow et al., 1985), was shown to stimulate hyper-proliferative 
response in PASMCs derived from patients exhibiting PAH (White et al., 2012). This was 
attenuated by co-treatment with potent CYP1B1 inhibitor, indicating the direct role of this 
CYP450 isoform in the induction of proliferative response in PAH. To demonstrate the role 
of 16αOHE1 in the onset of PAH, White and colleagues administered the metabolite to mice, 
showing animals developed increased RV systolic pressure, pulmonary vascular remodelling 
and RVH (White et al., 2012), indicating CYP1B1 and its metabolites may be imperative 
modifiers associated with increased probability for the onset of PAH. 
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 CYP1A1 
Although cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) isoform is 
generally considered as an extrahepatic CYP450 isoform, it is substantially expressed in the 
foetal liver during embryonic development (Omiecinski et al., 1990;Kitada and Kamataki, 
1994), with its levels reducing quickly, resulting in miniscule expression in the adult liver. 
CYP1A1 is not constitutively expressed in various tissues examined of the C57BL/6N 
mouse, however induction with 3MC caused significant increase in the lung, liver and ECs 
of blood vessels (Dey et al., 1999). CYP1A1 is barely detectable in the mouse heart 
(Choudhary et al., 2003). Due to its inducible nature, hundred-fold differences in the 
expression of CYP1A1 were reported human lung microsomes (Zanger and Schwab, 
2013;Kim et al., 2004). More than ten different polymorphisms of the CYP1A1 gene exist, 
with differing allele frequency, were characterised (Ingelman-Sundberg, 2004;Monostory et 
al., 2009;Sim, 2015). Although some research groups reported an association of CYP1A1 
polymorphisms with increased risk of lung, and oestrogen-related cancers, such as cervical 
and breast cancer (Wright et al., 2010;Sergentanis et al., 2012;Singh et al., 2007), no 
conclusive association was established (Masson et al., 2005). However, the MspI 
polymorphism of CYP1A1 gene, is associated with increased risk of CVD, especially in 
smokers (Wang et al., 2002). CPY1A1 genetic polymorphisms may exhibit racially distinct 
patterns (Cosma et al., 1993); leading to current insufficiency of conclusive evidence of 
whether CYP1A1 polymorphisms are functionally significant in disease onset. Nevertheless, 
it needs to be considered that simultaneous presence of a polymorphic variant of CYP1A1 
exhibiting increased metabolic rate of oestrogen metabolism and a variant of COMT and/or 
GST exhibiting low catalytic activity, might result in the accumulation of hydroxylated 
oestrogen metabolites, leading to increased production of oestrogen quinones and semi-
quinones, both having carcinogenic potential (Kisselev et al., 2005). The presence of COMT 
variant exhibiting low catalytic activity might be of special importance in disease, as reduced 
formation of methoxyoestrogens can affect the negative feedback regulation of oestrogen 
metabolism catalysed by i) CYP1A1, and ii) CYP1B1 (Dawling et al., 2003). Although the 
main metabolic pathway catalysed by CYP1A1 appears to be hydroxylation at position C2, 
according to Badawi and colleagues, this isoform exhibits higher catalytic activity for 16α-
hydroxylation compared to CYP1B1, representing the principle contributor to formation of 
16α-hydroxy-oestrogens (Badawi et al., 2001). 
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1.6.8.1 The Physiological Role of CYP1A1 
CYP1A1 null mice, generated by Dalton and colleagues, are viable and demonstrate no 
specific phenotype (Dalton et al., 2000). Interestingly, in AhR null mice the expression of 
CYP1A1 could not be detected, even upon treatment with potent AhR activator TCDD 
(Buters et al., 1999), indicating the expression of CYP1A1 is under complete control of AhR 
signalling pathway. Considering, the basal expression levels of CYP1A1 is low, it can be 
inferred that CYP1A1 is not imperative for normal physiological development (Buters et al., 
1999), rather the most significant physiological role of this CYP450 isoform is associated 
with oxidative metabolism of environmental pollutants, resulting in their removal and/or 
activation. Nonetheless, CYP1A1 was shown to catalyse a highly stereoselective formation 
of hydroxylated AA and epoxyeicosatrienoic acid (Schwarz et al., 2004), which are 
associated with vasodilation and anti-apoptotic properties (Carroll et al., 1996;Zhang et al., 
2001). 
1.6.8.2 The Role of CYP1A1 in Cardiovascular Disease and Cancer 
The level of CYP1A1 expression in individuals with established CVD, is significantly 
increased in the RV (Thum and Borlak, 2000). Moreover, in individuals with dilated 
cardiomyopathy, CYP1A1 expression was detected in the right atrium and associated aortas 
(Elbekai and El-Kadi, 2006). CYP1A1 expression in cardiomyocyte culture in rats was only 
observed in culture older than 24 hours (Thum and Borlak, 2000). CYP1A1 might also 
mediate its role in CVD by catalysing the conversion of omega 3 (n-3) polyunsaturated fatty 
acids (PUFAs) into highly potent vasodilator mediators. Deletion of the CYP1A1 gene in 
C57Bl/6J mice resulted in diminished NO-dependent regulation of blood pressure (Agbor et 
al., 2014). CYP1A1 might therefore contribute to eNOS activation, and therewith associated 
regulation of vasodilation and blood pressure. 
1.7  Sex and Pulmonary Arterial Hypertension 
The predominance of female sex in PAH was reported in numerous epidemiological studies 
and registries, as previously described (Rich et al., 1987;Badesch et al., 2010;Humbert et al., 
2006;Ling et al., 2012). Although recently it was reported that female predominance in the 
incidence of PAH is greatly diminished in elderly population (Hoeper et al., 2013), women 
generally develop a more severe disease as per NYHA functional classification (Farber et 
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al., 2015). The direct association between female sex hormones and the disease pathogenesis 
was first described in a report of six young women developing the disease after prolonged 
period of oral contraceptive use (Kleiger et al., 1976). A significant proportion of women 
with prolonged exposure to exogenous oestrogens, either through use of oral contraceptives 
or hormone replacement therapy, were also diagnosed with PAH (Sweeney and Voelkel, 
2009). Nonetheless, oral contraceptives are currently only contraindicated in women 
exhibiting Class III/IV PAH as per NYHA functional classification (Thorne et al., 2006), 
due to otherwise prohibitively high morbidity and mortality risk during pregnancy (Bedard 
et al., 2009). Generally, permanent contraception or progesterone-containing contraceptive 
are recommended instead of oestrogen-containing contraceptives (Hemnes et al., 2015). 
Despite the strong prevalence of females developing the disease, it was shown that men 
generally exhibit poorer prognosis and higher mortality rate (Escribano-Subias et al., 
2012;Humbert et al., 2010b), which could be directly related with poorer RV function in 
men (Swift et al., 2015;Marra et al., 2016). Higher serum levels of 17βE2 were reported to 
have a beneficial effect on the structure and/or function of the RV (Kawut et al., 
2011;Ventetuolo et al., 2011), while higher serum levels of testosterone and DHEA appear 
to be associated with increased RV mass and volume (Ventetuolo et al., 2011). Therefore, 
unsurprisingly, in a population of subjects without signs of clinical CVD, women have 
higher RV ejection fraction (Tandri et al., 2006). It also appears that in CVD, women exhibit 
preserved RV function (Cleland et al., 2003). Additionally, in PAH, men were shown to have 
less favourable pulmonary and cardiac haemodynamic parameters (Shapiro et al., 2012), and 
exhibit a more significant gradual deterioration in RV function following introduction of 
therapy compared to women (Jacobs et al., 2014). Therefore, the superior survival of women 
diagnosed with PAH might be a direct consequence of the protective effects that 17βE2 has 
on the RV function and structure. Recently in a population of PAH patients, it was shown 
that administration of anastrazole did not cause RV dysfunction in men (Kawut et al., 2017). 
Despite the evidence acquired in clinical studies, indicating exogenous oestrogens might be 
promoting the pathogenesis of PAH, the evidence gathered in animal studies contradicts 
human studies by showing endogenous 17βE2 might exert protective effects in pulmonary 
vasculature and the RV (Frump et al., 2015;Wang et al., 2018). 
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 Evidence of oestrogen in Experimental Models of 
Pulmonary Hypertension 
The discrepancy between the evidence derived from clinical and animal studies, leading to 
the recognition of the ‘oestrogen paradox’, will be discussed below. It should be noted 
however, that generally first reports on sex differences in animal models showed male 
animals developed more severe phenotypes compared to female animals in terms of mPAP 
and RV hypertrophy (Rabinovitch et al., 1981), which is now know to greatly depend on the 
choice of the animal model employed. 
1.7.1.1 Oestrogens in the Monocrotaline-Induced Pulmonary 
Hypertension 
The MCT model of PAH, is one of the classical and well-established models, and was 
extensively used extensively in the research of PAH. More than two decades ago, Farhat and 
colleagues investigated the effects of oestrogens in male rats administered with MCT, 
demonstrating that treatment with 17βE2 attenuated muscularisation of small PAs and RV 
hypertrophy (Farhat et al., 1993). Equally, although female animals appeared to develop less 
severe phenotype when exposed to MCT, exacerbated disease phenotype and poorer survival 
caused by ovariectomy was rescued by administration of 17βE2 (Tofovic et al., 2006; Yuan 
et al., 2013). Furthermore, in male rats with established PH phenotype, induced by MCT, 
treatment with 17βE2 resulted in the reversal of disease progression, as assessed by the loss 
of pulmonary micro-vessels and RV hypertrophy, and resulted in the survival of all animals 
(Umar et al., 2011). Curiously, inhibition of CYP1B1 improved survival in this model 
(Johansen et al., 2016). 
1.7.1.2 Oestrogen in the Hypoxia-Induced Pulmonary Hypertension 
The cHx model, although a classical animal model of PAH, does not completely recapitulate 
the human disease. Moreover, the extent of involvement of Hx-induced signalling pathways 
is not completely understood in human disease. In animals, prolonged exposure to Hx is 
associated with activation of Hx-induced signalling pathways, whereas intermittent Hx also 
results in altered oestrogen signalling through ERα (Wu et al., 2008). Similarly, as in the 
MCT model females develop a less severe disease phenotype, with ovariectomy severely 
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exacerbating the condition (Tofovic et al., 2006). In Hx models, the protective effects of 
exogenous 17βE2, mediated through both ER isoforms, were found to include attenuation 
of remodelling in pulmonary vasculature and RV (Lahm et al., 2012). Interestingly, the 
authors showed the protective effects of 17βE2 do not depend on its metabolism, as the use 
of specific inhibitor resulted in enhanced effects of 17βE2 on its haemodynamic targets. 
However, possibly more relevant to the disease, endogenous 17βE2 is pathogenic in this 
model, as anastrozole reverses experimental PH phenotype in female Hx animals (Mair et 
al., 2014). 
1.7.1.3 Oestrogens in Sugen 5416 and Chronic Hypoxia-Induced 
Pulmonary Arterial Hypertension 
The disease phenotype of PAH induced by combination of Sugen 5416 and Hx remarkably 
resembles that observed in humans, featuring complex vascular lesions and exceedingly 
elevated mPAP. Therefore, it might not be surprising that it is female animals who develop 
a more severe disease phenotype as characterised by vascular remodelling and the presence 
of complex vascular lesions in this model, yet exhibiting a lesser change in the RV mass and 
hypertrophy (Tofovic et al., 2012;Tofovic and Rafikova, 2009), which closely recapitulates 
the observations of epidemiological studies. Ovariectomy and/or inhibition of endogenous 
oestrogen production in this model is associated with lessened and delayed disease 
phenotype (Bilan et al., 2013;Tofovic and Rafikova, 2009). However, possibly more relevant 
to the disease, endogenous 17βE2 is pathogenic in this model as anastrozole and metformin 
(through aromatase inhibition) reverse PAH in female Su5416/Hx rats (Mair et al., 
2014;Dean et al., 2016). 
 Role of Oestrogens in Pulmonary Arterial 
Hypertension Onset and Progression 
The accumulating evidence of the involvement of oestrogens in the pathogenesis of PAH 
resulted in increased interest in the role of specific oestrogen metabolites in the underlying 
disease mechanisms. 
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1.7.2.1 The Role of 16α-Hydroxyoestrone in Pulmonary Arterial 
Hypertension 
Oestrogens in extrahepatic tissues are mainly metabolised to 4-hydroxyestrogens, however, 
numerous extrahepatic CYP450 isoforms were shown to exhibit high catalytic activity at 
position C2 and moderate activity at position C16α, with the formation of 2- and 16α-
hydroxylated oestrogens being mutually exclusive (Sepkovic and Bradlow, 2009). The ratio 
of circulating levels of 2OHE1/16αOHE1 was hypothesised to be a suitable indicator of 
breast cancer risk. The detrimental effects of 16αOHE1 were first shown in animal 
oestrogen-responsive cancer, where mice having elevated capacity of hydroxylation of 
oestrogens at position C16α spontaneously developed mammary tumours (Bradlow et al., 
1985). 16αOHE1 induced significant increase in spontaneous DNA repair synthesis in 
mouse mammary epithelial cells (Telang et al., 1992). The potency of 16αOHE1 signalling 
through ERs, is attributed to its capacity to form covalent adduct formation with the receptor 
(Swaneck and Fishman, 1988), resulting in constitutively active receptor complexes (Lustig 
et al., 1989). In the context of PAH, the 16αOHEs are regarded as pathogenic as the 
circulating and urinary levels of 16αOHE1 were significantly increased in patients (Austin 
et al., 2009). The levels of this metabolite were also increased in animals exposed to cHx 
(White et al., 2012;Austin et al., 2009). The influence of 16αOHE1 on the pathogenesis of 
PAH was further demonstrated by the direct induction of disease phenotype in in female 
mice (White et al., 2012) and in BMPRII haplo-sufficient mice (Fessel et al., 2011) when 
animals were treated with this metabolite. Amongst the hydroxylated oestrogen metabolites, 
16αOHE1 is the only metabolite to induce significant proliferation of hPASMCs (White et 
al., 2012). 
1.7.2.2 The Effects of 2-Methoxyoestradiol 
Numerous studies have reported protective effects of circulating oestrogens in the onset and 
progression of PAH in experimental animal models (Resta et al., 2001;Farhat et al., 
1993;Umar et al., 2011). The parental oestrogens are mainly metabolised to 2OHE1/2 by 
CYP1A1 in extrahepatic tissues (Aoyama et al., 1990), which are then biotransformed into 
methoxyoestrogens by COMT. All enzymes involved in the formation of 
methoxyoestrogens are expressed in vascular SMCs and ECs (Zacharia et al., 2001), 
suggesting these metabolites are regularly formed in vasculature. As an anti-carcinogenic 
agent, 2MeOE2 was shown to exhibit anti-mitogenic and anti-angiogenic properties in 
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vascular ECs (Fotsis et al., 1994). This metabolite can be converted under physiological 
conditions by the activity of 17βHSD type 2 to 2MeOE1, which is largely devoid of any 
protective properties in cardiovascular cells. The opposite transformation, catalysed by 
17βHSD type 1, was shown to occur in the vascular system and attenuates vascular 
remodelling in MCT-induced model of PH (Tofovic et al., 2008a;Tofovic et al., 2006). Co-
treatment of hPASMCs and lung fibroblasts with 2MeOE1 and 17βHSD type 2 inhibitor, 
inhibited the growth of both cell types (Tofovic et al., 2008b). Moreover, the 2MeOEs 
opposes the PAH onset and progression in animal models (Fotsis et al., 1994;Tofovic et al., 
2006), through i) the inhibition of VSMCs proliferation and migration, ii) enhancing 
production of vasodilators PGI2 and NO (Barchiesi et al., 2006;Seeger et al., 
1999;Tsukamoto et al., 1998), and iii) inhibiting ET-1 production (Dubey et al., 2001). The 
presence of CYP1A1 and COMT variants exhibiting high catalytic activity might be 
considered as protective in disease (Kisselev et al., 2005), as the resulting 
methoxyoestrogens, especially 2MeOE2, act as antiangiogenic and anti-carcinogenic 
compounds (Zhu and Conney, 1998), possibly reducing the extent of vascular remodelling 
in CVD (Kisselev et al., 2005). The antiproliferative effects of 2MeOE2 were shown to be 
concentration dependent in vascular SMCs, cardiac fibroblasts and breast cancer cells. SMCs 
and cardiac fibroblasts are intimately involved in the pathophysiological processes leading 
to clinical PAH (Dubey et al., 2003;Nishigaki et al., 1995;Tofovic et al., 2009;Dubey et al., 
1998;Vijayanathan et al., 2006). Nonetheless, several lines of evidence indicate the anti-
proliferative effects of 2MeOE2 might be highly dependent on experimental conditions and 
type of cells used (Lippert et al., 2000;Lai and Law, 2004). In vivo, 2MeOE2 can supress the 
expression of HIF1α, thereby affecting all the downstream target genes of this transcription 
factor (Becker et al., 2008a). Through its effects on the proteins involved in cell cycle 
regulation, and Akt/MAPK signalling pathway, 2MeOE2 also opposes the formation of 
neointima in rat carotid arteries, possibly indicating that this metabolite might reduce 
vasoocclusion (Barchiesi et al., 2006). Interestingly, 2MeOE2 only induced apoptosis in 
ECs, but not in SMCs (Fotsis et al., 1994;Yue et al., 1997). Moreover, similar observations 
were made in vitro, where treatment of A549 cells with 2MeOE2 under Hx conditions 
resulted in significantly reduced expression of both, HIF1α and HIF2α (Aquino-Galvez et 
al., 2016). Additionally, low circulating 2OHE1/16αOHE1 levels might be reflecting not 
only an increase in the production of pathogenic 16αOHE1, but also decreased hydroxylation 
of oestrogens at position C2, especially considering these two reactions might be mutually 
exclusive (Sepkovic and Bradlow, 2009). Furthermore, evidence indicated that the formation 
of protective 2MeOE2 might be inhibited by the 4-OHEs (Roy et al., 1990;Zhu and Conney, 
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1998). In accordance, cHx was shown to reduce the expression of CYP450 enzymes 
catalysing this reaction in extrahepatic tissues, e.g. CYP1A1 (Fradette et al., 2007). 
1.7.2.3 The Effects of 2- and 4-Hydroxyoestradiol 
In the liver, the dominant metabolic transformation of oestrogens is hydroxylation at position 
C2, with only small proportion of the hydroxylation occurring at position C4 (Zhu and 
Conney, 1998). In numerous extrahepatic tissues, however, the reaction of hydroxylation of 
oestrogens at position C4 represents the dominant metabolic conversion pathway, as most 
of extrahepatic CYP450 isoforms catalyse this reaction, previously reviewed in this work. 
Amongst extrahepatic isoforms, CYP1B1 exhibits preferential catalytic activity for 
hydroxylation at position C4, leading to the formation of biologically active metabolite, 
which has been associated with incidence of oestrogen-dependent cancers (Liehr, 2001). 
Interestingly, further biotransformation to methoxyoestrogens occurs much more rapidly in 
2-hydroxyoestrogens (Roy et al., 1990). 2- and 4OHEs exhibit similar affinity for both ER 
isoforms, which is 5–10-fold lower than that of the parental hormone 17βE2 (Schutze et al., 
1994). 4OHE2 was shown to mediate biological effects through pathways independent of 
ER (Das et al., 1997), however, the 4OHEs were also shown to potentially activate ER 
(Martucci and Fishman, 1976), and possibly have prolonged oestrogen effects due to slower 
dissociation rates (Zhu and Conney, 1998;Barnea et al., 1983). The possible mechanism by 
which 4OHEs could promote PAH, might depend on the promotion of cell proliferation and 
oxidative stress as observed in cancers (Gao et al., 2004;Liehr and Ricci, 1996;Rogan et al., 
2003). Interestingly, 4OHE2 decreases phospho-Smad1/5/8(9) and Id expression in female 
hPASMCs, while increasing these in males commensurate with a decreased proliferative 
effect in male hPASMCs (Mair et al., 2015). It therefore appears that distinct oestrogen 
metabolites might exert sex-dependent effects in hPASMCs, which is something that was 
not considered previously. Generally, catechol-oestrogens readily undergo oxidation, 
forming quinones and semiquinones, which can result, due to their highly reactive nature, in 
the formation of covalent adducts with proteins (Markides and Liehr, 2005) or DNA 
(Cavalieri et al., 2002;Cavalieri et al., 2000), leading to carcinogenicity and/or genotoxicity. 
During the formation of quinones and semiquinones, ROS are also formed, whose 
accumulation can result in DNA damage and cytotoxicity. Interestingly, 4OHE2, but not 
2OHE2, was shown to induce HIF1α and VEGFA expression at protein level through the 
PI3K/Akt pathway (Gao et al., 2004), however not all studies support this line of evidence 
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(Seeger et al., 2006). Contrary, Bradlow and colleagues have indicated that 2OHE1 might 
also exhibit anti-carcinogenic properties (Bradlow et al., 1996).  
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1.8  Aims and Objectives 
According to the Home Office statistics 3.87 million animals were used for research 
purposes and 3.93 million procedures were carried out in year 2016 alone (Office, 2013). As 
the necessity of animals in research of disease pathogenies is undeniable, considering the 
complexity of signalling pathways, in addition to the need for pre-clinical assessment of 
novel therapeutic approaches, it is the responsibility of the researchers to drive the progress 
of these models and substitute them where possible with similarly suitable alternative 
models. While numerous animal models have been developed for the research of pulmonary 
arterial hypertension, not all models resemble the human disease in the most important 
histopathological hallmarks, meaning not all aspects of disease pathogenesis can be 
investigated in every model. Therefore, more effort must be made to understand the 
underlying mechanisms leading to the establishment of disease phenotype, and to establish 
alternative models, which could replace the use of animals in the initial stages of research 
hypothesis testing. The objective of this research work was to develop a novel in vitro model, 
which could be used to investigate the role of oestrogens and their metabolites in pulmonary 
vascular disease. 
This was addressed by the following aims: 
1.) To investigate the mechanism through which the animal model of pulmonary arterial 
hypertension employing Sugen 5416 coupled with chronic hypoxia is induced, 
utilising in vitro methods. 
2.) To develop a liquid chromatography tandem mass spectrometry method to 
quantitively evaluate oestrogen metabolism in an in vitro model of pulmonary 
arterial smooth muscle cells. 
3.) To characterise the metabolic profile of oestrogens in pulmonary arterial smooth 
muscle cells derived from female and male patients and control subjects, 
respectively. 
4.) To investigate the effects of oestrogens metabolites in an in vitro model of pulmonary 
arterial smooth muscle cells, derived from patients and control subjects of both sexes, 
respectively.  
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Chapter II 
2  Methods 
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2.1  Chemical Reagents and Equipment 
All chemical and reagents were purchased from Sigma-Aldrich (UK) or Fisher Scientific 
(Loughborough, UK), unless stated otherwise. Materials for RNA and protein analyses were 
obtained from Qiagen (UK) and Life Technologies (UK), respectively. For experimental 
protocols involving RNA, reagents and plastic-ware, which were certified to be nuclease-
free, were supplied by Ambion, Life Technologies (UK). Plastic-ware used for cell culture 
was supplied by Corning, Fisher Scientific (UK). 
2.2  Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis 
 Protein Solubilisation and Preparation 
For in vitro experiments, hPASMCs, at the end time point of an experiment, were placed on 
ice. The media was aspirated off, and the monolayer of cells was then washed twice with 
DPBS. 120μL of 1% (v/v) lauryl maltoside (LM, Abcam, UK) buffer in DPBS was added to 
each well, when protein was extracted from 6-well plates. When protein was extracted from 
unstimulated hPASMCs growing in a T75cm2 culture flask, 600μL of 1% LM, supplemented 
with protease inhibitors (0.1mmol/L PMSF, 1μg/mL soybean trypsin inhibitor and 1μg/mL 
benzamidine), was used. The cells were then collected using a sterile plastic scraper, 
collected in pre-chilled 1.5mL Eppendorf tubes and left on ice for 30 minutes to allow for 
improved disassociation of protein complexes and protein solubilisation. Cell lysates were 
then sonicated in iced water, before centrifuging at 10,000rpm (4°C) to remove any debris. 
Alternatively, when extracting protein from tissue, a piece of tissue was placed in a 2mL 
Eppendorf tube, containing 300µL of 1% LM buffer. A 5mm stainless-steel ball (Qiagen, 
UK) was added, and the tissue homogenised using the Tissue Lyser II (Qiagen, UK). 
Homogenised tissue was then left on ice for 30 minutes to promote disassociation of protein 
complexes and improve protein solubilisation. Tissue samples were then centrifuged at 
10,000rpm for 10 minutes (4°C). 
Protein supernatant was collected into a new pre-chilled Eppendorf tube, and stored at -80°C 
until further. 
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 Bicinchoninic Protein Assay 
Protein concentration in supernatants was determined using the bicinchoninic acid (BCA) 
assay (Pierce, Thermo Fisher, USA). To quantify protein concentration in collected samples, 
a standard curve was constructed within the 0.0–2.0mg/mL concentration range, using the 
albumin standard ampules consisting the BCA Kit, diluted in 1% LM. Briefly, suitable 
volume of the albumin standards and unknown samples was pipetted into a 96-well plate. 
BCA assay working solution was prepared by combining 9.8mL of reagent A with 200µL 
of reagent B. 200µL of the working solution was quickly added to each well and incubated 
at room temperature with gentle agitation on micro-plate shaker for 30 minutes. Protein 
concentration was then evaluated against the standard curve, by measuring the absorbance 
at 652nm with POLARstar OPTIMA microplate reader (BMG Labtech, Germany). 
 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis 
Samples, containing equal amounts of protein, were prepared by adding NuPAGE® LDS 
(lithium dodecyl sulphate) Sample Buffer (4X) and NuPAGE® Reducing Agent (10X) 
(10mmolL/L dithiothreitol), and heated at 70°C for 10 minutes. Samples were then separated 
per their molecular weight on Novex® Tris-Glycine gels (Invitrogen, Life Technologies, 
UK) using Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis, under constant 
voltage at 110–150V in NuPAGE MOPS SDS running buffer (20x), containing 1% (v/v) 
NuPAGE® Antioxidant. 
 Protein Transfer 
Once adequate separation of protein according to their weight was achieved, the protein was 
blotted onto hydrophobic Immobilon polyvinylidene difluoride (PVDF) membrane 
(Millipore, USA) using a wet blotting system by Life Technologies. Due to its hydrophobic 
character, the membrane was immersed into 100% methanol prior to use in order to activate 
it and expose membrane’s full protein binding capacity. The buffer for wet blotting 
contained 5% (v/v) NuPAGE Transfer Buffer (20x) and 20% (v/v) methanol. Proteins were 
transferred onto PVDF membranes at constant voltage (35V) for 2 hours and 15 minutes. 
Transfer efficiency was assessed by a short incubation of membranes in 0.1% (w/v) solution 
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of Ponceau S stain, prepared in 5% (v/v) acetic acid solution. The stain was washed off the 
membranes in 10% (v/v) TBS buffer containing 0.1% (v/v) Tween-20 (Fisher Scientific, 
UK) (TBST) washing buffer, before blocking in 5% (w/v) milk prepared in TBST, for 1 hour 
at room temperature in order to minimise non-specific binding of the antibody. The residual 
blocking solution was washed off the membrane by numerous short washes in TBST. 
 Immunoblotting 
The detection of a specific protein was achieved by an overnight incubation of the membrane 
in primary antibody (the dilutions and concentrations are provided in Table 2-1 on a shaker 
at 4°C. The membranes were then washed for 3x10 minutes in TBST washing buffer to 
remove any unbound primary antibody, before incubating in secondary antibody conjugated 
with horseradish peroxidase (HRP) (Table 2-1) prepared in 5% (w/v) BSA (Sigma, UK) in 
TBST for 1 hour at room temperature. The membrane was again washed in TBST buffer for 
3x15 minutes. The secondary antibodies used were coupled with HPR, catalysing the 
oxidation reaction of the luminal, which is present in the substrate Immobilon western 
chemiluminescence HRP substrate (Merck Millipore, USA) or Pierce ECL Western Blotting 
Substrate (Thermo Scientific, USA). The light emitted during the reaction catalysed by HPR, 
was captured on X-ray film (Kodak, UK), allowing protein visualisation after film 
processing using MIN-R Mammography Processor. When samples were probed for several 
proteins, membranes were washed in TBST for 5 minutes, following a 15-minute incubation 
in the Restore western blot stripping buffer (Thermo Scientific, UK) on a shaker, during 
which the bound antibodies were stripped. Equally, to reduce the number of times the PVDF 
membranes were stripped, the membranes were cut alongside suitable  molecular-weight 
size markers, labelled and probed as described previously. 
The membranes were re-probed for another protein of interest, or for loading control (β-
actin, GAPDH). Protein expression was quantified by densitometry analysis using TotalLab 
TL100 v2006 programme (TotalLab, United Kingdom). In the following chapters the 
representative immunoblotting images are shown. Where images have been altered from full 
blots to remove redundant samples, it is stated in the legend.  
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Table 2-1: List of antibodies used for immunoblotting. 
Primary 
Antibody 
Dilution  Supplier Molecular 
Weight 
(kDa) 
Secondary 
Antibody 
Concentration 
AhRR 1:100 ab108518 Abcam 76 Rb 1:5000 
PHD2 1:1000 D31E11 Cell 
Signalling 
50 Rb 1:5000 
HIF1α 1:500 NB100-
105 
Novus 
Biologicals 
120/100 Ms 1:5000 
ARNT (HI1β) 1:2000 ab2771 Abcam 87 Ms 1:5000 
vHL 1:5000 NB100-
41384 
Novus 
Biologicals 
17 Go 1:5000 
Caspase 3 1:1000 9662 Cell 
Signalling 
35/19/17 Rb 1:5000 
VEGFR2 1:1000 ab39256 Abcam 151 Rb 1:5000 
p27/Kip1 1:500 ab54563 Abcam 22 Ms 1:5000 
Lamin A 1:1000 ab26300 Abcam 74 Rb 1:5000 
Nucleoporin 1:2500 ab2460 Abcam 55 Ms 1:5000 
β actin 1:1000 A5441 Sigma 42 Ms 1:10000 
CYP1A1 1:1000 ab79819 Abcam 58/51 Rb 1:5000 
CYP1A1 (A-
9) 
1:1000 sc-
393979 
Santa Cruz 56/51 Ms 1:5000 
CYP1B1 1:1000 ab78044 Abcam 61 Rb 1:10000 
CYP1B1 1:1000 ab33586 Abcam 61 Rb 1:5000 
17βHSD2 (H-
12) 
1:1000 sc-373990 Santa Cruz 43 Ms 1:5000 
AhR 1:500 ab84833 Abcam 95 Rb 1:5000 
α tubulin  ab80779 Abcam 50 Ms 1:10000 
BMPRII 1:500 612292 BD 
Biosystems 
115 Ms 1:5000 
Id1 1:1000 M085 Cal 
Bioreagents 
20 Rb 1:5000 
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Id3 1:1000 M100 Cal 
Bioreagents 
17 Rb 1:5000 
pSmad1/5/9 1:1000 9511 Cell 
Signalling 
55–60 Rb 1:5000 
GAPDH 1:1000 ab9484 Abcam 40 Ms 1:10000 
AhRR= AhR repressor, PHD2= Prolyl hydroxylase 2, HIF1α= Hypoxia-inducible factor 1α, ARNT 
(HI1β)= Aryl hydrocarbon receptor nuclear translocator, vHL= von Hippel-Lindau tumour 
suppressor , VEGFR2= Vascular endothelial growth factor receptor 2, p27/Kip1= Cyclin-dependent 
kinase inhibitor 1B (p27/Kip1), CYP1A1=, Cytochrome P450 1A1, CYP1B1=, Cytochrome P450 
1B1, 17βHSD2= 17β-hydroxysteroid dehydrogenase type 2, AhR= Aryl hydrocarbon receptor, 
BMPRII= Bone morphogenetic protein receptor II, Id1= Inhibitor of DNA binding 1, Id3= Inhibitor 
of DNA binding 3, pSmad1/5/9= phosphorylated Smad 1/5/9 
 
Table 2-2: List of positive controls. 
Protein Positive Control # Supplier 
CYP1A1 HeLa whole cell 
lysate 
ab29545 Abcam 
CYP1B1 Human liver tissue 
lysate, total protein 
ab29889 Abcam 
CYP1B1 Rat liver lysate  N/A 
AhR Rat kidney lysate  N/A 
HIF1α CoCl2-treated 
hPASMC lysate 
 N/A 
Caspase 3 Resveratrol-treated 
EC lysate 
 N/A 
HIF1α= Hypoxia-inducible factor 1α, ), CYP1A1=, Cytochrome P450 1A1, CYP1B1=, Cytochrome 
P450 1B1, AhR= Aryl hydrocarbon receptor  
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2.3  RNA Analysis 
 RNA Extraction 
To extract RNA from hPASMCs, 6-well plates or T75cm2 culture flasks were placed on ice 
at the end time point of an experiment. The media was aspirated, and the cell monolayer was 
washed with ice-cold DPBS, before adding 700µL of QIAzol (Qiagen, UK) per well in 6-
well plates or per culture flask. The cells were collected using a sterile plastic scraper and 
lysates placed in a pre-chilled 1.5mL Eppendorf tube. Whole tissue sample RNA was 
extracted by placing the lung tissue in a pre-chilled 2mL Eppendorf tubes containing 700μl 
of QIAzol. A 5mm stainless steel bead (Qiagen, UK) was added to each sample, and tissue 
was homogenised in Tissue Lyser II (Qiagen, UK) using 4x30 second intervals. The RNA 
samples were immediately stored at -80°C until RNA extraction. 
RNA purification was carried out using miRNeasy mini kit (Qiagen, Germany) as per the 
manufacturer’s instructions. Briefly, RNA samples were defrosted on ice and left at room 
temperature for 5 minutes to promote disassociation of nucleoprotein complexes. 140μL of 
chloroform was added to each tube containing the homogenate and capped securely. The 
tubes were then shaken vigorously for 15 seconds and left at room temperature for 3 minutes 
to improve the subsequent separation of phases. Samples were then centrifuged at 12,000g 
for 15 minutes (4°C). This step allowed for the separation of the sample in three distinct 
phases: aqueous (top, colourless), interphase (middle, white) and organic (bottom, red) 
phase. The aqueous phase, containing the RNA, was transferred to a new labelled RNase-
free 1.5mL Eppendorf tube, to which a 1.5 volume of 100% ethanol was added to precipitate 
the RNA. The aqueous phase and ethanol were thoroughly mixed by pipetting, before 
loading onto a RNeasy Mini spin column, and centrifuging at 8,000g for 15 seconds at room 
temperature. The flow through was discarded, and the column in which RNA was captured, 
was washed with 350µL of RWT buffer. The flow through was again discarded. A DNase 
digestion was performed on column to remove any residual trances of DNA in the sample. 
The working solution for DNase digestion was prepared by diluting DNase I stock solution 
with RDD buffer in a 1:7 ratio. 80µL of the working solution was then pipetted directly onto 
each RNeasy Mini spin column membrane and left to incubate at room temperature for 30 
minutes, to ensure complete DNA digestion. Following the DNase digestion, 350µL of RWT 
buffer was added to Mini spin column and centrifuged at 8,000g for 15 seconds. The flow 
through was discarded, before 500µL of RPE buffer was pipetted onto the column and 
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centrifuged at 8,000g for 15 seconds. The wash step with RPE buffer was immediately 
repeated, however, this time the samples were centrifuged at 8,000g for 2 minutes. To 
remove any residual RPE buffer, the Mini spin column was placed in a new 2mL collection 
tube, and centrifuged at maximal speed of 14,000rpm (Centrifuge 5417R, Eppendorf, UK) 
for 1 minute. The Mini spin column was then transferred to a new RNase-free 1.5mL 
Eppendorf tube, and 30µL of RNase-free H2O was pipetted directly onto each RNeasy Mini 
spin column membrane. To elute the RNA, the samples were then centrifuged at 10,000g for 
1 minute at room temperature. This step was repeated with the eluate, to maximise the RNA 
elution. Immediately after elution, the samples were transferred to ice or stored at -80°C. 
2.3.2 RNA Quantification 
The quality and concentration of the extracted RNA was determined using Nanodrop 1000 
spectrophotometer (Thermo Scientific, UK). The absorbance at 260nm and 280nm was 
measured, to assess the presence and concentration of RNA and protein, respectively. The 
quality of the RNA was assessed using the 260nm/280nm ratio. The ratio of approximately 
2 indicated the sample contains pure RNA. Values lower than 2 indicated, the presence of a 
contaminant, such as protein, phenol or other compounds with absorbance at 280nm. 
Samples with 260nm/280nm ratio of approximately 2 were considered to contain RNA of 
good purity. The concentration of RNA was determined by the spectrophotometer by using 
a form of the Beer-Lambert equation: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑅𝑁𝐴 (𝑛𝑔 𝜇𝐿)⁄ =
(260𝑛𝑚 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 × 𝐸𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑒𝑛𝑡)
𝑃𝑎𝑡ℎ 𝑙𝑒𝑛𝑔𝑡ℎ 𝑖𝑛 𝑐𝑚
, 
Where the extinction coefficient was 40ng-cm/µL. 
 Reverse Transcription 
Samples considered to contain good purity RNA were subjected to a two-step reverse 
transcription polymerase chain reaction (RT-PCR) to assess the levels of mRNA expression. 
Firstly, the samples were reverse transcribed to complementary DNA (cDNA), using the 
TaqMan® Reverse Transcription Reagents Kit (Life Technologies, UK). Briefly, for one 
20µL reverse transcription reaction, master-mix was prepared by mixing 10X RT buffer, 
25mM magnesium chloride, 2.5mM deoxynucleotide triphosphates (dNTPs), 50 µM random 
hexamers, 20U/μL RNase Inhibitor and 50 U/μL Multiscribe. The master-mix was pipetted 
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into wells on a MicroAmp 96-Well Plates (Thermo Fisher Scientific, UK), and 500ng–1µg 
of RNA template was added. The MicroAmp 96-Well Plate was quickly vortexed and 
centrifuged at 1,000rpm for 2 minutes. The RNA template was reverse transcribed using the 
Veriti® Thermal Cycler (Life Technologies, UK), per the following thermal cycling 
parameters: 
Table 2-3: Thermal cycling conditions for reverse transcription PCR. 
Stage Temperature (°C) Time (minutes) Action 
1 10 25 Annealing 
2 48 30 Reverse transcription 
3 95 5 Inactivation of reverse 
transcription 
4 4 ∞ Short-term storage 
 
 Quantitative Real Time Polymerase Chain Reaction 
To assess the levels of mRNA in the samples, the Applied Biosystems™ TaqMan™ Gene 
Expression Assays (Life Technologies, UK) quantitative real-time PCR (qRT-PCR) was 
used. Briefly, cDNA was added to a mixture of TaqMan® Universal Master Mix II and 
Taqman® probes (Life Technologies, UK) tagged with FAM fluorescent label, to measure 
the strength of the fluorescence, where a change in fluorescence after each amplification 
cycle is proportional to the level of the target gene expression. The ViiA7™ Real Time PCR 
System (Life Technologies, UK) was used to measure fluorescence of the qRT-PCR. 
Each sample was performed in triplicate and expression was determined relative to 
housekeeping control primers as listed in Table 2-4–Table 2-6.  
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Table 2-4: List of mRNAs TaqMan primers used in human samples. 
mRNA Name Assay ID 
HIF1α Hs00153153_m1 
vHL Hs00184451_m1 
P4HA2 Hs00990001_m1 
AhR Hs00907314_m1 
ARNT (HIF1β) Hs01121918_m1 
CYP1B1 Hs00164383_m1 
CYP1A1 Hs01054797_g1 
NQO1 Hs02512143_s1 
HSD17b2 Hs0015993_m1 
PTGIR Hs00168765_m1 
β2m Hs00187842_m1 
 
Table 2-5: List of mRNAs TaqMan primers used in rat samples. 
mRNA Name Assay ID 
HIF1α Rn01472831_m1 
vHL Rn00583795_m1 
P4HA2 Rn01495731_m1 
AhR Rn0565750_m1 
ARNT Rn00688999_m1 
CYP1A1 Rn01418021_g1 
CYP1B1 Rn00564055_m1 
AhRR Rn01537444_m1 
NQO1 Rn00566528_m1 
Kdr Rn00564986_m1 
β2m Rn00560865_m1 
 
Table 2-6: List of mRNAs TaqMan primers used in mouse samples. 
mRNA Name Assay ID 
CYP1A1 Ms00487218_m1 
β2m Ms00437762_m1 
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Table 2-7: Thermal cycling conditions for quantitative real time PCR. 
 Temperature (°C) Time Action Stage 
1 50 2 minutes  Hold 
2 95 10 minutes  Hold 
3 95 15 seconds Denaturing Cycle 
4 60 1 minute Polymerisation Cycle 
 
For quantitation analysis of gene expression, a comparative cycle threshold (CT) method 
was used, where CT is the number of cycles in the PCR reaction required for fluorescence 
to surpass a threshold level of fluorescence and is inversely proportional to the measured 
mRNA. The CT value is inversely proportional to the measured mRNA level. A ΔCT value 
was obtained from the difference between the CT value of the mRNA of interest and the CT 
value of the housekeeper CT. By calculating the difference of ΔCT values of the test sample 
and control sample, a ΔΔCT value was obtained. The relative quantitation (RQ) was 
calculated from the following equation: 
𝑅𝑄 = 2−ΔΔCT. 
This method of quantitative comparison allowed the test samples to be expressed as a fold 
change in contrast to the control samples. 
2.4  Cell Culture 
All cell culture experiments were performed under sterile conditions in a class II laminar 
flow cabinet. Cell culture was maintained in a humidified incubator at 37°C, with a supply 
of gaseous mixture of 5% CO2 95% air. 
 Human Pulmonary Arterial Smooth Muscle Cells 
Human pulmonary artery smooth muscle cells (hPASMCs) derived from the distal 
pulmonary arteries (with external diameter of 1mm) by explant protocols previously 
described in (Wharton et al., 2000;Johnson et al., 1994), from subjects with no reported 
presence of PAH and subjects diagnosed with either idiopathic or heritable form of PAH, 
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were generously provided by Prof Nicholas W. Morrell (University of Cambridge). Patient 
information for cell lines utilised in this work is shown in Table 2.3. 
Table 2-8: Information on cell lines derived from patient and control subjects. 
Cell 
line 
Gender Age Disease status Medications 
9MP M 72 Emphysema  
34MP M 62 Adenocarcinoma (Metastatic 
disease) 
 
75MP M 78 Squamous cell carcinoma  
79MP M 60 Mild 
bronchiectasis/adenocarcinoma 
 
103MP M 52   
110MP M  APAH (Eisenmenger’s 
Syndrome) 
 
23MP M 43 HPAH (C347R)  
56MP M  HPAH (W9X)  
67MP M 22   
80MP F    
82MP F 71 Adenocarcinoma  
84MP F 59  aspirin, simvastatin, 
bisoprolol, ramipril, 
metalazine, 
quinine sulphate, loperamide 
105MP F 57 COPD, Emphysema  
106MP F 70 Left lower lobectomy  
35MP F    
37MP F 24 IPAH  
38MP F    
73MP F 30 R899X IV prostanoids, warfarin, 
zopliclone, mebeverine, 
frusemide by transplantation 
113MP F  IPAH  
115MP F  Associated PAH (Congenital 
Heart Disease) 
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Primary cell line stocks were stored in the liquid nitrogen tank facility, in 10% (v/v) dimethyl 
sulfoxide (DMSO), 20% (v/v) FBS (Sera Laboratories International, UK) Dulbecco’s 
modified eagle medium (DMEM, Life Technologies, UK). To initiate cell culture, 
hPASMCs were taken on dry ice from the storing facility, and rapidly defrosted in water 
bath maintained at 37°C. Immediately after thawing, the content of the cryo-vial was 
transferred into a T75cm2 culture flask, and even dispersion was ensured by pipetting the 
cell suspension using stripette serological pipettes. HPASMCs were grown in DMEM 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic anti-mycotic (AA) solution 
(10,000 units/mL penicillin G, 10 mg/mL streptomycin sulphate and 25μg/mL amphotericin 
B, Sigma Aldrich, UK). Cell culture media was replenished every 48 hours. Herein, donated 
cells derived from male and female individuals were used, as specified in each of the 
following sections. 
2.4.1.1 Sub-culturing of Human Pulmonary Arterial Smooth Muscle 
Cells 
Cells were grown until 85-90% confluency, and then sub-cultured for experiments between 
passage 3 and 8. Cell culture media was aspirated from the culture flask, and the cell 
monolayer was then washed twice with sterile Dulbecco's phosphate-buffered saline (DPBS, 
Life Technologies, UK). 2mL of 0.25% trypsin/0.1% (w/v) EDTA solution in PBS (Life 
Technologies, UK) was equally distributed over the entire culture flask and incubated at 
37°C for between 2–3 minutes, or until the cells have started to detach. 8mL of 10% FBS 
DMEM was then immediately added to neutralise the trypsinisation process. Cells were 
seeded for experiments by diluting the cell stock suspension with an appropriate dilution 
factor. The medium was always replenished 24 hours after a newly generated sub-culture. 
2.4.1.2 Charcoal-Stripped Foetal Bovine Serum 
Oestrogens endogenously present in FBS were removed by charcoal stripping for all 
experiments. 0.1g of dextran-activated charcoal (Sigma-Aldrich, UK) was added per 100mL 
of FBS, and left under gentle agitation over night at 4°C. FBS was then centrifuged at 1811xg 
for 30 minutes at 4°C. The stripped serum was filtered using a sterile disposable filter unit 
with 0.22μm CN membrane filter (Thermo Fisher Scientific, UK). The process was repeated 
and CS-FBS was then aliquoted and frozen until use. In the results section this is referred to 
as Charcoal-stripped serum (CSS). 
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2.4.1.3 Pulmonary Artery Smooth Muscle Cell Proliferation Assay Using 
Haemocytometer 
HPASMCs were counted manually using a haemocytometer to evaluate proliferation of the 
cells in culture. For proliferation assays, cells were seeded in 24-well plates, were 1mL of 
cell suspension during passaging was added to 24mL of 10% FBS DMEM and maintained 
until reaching 60% confluency. HPASMCs were then serum deprived using 0.2% CS-FBS 
PRF DMEM between 16 and 24 hours, to synchronise cell cycle before stimulation. 
HPASMCs were stimulated with appropriately diluted agonist for 24–72 hours in the 
presence of 2% (v/v) CS-FBS PRF DMEM. Stimulations of 0.2%, 2 % and 10% CS-FBS 
PRF DMEM were studied as negative and positive controls, respectively. Where necessary, 
hPASMCs were stimulated with appropriately diluted antagonist, 45 minutes prior to agonist 
stimulation. The media, agonist and if appropriate antagonists, were replaced every 48 hours. 
Each experimental condition was performed in triplicate. Upon completion of appropriate 
stimulation duration, media was aspirated, and the cell monolayer was washed twice with 
sterile DPBS. 150μL of trypsin/EDTA solution was added to each well, and cells were 
incubated at 37°C for 2 minutes to aid trypsinisation. Once the cells had detached, they were 
re-suspended using 0.5mL of 10% FBS DMEM per well, and gently pipetted to mix. The 
content of each well was then transferred into 1.5mL Eppendorf tubes, and spun in a pre-
cooled centrifuge (4°C) at 4,000rpm for 10 minutes. The supernatant was then carefully 
aspirated, not to disturb the cell pellet, which was re-suspended in 200uL of 10% FBS 
DMEM and shortly vortexed to ensure even suspension. The haemocytometer is designed 
10μL of prepared cell suspension was applied onto AC1000 Improved Neubauer counting 
chamber (Hawksley, Lancing, UK), guaranteeing distribution of the suspension in the 
chamber due to capillary action. Using a hand tally counter, the number of cells was counted 
in four counting fields, with the set volume of 0.1mm3 (Figure 2–1). From the number of 
counted cells, the average number of cells in 1mL of cell suspension was calculated 
according to the following formulae: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 1𝑚𝐿 =
𝑁
4
× 104 
The number of cells in the volume used to suspend the cell pellet was then calculated. 
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2.4.1.4 Pulmonary Artery Smooth Muscle Cell Proliferation Assay Using 
Haemocytometer in Hypoxia 
HPASMCs were seeded as previously described in section 2.4.1.3, immediately after 
seeding, the 24-well plates were placed in a hypoxia incubator chamber (Bilrups 
Rothenburg, US), ensuring lowered atmospheric oxygen tension (1% O2, 5% CO2 (v/v)), 
where the cells were maintained between 24 and 72 hours. After every 24 hours, the hypoxia 
incubator chamber was opened in sterile environment and gassed to ensure that the cellular 
environment did not become overly acidic, causing cell death or altered cellular metabolism. 
The procedure was done as quickly as possible in order to reduce the exposure of cells to 
normal atmospheric oxygen tension. 
2.4.1.5 Pulmonary Artery Smooth Muscle Cell Proliferation Assay Using 
5-Bromo-2-deoxyuridine Incorporation 
The proliferation of hPASMCs was also evaluated using the 5-bromo-2-deoxyuridine 
(BrdU) incorporation assay. When added to the cells, the reagent, which is a derivative of 
uridine, acts as the natural structural analogue of thymidine, incorporating into the newly 
synthesised DNA during the cell cycle. Protocol for adherent cell culture, provided by the 
Calbiochem® BrdU Cell Proliferation Assay manufacturer (Calbiochem, Merck Millipore, 
Germany), was followed. Briefly, hPASMCs were seeded in a 96-well plate, using 100μL 
of cell suspension per 10mL, and grown maintained in 10% FBS DMEM until reaching 
Figure 2–1: Haemocytometer counting chamber. 
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approximately 60% confluence. HPASMCs were then serum-starved in 0.2% (v/v) FBS 
DMEM for 16-24 hours. Cells were stimulated with the appropriate agonist for a further 72 
hours in the presence of 1% (v/v) CSS-PRF DMEM. Control groups consisting of 0.2% and 
10% FBS DMEM stimulations were studied as a negative and positive control, respectively. 
Where necessary, hPASMCs were incubated with the appropriate antagonist 45 minutes 
prior to agonist stimulation. Each experimental condition was performed in quadruplicate. 
Two control conditions were utilised, blank control (1% CSS-PRF DMEM) and background 
control (no BrdU label). The BrdU label was prepared as follows, 1μL of the label was 
diluted in 2mL of 1% CSS-PRF DMEM, and 20μL of diluted stock was added to each well 
(except the background control group) 24 hours before assessment of proliferation. The 
contents of the wells were emptied, and the plate was carefully blotted dry, before adding 
200μL of fixative/denaturing solution was added to each well, resulting in fixation and 
permeabilization of cells, denaturation of the DNA for the incorporated BrdU to be 
subsequently detected. 
2.4.1.6 Fractionation 
HPASMCs were grown in 100mm cell culture dishes until they reached approximately 80-
90% confluence. Growth medium was then aspirated off, the cell monolayer washed with 
10mL of DPBS, and 10mL of 1% CSS-PRF DMEM media was to each cell culture dish. 
HPASMCs were then stimulated with 1µM Sugen 5416 for 1, 15, 30, 60 and 90 minutes, 
starting with the longest stimulation time point. At experimental endpoint, the cell culture 
dishes were immediately placed on ice, and the media was aspirated off and hPASMCs were 
washed with ice-cold DPBS twice. For separation of nuclear and cytoplasmic protein 
fractions we have employed modified R.E.A.P protocol described in (Suzuki et al., 2010). 
Briefly, cell monolayer was collected into pre-chilled 1.5mL Eppendorf tube by adding 1mL 
of ice-cold DPBS to each cell culture dish and scrapped using a sterile plastic cell scraper. 
The samples were then centrifuged for 10 seconds at 10,000rpm in a centrifuge pre-chilled 
to 4°C. The supernatant was carefully removed, and 900µL of 0.1% (v/v) NP-40 (Sigma, 
UK) prepared in DPBS was added to each cell pellet and triturated 5 times using a p1000 
pipette tip to ensure the cell pellet was equally dispersed. 300µL aliquot of the dispersed cell 
pellet was transferred into a new labelled 1.5mL Eppendorf tube. 100µL of the NuPAGE® 
LDS Sample Buffer (4X) was added to whole cell lysate and kept on ice. The remainder of 
the sample was again centrifuged as before. 330µL of the supernatant, forming the 
cytoplasmic fraction, were then carefully removed and transferred to a new labelled 1.5 mL 
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Eppendorf tube and kept on ice. 100µL of the NuPAGE® LDS Sample Buffer (4X) was 
added to the cytoplasmic fraction, heated at 70°C for 1 minute and stored on ice. The 
remainder of the supernatant was removed, and the remaining pellet was re-suspended in 
1mL of ice-cold 0.1% NP40-DPBS by triturating once using a p1000 pipette tip, followed 
by a 10 second centrifugation at 10,000rpm in a centrifuge pre-chilled to 4°C. The 
supernatant was removed and discarded, and the pellet was re-suspended in 90µL of 
NuPAGE® LDS Sample Buffer (4X). Whole cell lysate and nuclear fraction were sonicated 
in icy water for 10 seconds before heating at 70°C for 1 minute. Prepared samples were used 
for western blot. 
 Human Pulmonary Microvascular Endothelial Cells 
Human pulmonary microvascular endothelial cells (hPMECs) were purchased from 
Promocell (UK). Equally, media and products required for sub-culturing of HPMECs were 
supplied by Promocell. 
2.4.2.1 Sub-culturing of Human Pulmonary Microvascular Endothelial 
Cells 
Upon purchase, the vial of HPMECs was carefully defrosted in a water bath, set to 37°C, 
cleaned with 70% (v/v) ethanol, and then in sterile conditions immediately transferred to a 
T25cm2 containing Endothelial cell growth medium MV supplemented with Endothelial cell 
growth medium MV SupplementMix. The cells were left to adhere for 24 hours before the 
media was replaced. The cells were fed every 24–48 hours until reaching approximately 80% 
confluence. To sub-culture HPMECs, the Promocell DetachKit was warmed at room 
temperature for at least 30 minutes before use. The growth media was aspirated, and the 
monolayer of hPMECs was washed with HEPES Buffered saline solution (HEPES/BSS) 
(100µL/cm2 of vessel surface) by gentle agitation. The washing solution was then carefully 
aspirated, and 100µL/cm2 of vessel surface of Typsin/EDTA solution (0.04 %/0.03 %) was 
added, and the cells were left to detach at room temperature for 2 minutes. During this time 
cells were carefully monitored under the microscope, and when cells started to detach, this 
process was aided by gently tapping the sides of the cell culture vessel. To neutralise the 
activity of Typsin/EDTA solution, 100μL of Trypsin neutralization solution (TNS) per cm2 
of cell culture flask surface was added and mixed with gentle agitation. Cell suspension was 
carefully transferred into a 15mL falcon tube and centrifuged at 220xg for 3 minutes at room 
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temperature. The supernatant was then aspirated off, and the cell pellet was gently re-
suspended in supplemented Endothelial cell growth medium MV. The number of cells in the 
suspension was then assessed using a haemocytometer, and cells were seeded at 10,000–
20,000cells/cm2. 
2.4.2.2 Apoptosis Assay in Pulmonary Microvascular Endothelial Cell  
HPMECs were counted using the Countess II FL Automated Cell Counter (Thermo Fisher 
Scientific, UK), together with the disposable slides to evaluate the number of cells in culture. 
For apoptosis assays, cells were seeded in 24-well plates at 8,000–10,000 cells/cm2 and 
maintained until reaching approximately 90% confluency. HPMECs were then serum 
deprived using phenol red-free Endothelial cell basal medium MV, supplemented with 0.2% 
CS-FBS (v/v) for 2 hours, to synchronise cell cycle before stimulation. HPMECs were then 
stimulated with appropriately diluted agonists for 24 hours in the presence of 2% (v/v) CS-
FBS PRF Endothelial cell basal medium MV. Stimulations of 0.1%, 2 % and supplemented 
Endothelial cell growth medium MV were studied as negative and positive controls, 
respectively. Each experimental condition was performed in triplicate. Upon completion of 
appropriate stimulation duration, media was aspirated, and the cell monolayer was washed 
with sterile DPBS. 150μL of trypsin/EDTA (0.05%) solution was added to each well, and 
cells were incubated at room temperature for 2 minutes to allow the cells to begin 
trypsinisation. The cell culture plates were gently tapped to aid detaching. Once the cells had 
detached, they were re-suspended using 0.5mL of 10% FBS DMEM per well, and gently 
pipetted to mix. As represented the end time point of the experiment, we have used DMEM 
instead of Endothelial cell growth medium MV for resuspension, due to the cost of the 
Endothelial cell growth medium MV. The content of each well was then transferred into 
1.5mL Eppendorf tubes, and spun in a pre-cooled centrifuge (4°C) at 220g for 3 minutes. 
The supernatant was then carefully aspirated, not to disturb the cell pellet, which was re-
suspended in 200μL of 10% FBS DMEM and shortly vortexed to ensure even suspension. 
10μL of prepared cell suspension was applied onto disposable Countess II FL Automated 
Cell Counter slides, guaranteeing distribution of the suspension in the chamber due to 
capillary action. Resveratrol (Sigma-Aldrich, UK) at a concentration of 100μM was used as 
a positive control of apoptosis in these cells. 
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2.4.2.3 Measuring Prostacyclin Release Using an Enzyme-Linked 
Immunosorbent Assay 
PMECs were stimulated with 1nM oestrogen metabolites (Steraloids, USA) for 1 hour or 24 
hours. 20µM arachidonic acid was used as (Sigma, UK). The cell plates were kept on ice, 
while the media was collected and stored at -20°C until subsequent analyses. Cells were then 
washed twice with ice-cold PBS, and the cell monolayer was lysed with 60µL of 1% LM 
solution. Protein concentration in collected samples was determined as described previously 
(Chapter 2.2.2). 
The release of PGI2 was measured using 6-keto PGF1α ELISA Kit (Enzo Life Sciences, 
USA), as PGI2 is quickly oxidised to form a stable metabolite, 6-keto PGF1α. Our preliminary 
results have shown that 6-keto PGF1α levels were out of the detection limit of the ELISA 
Kit. To circumvent this, 6-keto PGF1α was extracted from the medium using liquid-liquid 
extraction, as described in Cayman Chemical 6-keto Prostaglandin F1α EIA Kit, Item No. 
515211. Briefly, the proteins present in 1mL of media were first precipitated with acetone 
(4x the sample volume). Samples were then thoroughly vortexed, and incubated at 4°C for 
5 minutes, before centrifugation at 3,000g for 10 minutes. Supernatant was decanted into 
fresh test tubes, and the acetone was evaporated by vacuum centrifugation. Solid residue was 
then resuspended in 1mL of NaCl solution (~28%, w/v). 6-keto PGF1α was extracted from 
hydrophilic NaCl solution phase by the addition of 5mL of ethyl acetate:acetone (75:25, 
v/v). The addition of organic phase was repeated twice, and the extracts were collected to a 
new test tube. Organic phases were collected and stored at -20°C. The organic solvent was 
evaporated using vacuum centrifugation immediately before carrying out the ELISA. The 
concentration of 6-keto PGF1α was quantified as per manufacturer’s instructions. Briefly, 6-
keto PGF1α was assayed with specific alkaline phosphatase-labelled conjugation, and 
quantification was determined by spectrophotometry analysis at 405nm with correction 
between 570 and 590nm (SpectraMax M2, Molecular Devices, US). 
The release of PGI2 was assayed in duplicate and is expressed as pg of PGI2 per µg of protein. 
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2.5  High Performance Liquid Chromatography 
 Flux/HPLC Analysis of Oestrogen Metabolism in 
Human Pulmonary Artery Smooth Muscle Cell In Vitro 
Model 
HPASMCs were plated in 100mm cell culture dishes and maintained in 10% FBS DMEM 
media until reaching approximately 70% confluence. The growth media was then replaced 
with 0.2% CSS-PRF DMEM for 16‒24 hours, to ensure the cells were in the same stage of 
the cell cycle. When stimulating the cells, quiescing media was replaced with 1% CSS-PRF 
DMEM to maintain adequate cell growth, and hPASMCs were stimulated for 48 hours with 
50nM (136.19ng) 17βE2 radioactively labelled with carbon (14C) at position C4. 14C-17βE2 
with specific activity 55mCi/mmol and concentration, 0.1mCi/mL was purchased from 
American Radiolabelled Chemicals, Inc. (Missouri, USA). At the end time point of the 
experiment, cell culture dishes were placed on ice, and the spent media was collected into 
pre-chilled 15mL falcon tubes containing 0.1% (w/v) L-ascorbic acid (Sigma Aldrich, UK). 
The L-ascorbic acid was used to prevent the oxidation and degradation of catechol 
metabolites of 17βE2, which are extremely sensitive to oxidation. Immediately after 
collection, the media samples were stored at -20°C until further use. The cell monolayer was 
washed twice with ice-cold DPBS, and protein samples were collected by adding 600µL of 
Lysis and Extraction Buffer (ThermoFisher Scientific, UK), scraped carefully using a sterile 
plastic cell scraper and collected into pre-chilled 1.5mL Eppendorf tubes. Protein samples 
were left on ice for 30 minutes, before storing at -20°C until protein concentration was 
determined for normalisation of results, as described in section 2.2.2. 
Metabolites formed form the radioactively labelled 17βE2 were extracted using solid-phase 
extraction (SPE), described in section 2.5.2. After SPE extraction, unlabelled metabolite 
standards prepared in 100% methanol were added to the extracted sample at a concentration 
of 10μg/mL for peak identification. 
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2.5.1.1 Analysis of Treprostinil Effects on Oestrogen Metabolism In 
Vitro 
PASMCs were stimulated with treprostinil at two time points: i) 24 hours prior to addition 
of 50nM 14C-17βE2 (136.7pg), and ii) at the same time as 17βE2. After 48 hours, media 
samples were collected into tubes containing 10mg L-ascorbic acid (Sigma, UK) to prevent 
oxidation of oestrogen metabolites. The cell monolayer was washed twice with ice-cold PBS 
and lysed with 300µL of RIPA buffer (Thermo Scientific, USA). This experimental design 
enables to determine whether i) treprostinil affects oestrogen metabolism by directly altering 
enzyme catalytic activities, or ii) treprostinil affects oestrogen metabolism by altering 
enzyme expression. 
 
Figure 2–2: Experiment design to investigate the effects of treprostinil treatment on 
oestrogen metabolism in human pulmonary artery smooth muscle cells. 
 Solid-Phase Oestrogen Metabolite Extraction 
The Oasis® HLB reverse-phase cartridges 3cc 60mg (Waters, UK) were used for solid-phase 
extraction of oestrogen metabolites from spent cell culture media. The cartridges were placed 
onto an extraction vacuum manifold (Waters, UK) to encourage the flow-through. The solid 
sorbent material in the cartridges was preconditioned first with 3mL of 100% methanol and 
then with 3mL of 100% water, prior to loading the biological sample or matrix containing 
known concentration of metabolite standards. The metabolites, having a steroid character, 
were retained in the sorbent material of the cartridge, which was subsequently re-equilibrated 
with 3mL of 100% water, followed by a wash of 3mL 5% (v/v) methanol in water. For 
flux/HPLC experiments, all solvents contained 0.1% (w/v) L-ascorbic acid. The oestrogen 
metabolites were eluted from cartridges with 3mL of 100% methanol. The eluents containing 
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concentrated and purified oestrogens were dried under a gentle stream of oxygen free 
nitrogen gas mixture at room temperature and reconstituted in the initial mobile phase 
containing water:acetonitrile:methanol (50:10:40, all HPLC Glass-distilled grade). 
For HPLC analysis, samples were reconstituted in 250μL of mobile phase (water:methanol 
in the ratio 32:68). To certain samples 15µL of unlabelled oestrogen metabolite standard 
mixture was added, whilst 15µL of mobile phase was added to the rest of samples. Oestrogen 
metabolite standard mixture was prepared by mixing 200µL of each of the 10X standards 
(0.25mg/mL), resuspended in 300µL of mobile phase, after drying down under oxygen free 
nitrogen gas mixture at room temperature. 
 Oestrogen Metabolism in Human Pulmonary Artery 
Smooth Muscle Cells 
A total of 40–70μL of each sample was injected onto the HPLC Sunfire C18 column 
(150mmx4.6mm, packed with 3.5μm C18 particles, 100Å, Waters, UK), maintained at 25°C, 
at a flow rate of 1mL/minute using the ASI-100 automated sample injector (Dionex, USA) 
and the P680 HPLC pump (Dionex, USA). Samples separated by HPLC were detected by 
UV and radio-labelled detection systems. To confirm peak identity, the samples were also 
separated with an Allure Biphenyl 5μm, 4.6x150mm column (Thames Restek, UK) 
maintained at 30°C, and using isocratic elution system with reverse phase chromatography 
with water and methanol in the mobile phase (water:methanol=32%:78%). %). Detection of 
radioactive metabolites was achieved by scintillation counting following mixing of column 
eluant with Ecoscint A scintillant (National Diagnostics, Georgia, USA; flow rate 1mL/min), 
using a LB509 β-scintillation counter (EG Berthold Technologies, Germany). Detection of 
unlabelled compounds was by ultra-violet (UV) absorption at wavelengths between 190nm 
to 220nm using a (PDA) Dionex PDA-100 detector (Dionex, USA). 
All peak integrations for quantification were obtained from the sample run in the Sunfire 
C18 column. All HPLC data analysis was performed using Chromeleon 6.5 software 
(Dionex, USA). 
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2.6  Metabolomic Screen 
 Cell Culture 
HPASMCs were plated in 100mm cell culture dishes, by adding 1mL of cell suspension to 
9mL of 10% FBS DMEM and maintained until reaching approximately 70% confluence. 
Cells were then washed twice with warm DPBS, and the media was replaced with 1% CS-
FBS PRF-DMEM. To assess the changes in the metabolome of hPASMCs, cells were 
stimulated with 50nM 17βE2 for 48 hours. Quenching of the metabolites was performed by 
putting the cell culture dishes on ice, and washing twice with DPBS, before 1 mL of 
methanol:acetonitrile:water=50:30:20 (v/v) was added to each dish. The extraction mixture 
was kept cold in a mixture of dry ice and methanol. Collected samples were then shaken for 
12 minutes at 4°C, before being spun at 13,000rpm for 15 minutes (0°C). The supernatant 
was then transferred to labelled HPLC vials (Thermo Scientific, UK), while the protein pellet 
was used for determining protein concentration. All samples were stored at -80°C until 
analysis using pHILIC method. 
 Metabolic Screen Using Liquid Chromatography 
Tandem Mass Spectrometry 
The samples were separated with a SeQuant® ZIC®-pHILIC Polymeric column (5µm, 
PEEK 150X4.6mm, Merck Millipore, UK) in gradient mode with 100% acetonitrile and 
20mmol ammonia carbonate. Separated ions were analysed using LTQ Orbitrap mass 
spectrometer from Thermo Fisher Scientific (Hemel Hempstead, UK). Metabolomic screen 
data analysis was performed with open-source MZmine 2.12.4 data system. 
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2.7 Liquid Chromatography Tandem Mass 
Spectrometry 
 Optimisation of Oestrogen Metabolite Extraction and 
Separation 
The purification of biological samples is generally required prior to sample analysis using 
the LC-MS/MS technique, to eliminate the major sources of interference and to concentrate 
the sample when low concentration of the analyte is present. This purification method must 
be optimised to permit efficient analyte recovery and to avoid presence of particulates, which 
might interfere with the LC-MS/MS method. To optimise the preparation of biological 
samples to be investigated using the Shimadzu QTRAP® 6500 LC-MS/MS System, the 
extraction of 1ng mixture of oestrogen metabolites was used to determine the nature of 1) 
sorbents in SPE cartridges, 2) wash steps and 3) elution solvents resulting in highest 
extraction yields and most reproducible LC-MS/MS results. 
2.7.1.1 Optimisation of Extraction 
The Oasis Hydrophilic-Lipophilic Balance (HLB) and Mixed-mode, strong Cation-
eXchange (MCX) 3cc/60mg (both Waters, UK) SPE cartridges have been compared, where 
both cartridges are described as reverse-phase and contain water-wettable polymers. The 
HLB SPE cartridges are characterised as strongly hydrophilic, having high capacity and 
retention, resulting in their wide application range, while the MCX cartridges allow greater 
selectively of retention through manipulation of pH, as per Watters website. To 
simultaneously assess the effects of the sample matrix on the investigated variables, the 
mixture of oestrogen metabolites was prepared either in aqueous medium or cellular 
medium. A mixture of all oestrogen metabolites, with the final amount of 10ng, was added 
to 10 mL of either water or PRF-DMEM cellular media complemented with 1% CSS and 
spiked with 10μL of 1μg/mL of I.S. prior to extraction. The solid sorbent material in the 
cartridges was preconditioned first with 3mL of 100% methanol and then with 3mL of 100% 
water, prior to loading the biological sample or matrix containing known concentration of 
metabolite standards. The metabolites, having a steroid character, were retained in the 
sorbent material of the cartridge, which was subsequently re-equilibrated with 3mL of 100% 
water, followed by a wash of 3mL 5% (v/v) methanol in water. The oestrogen metabolites 
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were eluted from the extraction cartridge by either 3mL of 100% methanol or 100% 
acetonitrile (Sigma-Aldrich, UK). Eluents containing concentrated and purified oestrogens 
were dried at 40°C under a gentle stream of oxygen-free nitrogen gas mixture at room 
temperature, and reconstituted in 70μL of the initial mobile phase containing 
H2O:ACN=90:10. Post-spiked samples were prepared by extracting 10mL of PRF-DMEM 
cellular media complemented with 1% CSS, as described above. The eluent was then spiked 
with 10μL of 1μg/mL oestrogen metabolite mixture and 10μL 1μg/mL I.S. The unextracted 
sample was prepared by pipetting 10μL of 1μg/mL oestrogen metabolite mixture and 10μL 
1μg/mL I.S. into a clean vial and drying at 40°C down under oxygen-free nitrogen stream. 
Together these samples allow assessment of recovery and matrix suppression. 
2.7.1.2 Optimisation of Wash Step 
A mixture of all oestrogen metabolites, with the final amount of 10ng, was added to 10mL 
of PRF-DMEM cellular media complemented with 1% CSS and spiked with 10μL of 
1μg/mL of I.S. prior to extraction. The solid sorbent material in the cartridges was 
preconditioned first with 3mL of 100% methanol and then with 3mL of 100% water, prior 
to loading the biological sample or matrix containing known concentration of metabolite 
standards. The metabolites, having a steroid character, were retained in the sorbent material 
of the cartridge, which was subsequently re-equilibrated with 3mL of 100% water, followed 
by a two wash steps with 1) 3mL 5% (v/v) methanol in water and 2mL 30% (v/v) methanol 
in water or 2) 3mL of 100% water, followed by 3mL 5% (v/v) methanol in water, 
respectively. The oestrogen metabolites were eluted from the extraction cartridge by either 
3mL of 100% methanol or 3mL of 100% ACN. Eluents containing concentrated and purified 
oestrogens were dried under a gentle stream of oxygen-free nitrogen gas mixture at room 
temperature and reconstituted in 70μL of the initial mobile phase containing 
H2O:ACN=90:10. The post-spiked and unextracted samples were prepared as described 
above. 
113 
 
 Liquid Chromatography Tandem Mass Spectrometry 
- Analysis of Oestrogen Metabolism in Human Pulmonary 
Artery Smooth Muscle Cells In Vitro Model 
HPASMCs were plated in 100mm cell culture dishes and maintained in 10% FBS DMEM 
media until reaching approximately 70% confluence. The growth media was then replaced 
with 0.2% CSS-PRF DMEM for 16‒24 hours, to ensure all cells were in the same stage of 
the cell cycle. When stimulating the cells, quiescing media was replaced with 1% CSS-PRF 
DMEM to maintain adequate cell growth, and hPASMCs were stimulated for 48 hours with 
50nM (136.19ng) 17βE2. At the end time point of the experiment, cell culture dishes were 
placed on ice, and the spent media was collected into pre-chilled 15mL falcon tubes. 
Immediately after collection, the media samples were stored at -80°C until further use. The 
cell monolayer was washed twice with ice-cold DPBS, and protein samples were collected 
by adding 600µL of 1% (v/v) LM buffer (Abcam, UK), scrapped carefully using a sterile 
plastic cell scraper and collected into pre-chilled 1.5mL Eppendorf tubes. Protein samples 
were left on ice for 30 minutes, before storing at -80°C until protein concentration was 
determined for normalisation of results, as described in section 2.2.2. 
Metabolites formed form the 17βE2 were extracted using SPE, described in section 2.5.2, 
and stored at -80°C until derivatisation. To all samples, 10μL of 1μg/mL of I.S., 13C3-E1 and 
13C3-17βE2 (Sigma-Aldrich, UK) was added prior to SPE extraction. For LC-MS/MS L-
ascorbic acid was not added to any of the solvents used in the SPE. 
 Derivatisation with PPZ in Methylation Conditions 
Extracted biological samples were dried under continuous stream of oxygen free nitrogen at 
40°C. Then, 10µL of 1M NaHCO3 (Sigma Aldrich, UK), 10µL 1mg/mL 1-(5-fluoro-2,4-
dinitrophenyl)-4-methylpiperazine (1,PPZ, Tokyo Chemical Industry Ltd, UK) and 70µL 
100% acetone were added to the dry residue, and shortly vortexed. Oestrogen metabolites 
and reagents were incubated at 60°C for 1 hour. The reaction was quenched by the addition 
of 500µL of H2O:methanol=1:1 to each sample. The samples were again dried under 
continuous stream of oxygen free nitrogen, at 40°C, to complete dryness. To introduce a 
permanent positive charge into each molecule of oestrogen metabolite, the samples were 
further methylated by adding 100µL of methyl iodide (CH3I, Sigma Aldrich, UK), and 
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incubating the mixture at 60°C for 30 minutes. The mixture was then dried down under a 
gentle stream of oxygen free nitrogen, and the dry residue was reconstituted in 70µL of initial 
mobile phase with composition H2O:acetonitrile=90:10. 
Derivatised samples were either analysed on an LC-MS/MS setting immediately, or they 
were stored at -80°C. 
Figure 2–3: Gradient programme used to separate oestrogen metabolites within ACE 
Excel 2 C18-PFP (150x2.1mm) column, maintained at 25°C. 
 Liquid Chromatography Tandem Mass Spectrometry 
Samples to be analysed on the Shimadzu QTRAP® 6500 LC-MS/MS System (AB SCIEX, 
UK), were maintained at 5°C. 30µL of each sample was injected onto the ACE Excel 2 C18-
PFP (150x2.1mm) column (Hichrom Ltd, UK). Gradient separation method was employed, 
by an eluent composition initially set to 10% (B) 0.1% formic acid in acetonitrile (v/v) and 
90% (A) 0.1% formic acid in water (v/v). The column was operated at 25°C with a flow rate 
of 0.5mL/min, with the following gradient program: 10% B to 50% B in 13 minutes, then 
maintained at 50% B for 2 minutes, linearly decreasing to 10% B in 3 minutes, finally the 
column was equilibrated with 10% B for 3 minutes (see Figure 2–3). 
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Turbo electron ion spray voltage (EIS) and temperature (TEM) were maintained at 5.5kV 
and 500°C, respectively. Multiple reaction monitoring (MRM), in positive polarity, with unit 
mass resolution for the precursor and product ions was used for quantitation of oestrogen 
metabolites. 
The triple quadrupole mass spectrometer contains two mass filters (Q1 and Q3), while Q2 is 
used as collision cell to fragment molecule of interest. The Q1 is typically used to select the 
parental ions of interest generated in the ion source, hence the Q1 mass corresponds to 
molecular weight of the derivatised parental ion to charge ratio (m/z). The precursor ions are 
then fragmented in Q2, and the product ions are separated by m/z ratio in Q3. Therefore, Q3 
mass is used to select specified fragments of precursor ion to the electron multiplier. The Q1 
and Q3 masses of oestrogen metabolites analysed in the spent media samples are provided 
in Table 2-9. 
Table 2-9: Characteristic Q1 and Q3 masses of oestrogen metabolites derivatised with 
PPZ/methylation conditions used for LC-MS/MS identification and analysis. 
Identification Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(ms) 
DP 
(Volts) 
CE 
(Volts) 
CXP 
(Volts) 
E1 549.1 502.3 30 141.0 59.0 20.0 
17βE2 551.1 504.3 30 51.0 59.0 20.0 
17αE2 551.1 504.3 30 51.0 59.0 20.0 
2OHE1 565.0 58.0 30 130.0 129.0 10.0 
4OHE1 565.0 58.0 30 130.0 129.0 10.0 
16αOHE1 565.0 58.0 30 130.0 129.0 10.0 
2OHE2 567.1 58.0 30 136.0 121.0 8.0 
4OHE2 567.1 58.0 30 136.0 121.0 8.0 
16αOHE2 567.1 58.0 30 136.0 121.0 8.0 
2MeOE1 579.0 58.0 30 66.0 121.0 8.0 
4MeOE1 579.0 58.0 30 66.0 121.0 8.0 
2MeOE2 581.0 280.0 30 111.0 57.0 28.0 
4MeOE2 581.0 250.0 30 61.0 63.0 24.0 
13C-E1 552.3 505.3 30 135.0 39.0 15.0 
13C-17βE2 554.3 507.3 30 135.0 35.0 15.0 
DP= De-clustering potential, CE= Collision energy, CXP= Collision exit potential 
Nineteen MRM transitions were monitored with dwell time set at 30ms. Collision energy 
was set for each metabolite separately. Data acquisition and processing were controlled by 
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the Analyst Software (version 1.6.3) of the instrument. All LC-MS/MS data analyses was 
performed using MultiQuant 3.0.2 software (AB SCIEX, UK). 
2.7.5 Validation of Assay for Oestrogen Metabolites in Cell 
Media 
The limits of detection (LODs) was determined for each of the oestrogen metabolites of 
interest as the lowest concentration at which the observed signal was clearly separable from 
the baseline noise. Calibration curves for oestrogen metabolites of interest were obtained 
using linear regression without weighting. The linearity of the assay was assessed daily on 
three consecutive days using six concentrations from 0.2 to 100ng/mL, while the 
concentration of I.S. (13C3-E1 and 
13C3-17βE2) was kept constant at 100ng/mL for both 
standards. The uncertainty of measurements for the same sample was expressed in 
coefficient of variation (%CV), calculated by dividing standard deviation of the sample 
measurements with average value, multiplied by 100. Recovery and matrix effects were 
determined at concentration of 200ng/mL (n=2). The recovery (%RE) for each oestrogen 
metabolite was estimated as the ratio of peak areas for each analyte to I.S. spiked before 
extraction, divided by the ratio of peak areas of each analyte analyte to IS spiked post-
extraction, multiplied by 100: 
%𝑅𝐸 =
(
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 − 𝑃𝑟𝑒𝑠𝑝𝑖𝑘𝑒𝑑)
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 (𝐼𝑆 − 𝑃𝑟𝑒𝑠𝑝𝑖𝑘𝑒𝑑)
)
(
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 − 𝑃𝑜𝑠𝑡𝑠𝑝𝑖𝑘𝑒𝑑)
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 (𝐼𝑆 − 𝑃𝑜𝑠𝑡𝑠𝑝𝑖𝑘𝑒𝑑)
)
× 100 
It is important to consider matrix effects (%ME) when developing a quantitative LC-MS/MS 
method, as the presence of unknown compounds, which react unpredictively, in the sample 
might affect the methods’ accuracy and reproducibility. %ME was calculated as the ratio of 
peak areas of each post-spiked analyte with the peak area of unextracted analyte: 
%𝑀𝐸 =
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 − 𝑃𝑜𝑠𝑡𝑠𝑝𝑖𝑘𝑒𝑑)
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝑈𝑛𝑒𝑥𝑡𝑟𝑐𝑡𝑒𝑑)
 . 
Ion suppression (%IS) is defined as reduced response of the detector due to competition of 
compounds present in the sample with the analyte of interest for the efficiency in the 
ionisation source. When looking at several analytes of interest within a complex sample, the 
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competition of these compounds for the efficiency in the ionisation source might also result 
in ion suppression. %IS was estimated as the ratio of each oestrogen metabolite to IS 
response ratio, divided by unextracted mixture of oestrogen metabolites, multiplied by 100: 
%𝐼𝑆 =
(
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 − 𝑝𝑟𝑒𝑠𝑝𝑖𝑘𝑒𝑑)
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 (𝐼𝑆 − 𝑝𝑟𝑒𝑠𝑝𝑖𝑘𝑒𝑑)
)
(
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝑈𝑛𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑀𝑖𝑥𝑡𝑢𝑟𝑒)
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 (𝐼𝑆 − 𝑈𝑛𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑀𝑖𝑥𝑡𝑢𝑟𝑒)
)
× 100 
2.8  Statistical Analysis and Data Handling 
Data presented herein was processed and analysed using GraphPad Prism (California, USA), 
version 5 and 6. The values are expressed as the mean value ± the standard error of the mean 
(SEM). Herein, N denotes the number of cell lines used in an experiment, while the number 
of replicates indicates the number of times the experiment was repeated using a cell line. To 
evaluate the statistical significance of differences between groups, One-Way ANOVA 
followed by Tukey’s or Bonferroni post-hoc tests, depending on whether all possible 
pairwise comparisons across all groups were examined or not. Where required, a Two-Way 
ANOVA followed by Sidak Post-hoc test was utilised. A probability level of p<0.05 was 
defined as being statistically significant.  
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Chapter III 
3 In Vitro Investigation of Mechanisms 
Involved in the Establishment of 
Experimental Pulmonary Arterial 
Hypertension Phenotype in the Sugen 5416 
and Chronic Hypoxia Model 
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3.1 Introduction 
Numerous advances in medical research have been attributed to the use of animal models. 
According to Ericsson and colleagues, pre-clinical studies using animal models to 
appropriately and accurately replicate human diseases, offer rapid access to robust data, 
leading to imperative insight into the pathophysiological disease mechanisms and aid the 
development of novel treatment options (Ericsson et al., 2013). The research of complex 
diseases associated with numerous co-founding factors and aetiologies, such as PAH, might 
therefore rely heavily on animal models to elucidate underlying biological mechanism. This 
may require utilising more than one model to ensure robustness of gathered information. 
Although recent advances in genetic engineering have resulted in the generation of numerous 
novel models, these unfortunately do not generally recapitulate all the complex features of 
PAH pathophysiology. Moreover, larger number of genetically modified animals are 
required to maintain the genetically engineered line. Hence, it is not surprising that the 
number of animals in research has been increasing slowly since the beginning of 21st century, 
mostly due to increasing proportion of procedures using animals that have been genetically 
modified or harbour genetic mutations. 
 
Figure 3–1: The trend of use of animals in research since 1930s to date. 
The diagram showing the number of animals used in biomedical research per year was acquired from 
Understanding Animal Research. 
In the UK, however, due to the efforts of British government to regulate more stringently 
the use of animals in research through establishment of the National Centre for the 
Replacement, Refinement and Reduction of Animals in Research, the proportion of 
percentage of experimental procedures on animals has not increased compared to the 
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increase in all bioscientific experiments. The main aims of the NC3Rs are to promote 
researchers to develop novel methods enabling i) minimisation of the number of animals 
used per experiment, ii) replacement or complete avoidance of the use of animals, and iii) 
improvement the welfare of animals and minimise their suffering (NC3Rs). It has been 
proposed that, the development of new research technologies and refinement of existing 
models could in the future lead to significant reduction, and possible absolute replacement, 
of the use of animals in research. 
To accurately replicate human PAH in terms of the histopathological changes observed 
within the distal pulmonary vasculature, including the occurrence of angio-obliterative 
lesions generally requires multiple stimuli. The Su5416/Hx model in rats is established by 
administration of a single dose of 20mg/kg of Sugen 5416 to the animals, which are then 
exposed to hypoxia for 14 or 21 days. Animals are then retained in Nx conditions for 6 to 10 
weeks so that the experimental PH phenotype develops fully. This model recapitulates the 
human disease in terms of the presence of occlusive lesions. Additionally, the animals 
developed higher mPAP than Hx alone. In this model female animals developed the disease 
more frequently compared to males, and oestrogens apparently mediate a detrimental role in 
this specific model (Tofovic et al., 2012), this model could be regarded as most appropriate 
model to investigate PAH pathophysiology and the effectiveness of novel therapeutic 
approaches. As Su5416 is considered to be a potent ligand of the AhR, expressing high 
affinity for the receptor, the role of the AhR has been considered in the mechanism driving 
the onset of PAH phenotype in this animal model. In terms of the AhR mediating CVD, the 
receptor absence was associated with the occurrence of abnormal hepatic vascular structures 
according to (Lahvis et al., 2000). The absence of the receptor in AhR null mice also resulted 
in increased expression of HIF1α and VEGF in the heart (Thackaberry et al., 2002), both of 
which have been associated with compensatory mechanisms resulting in cardiac hypertrophy 
(Vasquez et al., 2003). According to Sauzeau, absence of AhR in the vasculature was 
associated with increased thickness of arteria media vessel wall due to increased number of 
SMCs (Sauzeau et al., 2011). The activation of AhR in the cardiovascular system was also 
shown to increase the expression of Phase I metabolising enzymes, leading to subsequent 
increase in ROS (Park et al., 1996). 
However, as the mechanism by which the disease phenotype is established in the Su5416/Hx 
model is largely unknown, it is important to determine which cellular pathways are involved 
to comprehend the suitability of the model. 
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Aims of this chapter: 
1) To investigate the mechanism through which the animal model of pulmonary arterial 
hypertension employing Sugen 5416 coupled with chronic hypoxia is induced, 
utilising in vitro methods. 
2) To establish whether proteins involved in the AhR/HIF1α signalling pathways are 
differentially expressed in the lungs of animals with established disease phenotype 
and their control littermates, and in hPASMCs, derived from patients and control 
subjects of both sexes. 
3) To establish an in vitro cellular model using human pulmonary arterial and human 
pulmonary microvascular endothelial cells, recapitulating the molecular changes 
observed in animal model of Sugen 5416 coupled with chronic hypoxia.  
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3.2  Results 
 Cells Derived from Female Patients with Pulmonary 
Arterial Hypertension Exhibit Decreased Gene 
Expression of Cytochrome P450 1A1 
White and colleagues conduced a microarray analysis to determine any sex differences in 
the genetically altered mouse that overexpresses the human gene for the serotonin transporter 
(SERT+ mouse), as only female SERT+ mice developed the PAH phenotype (White et al., 
2011b). Thearray revealed the up-regulation of several genes in female SERT+ PAs, 
including CYP1B1, CEBPβ and FOS genes (White et al., 2011b). CYP1A1 is induced by the 
AhR and is a good marker of AhR activity (Hu et al., 2007). To assess whether sex 
differences in CYP1A1 gene expression levels exist and establish the importance in the 
disease onset and progression, we examined the expression of the gene encoding this enzyme 
in models of PAH. 
Firstly, we examined hPASMCs derived from female PAH patients compared to female 
control cells. We observed that level of expression of the CYP1A1 gene, determined using 
quantitative RT-PCR analysis, might be decreased in hPASMCs derived from female PAH 
patients compared to female control cells (Figure 3–2).  
A slight variability in the Ct value of the housekeeper gene β-2-microglobulin was detected 
in the group of hPASMCs derived from female PAH patients. The normalisation of the Ct 
values of the gene of interest is important, as it enables the compensation of intra- and inter-
kinetic RT-PCR variations, allowing to compare samples in the same experiment and 
between experiments. The quality of the data was examined by calculating the standard 
deviation of the Ct values. Generally, within our lab, the results for which the variability 
described by standard deviation of less than 1 amongst all groups were considered useable, 
and this criterion was also applied for this work. When the fold change in the expression of 
the gene of interest is high, there is a greater tolerance for the variation in the expression of 
the housekeeping gene, which has a lesser impact the interpretation of the results. 
Conversely, when looking at relatively small fold differences, the tolerance in the variation 
of housekeeping gene may be less. Therefore, optimisation of the assay may be required. 
The coefficient of variation for these experiments, calculated by dividing the standard 
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deviation with the mean Ct value, was less than 5%, which is still acceptable. We recognise 
that with borderline results, larger variability of the housekeeper gene) could artificially 
result in greater significance of results, however, the variability of the housekeeper gene Ct 
values was within the acceptable limits of variation. To improve the experiment in order to 
produce highly accurate and reliable results, other housekeeping genes, which generally 
exhibit less variability could be employed, as described in (de Jonge et al., 2007). According 
to de Jonge et al., the housekeeping genes exhibiting the least variability are different 
ribosomal proteins and ornithine decarboxylase antizyme 1. 
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Pulmonary artery smooth muscle cells (PASMCs) were explanted from distal arteries of control subjects and patients suffering from pulmonary arterial hypertension (PAH) 
and cultured as described previously. The expression of CYP1A1 was assessed by Taqman quantitative Real Time-PCR. Results were normalised to the β-2-microglobulin. 
N=3‒4 per group in triplicate, **p≤0.01, One-way ANOVA followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
 
  
 
Figure 3–2:The relative expression of the gene encoding the CYP1A1 is decreased in human pulmonary artery smooth muscle cells from female PAH 
patients. 
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Whole lungs of Smad1 heterozygous mice of both sexes, and their age-matched C57BL/6 litter mates, used as control animals, were prepared, as described previously, 
to assess the expression level of CYP1A1 by Taqman quantitative Real Time-PCR. Results were normalised to the β-2-microglobulin. N=4‒6 per group in triplicate, 
*p<0.05, **p≤0.01, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–3:The relative expression of the gene encoding the CYP1A1 is decreased in whole lungs from female Smad1 heterozygous mice. 
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 Female Smad1 Heterozygous Mice Exhibit 
Decreased Gene Expression Levels of Cytochrome P450 
1A1 
The tissue of Smad1 heterozygous mice and their WT counterparts used in these experiments 
was kindly provided by Dr Mair. The haemodynamic and remodelling parameters observed 
in these animals are published in (Mair et al., 2015). The expression of the CYP1A1 gene 
was also assessed in whole lung from female and male Smad1 heterozygous mice, and their 
age-matched C57BL/6 litter mates, which served as controls. The relative quantitation of the 
gene showed that CYP1A1 gene is significantly decreased in the lungs derived from Smad1 
heterozygous mice compared to female control animals (Figure 3–3). This observation 
indicates that in this Nx PAH generic model exhibiting the PAH disease phenotype (Han et 
al., 2013;Mair et al., 2015), the expression of CYP1A1 is decreased compared to age-
matched female litter mates. Interestingly, unlike the increased expression level of CYP1B1, 
reported previously in animals and hPASMCs (White et al., 2012) exhibiting PAH 
phenotype, the expression of CYP1A1 was reduced. 
 The expression level of Cytochrome P450 1A1 is 
Significantly Decreased in Experimental Pulmonary 
Hypertension Induced by Hypoxia in Sprague-Dawley Rats 
of Both Sexes 
To further investigate the expression of CYP1A1 gene in models of PAH, the relative 
quantitation of the gene was assessed in lungs from the classical cHx model of PH. We 
studied this in Sprague-Dawley rats exposed to either Hx or Nx conditions for 28 days. The 
tissue used in these experiments was kindly provided by Dr Murphy. The haemodynamic 
and remodelling parameters observed in these animals after exposure to chronic hypoxia 
were published in (Murphy, 2017). We observed a significant decrease in the relative 
quantitation of the CYP1A1 gene in female and male animals exposed to Hx compared to 
their Nx controls (Figure 3–4). 
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Whole lung of Sprague-Dawley rats of both sexes, exposed to hypoxia for 28 days, and their normoxic litter mates, used as control animals, were prepared, as described 
previously, to assess the expression level of CYP1A1 by Taqman quantitative Real Time-PCR. Results were normalised to the β-2-microglobulin. N=4‒6 per group in 
triplicate, *p<0.05, **p≤0.01, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
 
Figure 3–4: The relative expression of the gene encoding the CYP1A1 is decreased in female and male rats exposed to hypoxia for 28 days. 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, 
as described previously, to assess the expression level of CYP1A1 by Taqman quantitative Real Time-PCR (A). Results were normalised to β-2-microglobulin. N=4‒6 
per group in triplicate, ****p≤0.0001, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. The 
level of CYP1A1 protein expression was assessed using immunoblotting (B). N=3‒6 per group in duplicate, *p<0.05, ****p≤0.0001, One-way ANOVA followed by 
Dunnett’s post-hoc test. Representative immunoblot is shown in (C). 
CYP1A1 
(56kDa) 
β actin 
(42kDa) 
A 
Figure 3–5: The expression of CYP1A1 is increased in whole lungs from female and male rats treated with Sugen 5416 and exposed to hypoxia. 
B 
E
x
p
r
e
s
s
io
n
 o
f 
C
Y
P
1
A
1
r
e
la
ti
v
e
 t
o

 a
c
ti
n
F
e
m
a
le
 N
o
rm
o
x
ic
F
e
m
a
le
 S
U
5
4
1
6
/H
x
M
a
le
 N
o
rm
o
x
ic
M
a
le
 S
U
5
4
1
6
/H
x
0
1
2
3
4
5
*
****
****
C 
129 
 
 The Expression of Cytochrome P450 1A1 Gene is 
Increased in Experimental Pulmonary Hypertension 
Induced by Sugen 5416 and Chronic Hypoxia 
Lastly, the level of CYP1A1 gene expression was addressed in the Su5416/Hx model, which 
is currently widely used to investigate the pathophysiological mechanisms of PAH onset and 
progression, due to histological, pathophysiological and epidemiological characteristics 
similar to those observed in humans. Here, the relative quantitation of the gene was assessed 
in the whole lungs from Wistar Kyoto rats treated with Su5416 and exposed to Hx or in age-
matched litter mates kept in Nx conditions (Mair et al., 2014). The experimental PH 
phenotype in Su5416/Hx model was established by a single dose of 20mg/kg Su5416, 
followed by 14 days in Hx and further 14 days in Nx (Mair et al., 2014). Su5416/Hx-treated 
animals developed right ventricular systolic pressure of approximately 110mmgHg, with 
10–15% remodelled and 20–30% occluded vessels, and right ventricular hypertrophy index 
(RV/LV+S) of 0.6 (Mair et al., 2014). The relative expression of the CYP1A1 gene in female 
and male treated animals was significantly increased (Figure 3–5A), while no difference 
between the sexes was detected. Using immunoblotting technique to assess the level of 
protein expression we show that CYP1A1 protein expression was also increased in 
Su5416/Hx-treated animals of both sexes. The quantification of the protein expression also 
indicated that the CYP1A1 expression in male rats treated with Su5416/Hx is significantly 
higher than in age-matched female rats (Figure 3–5B). 
The AhR signalling pathway is considered to be an organism’s innate mechanisms to 
efficiently deal with exposure to environmental toxins Therefore, the activation results in 
induction of genes involved in metabolism of these substances, including the CYP1B1 gene. 
We have therefore also examined the level of relative quantitation of CYP1B1 in the whole 
lungs. We observed that in male and female animals exposed to Su5416 and cHx resulted in 
a significantly increased expression of CYP1B1 compared to their corresponding Nx 
controls, on both gene and protein level (Figure 3–6). The evaluation of the expression of 
CYP1B1 protein, however, was limited by the quality of the western blot. The diffuse nature 
of the bands and relatively high background limited the accuracy of determining the boarders 
of the protein bands and hence the measurement of optical density. The diffuse nature of the 
bands could be associated with the presence of post-translational modifications of CYP1B1 
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or the condition of the tissue used for this experiment. Additionally, the anti-CYP1B1 
antibody used exhibited some off-target binding, leading to poorer results. 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, as 
described previously, to assess the expression level of CYP1B1 by Taqman quantitative Real Time-PCR (A). Results were normalised to the β-2-microglobulin. N=4‒6 per 
group in triplicate, *p<0.05, **p≤0.01, ***p≤0.001, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative 
quantification. The level of CYP1B1 protein expression was assessed using immunoblotting (B). N=3‒6 per group in duplicate, *p<0.05, ****p≤0.0001, One-way ANOVA 
followed by Dunnett’s post-hoc test. Representative immunoblot is shown in (C). 
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Figure 3–6: The expression of CYP1B1is increased in whole lung from female and male rats treated with Sugen 5416 and exposed to chronic hypoxia. 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, 
as described previously, to assess the expression level of AhR by Taqman quantitative Real Time-PCR (A). Results were normalised to β-2-microglobulin. N=4‒6 per 
group in triplicate, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. The level of AhR 
protein expression was assessed using immunoblotting (B). N=3‒6 per group in duplicate, One-way ANOVA followed by Dunnett’s post-hoc test. Representative 
immunoblot is shown in (C). 
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Figure 3–7: The expression of aryl hydrocarbon receptor is unchanged in whole lung samples from female and male rats treated with Sugen 5416 and 
exposed to chronic hypoxia. 
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When we assessed the relative quantitation of the AhR gene in lungs from male and female 
Su5416/hx rats and their controls, no significant differences were observed (Figure 3–7). 
The evaluation of the expression of AhR on protein level was limited by the level of 
expression and the diffuse nature of the bands, limiting the accuracy of determining the 
boarders of the protein bands and hence the measurement of optical density. ARNT(HIF1β) 
is the key binding partner of the AhR to produce an active receptor dimer. ARNT(HIF1β) 
gene levels in Su5416/Hx-treated females was significantly lower compared to female Nx 
controls (Figure 3–9). In male animals no such significant differences were observed (Figure 
3–9). 
The AhR signalling pathway is negatively regulated by the induction of the AhRR, which 
serves to bind to the AhR instead of the ARNT, and hence prevents the receptor’s activity. 
Therefore, the relative expression level of the AhRR is another useful measure of the activity 
of the AhR signalling pathway. To confirm the AhR signalling pathways is greatly induced 
in the Su5416/Hx-treated animals, we have examined the relative quantitation of AhRR gene 
in whole lung samples. As previously with CYP1A1 expression levels, we reported that the 
expression of AhRR gene was significantly higher in the Su5416/Hx-treated animals 
compared to their sex- and age-matched Nx controls (Figure 3–8). The magnitude of increase 
in the gene expression level of AhRR observed was comparable to that of CYP1A1 gene. 
Moreover, we have also established that the expression of AhRR in Su5416/Hx male rats 
was significantly higher than in Su5416/Hx female rats. Equally, we observed that AhRR 
expression in Nx male rats was also significantly higher than in Nx female rats. Hence it 
appeared that there might be a sex specific difference in the level of AhRR expression, and 
therefore the AhR pathway might be differentially negatively regulated. The evaluation of 
the expression of AhRR protein, was limited by the quality of the western blot. The diffuse 
nature of the bands and relatively high background limited the accuracy of determining the 
boarders of the protein bands and hence the measurement of optical density. Additionally, 
the anti-AhRR antibody used exhibited some off-target binding, leading to poorer results. 
As there is significant crosstalk between the AhR and the HIF1α signalling pathways, we 
also aimed to examine the levels of HIF1α gene expression in Su5416/Hx treated animals. 
As the HIF1α gene is normally expressed regardless of the partial pressure of O2, and the 
latter only influences the stability and degradation of HIF1α on protein level, we investigated 
whether the basal level of gene expression is altered in treated animals compared to their Nx 
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controls. Herein, we report that the relative expression of HIF1α was significantly higher in 
Su5416/Hx treated males compared to treated females (Figure 3–10). 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, 
as described previously, to assess the expression level of AhRR by Taqman quantitative Real Time-PCR (A). Results were normalised to β-2-microglobulin. N=3‒6 per 
group in triplicate, ****p≤0.0001, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. The 
level of AhRR protein expression was assessed using immunoblotting (B). N=3‒6 per group in duplicate, *p<0.05, ****p≤0.0001, One-way ANOVA followed by 
Dunnett’s post-hoc test. Representative immunoblot is shown in (C). 
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Figure 3–8: The expression of aryl hydrocarbon receptor repressor is increased in whole lungs derived from female and male rats treated with Sugen 
5416 and exposed to chronic hypoxia. 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with a single dose of Sugen 5416 and subsequently exposed to chronic hypoxia, were prepared, as 
described previously, to assess the expression level of ARNT (HIF1β) by Taqman quantitative Real Time-PCR. Results were normalised to the β-2-microglobulin. N=4‒
6 per group in triplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification.  
Figure 3–9: The relative expression of the gene encoding the ARNT (HIF1β) is decreased in whole lungs derived female rats treated with Sugen 5416 
and exposed to chronic hypoxia. 
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Samples of whole lung of Wistar Kyoto rats, of both sexes, treated with a single dose of Sugen 5416 and subsequently exposed to chronic hypoxia, were prepared, as 
described previously, to assess the expression level of HIF1α by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group 
in triplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
 
Figure 3–10: The relative expression of the gene encoding the hypoxia-inducible factor 1α is increased in whole lungs from male rats treated with 
Sugen 5416 and exposed to chronic hypoxia. 
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 The Expression of NAD(P)H Quinone Dehydrogenase 
1 is Increased in the Lung of Sugen 5416-Hypoxic-
Treated Animals, but not in Animals Exposed to 
Chronic Hypoxia 
The activation of AhR in mice results in the induction of a battery of genes through the 
nuclear factor erythroid 2–related factor 2 (Nrf2), which includes CYP1A1 and NQO1 
(Yeager et al., 2009). The aim of assessing NQO1 gene expression was to determine the 
animal model in which, the AhR signalling pathways is most likely activated. We also 
wished to assess the expression of another gene known to be regulated through AhR 
signalling pathway in Su5416/Hx treated animals. Prolonged vessel wall sheer stress has 
been associated with altered expression of the NQO1 gene in the endothelial cells ECs (Chen 
et al., 2003), with the enzyme mediating the removal of genotoxic quinones to form 
hydroquinone, thereby conferring protective role against oxidative stress. 
In the cHx model of PH, the only significant difference in NQO1 observed was that females 
exhibited significantly higher expression level of the NQO1 gene compared to males (Figure 
3–11A). The NQO1 gene was upregulated in Su5416/Hx treated animals of both sexes 
(Figure 3–11B). 
A slight variability was observed in the Ct values of the housekeeper gene β-2-microglobulin 
for animal kept in Hx for 28 days and their Nx controls. The quality of the data was examined 
by calculating the standard deviation of the Ct values. Generally, we considered results with 
variability described by standard deviation of less than 1 to be useable, and this criterion was 
also applied for this work. Considering, the standard deviation of the housekeeper gene Ct 
values was within the acceptable limits, we believe the results are satisfactory. However, we 
recognise that with borderline results, larger variability of the housekeeper gene) could 
artificially result in greater significance of results, however, the variability of the 
housekeeper gene Ct values was within the acceptable limits of variation. The impact of the 
level of variability in the housekeeping gene expression is described in Chapter 3.2.1. 
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Samples of whole lungs of two experimental PH rat models: cHx (A) and Su5416/Hx (B) of both sexes, were prepared, as described previously, to assess the expression level of 
NQO1 by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=3‒6 per group in triplicate, **p<0.01, One-way ANOVA followed by Tukey’s 
post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–11: The relative quantitation NAD(P)H quinone dehydrogenase 1 is increased in the whole lungs from Sugen 5416 and hypoxia-treated 
animals. 
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 Treatment of Human Pulmonary Artery Smooth 
Muscle Cells with Sugen 5416 Leads to Increased 
Expression of Cytochrome P450 1A1 and 1B1, but not 
Aryl Hydrocarbon Receptor or Hypoxia-Inducible 
Factor 1β 
As previously reported, AhR expression is increased in female PAH patient hPASMCs 
(Dean et al., 2016). Moreover, the AhR signalling pathway may be involved in the 
establishment of the disease-like phenotype in the Su5416/Hx animal model. We therefore 
aimed to assess the effect that stimulation of the AhR signalling pathway may have on the 
expression of CYP enzymes in female hPASMCs derived from control patients with no 
PAH. Both, CYP1A1 and CYP1B1, metabolise oestrogens and produce protective and/or 
detrimental oestrogen metabolites (Lee et al., 2003;White et al., 2012), which may be 
involved in PAH pathogenesis. 
24 hour-long stimulation with Su5416 (1μM and 5μM) resulted in significant increase in the 
protein expression of CYP1A1 (Figure 3–12) and CYP1B1 (Figure 3–13) enzymes in female 
hPASMCs derived from control patients, while no such increase was observed for the AhR 
(Figure 3–15). We also showed that at gene expression levels, genes encoding for CYP1A1 
and CYP1B1 were significantly increased with Su5416 stimulation, while no such increase 
was detected for AhR gene expression (Figure 3–14). Furthermore, in these cells, pre-
treatment with AhR antagonist, CH223191 (100nM), antagonised the Su5416-induced 
decreased in CYP1A1 expression (Figure 3–12), but not CYP1B1 expression (Figure 3–13).  
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. (A) Protein expression of CYP1A1 was 
assessed as previously described, with representative immunoblotting image (B). N=3 per group, in 
duplicate, One-Way ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of 
Control group±SEM.  
E
x
p
r
e
s
s
io
n
 o
f 
C
Y
P
1
A
1
R
e
la
ti
v
e
 t
o

 A
c
ti
n
B
a
s
a
l
1 
M
 S
u
g
e
n
 5
4
1
6
5 
M
 S
u
g
e
n
 5
4
1
6
1 
M
 S
u
g
e
n
 5
4
1
6
 +
 3
0
n
M
 C
H
2
2
3
1
9
1
5 
M
 S
u
g
e
n
 5
4
1
6
 +
 3
0
n
M
 C
H
2
2
3
1
9
1
1 
M
 S
u
g
e
n
 5
4
1
6
 +
 1
0
0
n
M
 C
H
2
2
3
1
9
1
5 
M
 S
u
g
e
n
 5
4
1
6
 +
 1
0
0
n
M
 C
H
2
2
3
1
9
1
0
1
2
3
*
***
*
*
CYP1A1 
(49 kDa) 
+30nM 
CH223191 
+100nM 
CH223191 
β Actin 
(42 kDa) 
A 
B 
Figure 3–12: Expression of CYP1A1 is increased by treatment with Sugen 5416, and 
attenuated by AhR antagonist, CH223191, in human pulmonary artery smooth muscle 
cells from female controls. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. (A) Protein expression of AhR were 
assessed as described previously, with representative immunoblotting image (B). N=3 per group, in 
duplicate, One-Way ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of 
Control group±SEM. 
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Figure 3–13: Expression of CYP1B1 is increased after treatment with Sugen 5416 in 
human pulmonary artery smooth muscle cells from female controls. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 
100nM), which was added 30 minutes before Sugen 5416, in the presence of 1% CSS PRF DMEM. The expression level of CYP1A1 and CYP1B1 was assessed by 
Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=3–4 per group, in duplicate, *p<0.05,**p≤0.01, One-Way ANOVA with 
Bonferroni’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
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Figure 3–14: Expression of CYP1A1 and CYP1B1 at gene level is increased in human pulmonary artery smooth muscle cells from female controls 
after treatment with Sugen 5416 in the presence or absence of AhR antagonist, CH223191. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. N=3 per group, in duplicate, One-Way 
ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of Control group±SEM. 
The representative blot shown (B) was altered to remove Control, 1μM and 5μM Sugen 5416 
treatment groups, otherwise appearing in the position now replaced by vertical line, on the same 
immunoblot.  
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Figure 3–15: Protein expression of aryl hydrocarbon receptor remains unaltered by 
treatment with Sugen 5416 in the presence or absence of AhR antagonist, CH223191, in 
human pulmonary artery smooth muscle cells from female controls. 
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 Treatment of Human Pulmonary Artery Smooth 
Muscle Cells with Sugen 5416 Leads to Increased 
Expression of Cytochrome P450 1A1 and 1B1, but not 
Aryl Hydrocarbon Receptor in Cells Derived from 
Female Patients 
As treatment of animals with Su5416 resulted in increased expression of target genes of the 
AhR signalling pathway, we aimed to investigate whether the use of Su5416 in the in vitro 
model of PAH might have a similar effect, considering the AhR is increased in PASMCs 
derived from female patients. The exposure of hPASMCs from female PAH patients to 
Su5416 yielded a significant increase in CYP1A1 and CYP1B1, at gene (Figure 3–16) and 
protein levels (Figure 3–17 and Figure 3–18), respectively. The difference in CYP1A1 
expression compared to control treatment was more considerable as the change in CYP1B1 
expression. Although the treatment with the AhR antagonist, CH223191 (30nM and 100nM) 
resulted in decreased expression of both CYP enzymes, this alteration was not statistically 
significant. 
Although the results of immunoblotting indicate that there might be no change in the protein 
expression of AhR, the results are limited by the quality of the blot. The overexposed and 
diffuse nature of the bands, together with relatively high background limit the accuracy of 
determining the boarders of the protein bands and hence the measurement of optical density. 
The diffuse nature of the bands could be associated with the presence of post-translational 
modifications of AhR. Additionally, the anti-AhR antibody used might exhibited some off-
target binding, leading to poorer results, or it should be considered that multiple isoforms of 
the protein exist. In the latter instance the role of these isoforms should be investigated. 
 Treatment with Sugen 5416 does not Affect the 
Expression of Other Proteins Involved in the AhR and 
HIF1α Signalling Pathways 
We also examined the expression of AhR, the main receptor mediating the alterations in the 
expression of CYP1A1 and CYP1B1 enzymes, to determine whether the observed 
upregulation might be a direct consequence of an increased expression of the AhR gene. 
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Stimulation of female patient PASMCs with Su5416 did not result in significant changes in 
the expression of AhR, on gene or protein levels, respectively (Figure 3–19). Nor did we 
observe any significant changes in the expression of HIF1β and HIF1α (Figure 3–20 and 
Figure 3–21). Equally, treatment with Su5416 did not affect the protein expression levels of 
PHD2 and vHL, which are involved in the regulation of HIF1α oxygen-dependent 
degradation (Figure 3–22 and Figure 3–23). In Nx conditions, PHD2 catalyses hydroxylation 
of HIF1α, thereby enabling the binding of a complex formed of vHL and ubiquitin ligase E3 
(Kamura et al., 2000). This then leads to poly-ubiquitination of and proteasomal degradation 
of HIF1α. In hypoxia, PHD2 is inactive, or its activity is greatly reduced, as the enzyme 
requires molecular oxygen as its co-factor, therefore, HIF1α is stabilised due to greatly 
decreased proteasome-mediated degradation, leading to its accumulation in the nucleus, 
(Jiang et al., 1996). The role of PHD2 and vHL in HIF1α signalling pathway were also 
described in Chapter 1.6.5. 
The evaluation of protein expression of HIF1α and HIF1β were limited by the low expression 
levels of these proteins, leading to diffuse bands and higher background, rendering the 
determination of optical density difficult. Hence, it is difficult to draw solid conclusions 
regarding whether Su5416 might affect the expression of these two proteins. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 
100nM), which was added 30 minutes before Sugen 5416, in the presence of 1% CSS PRF DMEM. The expression level of CYP1A1 and CYP1B1 was assessed by 
Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=3–4 per group, in duplicate, **p≤0.01, ***p≤0.001, ****p≤0.0001, One-Way 
ANOVA with Bonferroni’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
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Figure 3–16: Expression of CYP1A1 and CYP1B1 at gene level is increased in human pulmonary artery smooth muscle cells from female PAH patients 
after treatment with Sugen 5416 in the presence or absence of AhR antagonist, CH223191. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. (A) Protein expression of CYP1A1 
were assessed as described previously, with representative immunoblotting image (B). N=3–4 per 
group, in duplicate, *p<0.05, **p≤0.01, One-Way ANOVA with Bonferroni’s post-hoc test. Data is 
expressed as fold-change of Control group±SEM.  
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Figure 3–17: Protein expression of CYP1A1 is increased by stimulation with Sugen 5416 
in the presence or absence of AhR antagonist, CH223191, in human pulmonary artery 
smooth muscle cells from female PAH patients. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. (A) Protein expression of CYP1B1 
were assessed as described previously, with representative immunoblotting image (B). N=4 per 
group, in duplicate, *p≤<0.01, One-Way ANOVA with Bonferroni’s post-hoc test. Data is expressed 
as fold-change of Control group±SEM. 
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Figure 3–18: Protein expression of CYP1B1 is increased by stimulation with Sugen 5416  
in the presence or absence of AhR antagonist, CH223191, in human pulmonary artery 
smooth muscle cells from female PAH patients. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 
100nM), which was added 30 minutes before Sugen 5416, in the presence of 1% CSS PRF DMEM. (A) When the expression level of the gene encoding for AhR was 
assessed by Taqman quantitative Real Time-PCR, the results were normalised to the β-2-microglobulin. N=4 per group, in duplicate, One-Way ANOVA with 
Bonferroni’s post-hoc test. (B) Protein expression was assessed by immunoblotting. Data is expressed as fold-change of Control group±SEM or as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where 
RQ=Relative quantification. Representative immunoblot is shown in (C). 
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Figure 3–19: Expression of aryl hydrocarbon receptor remains unchanged by stimulation with Sugen 5416 in the presence or absence of AhR 
antagonist, CH223191, in human pulmonary artery smooth muscle cells from female PAH patients. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. N=2–3 per group, in duplicate, One-
Way ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of Control 
group±SEM. The representative blot shown above was altered to remove Control, 1μM and 5μM 
Sugen 5416 treatment groups, otherwise appearing in the position now replaced by vertical line, on 
the same immunoblot.  
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Figure 3–20: Protein expression of hypoxia-inducible factor 1β is unaltered by 
stimulation with Sugen 5416 in the presence or absence of AhR antagonist, CH223191, 
in human pulmonary artery smooth muscle cells from female PAH patients. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. N=3 per group, in duplicate, One-Way 
ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of Control group±SEM.  
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Figure 3–21: Expression of hypoxia-inducible factor 1α is unaltered by stimulation with 
Sugen 5416 in the presence of absence of AhR antagonist, CH223191, in human 
pulmonary artery smooth muscle cells from female PAH patients. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. N=4 per group, in duplicate, One-Way 
ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of Control group±SEM.  
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Figure 3–22: Expression of prolyl hydroxylase 2 is unchanged by stimulation with Sugen 
5416 in the presence or absence of the AhR antagonist, CH223191, in human pulmonary 
artery smooth muscle cells from female PAH patients. 
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Figure 3–23: Expression of von Hippel-Lindau tumour factor is unchanged by 
stimulation with Sugen 5416 in the presence or absence of the AhR antagonist, 
CH223191, in human pulmonary artery smooth muscle cells from female PAH patients. 
HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then treated 
with Sugen 5416 (1μM and 5μM) and CH223191 (30nM and 100nM), which was added 30 minutes 
before Sugen 5416, in the presence of 1% CSS PRF DMEM. N=3 per group, in duplicate, One-Way 
ANOVA with Bonferroni’s post-hoc test. Data is expressed as fold-change of Control group±SEM.  
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 The Expression of Cytochrome P450 1A1 Gene is 
Significantly Increased Only in Male Hyper-
Responsive Animals Treated with Sugen 5416 
Recently, it was observed that a specific colony of Sprague Dawley (SD) rats develop severe 
PAH-like phenotype with a single dose of Su5416 and without subsequent exposure to cHx 
(Jiang, 2016). The SD-hyper-responsive rats exhibited enhanced mortality at 8 weeks 
compared to rats of other rat strains and colonies (Jiang, 2016). Interestingly, unlike the 
Su5416/Hx model in more common rat colonies, the proportion of male rats exhibiting 
severe phenotype of the disease exceeds that of female rats in SD-hyper-responsive colony 
(Jiang, 2016). In the following text we have termed SD-typical colony rats as non-
responders, as they did not develop severe PAH phenotype after administration of a single 
dose of Su5416. While we have termed SD-hyper-responsive rats, which have developed 
severe PAH phenotype with Su5416 alone, as responders. 
We have investigated the expression of gene encoding for the CYP1A1 to assess the level of 
expression in hyper-responsive animals. The relative quantitation of CYP1A1 gene was 
significantly increased in male hyper-responsive group compared to the male animals 
characterised by normal response to treatment with Su5416 (Figure 3–24). Exposure of 
female animals to a single dose of Su5416 did not result in significant difference in the 
relative expression of CYP1A1 gene. Moreover, no difference between relative quantitation 
of CYP1A1 gene between female and male normally responsive animals was observed. 
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described previously, 
to assess the expression level of CYP1A1 by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, **p<0.01, 
One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–24: The relative expression of the gene encoding the CYP1A1 is increased in whole lungs from male hyper-responsive rats. 
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 The Relative Expression of Cytochrome P450 
1B1 and Aryl Hydrocarbon Receptor Repressor is 
Increased in Male Hyper-Responsive Rats, but not in 
Female 
Unlike the Su5416/Hx animal model of PAH, the treatment of male animals of hyper-
responsive SD rat colony with a single dose of Su5416 results in the onset of a severe disease 
phenotype, without requiring exposure to cHx. As the expression of CYP1B1 was previously 
reported to be increased in cHx and Su5416/Hx animal models, and CYP1B1 is considered 
as an important modulator of PAH development and progression, we wished to determine 
whether the expression of this gene is altered in animals who exhibit enhanced sensitivity to 
treatment with Su5416. We observed that the CYP1B1 mRNA expression was significantly 
increased in whole lungs from male animals exhibiting hyper-responsive character, while 
the increase in female hyper-responsive animals was not significant (Figure 3–25). No 
difference between normally responsive animals to Su5416 of both sexes was observed, 
while hyper-responsive males exhibited significantly higher gene expression level as hyper-
responsive females (Figure 3–25). 
To determine whether the AhR signalling pathway may be ubiquitously activated in animals 
who exhibit hyper-responsive character for Su5416 treatment, we also aimed to assess the 
AhRR gene expression levels, as this gene is not normally expressed. The levels of AhRR 
gene in whole lung samples from male animals that develop a severe PAH-like phenotype 
in the absence of cHx was significantly higher than in male animals, that are characterised 
as normally responsive to Su5416 (Figure 3–26). 
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described 
previously, to assess the expression level of CYP1B1 by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=3‒6 per group 
in triplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as RQ ±
RQmax
RQmin
, where RQ=Relative quantification.  
Figure 3–25: The relative expression of the gene encoding the CYP1B1 is increased in whole lungs from male hyper-responsive rats. 
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described 
previously, to assess the expression level of AhRR by Taqman quantitative Real Time-PCR. Results were normalised to the β-2-microglobulin. N=3‒6 per group 
in triplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as RQ ±
RQmax
RQmin
, where RQ=Relative quantification. 
 
Figure 3–26: The relative expression of the gene encoding the aryl hydrocarbon receptor repressor is increased in whole lungs from male hyper-
responsive rats. 
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 The Expression of the Aryl Hydrocarbon 
Receptor is Higher in Female Rats Exhibiting Hyper-
Responsive Character to Sugen 5416 Treatment 
Compared to their Male Counterparts 
Considering, the expression of CYP1A1 and CYP1B1 were increased in male rats exhibiting 
hyper-responsive phenotype to treatment with Su5416, we determined the relative 
expression of the AhR gene in these samples to show whether male animals, which developed 
severe disease-like phenotype also exhibited increased expression of the AhR gene, 
responsible for the induction of these genes. The relative expression of the AhR as per Real-
Time Quantitative PCR was significantly higher in female animals, which were 
characterised as hyper-responsive to Su5416 compared to hyper-responsive male animals 
(Figure 3–27). 
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described previously, 
to assess the expression level of AhR by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, *p<0.05, 
***p≤0.001, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–27: The relative expression of the gene encoding the aryl hydrocarbon receptor is increased in whole lungs from female hyper-responsive 
rats. 
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 The Expression of ARNT (HIF1β) is Increased 
Only in Female Rats Exhibiting Hyper-Responsive 
Character to Sugen 5416 
The AhR is only capable of mediating the alterations in the gene expression of its target 
genes when coupled with the ARNT (HIF1β). Moreover, a crosstalk between the AhR and 
HIF1α signalling pathways exists, where the ARNT (HIF1β) also serves as binding partner 
for HIF1α. A diagram of the cross talk between the mentioned pathways is shown in Chapter 
1.6.5. Importantly, the latter exhibits higher binding affinity for the ARNT (HIF1β) 
compared to AhR. Therefore, we examined the relative gene expression of the ARNT 
(HIF1β) in normally responsive animals and animals exhibiting a hyper-responsive 
character, of both sexes. The relative gene expression of ARNT (HIF1β) was significantly 
increased in female hyper-responsive animals compared to their normally responsive female 
controls (Figure 3–28). In male hyper-responsive animals, the relative expression of ARNT 
(HIF1β) was not altered when compared to males, which have normal response to Su5416 
treatment. Moreover, the relative expression of ARNT (HIF1β) in normally responsive 
female animals was significantly lower than in corresponding male animals (Figure 3–28). 
The increased expression of ARNT (HIF1β) could be associated with increased number of 
male animals form the SD colony, which exhibit hyper-responsive character to Su5416 
stimulation. 
No change was observed in the expression of HIF1α (Figure 3–29) and NQO1 (Figure 3–
30) between hyper-responsive and normally responsive.  
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described previously, 
to assess the expression level of ARNT (HIF1β) by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, 
*p<0.05, One-way ANOVA followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification.  
Figure 3–28: The relative expression of the gene encoding the aryl hydrocarbon receptor nuclear translocator protein (HIF1β) is increased in whole 
lungs from female hyper-responsive rats. 
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Whole lungs from hyper-responsive and typical Sprague-Dawley rat colonies, of both sexes, treated with a single dose of Su5416, were prepared, as described previously, 
to assess the expression level of HIF1α by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, One-way 
ANOVA followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–29: The relative expression of the gene encoding the hypoxia-inducible factor 1α in whole lungs derived from hyper-responsive rats of both 
sexes is unaltered. 
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Samples of whole lungs from hyper-responsive and typical Sprague Dawley rat colonies of both sexes, were prepared, as described previously, to assess the expression 
level of NQO1 by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=3‒6 per group in triplicate, One-way ANOVA followed by 
Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
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Figure 3–30: The relative expression of NAD(P)H quinone dehydrogenase 1 in the whole lungs from hyper-responsive rats of both sexes is unchanged. 
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 Male Rats Treated with Sugen 5416 and Chronic 
Hypoxia Exhibit Higher Levels of the Regulators of 
Hydroxylation-Dependent Proteasome-Mediated 
Degradation of HIF1α 
We previously discussed that we observed increased whole lung CYP1A1 expression at gene 
and protein level in Su5416/Hx-treated rats. Additionally, we looked at the expression of 
AhR and CYP1B1 in these animals. We have found no difference in the expression of AhR, 
however CYP1B1 expression was increased in treated animals of both sexes, with 
significantly higher levels in male treated animals compared to females. 
Moreover, we investigated the levels of proteins involved in HIF1α signalling pathway, due 
to the crosstalk between both signalling pathways (diagram is shown in Chapter 1.6.5). We 
found that HIF1α was significantly increased in female Su5416/Hx-treated animals 
compared to Nx females, probably due to exposure to Hx. Interestingly, the levels of HIF1α 
in male Nx animals were significantly higher than in their female counterparts (Figure 3–
31A). Nonetheless, no difference exists between Su5416/Hx-treated males and their Nx 
controls. When examining the expression of PHD2 and vHL, which are both involved in the 
regulation of hydroxylation-dependent proteasome-mediated degradation of HIF1α (see 
Figure 1–19), we discovered that Nx male animals exhibited higher levels of vHL compared 
to female rats kept in Nx conditions (Figure 3–31C). The levels of vHL in male treated 
animals are also significantly higher than those in treated females. The only significant 
difference in the expression of PHD2 was observed in male Su5416/Hx-treated animals 
compared to their female counterparts, where the expression in males was significantly 
higher than in females (Figure 3–31B). 
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Samples of whole lungs from Wistar Kyoto rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, 
as described previously, to assess the expression level of HIF1α, PHD2 and vHL by immunoblotting (A, B, C) with representative images shown in (D). Results were 
normalised to the β Actin. N=3‒4 per group in duplicate, **p≤0.01, ***p≤0.001, ****p≤0.0001, One-way ANOVA followed by Bonferroni’s post-hoc test. Data is 
expressed as mean±SEM. 
Figure 3–31: Prolyl hydroxylase 2 and von Hippel-Lindau tumour suppressor expression is increased in whole lungs from male rats treated with Sugen 
5416 and chronic hypoxia. 
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 Relative Expression of Hypoxia-Inducible Factor 
β in Pulmonary Arterial Smooth Muscle Cells Derived 
from Female Patients 
The level of expression of HIF1α and β have not yet been examined in hPASMCs derived 
from control and PAH patients of both sexes. We therefore assessed the expression in 
unstimulated protein samples. The results indicate the expression of HIF1β could be 
significantly higher in female PAH patients compared to controls (Figure 3–32). However, 
due to high background and apparent low expression levels of HIF1β, it is only warranted to 
report an observational trend based on accumulative results of repeating the experiment on 
different occasions. As due to poorer quality of the HIF1β blot, the unequal loading could 
result in artificially increased expression. 
The quantitation of expression level of the gene encoding HIF1α showed no difference 
between hPASMCs derived from control and patient subjects of both sexes (Figure 3–33A). 
However, when we examined the expression at protein level, we observed significant 
increase in HIF1α in hPASMCs derived from female PAH patients compared to controls 
(Figure 3–33B, C).  
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. 
PASMCs were then washed with ice-cold PBS and protein samples were collected and prepared as 
previously described. N=3–4 per group, in duplicate, *p<0.05, **p≤0.01, One-Way ANOVA 
followed by Bonferroni’s post-hoc test. Data is expressed as mean±SEM. 
 
Figure 3–32: Expression of ARNT (HIF1β) is increased in unstimulated human 
pulmonary artery smooth muscle cells derived from female PAH patients. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS and samples were collected 
and prepared as previously described to assess gene (A) and protein (B) expression levels. For assessment of gene HIF1α expression by Taqman quantitative Real Time-
PCR, results were normalised to β-2-microglobulin expression level. N=3–5 per group, in duplicate, *p<0.05, **p≤0.01, One-Way ANOVA followed by Bonferroni’s 
post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. HIF1α expression at protein level was assessed using immunoblotting (B). N=3–5 
per group, in duplicate, *p<0.05, unpaired t-test. Data is expressed as mean±SEM. Representative image of immunoblotting is provided in (C).  
HIF1α 
(86 kDa) 
β Aactin 
(42 kDa) 
Female Non-PAH Female PAH 
Figure 3–33: The basal expression of HIF1α at protein level is increased in unstimulated human pulmonary artery smooth muscle cells derived from 
female PAH patients. 
B 
E
x
p
r
e
s
s
io
n
 o
f 
H
IF
1

R
e
la
ti
v
e
 t
o

 A
c
ti
n
F
e
m
a
le
 N
o
n
-P
A
H
F
e
m
a
le
 P
A
H
0 .0
0 .5
1 .0
1 .5
2 .0
**
C 
R
Q
- 
H
IF
1

(R
e
la
ti
v
e
 t
o
 F
e
m
a
le
 N
o
n
-P
A
H
)
F
e
m
a
le
 N
o
n
-P
A
H
F
e
m
a
le
 P
A
H
M
a
le
 N
o
n
-P
A
H
M
a
le
 P
A
H
0 .0
0 .5
1 .0
1 .5
C
t 
 V
a
lu
e
s
 -
 H
IF
1

F
e
m
a
le
 N
o
n
-P
A
H
F
e
m
a
le
 P
A
H
M
a
le
 N
o
n
-P
A
H
M
a
le
 P
A
H
0
1 0
2 0
3 0
2 6 .1 6 2 5 .8 0 2 5 .5 4 2 6 .3 0A 
171 
 
 Chronic Hypoxia Elicits Significant Changes in 
Relative Quantitation of Genes Involved in Aryl 
Hydrocarbon Receptor and Hypoxia-Inducible Factor 
1α Signalling Pathways in Female, But Not in Male 
Rats 
In whole lungs from male SD rats exposed to cHx alone, the relative expression of AhR was 
significantly reduced compared to their Nx controls. When female rats exposed to cHx alone 
were compared to their Nx controls, no difference in the level of AhR expression was 
observed (Figure 3–34). However, the relative quantitation of HIF1β (ARNT) expression was 
significantly increased in female animals exposed to cHx compared to Nx controls (Figure 
3–35). And while no significant difference was observed in male animals, we demonstrated 
that relative expression of HIF1β (ARNT) in male rats exposed to cHx alone was 
significantly less than in equally treated female animals (Figure 3–35). 
Due to the possible crosstalk between the AhR and HIF1α signalling pathways, we also 
examined the relative quantitation of HIF1α gene expression in the whole lungs. We 
determined that only in female rats exposed to cHx alone, the relative quantitation of HIF1α 
gene expression was significantly increased compared to Nx controls (Figure 3–36). 
Interestingly, exposure to cHx did not elicit a significant change in HIF1α gene expression 
in males. 
 
172 
 
 
 
 
 
 
 
 
 
Samples of whole lung of Sprague-Dawley rats, of both sexes, exposed to chronic hypoxia or normoxia for 28 days, were prepared, as described previously, to assess the 
expression level of AhR by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, **p≤0.01, One-way 
ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification.
Figure 3–34: The relative expression of the gene encoding the aryl hydrocarbon receptor is decreased in whole lungs from male rats exposed to chronic 
hypoxia for 28 days 
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Samples of whole lung of Sprague-Dawley rats, of both sexes, exposed to chronic hypoxia or normoxia for 28 days, were prepared, as described previously, to assess the 
expression level of HIF1β (ARNT) by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, **p≤0.01, 
One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification.  
Figure 3–35: The relative expression of the gene encoding the HIF1β (ARNT)was only increased in whole lungs from female rats exposed to chronic 
hypoxia for 28 days. 
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Samples of whole lung of Sprague-Dawley rats, of both sexes, exposed to chronic hypoxia or normoxia for 28 days, were prepared, as described previously, to assess the 
expression level of HIF1α by Taqman quantitative Real Time-PCR. Results were normalised to β-2-microglobulin. N=4‒6 per group in triplicate, **p≤0.01, One-way 
ANOVA followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. 
Figure 3–36: The relative expression of the gene encoding the HIF1α was only increased in whole lungs from female rats exposed to chronic hypoxia 
for 28 days. 
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 Male Pulmonary Artery Smooth Muscle Cells 
Derived from PAH Patients Exhibit Higher Expression 
Levels of Proteins Regulating the Hydroxylation-
Dependent Proteasome-Mediated Degradation of 
Hypoxia-Inducible Factor 1α Signalling Pathway, Aryl 
Hydrocarbon Receptor and its Repressor 
To determine whether the expression of proteins involved in the AhR and HIF1α signalling 
pathways are altered in diseased condition, we compared the basal levels of expression in 
protein samples derived from control and patient hPASMCs, of both sexes. We determined 
that in male hPASMCs the expression of AhR is increased in PAH patients compared to 
controls (Figure 3–37). Equally, basal expression of AhRR at protein level was also 
increased in male PAH patients compared to male controls (Figure 3–38). While, the basal 
expression of CY1B1, an important modulator of PAH onset and development, was found 
to be increased in female and male patient hPASMCs compared to suitable controls (Figure 
3–40), no significant difference was observed for CYP1A1 (Figure 3–39). 
When examining the basal level of expression of regulators of hydroxylation-dependent 
proteasome-mediated degradation of HIF1α (PHD2 and vHL), we observed that observed 
that PHD2 and vHL expression was increased in male patient PASMCs but decreased in 
female patient PASMCs (Figure 3–41 and Figure 3–42).  
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. 
PASMCs were then washed with ice-cold PBS, and protein samples were collected and prepared as 
previously described. N=3–5 per group, in duplicate. **p≤0.01, unpaired t-test. Data is expressed as 
mean±SEM. 
AhR 
(92 kDa) 
β Actin 
(42 kDa) 
Male Non-PAH Male PAH 
Figure 3–37: In human pulmonary artery smooth muscle cells from male PAH patients, 
the basal expression of aryl hydrocarbon receptor is increased at protein level. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS, and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate. *p<0.05, unpaired t-test. Data is expressed as mean±SEM.  
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Figure 3–38: The basal expression of aryl hydrocarbon receptor repressor in human pulmonary artery smooth muscle cells from male PAH patients, 
is increased at protein level. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS, and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate. unpaired t-test. Data is expressed as mean±SEM.  
CYP1A1 
(56 kDa) 
β Actin 
(42 kDa) 
Male 
Non-PAH 
Male 
PAH 
CYP1A1 
(56 kDa) 
β Actin 
(42 kDa) 
Female 
Non-PAH 
Female 
PAH 
Figure 3–39: The basal expression of cytochrome P450 1B1 level in human pulmonary artery smooth muscle cells from male and female PAH patients, 
is not altered at protein level. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS, and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate. *p<0.05, **p≤0.01, unpaired t-test. Data is expressed as mean±SEM.  
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Figure 3–40: The basal expression of cytochrome P450 1B1 in human pulmonary artery smooth muscle cells from male and female PAH patients, is 
increased at protein level. 
 
Figure 3-C \s 1 39: The basal expression of cytochrome P450 1B1 in human pulmonary artery smooth muscle cells from male  
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS, and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate. *p<0.05, unpaired t-test. Data is expressed as mean±SEM.  
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Figure 3–41: The basal expression of prolyl hydroxylase 2 in human pulmonary artery smooth muscle cells from male PAH patients, is increased at 
protein level. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS, and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate. *p<0.05, **p≤0.01, unpaired t-test. Data is expressed as mean±SEM. 
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Figure 3–42: The basal expression of von Hippel-Lindau tumour suppressor in human pulmonary artery smooth muscle cells from male PAH patients, 
is increased at protein level. 
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 Male Pulmonary Artery Smooth Muscle Cells 
Derived from Control Patients Exhibit Lower Levels of 
Hypoxia-Inducible Factor 1β and Cytochrome P450 
1B1 than Female Cell Lines 
The AhR and HIF1α signalling pathways both appear to be involved in the onset of disease 
phenotype in PAH (Dean et al., 2017;Ray et al., 2008). Although, we have observed no 
difference in the expression of AhR (Figure 3–43 and Figure 3–44) and HIF1α in hPASMCs, 
there was a significant difference in the expression of ARNT (HIF1β). The expression of 
CYP1A1 did not differ between female and male control hPASMCs, possibly due to its 
inducible nature. Significantly less CYP1B1 was expressed in male control hPASMCs 
compared to female counterparts (Figure 3–43 and Figure 3–44). No significant difference 
in the expression of PHD2 and vHL was observed (Figure 3–43 and Figure 3–44). 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS and protein samples were 
collected and prepared as previously described. N=3–6 per group, in duplicate, *p<0.05, unpaired t-test. Data is expressed as mean±SEM. 
Figure 3–43: In human pulmonary artery smooth muscle cells from male control patients, the basal expression of cytochrome P450 1B1 and hypoxia-
inducible factor 1β is decreased. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. 
PASMCs were then washed with ice-cold PBS, and protein samples were collected and prepared as 
previously described. N=3–6 per group, in duplicate.  
Figure 3–44: Representative immunoblot images of basal expression levels of proteins 
involved in AhR and HIF1α signalling pathways in pulmonary artery smooth muscle cells 
derived from controls. 
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 Male Pulmonary Artery Smooth Muscle Cells 
Derived from Clinical Patients Exhibit Higher Levels 
of Aryl Hydrocarbon receptor, and Proteins Involved 
in the Regulation of Oxygen-Dependent Degradation 
of Hypoxia-Inducible Factor 1α 
The expression of the mediators of AhR and HIF1α signalling pathways have not been 
assessed in terms of protein expression in female and male patient hPASMCs to determine 
whether a sex-related difference exists. A possible sex dimorphism might contribute to the 
higher penetrance of the disease in female population (Ling et al., 2012;Escribano-Subias et 
al., 2012). 
No significant difference in the expression of HIF1α and 1β was observed between samples 
derived from female and male hPASMCs derived from PAH patients (Figure 3–45 and 
Figure 3–46). Moreover, the expression of CYP1A1 and CYP1B1 did not differ between 
male and female PAH patients (Figure 3–45 and Figure 3–46). However, significant 
differences were observed in the protein expression of AhR, vHL and PHD2, with 
significantly more protein expressed in male PAH patient hPASMCs compared to female 
counterparts (Figure 3–45 and Figure 3–46). 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS and protein samples were 
collected and prepared as previously described. N=3–5 per group, in duplicate, *p<0.05, **p≤0.01, unpaired t-test. Data is expressed as mean±SEM. 
Figure 3–45: In human pulmonary artery smooth muscle cells derived from male PAH patients, the basal expression of aryl hydrocarbon receptor, 
prolyl hydroxylase 2 and von Hippel-Lindau tumour suppressor is increased. 
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HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. 
PASMCs were then washed with ice-cold PBS, and protein samples were collected and prepared as 
previously described. N=3–5 per group, in duplicate.   
AhR 
(92 kDa) 
HIF1α 
95 kDa) 
HIF1β 
(86 kDa) 
CYP1B1 
(62 kDa) 
CYP1A1 
(56 kDa) 
PHD2 
(51 kDa) 
vHL 
(19 kDa) 
β actin 
(42kDa) 
Female PAH Male PAH 
Figure 3–46: Representative immunoblot images of basal expression levels of proteins 
involved in AhR and HIF1α signalling pathways in pulmonary artery smooth muscle cells 
from patients. 
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 The Expression of Vascular Endothelial Growth 
Factor Receptor 2 is Significantly Decreased in Sugen 
5416/Hypoxia-Treated Female Rats 
As Su5416 is a known selective inhibitor of the VEGF receptor 1/2. We investigated 
VEGFR2, for which Su5416 exhibits the greatest affinity, is expressed in whole lungs of 
Su5416/Hx model. For clarity, VEGFR isoforms 1 and 2 were previously known as Flk-1 
and Kdr. 
We observed that the relative expression level of Kdr gene is decreased in female rats, treated 
with a single dose of Su5416 and exposed to cHx, compared to Nx controls (Figure 3–47A), 
while in male animals no significant changes were observed. Equally, using immunoblotting 
technique we showed that at protein level, the expression of VEGFR2 was decreased in 
Su5416/Hx-treated female animals compared to their Nx controls (Figure 3–47B, C).
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Samples of whole lung of Sprague-Dawley rats, of both sexes, treated with single dose of Sugen 5416 and exposed to hypoxia and their normoxic controls, were prepared, 
as described previously, to assess the expression level of VEGFR2 by Taqman quantitative Real Time-PCR (A). Results were normalised to β-2-microglobulin. N=4‒6 
per group in triplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative quantification. The level 
of VEGFR2 (Kdr) protein expression was assessed using immunoblotting (B). N=3‒6 per group in duplicate, *p<0.05, One-way ANOVA followed by Dunnett’s post-
hoc test. Representative immunoblotting image is shown in (C). 
R
Q
 -
K
d
r
(R
e
la
ti
v
e
 t
o
 F
e
m
a
le
 N
o
r
m
o
x
ic
)
F
e
m
a
le
 N
o
rm
o
x
ic
F
e
m
a
le
 S
u
5
4
1
6
/H
x
M
a
le
 N
o
rm
o
x
ic
M
a
le
 S
u
5
4
1
6
/H
x
0 .0
0 .5
1 .0
1 .5
*
F
e
m
a
le
 N
o
rm
o
x
ic
F
e
m
a
le
 S
u
5
4
1
6
/H
x
M
a
le
 N
o
rm
o
x
ic
M
a
le
 S
u
5
4
1
6
/H
x
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
E
x
p
r
e
s
s
io
n
 o
f 
V
E
G
F
R
2
 (
K
d
r
)
R
e
la
ti
v
e
 t
o

  
A
c
ti
n
*
C
t 
V
a
lu
e
s
 -
 K
d
r
F
e
m
a
le
 N
o
rm
o
x
ic
F
e
m
a
le
 S
u
5
4
1
6
/H
x
M
a
le
 N
o
rm
o
x
ic
M
a
le
 S
u
5
4
1
6
/H
x
0
5
1 0
1 5
2 0
2 5 2 3 .1 6 2 3 .2 0 2 2 .9 8 2 3 .2 0
VEGFR2 (Kdr) 
(150 kDa) 
β Actin 
(42 kDa) 
Figure 3–47: Expression of vascular endothelial growth factor receptor 2 in whole lung from Sugen 5416 model. 
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 The Effects of Sugen 5416 in Control Human 
Microvascular Endothelial Cells 
The disruption of vascular endothelium, resulting in endothelial dysregulation, leads to 
increased vascular tone due to imbalance in the production of vasoactive compounds 
favouring vasoconstriction, as well as dysregulated proliferation and growth of SMCs due 
to alterations in molecules influencing proliferative pathways in these cells (Peiro et al., 
1995). Several research groups have reported the imperative role of endothelium in the onset 
of PAH-like phenotype in animal models (Taraseviciene-Stewart et al., 2001;Ciuclan et al., 
2011). In the Su5416/Hx model of PAH, early transient apoptosis of ECs is closely 
associated with the onset of experimental phenotype (Ciuclan et al., 2011) and expansion of 
apoptosis-resistant sub-population of ECs (Jurasz et al., 2010). 
As previous studies reported the effects of Su5416 on ECs in whole lungs derived from 
animals exposed to Su5416/Hx, we aimed to investigate its effects in control human 
microvascular ECs. We assessed apoptosis of ECs by cell number and immunoblotting 
quantification of active Caspase 3. We have observed no significant difference between 
treatment with 2% CSS and 2% CSS with DMSO, indicating the percentage of DMSO added 
to deliver treatments did not affect the overall cell number. The number of cells was 
significantly reduced in 0.1% CSS and 100μM resveratrol treated cells, serving as positive 
control groups for apoptosis compared to 2% CSS (Figure 3–48A, B). In the negative control 
group, where ECs were exposed to endothelial cell growth medium MV SupplementMix, 
the number of cells was significantly increased compared to control group. The decrease in 
cell number in Su5416 treatment groups appeared to be dose related, with significant effect 
observed only in 1μM Su5416 treatment group (Figure 3–48A, B). FICZ, a potent AhR 
pathway activator, induced a significant decrease in cell number only at the concentration of 
50nM (Figure 3–48A). 
Treatment of ECs with positive control for apoptosis, 100μM resveratrol, resulted in 
significantly increased cleaved Caspase 3, while there was no significant difference in the 
growth medium treatment group, serving as negative control, compared to 2% CSS treated 
cells. Moreover, the treatment of ECs with FICZ also resulted in significantly increased 
proportion of cleaved Caspase 3 (Figure 3–48B). Stimulation of ECs with 1μM and 5μM 
Su5416 resulted in significantly increased cleavage of Caspase 3 compared to the 2% CSS 
control group (Figure 3–48B). Administration of 16αOHE1 in vivo in mice has been 
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previously shown to inflict a PH phenotype only in female animals (White et al., 
2012;Johansen, 2014). We therefore wanted to determine whether the observed changes in 
the haemodynamic and remodelling parameters could be preceded by endothelial injury. 
Pro-apoptotic signalling as per increased active Caspase 3 was also observed upon exposure 
of ECs to 1nM 16αOHE1, but not 100nM 16αOHE1 (Figure 3–48B). 
 The Proliferation of Human Pulmonary Arterial 
Smooth Muscle Cells in Normoxic Conditions is Not 
Affected by Sugen 5416 
During the onset and progression of PAH, the vascular wall of the distal non-muscular 
vessels of the pulmonary circulation gradually becomes thickened and muscularised (Barst 
et al., 2011) either through i) differentiation of pericytes and/or and fibroblasts, into SMCs, 
followed by their subsequent proliferation and hypertrophy (Tuder et al., 2007; Rabinovitch, 
2012) or ii) the transition of SMCs phenotype from contractile to synthetic and/or 
proliferative phenotype, where the metabolic pathways regulating SMCs proliferation, 
migration and apoptosis, e.g RhoA/ROCK (Barst et al., 2011; Chan and Loscalzo, 2008; 
Sheikh et al., 2014) are dysregulated. There was extensive vascular muscularisation and 
significantly increased percentage of fully muscularised vessels in the lungs of their murine 
Su5416/Hx model compared to control group, or groups of animals exposed to Hx or Su5416 
alone(Ciuclan et al., 2011). 
To determine whether 48-hour stimulation with Su5416 affects the proliferation of SMCs, 
we have assessed the effects of stimulation with (100nM, 500nM, 1μM and 5μM) Su5416 
in SMCs in Nx conditions by cell counting. We have compared the cell number in treatment 
groups to 1% CSS with 0.5% (v/v) DMSO. The culturing of cells in the presence of 10% 
CSS resulted in significantly increased number of cells, indicating increased proliferation. 
However, over a wide range of Su5416 concentration, we did not observe a statistically 
significant change in the cell number of SMCs compared to control group (Figure 3–49). 
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Samples of human pulmonary microvascular ECs derived from a female control subject, treated with 
Su5416(500nM–5μM), FICZ (5–50nM) and 16αOHE1 (1nM and 10nM), were prepared as 
described previously, to assess the cell number using automatic cell counter (A) and the level of 
protein expression of activated cleaved Caspase 3 (B) with representative visualisation shown in (C). 
Results of protein expression were normalised to the total Caspase 3. N=4 per group in duplicate, 
***p<0.001, **p<0.01, *p≤0.05, One-way ANOVA followed by Dunnett’s post-hoc test. Data is 
expressed as mean±SEM. 
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Figure 3–48: The Effects of Sugen5416 stimulation in human microvascular endothelial 
cells. 
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HPASMCs from female patients were quiesced for 24 hours in 0.5% CSS PRF DMEM media. Cells 
were incubated with a range of concentrations of Su5416. Experiments were conducted in the 
presence of 1% CSS PRF DMEM media. Cell number was assessed after 48 hours by 
haemocytometer. N=4 per group in triplicate, ***p≤0.001, **p≤0.01. One-way ANOVA followed 
by Bonferroni’s post-hoc test. Data is expressed as percentage of 1% CSS +DMSO control ± SEM.  
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Figure 3–49: In normoxic conditions, Sugen 5416 does not increase proliferation 
pulmonary artery smooth muscle cells derived from females diagnosed with pulmonary 
arterial hypertension. 
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 The Proliferation of Human Pulmonary Arterial 
Smooth Muscle Cells in Hypoxic Conditions is 
Increased by Sugen 5416 
Animals treated with Su5416 only develop severe phenotype of PAH when exposed to cHx, 
while only a moderate phenotype is observed in animals in Nx conditions.  
We have carried out preliminary experiments assessing the suitability of time points to 
determine the effects of Su5416 stimulation in ECs in Hx. To summarise, upon stimulation 
with Su5416, cells were placed in a Hx incubator chamber in sterile conditions. The chamber 
was then flushed with gas mixture containing lowered atmospheric oxygen tension (1% O2, 
5% CO2 (v/v)) and placed in the incubator. This procedure was repeated every 24 hours. 
Out of the three time-points considered, at 24 (Figure 3–50A) and 72 hours (Figure 3–50B), 
stimulation with Su5416 either did not result in significant alterations in cell number, or 
resulted in drastically reduced cell number, indicating cellular death due to prolonged 
exposure to Hx. Therefore, all further experiments were considered at 48-hour time-point.  
As in Nx conditions, culturing SMCs in the presence of 10% CSS prompted a significant 
increase in the cell number, indicating increased proliferation of these cells compared to the 
control group. In cHx, treatment with Su5416 elicited a concentration-dependent increase in 
cell number, with 1μM resulting in statistically significant changes in cellular proliferation 
(Figure 3–51).  
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HPASMCs from female patients were quiesced for 24 hours in 0.50% CSS PRF DMEM media. Cells 
were incubated with a range of concentrations of Su5416 and exposed to hypoxia for 24 (A) and 72 
(B) hours, respectively. Experiments were conducted in the presence of 1% CSS PRF DMEM media. 
Cell number was assessed after 48 hours by haemocytometer. N=4 per group in triplicate, 
***p≤0.001, **p≤0.01, *p<0.05. One-way ANOVA followed by Bonferroni’s post-hoc test. Data is 
expressed as percentage of 1% CSS +DMSO control ± SEM.  
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Figure 3–50: Time course experiment showed 24 hour and 72 hour time points were not 
suitable for further experiments in female human pulmonary artery smooth muscle cells. 
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HPASMCs from female patients were quiesced for 24 hours in 0.50% CSS PRF DMEM media. Cells 
were incubated with a range of concentrations of Su5416. Experiments were conducted in the 
presence of 1% CSS PRF DMEM media. Cell number was assessed after 48 hours by 
haemocytometer. N=4 per group in triplicate, ***p≤0.001, **p≤0.01, *p<0.05. One-way ANOVA 
followed by Bonferroni’s post-hoc test. Data is expressed as percentage of 1% CSS +DMSO control 
± SEM.  
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Figure 3–51: Stimulation with Sugen 5416 in hypoxia (0.1% O2, 5% CO2) increased 
proliferation of pulmonary artery smooth muscle cells derived from females diagnosed 
with pulmonary arterial hypertension. 
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 Sugen 5416 Increased Localisation of the Aryl 
Hydrocarbon Receptor in the Nucleus in Female 
Patient Pulmonary Artery Smooth Muscle Cells 
In the absence of a suitable ligand, the inactive AhR is localised in the cytoplasm, where it 
is bound to accessory proteins, which keep the receptor in a conformation capable of binding 
a suitable ligand (see Figure 1–18). Upon receptor’s activation, the ligand-bound receptor is 
translocated into the nucleus, where it encounters and binds to the ARNT (HIF1β), thereby 
forming the transcriptionally active complex, resulting in the induction of target genes. To 
determine whether stimulation of hPASMCs with Su5416 might result in the activation of 
the AhR, we have examined the expression of AhR in nuclear and cytoplasmic fraction 
utilising the REAP protocol. 
We have observed that exposure of hPASMCs derived from female patients to Su5416 
elicited increased expression of AhR in the nuclear fraction (Figure 3–52A). A significant 
difference in AhR expression between cytoplasmic and nuclear fractions was recorded at 90 
minutes (Figure 3–52A). Our results indicate that at short time-points, stimulation with 
Su5416 directly resulted in the translocation of the AhR from cytoplasm to the nucleus.  
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HPASMCs from female patients were washed with ice-cold PBS solution and incubated with 1μM 
Sugen5416 as indicated. Experiments were conducted in the presence of 1% CSS PRF DMEM 
media. Protein samples were prepared according to the REAP fractionation protocol. N=3 in 
duplicate, *p<0.05. Two-way ANOVA followed by Dunnett’s post-hoc test. Data is expressed as 
fold-change to Veh±SEM.  
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Figure 3–52: Nuclear translocation of aryl hydrocarbon receptor in pulmonary artery 
smooth muscle cells following time-dependent stimulation with 1μM Sugen 5416. 
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3.3 Discussion 
The evidence for the underlying reasons for the prevailing occurrence of PAH in females is 
still limited. However, recently emerging literature is supportive of a causative role of 
oestrogens and their altered metabolism in females (Rajkumar et al., 2010;White et al., 
2011a;White et al., 2012;Mair et al., 2014). The pathogenesis of PAH in humans is 
characterised by numerous cofounding molecular processes, resulting in a disease, whose 
complex mechanism and novel therapeutic approaches are difficult to investigate. Thus, 
numerous animal models were developed to explore the individual contributions of these 
processes. Experimental models which recapitulate the important hallmarks of PAH, such 
as the Su5416/Hx model, are becoming the gold standard in the field of PAH research. The 
mechanism responsible for the development of Su5416/Hx experimental phenotype are still 
largely unknown. This work provides an understanding of the mechanisms driving the 
experimental PH in the Su5416/Hx animal model. 
 CYP1A1 in Animal Models of Pulmonary Arterial 
Hypertension 
A significant upregulation of the gene encoding for the inducible oestrogen-metabolising 
enzyme CYP1A1 was observed and considering that altered oestrogen metabolism was 
associated with the development of experimental and clinical PAH, we aimed to determine 
whether its expression might exhibit sex- or disease-related expression patterns. The relative 
expression of CYP1A1 in clinical samples of Smad1 heterozygous female mice and cHx 
animals of both sexes was significantly reduced. In samples derived from hPASMCs, 
however, the determination of CYP1A1 gene expression was less reliable, probably due to 
more marginal expression of the enzyme in these cells and larger variability in the stability 
of housekeeper gene. Interestingly, the expression of CPY1A1 in whole lungs from 
Su5416/Hx model was significantly increased in male and female animals. Our observations 
were consistent with previous reports that prior exposure to Hx greatly hindered AhR 
signalling induced by receptor activator 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in human 
hepatocytes (Vorrink et al., 2014). Albeit the reduction in CYP1A1 transcription was 
reported to be independent of HIF1α signalling in these cells (Allen et al., 2005). 
Nonetheless, microarray analysis in breast cancer cell line MCF7 indicated that the 
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expression of CYP1A1 in these cells might be increased in Hx with unknown underlying 
mechanism (Elvidge et al., 2006). 
We therefore wished to determine why CYP1A1 expression was highly increased in the 
Su5416/Hx model, considering it was largely decreased in other experimental PH models. 
Recent report on the reversal of experimental PAH by metformin revealed that the 
hypoglycaemic drug mediates a decrease in the circulating levels of oestrogen and its 
metabolites by decreasing the expression of aromatase, CYP1B1 and the transcription factor 
affecting the expression of the latter enzyme, the AhR. CYP1A1 gene expression was 
considerably more than that of CYP1B1, in female and male animals, respectively. This is 
likely to be due to the fact that CYP1B1 is constitutively expressed whilst CYP1A1 is an 
inducible enzyme and not normally expressed at significant levels. Therefore, the expression 
of CYP1A1 is the most sensitive marker for AhR activation (Taraseviciene-Stewart et al., 
2001). Although an increase in AhR expression was previously reported (Dean et al., 2016), 
we did not note such changes in the expression of AhR in animals with established 
Su5416/Hx-induced PAH phenotype. We hypothesised that the mechanism of Su5416/Hx-
induced experimental PH might involve the activation of the AhR signalling pathway, as 
Su5416 was shown to activate AhR, and the corresponding murine receptor isoforms, with 
a potency comparable to that of TCDD (Mezrich et al., 2012). The regulation of the 
localisation of a ligand-activated transcription factor is a highly dynamic process, involving 
a mechanism associated with stabilisation of the receptors and retention in the cytoplasm, as 
well as its transport to the nucleus. The transportation of AhR between the cytoplasm and 
the nucleus was shown to occur also in the absence of an exogenous ligand (Richter et al., 
2001). However, in the presence of an exogenous ligand, the import of AhR to the nucleus 
is significantly increased, without stopping nuclear export of the receptor (Richter et al., 
2001). Hence, the binding of a suitable ligand, leading to enhanced receptor translocation to 
nucleus, might be important, and the increase in expression of the receptors might not be 
required for its enhanced transcriptional activity. 
To determine whether the AhR signalling pathway may be activated in animals with 
established experimental disease phenotype, we have assessed the expression of several 
downstream target genes, such as the AhRR and NQO1, both of which have been found to 
be significantly increased in the lungs from Su5416/Hx animals. While the increment in the 
expression of AhRR gene was similar in magnitude of CYP1A1, the magnitude of change in 
the expression of NQO1 was significantly lower. In the cHx animal model, we observed that 
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the NQO1 gene was significantly reduced in male animals exposed to cHx alone when 
compared to their female counterparts. This might indicate that Hx might interfere with the 
induction of AhR signalling, as previously reported (Vorrink et al., 2014). 
We demonstrated that several of the transcription target genes of the AhR signalling pathway 
are induced in the Su5416/Hx model, therefore we were interested to determine the effects 
of Su5416 compound in the in vitro model of hPASMCs. The importance of the use of in 
vitro models in research became increasingly significant, since the care for welfare of 
animals in research has become stringently regulated by the government and criticised by 
the public. We reduced the number of animals studied by carrying out all expression 
experiments in the lungs of animals used for previous studies. As an innovative approach to 
understanding the mechanism behind the Su5416/Hx-induced experimental PAH, we 
employed our established in vitro model, where we have stimulated hPASMCs derived from 
female control and clinical patients and assessed the expression of AhR target genes involved 
in oestrogen metabolism. We showed that in both cases, stimulation with Su5416 resulted in 
significant increase in protein and gene expression of CYP1A1. The observed increase in 
CYP1A1 expression, however, was significantly larger than that observed with CYP1B1. 
Moreover, the assessment of CYP1B1 expression was hindered by the selection of available 
antibodies, which did not give reliable and precise results. Where possible, monoclonal 
antibodies were utilised, however, due to existence of different CYP isoforms, several bands 
were shown, despite taking great care to optimise the protocol. We have analysed the bands, 
which corresponded closely to the molecular weight specified by the provider. Nonetheless, 
the observed difference might be attributed to the inducible nature of CYP1A1, while 
CYP1B1 an inducible and constitutively expressed forms of exist (Eltom et al., 1999). 
Interestingly, changes in the expression of CYP1B1 due to gene induction, through 
activation of AhR by 3MC, was only observed at protein level (McFadyen et al., 2003), 
which corresponds with our observations in female control hPASMCs. Our published 
findings indicate that in Nx rats CPY1A1 was expressed mainly in the PA endothelium, 
while in Su5416/Hx-treated animals the expression was also detected in the medial layer of 
small PAs (Dean et al., 2017). It appeared that Su5416 administration influenced CYP1A1 
expression in the Su5416/Hx model. When hPASMCs were pre-treated with an AhR 
antagonist, CH223191, prior to stimulation with Su5416, to determine whether the observed 
changes in the expression of oestrogen metabolising enzymes occurs through activation of 
the AhR, the effects in protein expression were reversed, but only in female hPASMCs 
derived from control subjects. This observation could be associated with reported increased 
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expression of AhR in female cell lines derived from clinical patients (Dean et al., 2016). We 
found that AhR expression was not changed by Su5416, specifically in hPASMCs. However, 
as previously discussed, it is possible that an increase in AhR expression is not required for 
the reported increase in the induction of CYP1A1 and CYP1B1 (Dean et al., 2017), as 
receptors’ activation might be sufficient to confer the changes in transcription of target 
genes. We were interested in the effects Su5416 of on expression of ARNT (HIF1β), and 
mediators involved in Hx-inducible signalling pathway (HIF1α, PHD2 and vHL). This is of 
interest as there is possible crosstalk between the two pathways. Overexpression of ARNT 
(HIF1β) can alleviate Hx-induced decrease in CYP1A1 expression (Vorrink et al., 2014). 
Therefore, we wanted to determine whether activation of the AhR pathway by Su5416 might 
affect its expression in hPASMCs. We found that Su5416 did not change the expression of 
ARNT (HIF1β) in hPASMCs. Equally, we assessed the expression of PHD2 and vHL, which 
are vital in the regulation of proteasome-mediated degradation of HIF1α in Nx. If Su5416 
increased the expression of PHD2 and vHL in Nx, this could also affect the degradation of 
HIF1α in Hx, thereby enhancing the induction of AhR-regulated gene expression. No change 
in the expression of PHD2, vHL and HIF1α by Su5416 in Nx was observed. In Hx 
conditions, however, we previously reported that Su5416 reduced the levels of HIF1α in 
cytoplasmic and nuclear fractions (Dean et al., 2017), showing also AhR signalling pathway 
might interfere with the induction of Hx-inducible genes. 
 AhR Signalling in Rat Colony Exhibiting Hyper-
Responsiveness to Sugen 5416 Exposure 
The establishment of experimental PH in Su5416/Hx model was closely related to exposure 
of animals to cHx, as otherwise animals would only develop a moderate disease phenotype. 
However, a specific SD rat colony discovered in Canada developed a severe PAH phenotype 
when treated only with a single dose of Su5416, without the exposure to cHx (Jiang, 2016). 
The genetic background of rat strain played an important role in the response of animals to 
Su5416 treatment. Hyper-responsive animals exhibited increased haemodynamic and 
vascular remodelling parameters compared to typical SD strain and other commonly 
available rat strains (such as Lewis and Fischer rats), as assessed by RVSP and RV/(LV+S) 
parameters (Jiang, 2016). Additionally, the presence of angio-proliferative plexiform-like 
lesions in Nx was only reported in hyper-responsive animals (Jiang, 2016). These animals 
also exhibited increased apoptosis of ECs in small arterioles shortly after administration of 
Su5416 (Jiang, 2016). The genetic background differences of rat strains used to establish 
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experimental PAH models influenced the severity of experimental phenotype in Su5416/Hx 
model (Jiang, 2016). Unpublished data indicated that the SD strain with enhanced response 
to Su5416 treatment exhibits sex dimorphism, favouring the development of the disease in 
male animals (Stewart et al., unpublished). As exogenous 17βE2 was shown to exacerbate 
the Su5416/Hx phenotype in typical rat strains (Tofovic et al., 2012), it was our intention to 
employ an in situ approach to determine whether hyper-responsive male SD rats exhibit 
differential expression of mediators involved in AhR and HIF1α signalling pathways. Any 
observed differences might point towards important modifiers of PAH-like phenotype in 
these animals and link-in with our observations in Su5416/Hx model in typical rat strains. 
We therefore aimed to assess the expression of CYP enzymes associated with oestrogen 
metabolism and other proteins involved in the AhR and HIF1α signalling pathways in the 
lungs from normally responsive and hyper-responsive rats. The expression of CYP1A1 and 
CYP1B1 in this PH experimental model was only increased in males, which were confirmed 
to develop severe experimental PH without exposure to cHx, hence characterised as ‘hyper-
responsive’. Moreover, the expression of the AhRR, which is induced by the activation of 
the AhR to serve as negative regulator of this signalling pathway, was also increased in 
hyper-responsive male animals. Surprisingly, the expression of AhR in hyper-responsive 
male animals was significantly lower than in their female counterparts. Further 
investigations showed that ARNT (HIF1β), which binds to AhR and thereby forms an active 
transcriptional heterodimer, was significantly increased in female hyper-responsive animals. 
In typical SD strain, males exhibited reduced expression of ARNT (HIF1β). The 
overexpression of ARNT (HIF1β) was shown to rescue the inhibitory effects of Hx enforced 
upon AhR signalling pathway (Vorrink et al., 2014). The basal levels of expression of this 
particular protein might therefore be of utmost importance in the establishment of the 
experimental PH in female animals. Interestingly, in the SD colony exhibiting enhanced 
sensitivity to Su5416, the hyper-responsive female rats increased expression of ARNT 
(HIF1β), while the expression of HIF1α remained unchanged at gene level in all the groups. 
We therefore examined whether the expression of HIF1α, and the regulator proteins involved 
in the oxygen-dependent ubiquitination and degradation, PHD2 and vHL in whole lung 
samples of Su5416/Hx model. The increase in the expression of HIF1α was observed at 
protein level in Su5416/Hx-treated female animals compared to their Nx controls, which 
may be due to the exposure of animals to Hx. Some caution is required with the interpretation 
of this data, as the level of HIFs was shown to be rather low in these tissues. Furthermore, 
we also noted that Nx males had significantly higher levels of HIF1α compared to Nx 
females. Unpublished results from our research group indicated that hyper-responsive 
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female SD rats had significantly more HIF1α at protein levels (Docherty, unpublished). 
Therefore, the possible increased expression of AhR, ARNT (HIF1β) and HIF1α in hyper-
responsive SD female rats might result in higher coupling of these signalling pathways, 
resulting in the onset of experimental PAH. Whereas, in male hyper-responsive rats 
enhanced signalling through AhR might be important. Increased expression of AhR target 
genes in male hyper-responsive SD rats pointed toward a constitutively active receptor in 
these animals, warranting the investigation of such possibility. The investigation of the 
genetic background of hyper-responsive SD colony indicated that enhanced expression of 
genes under the transcriptional activation of AhR, such as CYP1A1 and CYP1B1 might be 
associated with increased probability of PAH phenotype establishment in these animals. It 
appears that the mechanisms driving the experimental PAH phenotype depended on the sex 
of the animal. 
 Hypoxia-Inducible Factor 1α in Human Pulmonary 
Artery Smooth Muscle Cells 
A difference in gene induction in response to reduced O2 exists between males and females 
in the right and left heart ventricles (Bohuslavova et al., 2010). Although the initial induction 
of genes in response to O2 deprivation is higher in females, it is males who exhibit 
significantly higher levels of target genes regulated by Hx (Bohuslavova et al., 2010). To 
determine the basal expression of receptors and their binding partners involved in AhR and 
HIF1α signalling pathways, we prepared unstimulated hPASMCs derived from control and 
IPAH patients of both sexes. A trend of increased expression of HIF1β in female PAH 
patient hPASMCs was observed. However, due to lower expression level in hPASMCs and 
poor response of the employed antibody, the quantitation of this particular protein is not 
completely reliable. Nonetheless, the expression of HIF1α in these cells compared to female 
controls was significantly higher. Considering the affinity of the HIF1α for its obligatory 
binding partner for heterodimerisation is significantly higher than that of AhR, increased 
expression of the HIF1α might interfere with AhR signalling. Even though the documented 
increased binding of HIF1α to ARNT may be a direct consequence of decreased degradation 
of HIF1α during O2 deprivation, resulting in increased proportion of the receptor in the 
receptive form to bind to ARNT, compared to AhR (Chan et al., 1999). Interestingly, in male 
rats exposed to cHx alone, we observed a significant decrease in the gene expression of AhR, 
which was not observed in females. 
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ARNT (HIF1β), the obligate partner of the AhR, is ubiquitously and constitutively expressed 
in all cells, as it is involved in pathways other than HIF1 signalling. Recently, conflicting 
evidence on the effects of Hx on the expression of ARNT (HIF1β) were reported. Mandl and 
Depping observed that Hx does not affect the expression levels (Mandl and Depping, 2014). 
Whilst others reported that decreased partial pressure of O2 increases the expression of 
HIF1α and ARNT (HIF1β) (Wang et al., 1995). It appears that the induction of ARNT 
(HIF1β) by Hx greatly depends on the cell and tissue type, with induction being more 
common in tumour tissues. Moreover, ARNT (HIF1β) might also have a more restricted 
pattern of expression compared to HIF1α subunit. Our results indicate that in the whole lung 
samples from rats exposed to cHx alone, the expression of HIF1β is only increased in female 
animals, while the expression in Hx males is significantly reduced. Equally, in these animals 
only female Hx rats showed an increase in HIF1α. Hx therefore appeared to increase the 
expression of both HIFs in female rats, corroborating the findings of (Wang et al., 1995). 
A comparison of basal levels of proteins involved in the AhR and HIF1α signalling pathways 
was not yet reported, therefore we aimed to examine the existence of possible basal 
differences in hPASMCs. When comparing the basal protein expression between control and 
patient PASMCs for each sex, we observed that in male patient hPASMCs the expression of 
AhR, AhRR, CYP1B1, PHD2 and vHL are significantly increased compared to controls, 
whilst in female cell lines, patient cells exhibited more CYP1B1, and less PHD2 and vHL. 
It appears that similarly, as in hPASMCs derived from male clinical patients, the expression 
of vHL and PHD2 was also increased in whole lungs of male rats with Su5416/Hx-induced 
experimental PAH. Some of these results should be considered with caution, as the protein 
expression is low, bands obtained for quantification do not have sharp edges despite 
considerable optimisation procedures, and on occasion contain multiple bands, indicating 
the presence of multiple isoforms. Nonetheless, the observations in the whole lung samples 
from female Su5416/Hx animals are in accordance with the observed increase in HIF1α 
expression in female animals. Moreover, the decreased expression of PHD2 and vHL might 
affect the basal expression of HIF1α and/or its expression in Hx. It may also be associated 
with less severe disease phenotype in male animals due to the absence of a synergy between 
AhR and HIF1α signalling pathways. We believe that this aspect of PAH pathogenesis must 
be further investigated. Since Hx was shown to induce the proliferation of SMCs derived 
from systemic arteries (Ray et al., 2008), increased expression of HIF1α observed in 
hPASMCs from female PAH patients might have implications in establishment of more pro-
proliferative phenotype of these cells. Equally, in male patient hPASMCs increased 
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expression of protein regulating HIF1α degradation in basal levels might affect proliferation 
of these cells in Hx. 
 Effects of Sugen 5416 in Pulmonary Microvascular 
Endothelial Cells 
In the Su5416/Hx animal model, establishment of the experimental disease phenotype 
involves vascular injury and hyper-proliferation of vascular cells (Taraseviciene-Stewart et 
al., 2001). As EC apoptosis may initiate vascular remodelling, and Su5416 induced apoptosis 
of ECs in animal models (Taraseviciene-Stewart et al., 2001;Jiang, 2016), we wished to 
examine this in hPMECs, which we considered as control ECs. Increased apoptosis of ECs 
might result in the selection of apoptosis-resistant ECs that contribute to the formation of 
angio-proliferative plexiform lesions in clinical and experimental PAH (Jurasz et al., 2010). 
Here we established that stimulation with Su5416, as well as with FICZ, which is a known 
AhR agonist, caused apoptosis of ECs as assessed by a reduction in cell number and 
immunoblotting for active Caspase 3. Recently we reported that stimulation of BOECs from 
PAH patients with Su5416 resulted in increased proliferation of these cells (Dean et al., 
2017). Indeed, Su5416 might contribute to the development of plexiform-like lesions in 
some animals through imbalance in EC turnover, resulting in selection of apoptosis-resistant 
cells and increased proliferation of these apoptosis-resistant cells (Sakao et al., 2009;Dean 
et al., 2017). We also wished to assess whether Su5416 alone, or in the combination with 
cHx might affect the proliferation of hPASMCs. Our results indicated that in Nx stimulation 
of hPASMCs from female clinical patients with Su5416 had no effect on the proliferation of 
these cells. However, when cells were subsequently exposed to cHx, a significant increase 
in proliferation was recorded (Dean et al., 2017). There was increased proliferation of SMCs 
in animals after stimulation with Su5416 (Taraseviciene-Stewart et al., 2001). Contrary, the 
number of PCNA positive vessels and the percentage of fully muscularised vessels was only 
significantly increased when mice were treated with Su5416 and cHx (Ciuclan et al., 2011). 
Finally, to investigate further the effects of Su4516 in the activation of the AhR in 
hPASMCs, we carried out fractionation analysis, thereby assessing the change in the 
localisation of this receptor from the cytoplasm to the nuclear fraction. We determined that 
stimulation of female hPASMCs derived from patients with Su5416 directly resulted in 
significantly increased localisation of AhR in the nucleus at 90-minute time-point. This is 
the first report of AhR translocation by SU5416 treatment in hPASMCs. Interestingly, in 
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BOECs stimulation with Su5416 reduced cytoplasmic expression of AhR, whilst nuclear 
expression remained constant (Dean et al., 2017). Therefore, it appeared that the expression 
of AhR in BOECs from patients was decreased, with unaltered activity of AhR within the 
nucleus. 
In summary, the data presented herein, and published in (Dean et al., 2017), provides a new 
insight into the potential mechanisms behind the Su5416/Hx experimental PH model. In Nx, 
the AhR is expressed at low levels in whole lungs. Exposure to Su5416/Hx, results in 
increased expression of AhR (Dean et al., 2016). The in the animals showing PH phenotype, 
the RVSP, RVH and pulmonary vascular remodelling are all markedly increased by 
Su5416/Hx. The mechanism behind the induction of experimental PH is thought to affect 
the cell turn-over of ECs, resulting in Su5416-induced. Increased apoptosis of ECs may 
initiate vascular remodelling in experimental PAH. This could cause degeneration of pre-
capillary arterioles or select apoptosis-resistant ECs that contribute to "angio-proliferative" 
plexiform lesions (Jurasz et al., 2010) As ECs are subject to stricter contact inhibition in 
intact arteries than hPASMCs, they do not normally proliferate. However, it was shown that 
BOECs from patients with PAH can exhibit increased proliferation (Toshner et al., 2009). 
Indeed, the dysregulated proliferation of ECs is considered a fundamental process in the 
development of clinical PAH (Tuder et al., 1994). Su5416 induced the proliferation of 
BOECs from PAH patients, which could perhaps precede and contribute to the selection of 
apoptosis-resistant ECs, leading to vascular remodelling and the development of occlusive 
lesions in some animals. The exposure of hPASMCs to Su5416 leads to increased activation 
of AhR, which is a complex and dynamic process involving the mechanism of receptor 
retention and stabilisation in the cytosol, and continuous nuclear export. Increased activation 
results in increased rate of nuclear AhR import without affecting nuclear AhR export 
(Richter et al., 2001). Firstly, increased activation of AhR induces the expression of 
aromatase, leading to increased local production of 17βE2 within the lung. 17βE2 can be 
converted to 2OHE2 by CYP1A1/2, CYP1B1 and CYP3A4. Moreover, CYP1A1 also 
metabolises E1 and 17βE2 to 2OHE2 and 16αOHE1, which are mitogenic in hPASMCs and 
may contribute to the development of PAH (White et al., 2012;Hood et al., 2016). Indeed, 
increased activation of AhR leads to increased expression of CYP1A1, and possibly 
CYP1B1, resulting in altered oestrogen metabolism. In Hx, exposure of hPASMCs to 
Su5416 results in increased proliferation, perhaps through the synergy of Su5416 and Hx 
signalling pathways via ARNT (HIF1β). 
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The effects of AhR on 17βE2 synthesis and metabolism are of interest as major PAH 
registries report a greater incidence of PAH among women than men (Shapiro et al., 2012) 
and 17βE2 metabolism is implicated in the increased penetrance of heritable PAH (HPAH) 
among female patients harbouring a mutation in the gene encoding (Austin et al., 2009). The 
resulting increase in EC apoptosis, as well as 17βE2 synthesis and metabolism, may 
contribute to experimental PH. This is summarized in Figure 3–54.Therefore, inhibition of 
AhR may be a potential novel approach to the treatment of PAH, should these new findings 
translate to the human situation.  
To summarise, the AhR and HIF1α signalling pathways appear to have an important role in 
the establishment of experimental as well as clinical PAH and might possibly offer another 
attractive target for the development of novel treatment approaches for PAH. 
 Limitations of the Study 
Genotypic and phenotypic variation amongst animals used in research might limit scientific 
validity by enhancing experimental variability. Genetic background of animals is defined as 
an assortment of interactions of the complete genotype of the animal with the particular gene 
of interest, potentially resulting in the appearance of a specific phenotype. Therefore, the 
understanding of the effects of genetic background on phenotype is of utmost importance in 
research. Herein, a well-established SD rats from Canada exhibited hyper-responsive 
phenotype to treatment with Su5416. With the determination of complete genotypes of 
numerous animals used in research, the understanding of genetic background was improved. 
Most animals used research are namely derived from established laboratory strains, hence 
the genetic variation is expected to be rather uniform, due to prolonged in-breeding process. 
Although in-breeding should theoretically result in animal populations that are relatively 
genetically unvarying, mutations can occur and accumulate naturally, resulting in 
phenotypic variance (Yoshiki and Moriwaki, 2006). This could be the reason behind the 
apparent hyper-responsiveness to Su5416 reported in a colony of SD rats in Canada. Another 
issue arises when using specific transgenic strains, such as Smad1 heterozygous mice. 
Transgenic animals usually have mixed genetic backgrounds, as the main effort is to create 
animals with specific genotype in order to investigate the role of that particular gene. Hence, 
the varying genetic background of such animals might have even more apparent influence 
on animals’ phenotype. The natural presence/occurrence of such significant phenotypic 
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variance exposes the question whether it is appropriate to compare the effects of a treatment 
across different animal strains, and even species. 
The age at which the animal was subjected to experiments might be another limiting factor. 
As shown by several transgenic models, described in Chapter 1.4, the phenotype might 
greatly depend on the age (and sex) of the animal, with specific phenotype only being present 
in older animals. The age-dependent changes in the phenotype might be attributable to 
significant effect ageing might have on transcription. Indeed, changes in the level of 
circulating oestrogens might affect the pattern of gene expression in the genes under 
oestrogen regulation. However, with age mutations might naturally accumulate, resulting in 
phenotypic variance. Hence for quality and comparable data, the age of animals for 
experiments should be determined on the basis of development or cellular ageing. 
The choice of the housekeeping gene could also pose a further limitation of the study, as 
described above. The characteristic for the selection of an appropriate housekeeping gene 
for normalisation of RT-qPCR results is stable expression, which can be described by: i) 
small coefficient of variation and ii) maximal fold change. De Jonge and colleagues 
described the experiments undertaken to determine the most appropriate housekeeping genes 
(de Jonge et al., 2007). The variation of traditionally used housekeeping genes, i.e. β–2–
macroglobulin (B2M), glyceraldehyde-3 phosphate dehydrogenase (GAPDH) and β actin 
(ACTB) was found to fluctuate considerable. Therefore, other genes were proposed to be 
used as housekeeping genes of choice. Equally, the low protein expression levels and the 
presence of multiple isoforms, with possible off-target binding, have limited some aspects 
of this study. Further optimisation should be considered in terms of using more specific 
protein detection systems with the exclusive used of monoclonal antibodies for detection 
and localisation.  
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Figure 3–53: Proposed synergy of aryl hydrocarbon receptor and hypoxia-inducible factor 
1α signalling pathways. 
Herein we demonstrated the existence of a possible synergy of both insults in the 
establishment of the Su5416/Hx model. First, we provided data, that stimulation with 
Su5416 in female hPASMCs from PAH patients, results in increased localisation of AhR in 
the nucleus, indicating increased receptor activation. In vivo studies showed that the ARNT 
(HIF1β) protein levels are increased in diseased animals, and the levels of the protein are 
returned to normal by AhR antagonist CH223191. Second, we showed that exposure of 
hPASMCs derived from female PAH patients results in increased proliferation of these cells, 
while in Nx conditions proliferation was not significant. Hx may synergise with AhR 
activation through the ARNT (HIF1β). A simplified diagram of the proposed synergy is 
shown in Figure 3–53. Third, we provided evidence that in female hPASMCs stimulation 
with Su5416 results in increased expression of CYP1A1 and CYP1B1. And while exposure 
to AhR antagonist CH223191 only resulted in decreased expression of CYP1A1 in 
hPASMCs derived from female control subjects, it is anticipated that increased expression 
of these CYP enzymes might result in increased production of oestrogen metabolites 
promoting proliferation.  
211 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In ECs, Su5416 causes an imbalance in cell turnover, favouring apoptosis of these cells. The insult 
result in vascular injury, leading to vascular remodelling and selection of apoptosis-resistant ECs. 
Furthermore, Su5416 activates AhR, leading to increased expression of oestrogen-metabolising 
enzymes, resulting in altered oestrogen metabolism. In SMCs, Su5416 leads to increased 
translocation of AhR from the cytoplasm to the nucleus, resulting in induced expression of ARNT 
(HIF1β), CYP1A1 and aromatase. Increased production of 17βE2 and altered oestrogen metabolism, 
through the synergy of AhR and HIF1α signalling pathways lead to increased proliferation of SMCs 
and vascular remodelling. 
ECs= Endothelial cells, SMCs= Smooth muscle cells, AhR= Aryl hydrocarbon receptor, 17βE2= 
17β-oestradiol, CYP1A1= Cytochrome P450 1A1  
Figure 3–54: Proposed mechanism of Sugen 5416 and hypoxia-induced experimental 
phenotype of pulmonary arterial hypertension mediated through activation of the aryl 
hydrocarbon receptor. 
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Chapter IV 
4 An In Vitro Model to Investigate the Role of 
Oestrogen and Oestrogen Metabolism 
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4.1 Introduction 
The importance of sex hormones in the pathogenesis of PAH was exposed when numerous 
large national registries and surveys repeatedly demonstrated that PAH affects 
predominantly women (Rich et al., 1987;Badesch et al., 2009;Escribano-Subias et al., 
2012;Ling et al., 2012;Galiè et al., 2015). Therefore, much research was focused on 
discovering the causative mechanism by which oestrogen might possibly contribute to 
disease development in animal models and, most recently, in clinical setting. In animal 
models, disease susceptibility and severity were associated with abnormal synthesis of 
17βE2, as shown in (Mair et al., 2014). It appeared that stimulation of vascular cells derived 
from female control subjects with 17βE2, suppresses the expression of final effectors of 
BMPRII signalling pathway (Mair et al., 2015). While Austin and colleagues reported that 
17βE2 suppressed the expression of BMPRII receptor (Austin et al., 2012). Hence, increased 
levels of circulating hormone might contribute to establishment of conditions favouring 
SMC proliferation, leading to muscularisation and remodelling of distal PAs. The 
probability of clinical PAH in men, but not in women, was also shown to correlate with 
higher levels of endogenous 17βE2 (Ventetuolo et al., 2016). Increased level of endogenous 
17βE2 and decreased levels of circulating sex hormone precursor DHEA-S in men were 
associated with more severe haemodynamic impairment and patient’s lower tolerance of 
physical activity (Ventetuolo et al., 2016). 
17βE2 is metabolised to numerous metabolites through oxidative biotransformation 
reactions, with most oestrogen-metabolising enzymes exhibiting high activity for 
hydroxylation at positions C2 and C4, and only moderate activity at position C16α. Evidence 
suggested that amongst most commonly produced hydroxylated oestrogens, only 16αOHE1 
induced significant proliferation of PASMCs (White et al., 2012). White and colleagues 
provided evidence of dysregulation of oestrogen metabolism in PAH, reporting that the 
expression of CYP1B1 oestrogen-metabolising enzyme was increased in clinical PAH as 
well as in experimental models of PH (White et al., 2012). The anomalous metabolism of 
oestrogens, arising from pathogenic expression of oestrogen-metabolising enzymes, might 
therefore result in the accumulation of metabolites, capable of driving the pathological 
changes in the distal pulmonary vasculature due to their pro-proliferative properties. The 
hydroxylated oestrogens serve as precursors for conjugation reactions, resulting in 
metabolites that are easily excretable due to enhanced hydrophilic character and/or 
metabolically/pharmacologically inactive (Jancova et al., 2010). 2-Methoxyoestrogens have 
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been shown to mediate protective effects in terms of PAH pathogenesis, with demonstrated 
anti-mitotic and anti-angiogenic properties (Fotsis et al., 1994), further affecting the 
production of vasoactive compounds to favour vasodilation (Barchiesi et al., 2006;Seeger et 
al., 1999;Tsukamoto et al., 1998;Dubey et al., 2001). Administration of these metabolites 
resulted in protection against or reversal of haemodynamic impairment and vascular 
remodelling in animals with established PH phenotype (Tofovic et al., 2006;Tofovic et al., 
2008b;Tofovic and Rafikova, 2009;Fotsis et al., 1994). It was previously suggested that the 
dysregulated oestrogen metabolism in disease setting might also include reduced formation 
of protective metabolites, due to the presence of enzyme isoform exhibiting decreased 
activity of MeOE formation and the presence of oestrogen-metabolising enzymes with 
increased activity (Kisselev et al., 2005). In such circumstances, the accumulation of 
hydroxylated oestrogens, which are normally rapidly metabolised to form 
methoxyoestrogens, could lead to formation of quinones and semiquinones, which due to 
their reactive character might result in increased production of ROS (Yager and Liehr, 1996) 
leading to protein as well as DNA damage (Cavalieri et al., 1997). 
As discussed previously (in Chapter 3.1), each year millions of animals are used in research. 
According to the viewpoint of the Committee for Proprietary Medicinal Products, published 
in 1997, the ethical consideration requires the use of animals in research to be limited as 
much as possible. Approximately 30 years ago, Pearson has produced a perspective article 
on the possibility of in vitro models replacing the use of animals, especially in the assessment 
of drug toxicity and safety. Published work stated that in vitro studies might offer the 
advantage of producing relevant and precise results much more rapidly than animal studies 
(Pearson, 1986). Albeit, the use of animals in research might not be completely avoidable, 
the use of animal models to investigate the contribution of specific molecular processes to 
disease development is hindered by i) the lack of recapitulating the human condition, ii) the 
un-feasibleness of varying individual molecular processes to identify their contribution to 
the disease pathogenesis, and iii) incapability of measuring the responses to stimulation in 
real time (Benam et al., 2015). The in vitro model using hPASMCs was employed in the 
research of PAH pathology previously, however the role oestrogen metabolism in this model 
has not yet been fully investigated. 
Although the primary biological functions of oestrogens are mediated in endocrine manner, 
the paracrine effects of oestrogens, due to high concentrations of locally produced hormones, 
might be importantly associated with pathological processes in numerous diseases (Simpson 
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and Davis, 2001;de Jong et al., 1997). Considering that emerging evidence points to the 
importance of individual oestrogen metabolites in the pathogenesis of PAH, the qualitative 
and quantitative assessment of the levels of oestrogen metabolites produced locally by the 
vascular cells to ascertain actual metabolomic profile of oestrogens in normal and diseased 
conditions is required. Currently, the available techniques to quantitatively measure 
oestrogen metabolites encompass various immunoassays and chromatographic techniques. 
Unfortunately, the use of these well-established techniques to determine the normal and 
diseased metabolic profile of oestrogens is hindered by i) poor reproducibility of results of 
immunoassays due to assay interferences (Tate and Ward, 2004), ii) the extremely low 
physiological concentration range of oestrogens, and iii) structural similarity of these 
compounds. Previously, significant efforts were made to establish a precise and sensitive 
measuring technique, using the high-performance liquid chromatography approach (HPLC) 
(Johansen, 2014), which has been successfully used to investigate oestrogen metabolism by 
several research groups (Rogan et al., 2003;Johansen et al., 2014;Delvoux et al., 2007). 
Nonetheless, the use of this technique to ascertain the metabolomic profile of oestrogens is 
hindered by i) difficult quantitation of oestrogen metabolites, ii) method’s relatively high 
detection limit and low concentrations range of certain oestrogen metabolites, and iii) 
difficulty of peak identification, introducing the possible error of subjective analysis. 
According to Gaikwad, gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry have been extensively used to date for quantification of 
oestrogen metabolism (Gaikwad, 2013), with reported simultaneous detection and 
quantitation of oestrogen metabolites in tissue, urine and serum samples (Flores-Valverde 
and Hill, 2008;Dai et al., 2012;Carvalho et al., 2008). However the elaborate sample 
preparation methods and the requirement of analyte derivatisation, resulting in significant 
matrix effects and hence less robust assays (Ke et al., 2014), render these methods rather 
unsuitable.  
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For this study, the general hypothesis was that oestrogen metabolism is dysregulated in 
pulmonary arterial hypertension, and that the disparity observed in the incidence of this 
vasculopathy in women might be associated with increased production of oestrogen 
metabolites having pathogenic properties. 
Aims of this chapter: 
1) To assess the effects of oestrogen metabolites on the expression and activity of 
prostacyclin synthase in microvascular endothelial cells derived from control female 
subject. 
2) To assess the effects of oestrogen metabolites on the expression of BMPRII 
signalling pathway in human pulmonary artery smooth muscle cells. 
3) To assess the extent of anti-proliferative effects of 2-methoxyoestradiol in in vitro 
model of pulmonary hypertension consisting of pulmonary artery smooth muscle 
cells derived from control and patient subjects of both sexes. 
4) To develop and validate a precise and sensitive liquid chromatography tandem mass 
spectrometry method to quantitatively assess the concentration of oestrogen 
metabolites in in vitro model of pulmonary hypertension consisting of pulmonary 
artery smooth muscle cells derived from control subjects and individuals with 
clinical pulmonary arterial hypertension. 
5) Establishment of the oestrogen metabolic profile in in vitro model of pulmonary 
hypertension consisting of pulmonary artery smooth muscle cells derived from 
control and patient subjects of both sexes, using the novel quantitative technique. 
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4.2 Results 
 2-Methoxyoestradiol and 2-Methoxyoestrone 
Significantly Increase Expression of Prostacyclin 
Synthase in Pulmonary Microvascular Endothelial 
Cells 
Sustained vasoconstriction is an important hallmark of PAH pathogenesis and is associated 
with dysregulated synthesis of vasoactive compounds. The circulating levels of endogenous 
vasodilator PGI2 were reduced in patients (Moncada and Vane, 1978;Badesch et al., 
2004;Barst et al., 2009); (Christman et al., 1992). PGIS is expressed in all vascular cells of 
proximal and distal PAs, with greater expression in the ECs (Badesch et al., 1989). Hx 
increased the expression of PGIS and release of PGI2 in VSMC and ECs (Camacho et al., 
2011). The effects of oestrogen metabolites on the release of PGI2 were recently examined 
in human umbilical ECs (Jobe et al., 2013). Hydroxy and methoxy metabolites of oestradiol 
significantly increased the production of PGI2 in pregnant and non-pregnant women, at 
physiological concentrations (Jobe et al., 2013). As the lung, is highly sensitive to 
oestrogens, we aimed to determine the effects of stimulation of ECs derived from pulmonary 
micro-vessels. Considering, the reported changes were rapid, we treated the hPMECs with 
1nM oestrogen metabolites for 24 hours to assess whether these metabolites might affect the 
expression of PGIS. Herein, we showed that stimulation with oestrogen metabolites did not 
affect the expression of PGIS at gene level (Figure 4–1A). Nonetheless, significant increase 
in PGIS protein expression was caused by stimulation with 2-methoxyoestradiol and 2-
methoxyoestrone (Figure 4–1B, C). 17βE2 and 4-methoxy metabolites caused an 
insignificant increase in PGIS expression at protein level. Equally, 2- and 4OHE2 had no 
effect on the expression of PGIS at protein level. 
1nM concentration of oestrogen metabolites was selected for these experiments, as this was 
approximately close to the average reported physiological concentrations of oestrone and 
oestradiol. Furthermore, as currently the physiological plasma concentrations of other 
prominent oestrogen metabolites are not known, we concluded the estimate of oestrone, and 
oestradiol concentrations would be a good approximation. 
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We further wished to assess the release of PGI2 in these cells to determine whether increased 
expression of PGIS might be associated with increased release of its product. We used 6-
keto PGF1α immunoassay to determine the level of stable PGI2 metabolite. Acute 
stimulation with oestrogen metabolites led to significantly decreased expression of 6-keto 
PGF1α when cells were treated with 16αOHE2 and 2MeOE1 (Figure 4–2A), indicating 
decreased release of its parental molecule PGI2. The release of 6-keto PGF1α in positive 
control group, where cells were treated with 20μM arachidonic acid, was like that observed 
in treatment groups 16αOHE2, 2MeOE1 and 2MeOE2. Prolonged treatment with oestrogen 
metabolites though did not result in significant changes in the release of PGI2 as assessed 
per 6-keto PGF1α levels (Figure 4–2B). Prolonged stimulation with 20μM arachidonic acid 
resulted in significantly increased production of 6-keto PGF1α, indicating the production of 
PGI2 was also increased in this instance (Figure 4–2B). 
 2-Methoxyoestradiol Increases Expression of 
Prostacyclin Synthase in Pulmonary Artery Smooth 
Muscle Cells from Male Control Subjects, but not in 
Female Cells 
Although the PGI2 production has only been documented in ECs, the expression of PGIS 
has been also reported in vascular SMCs (Nakayama, 2005). As we have previously shown 
that certain oestrogen metabolites affect the expression of PGIS in hPMECs (Chapter 4.2.1), 
we wanted to investigate whether oestrogens also affect the expression of PGIS in 
hPASMCs. Herein, we show that the expression of PGIS is only significantly increased by 
100nM 2MeOE2 in hPASMCs derived from male control subjects (Figure 4–3), while no 
change was observed in female cells (Figure 4–4). It appears that PGIS expression in 
PASMCs is only affected at higher pharmacological concentrations of oestrogens compared 
to PMECs, as significant changes were observed with 100nM and 1nM 2MeOE2, 
respectively. Moreover, oestrogen-induced changes in the expression of PGIS in PASMCs 
seem to be sex-dependent, with female hPASMCs not responding to oestrogen treatment.  
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Human pulmonary microvascular endothelial cells (hPMECs) derived from female control, 
purchased from Qiagen, were grown as previously described to approximately 80% confluence. 
Before stimulation with oestrogen metabolites (1nM) for 24 hours, cells were washed twice with ice-
cold DPBS. (A) The expression of PGIS was assessed by Taqman quantitative Real Time-PCR. 
Results were normalised to β-2-microglobulin. N=3 per group in triplicate, One-way ANOVA 
followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative 
quantification. (B) The level of PGIS protein expression was addressed using immunoblotting. N=3‒
6 per group in duplicate, *p<0.05, **p≤0.01, One-way ANOVA followed by Tukey’s post-hoc test. 
Data is expressed as fold change to Control group±SEM. The representative immunoblotting image 
is shown in (C).  
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Figure 4–1: The protein expression of prostacyclin synthase in human microvascular 
endothelial cells derived from female control subjects is significantly increased by 1nM 
methoxyoestrogens. 
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Human pulmonary microvascular endothelial cells (hPMECs) derived from female control subjects, 
purchased from Qiagen, were grown as previously described to approximately 80–90% confluence. 
Before stimulation with oestrogen metabolites (1nM) for 1 hour (A) or 24 hours (B), cells were 
washed twice with ice-cold DPBS. The release of PGI2 was assessed using 6-keto PGF1α ELISA Kit 
(Enzo Life Sciences, USA). Results were normalised to protein amount. N=3 per group in duplicate, 
****p≤0.0001One-way ANOVA followed by Tukey’s post-hoc test. Data is expressed as 
mean±SEM.  
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Figure 4–2: Acute stimulation with 1nM methoxyoestrogens decreases the release of 
prostacyclin from human microvascular endothelial cells. 
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HPASMCs were grown to reach approximately 70% confluence in 10% FBS DMEM media. 
PASMCs were then serum starved for 24 hours, before stimulation with oestrogen metabolites (1nM, 
100nM). Protein samples were collected and prepared as previously described. N=3 per group, in 
duplicate, *p<0.05, One-Way ANOVA, followed by Tukey’s post-hoc test. Data is expressed as fold 
change of Control group±SEM Representative immunoblotting image is shown in (B).  
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Figure 4–3: The protein expression of prostacyclin synthase is increased by 100nM 2-
methoxyoestradiol in human pulmonary artery smooth muscle cells derived from male 
controls. 
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HPASMCs were grown to reach approximately 70% confluence in 10% FBS DMEM media. 
PASMCs were then serum starved for 24 hours, before stimulation with oestrogen metabolites 
(1nM, 100nM). Protein samples were collected and prepared as previously described. N=3 per 
group, in duplicate, One-Way ANOVA, followed by Tukey’s post-hoc test. Data is expressed as 
fold change of Control group±SEM. Representative immunoblotting image is shown in (B).  
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Figure 4–4: Methoxyoestrogens do not affect the protein expression of prostacyclin 
synthase in human pulmonary artery smooth muscle cells derived from female controls. 
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 Exposure to 2-Methoxyoestradiol Reduces 
Proliferation in Human Pulmonary Artery Smooth 
Muscle Cells of Both Sexes 
2-MeOE2 was shown to prevent and/or rescue the experimental PH phenotype in animal 
models (Fotsis et al., 1994;Tofovic et al., 2006;Tofovic et al., 2008b). As the protective 
properties of methoxy-oestradiol are partially mediated by their anti-proliferative effects on 
vascular cells (Barchiesi et al., 2006), we wished to assess these in in vitro models using cell 
lines derived from control subjects, which were subjected to pro-proliferative conditions. 
Here we showed that exposure to physiological concentration of 2MeOE2 results in a trend 
of reduced proliferation in male hPASMCs derived from control subjects, as assessed by 
BrDU assay (Figure 4–5A). Equally, exposure to MeOEs reduced serum-induced 
proliferation in female hPASMCs from controls (Figure 4–6). At higher pharmacological 
concentrations all MeOEs seemed to diminish cell proliferation induced in the presence of 
10% CSS. When hPASMCs were treated with inhibitors of ERα, ERβ and gpr30 receptors 
through which oestrogens mediate their effects, inhibition of all three receptors appeared to 
restore proliferation compared to 2MeOE2 only treated cells (Figure 4–7). Whilst inhibition 
of gpr30 had no effect on diminished proliferation when cells were treated with 4MeOE2, 
inhibition of both classical oestrogen receptors resulted in increased proliferation of cells 
despite treatment with 4MeOE2 (Figure 4–7). It therefore appeared that the anti-proliferative 
effects of 2MeOE2 and 4MeOE2 are mediated through ERα and β, while only 2MeOE2 
might also affect proliferation through non-classical oestrogen signalling. These trends were 
also observed with BrDU assay (Figure 4–8), although more cell lines would need to be 
tested. 
In female control cell lines, treatment with 2MeOE2 and 4MeOE2 resulted in significantly 
decreased serum-induced proliferation (Figure 4–9). Pre-exposure to ERα and ERβ 
antagonists resulted in observable trend of apparently increased proliferation, while the 
antagonism of gpr30 had no effect. Moreover, in these cell lines exposure to 2MeOE2 
appeared to induce a concentration-dependent increase in the p27/Kip1 protein expression 
(Figure 4–10), showing this could be a potential mechanism through which 2MeOE2 
protective properties are mediated.  
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by methoxyoestrogens (2MeOE1, 2MeOE2, 4MeOE1 and 4MeOE2) at physiological and 
pharmacological concentrations (1nM, 100nM). Experiments were carried out in the presence of 10% 
CSS PRF DMEM media. Cell counts were assessed after 72 hours by BrDU assay (A) or 
haemocytometer (B). (A) N=2 per group, repeated 8 times, One-Way ANOVA with Tukey’s post-
hoc test. Data expressed as mean±SEM. (B) N=3 per group, in triplicate, *p<0.05, **p≤0.01, One-
Way ANOVA with Tukey’s post-hoc test. Data expressed as fold change of 10% control 
group±SEM.  
A 
B 
Figure 4–5: The anti-proliferative effects of methoxyoestrogens in male pulmonary 
artery smooth muscle cell lines derived from control subjects. 
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by methoxyoestrogens (2MeOE1, 2MeOE2, 4MeOE1 and 4MeOE2) at physiological 
and pharmacological concentrations (1nM, 100nM). Experiments were carried out in the presence 
of 1% CSS PRF DMEM media. Cell counts were assessed after 72 hours by haemocytometer. N=4 
per group, in triplicate, *p<0.05, **p≤0.01, ****p<0.0001, One-Way ANOVA with Tukey’s post-
hoc test. Data expressed as fold change of 10% control group±SEM.  
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Figure 4–6: The anti-proliferative effects of methoxyoestrogens in female pulmonary artery 
smooth muscle cell lines derived from control subjects. 
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by ERα inhibitor (MPP, 10nM), ERβ inhibitor (PHTPP, 10nM), and gpr30 receptor (G15, 
100nM) 30 minutes prior to stimulation with methoxyoestrogens (2MeOE2 and 4MeOE2) at 
physiological concentrations (1nM). Experiments were carried out in the presence of 10% CSS PRF 
DMEM media. Cell proliferation were assessed after 72 hours by BrDU assay. N=1 per group, 
repeated 4 times. Data expressed as mean±SEM.  
Figure 4–7: Inhibition of ERα and ERβ appears to restore proliferation of male control 
human pulmonary artery smooth muscle cells treated with 2- and 4-methoxyoestradiol. 
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by ERα inhibitor (MPP, 10nM), ERβ inhibitor (PHTPP, 10nM), and gpr30 receptor (G15, 
100nM) 30 minutes prior to stimulation with methoxyoestrogens (2MeOE2 and 4MeOE2) at 
physiological concentrations (1nM). Experiments were carried out in the presence of 10% CSS PRF 
DMEM media. Cell proliferation were assessed after 72 hours by haemocytometer. N=2 per group, 
in triplicate, One-Way ANOVA with Dunnett’s post-hoc test. Data expressed as fold change of 10% 
CSS group±SEM.  
Figure 4–8: The mechanism of anti-proliferative properties of 2-methoxyoestradiol and 
4-methoxyoestradiol in male human pulmonary artery smooth muscle cells derived from 
male control subject. 
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by ERα inhibitor (MPP, 10nM), ERβ inhibitor (PHTPP, 10nM), and gpr30 receptor (G15, 
100nM) 30 minutes prior to stimulation with methoxyoestrogens (2MeOE2 and 4MeOE2) at 
physiological concentrations (1nM). Experiments were carried out in the presence of 10% CSS PRF 
DMEM media. Cell proliferation were assessed after 72 hours by haemocytometer. N=3–4 per 
group, in triplicate, One-Way ANOVA with Dunnett’s post-hoc test. Data expressed as fold change 
of 10% CSS group±SEM.  
Figure 4–9: 2- and 4-methoxyoestradiol reduce serum-induced proliferation in female 
control pulmonary artery smooth muscle cells. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then 
stimulated by 2MeOE2 (1nM, 10nM, 100nM and 1μM) in the presence of 10% CSS PRF DMEM. 
N=2 per group, in duplicate, One-Way ANOVA with Bonferroni’s post-hoc test. Data is expressed 
as fold-change of 10% CSS group±SEM. The 10% CSS was set to 1, and other treatment groups are 
shown as fold change.  
β Actin 
(42 kDa) 
p27/Kip1 
(22 kDa) 
Figure 4–10: In human pulmonary artery smooth muscle cells from female control 
subjects, 2-mtehodyoestradiol induces protein expression of the cell cycle inhibitory 
protein p27/Kip1. 
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 2-Methoxyoestradiol Reduces Proliferation in 
Female, but not in Male Patient Pulmonary Artery 
Smooth Muscle Cells 
Evidence up to date, indicates that in animal models, administration of 2MeOE2 opposed 
the onset of experimental PH phenotype, while in diseased animals the metabolite improves 
the haemodynamic parameters and improved pulmonary vascular remodelling (Tofovic et 
al., 2008b). Therefore, we aimed to assess the documented anti-proliferative properties of 
2MeOE2 in PAH in vitro model using cell lines derived from subjects with clinical PAH. 
Stimulation with 1nM 2MeOE2 and 4MeOE2 resulted in significant reduction of 
proliferation in female cell lines derived from patients (Figure 4–11A), while we observed 
no changes in male cell lines (Figure 4–11B). Moreover, it appeared that the metabolites had 
significant effects only at lower physiological concentrations.  
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HPASMCs from female (A) and male (B) clinical patient subjects were serum starved for 24 hours. 
PASMCs were then stimulated by 2MeOE1, 2MeOE2, 4MeOE1 and 4MeOE2 (1nM, 100nM). 
Experiments were carried out in the presence of 10% CSS PRF DMEM media. Cell counts were 
assessed after 72 hours by haemocytometer. N=3–4 per group, in triplicate, *p≤0.05, **p<0.01, 
***p<0.001, One-Way ANOVA with Dunnett’s post-hoc test. Data expressed as fold change of 10% 
control group±SEM.  
Figure 4–11: Methoxyoestrogens do not attenuate serum-induced proliferation in male 
patient pulmonary artery smooth muscle cells. 
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 In Female Control Pulmonary Artery Smooth Muscle 
Cells Only Methoxyoestrogens Appear to Increase 
the Expression of the BMPRII Signalling Pathway 
The protective effects of oestradiol in PAH could partially be attributed to the formation of 
protective MeOEs, which were shown to oppose the onset of experimental PH in animal 
models (Tofovic et al., 2006;Tofovic and Rafikova, 2009). 2MeOE2 decreased proliferation 
of vascular cells (Dubey et al., 1998;Tofovic and Rafikova, 2009;Vijayanathan et al., 2006), 
albeit experimental conditions and cellular type appear to be of noteworthy importance 
(Lippert et al., 2000;Lai and Law, 2004). As the arrest of proliferation of vascular cells seems 
to be one of the most important protective effects of 2MeOE2 in PAH, we aimed to assess 
the effects of 15 oestrogen metabolites, including methoxy-oestradiols, on the expression of 
mediators of the BMPRII signalling pathway in female hPASMCs derived from control 
subjects. 
A trend of increased expression of BMPRII, pSmad1/5/(8)9 and Id3 at protein level was 
observed when cells were treated with MeOEs, however this increase was not statistically 
significant due to large variations in the response of the cell lines used (Figure 4–12). 
Therefore, we decided to further evaluate the effects of methoxyoestrogens at physiological 
and pharmacological concentrations, in hPASMCs of both sexes.  
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then 
stimulated by oestrogen metabolites (1nM) in the presence of 1% CSS PRF DMEM. The expression 
level of BMPRII, pSmad1/5/(8)9 was assessed using immunoblotting. Results were normalised to 
the GAPDH. N=3 per group, in duplicate, One-Way ANOVA with Bonferroni’s post-hoc test. Data 
is expressed as fold change of Control group±SEM.  
BMPRII 
(100 kDa) 
ID1 
(20 kDa) 
GAPDH 
(39 kDa) 
pSMAD1/5/(8)9 
(60 kDa) 
GAPDH 
(39 kDa) 
Figure 4–12: Methoxyoestrogens appear to increase the protein expression of effectors 
involved in the BMPRII signalling pathway in female control pulmonary artery smooth 
muscle cells. 
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 2-Methoxyoestradiol Significantly Increased 
Expression of DNA-binding protein inhibitor Id-1 in 
Male but not in Female Control Pulmonary Artery 
Smooth Muscle Cells  
The mutations in the gene encoding the BMPRII receptor usually result in reduced receptor 
expression and/or activity (Atkinson et al., 2002). Although these mutations are present in 
most patients with HPAH, and in approximately 20–25% of patients with IPAH (Atkinson 
et al., 2002;Machado et al., 2009;Hamid et al., 2009), the low penetrance of the disease in 
these individuals indicates a second factor is required for disease onset. The basal expression 
of proteins involved in the BMPRII signalling pathway was significantly reduced in 
hPASMCs derived from female control subjects compared to males (Mair et al., 2015). 
Additionally, 17βE2 decreased the expression of DNA-binding protein inhibitor Id1 and Id3 
in male control cells (Mair et al., 2015). The suppressive effects that 17βE2 exerted on the 
expression of BMPRII receptor were mediated through ERα receptor (Austin et al., 2012). 
As the anti-proliferative properties of 2MeOE2 are well documented, and the metabolite was 
shown to oppose the onset of experimental PH in animal models, we wished to assess the 
effects of methoxy metabolites on expression of proteins involved in BMPRII signalling 
pathway, at a physiological and pharmacological concentrations. 
Treatment with MeOEs did not affect the protein expression levels of BMPRII and 
pSmad/5/(8)9 in hPASMCs from control subjects of both sexes (Figure 4–13 and Figure 4–
14). Exposure of male hPASMCs from control subjects to pharmacological concentration of 
2MeOE2 resulted in increased expression of Id1, while Id3 expression was unaffected 
(Figure 4–13). In female cell lines, treatment with MeOEs did not result in significantly 
altered expression of Id1 and Id3 (Figure 4–14).  
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then 
stimulated by oestrogen metabolites (1nM, 100nM) in the presence of 1% CSS PRF DMEM. The 
expression level of BMPRII, pSmad1/5/(8)9, ID1 and ID3 was assessed using immunoblotting. 
Results were normalised to the GAPDH. N=3 per group, in duplicate, *p<0.05, One-Way ANOVA 
with Bonferroni’s post-hoc test. Data is expressed as fold change of Control group±SEM.  
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Figure 4–13: 2-Methoxyoestradil increases the protein expression of DNA-binding 
protein 1 in male control pulmonary artery smooth muscle. 
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HPASMCs were quiesced for 24 hours in 0.5% CSS PRF DMEM media. PASMCs were then 
stimulated by oestrogen metabolites (1nM, 100nM) in the presence of 1% CSS PRF DMEM. The 
expression level of BMPRII, pSmad1/5/(8)9 , ID1 and ID3 was assessed using immunoblotting. 
Results were normalised to the GAPDH. N=3 per group, in duplicate, One-Way ANOVA with 
Bonferroni’s post-hoc test. Data is expressed as fold change of Control group±SEM.  
ID3 
(17 kDa) 
pSMAD1/5/(8)9 
(60 kDa) 
GAPDH 
(39 kDa) 
ID1 
(20 kDa) 
BMPRII 
(100 kDa) 
GAPDH 
(39 kDa) 
1nM 100nM 
Figure 4–14: Methoxyoestrogens do not alter protein expression of effectors involved in 
the BMPRII signalling pathway in female control pulmonary artery smooth muscle cells. 
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 2- and 4-Hydroxyoestradiol Oppose Proliferation in 
Male Control Pulmonary Artery Smooth Muscle Cells 
Albeit the presence of oestrogen-metabolising enzymes with increased activity has been 
linked to the pathology of numerous diseases, due to high production of hydroxylated 
oestrogens which may be metabolised to form highly reactive quinones and semiquinones, 
mutagenic activity has only been attributed to 4OHE2 (Liehr et al., 1986). Nonetheless, 
administration of 4OHE2 did not result in the onset of experimental PH in animals 
(Johansen, 2014). In male hPASMCs 4OHE2 increased expression of Id1, Id3 and 
pSmad1/5/8 (Mair et al., 2015). Firstly, we showed using the BrDU assay that treatment of 
male control PASMCs with 2OHE2 and 4OHE2 significantly decreased number of cells 
(Figure 4–15A). Considering both catechol oestrogens serve as precursor molecules for the 
COMT, forming protective oestrogen metabolites, we wished to ascertain whether the 
mechanism for observed decreased proliferation of hPASMCs might be due to their 
conversion to methoxyoestrogens. We therefore treated male control cell lines with COMT 
inhibitors, entacapone and OR-486, prior to stimulation with both oestrogen metabolites. 
Pre-treatment with entacapone opposed the anti-proliferative properties of 2OHE2, while the 
inhibition of COMT had no effect on anti-proliferative properties of 4OHE2 (Figure 4–15B). 
When male control cell lines were stimulated with inhibitors of oestrogen receptors prior to 
stimulation with 2OHE2, inhibition of ERα and ERβ resulted in increased proliferation 
compared to 2OHE2 only treated cells (Figure 4–16). This indicates that in addition to the 
protective properties of 2MeOE2, protective properties of 2OHE2 might also be mediated 
through ER signalling. Additionally, inhibition of ERα also opposed the anti-proliferative 
properties of 4OHE2, indicating the decrease in the cell number might be also be mediated 
through ER signalling as opposed to the metabolite being biotransformed to 4MeOE2 
(Figure 4–16).  
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated 2OHE2 or 4OHE2 (1nM, 10nM, 100nM, 1μM). Otherwise, cells were pre-treated with 
COMT inhibitor entacapone (10nM) OR or-486 (100nM). Experiments were carried out in the 
presence of 10% CSS PRF DMEM media. Cellular proliferation was assessed after 72 hours either 
by BrDU assay (A) or haemocytometer (B). N=3 per group, in triplicate, One-Way ANOVA with 
Tukey’s post-hoc test. Data expressed as fold change of mean±SEM (A) or fold change of 10% 
control group±SEM (B).  
Figure 4–15: Treatment of male control cell lines with 2- and 4-hydroxyoestradiol results 
in decreased proliferation. 
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HPASMCs from male control subjects were serum starved for 24 hours. PASMCs were then 
stimulated by ERα inhibitor (MPP, 10nM), ERβ inhibitor (PHTPP, 10nM), gpr30 receptor (G15, 
100nM) or an ERα/β inhibitor (ICI182780, 10nM) 30 minutes prior to stimulation with 2OHE2 or 
4OHE2 (10nM). Experiments were carried out in the presence of 10% CSS PRF DMEM media. Cell 
counts were assessed after 72 hours by haemocytometer. N=3 per group, in triplicate, One-Way 
ANOVA with Tukey’s post-hoc test. Data expressed as fold change of 10% control group±SEM.  
Figure 4–16: The anti-proliferative effects of 2- and 4-hydroxyoestradiol in male control 
pulmonary artery smooth muscle cells are mediated through classical oestrogen 
receptors. 
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 High-Performance Liquid Chromatography Method 
to Investigate Oestrogen Metabolism In Vitro 
4.2.8.1 Treatment of Human Pulmonary Arteries with 
Treprostinil Significantly Alters the Production of 
Oestrone in Male Patient Pulmonary Artery Smooth 
Muscle Cells 
Albeit prostacyclin analogues were the first approved class of therapeutics for the treatment 
of PAH, they are still frequently prescribed as part of combinational therapy to manage 
persistent symptoms. The beneficial effects of prostacyclin analogues include i) 
vasorelaxation and vasodilation (Narumiya et al., 1999; Wise, 2003), and ii) the inhibition 
of SMC proliferation (Clapp et al., 2002; Yang et al., 2010). Approved prostacyclin 
analogues, such as treprostinil and iloprost, are currently used to manage moderate to severe 
PAH. 
Gathered evidence indicates that RXR can modulate the expression of oestrogen-regulated 
genes due to their interaction with promotor regions of these genes (Segars et al., 1993;Keller 
et al., 1995). PPARs affect oestrogen signalling through i) competitive inhibition of ERs 
(Keller et al., 1995), and ii) increased degradation of ERα (Qin et al., 2003), resulting in 
altered oestrogen signalling. Moreover, Becker and colleagues reported that PPARα, which 
is constitutively expressed in the mouse lung (Becker et al., 2008b), altered oestrogen 
metabolism through an increase of 17βHSD type 1 expression (Corton et al., 1997;Davis et 
al., 1994). Inhibition of PPARs was shown to modulate the expression of certain oestrogen 
metabolising enzymes according to (Corton et al., 1997). As evidence indicated that 
CYP1B1 may be induced through the activation of PPARα (Lovekamp-Swan et al., 
2003;Murray et al., 2001), we were interested in the assessment of oestrogen metabolism in 
cell lines treated with a prostacyclin analogue, as the endogenous molecule and its 
metabolites were shown to activate certain PPAR isoforms (Forman et al., 1995;Nemenoff 
et al., 2008), directly (Forman et al., 1997) or indirectly, though the IP receptor (Falcetti et 
al., 2007). Prostacyclin and its analogues only have a marginal effect on PPAR activation 
due to their rapid elimination and degradation (Yu et al., 1995). Recently, iloprost and 
treprostinil, were shown to activate PPAR isoforms (Forman et al., 1997;Ali et al., 2006), 
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further stimulating our interest in the effects of prostacyclin analogue on oestrogen 
metabolism. 
We employed high performance liquid chromatography (HPLC) to assess the effects of 
stimulation of treprostinil on oestrogen metabolism in in vitro model of PAH. Cells were 
treated with 14C4-17βE2, which enabled the tracking and flux analysis of oestrogen 
metabolism in these cells. All cells were exposed to 50nM 14C4-17βE2. Treatment groups 
T24B and TE48 referred to the time points when cells were stimulated with treprostinil 
(1μM): i) 24 hours prior to addition of 50nM 14C4-17βE2 (T24B), and ii) at the same time as 
17βE2 (TE48). Cells were then incubated with 50nM 14C4-17βE2 for 48 hours, and the 
differences in cell growth during the duration of the experiment, was eliminated by 
normalisation of metabolite amount per amount of protein. It appears that the treatment of 
female cell lines derived from control subjects with treprostinil resulted in increased 
metabolism of 17βE2, as the amount of the parental oestrogen was decreased in both groups 
treated with treprostinil compared to control treatment (Figure 4–17A). Moreover, the 
metabolism of 17βE2 in other cell lines appeared to be faster, as the HPLC/flux experiments 
show that the amount of labelled 17βE2 was lower compared to female control cell lines, 
indicating the hormone was metabolised to other metabolites. Radioactively labelled 17βE2 
was mainly metabolised to E1 in cell lines derived from female patient, male control and 
male patient subjects, respectively. The formation of E1 was considerably higher in female 
patient cell line compared to female and male control cell lines (Figure 4–17B). Treatment 
with treprostinil had no effect on the formation of E1 in female control and patient cell line. 
Preliminary results indicate that in male patient cell line, pre-treatment with treprostinil 
might resulted in increased production of E1 compared to control treatment, while co-
treatment of cells with treprostinil and 17βE2 might result in decreased in E1 production 
compared to pre-treatment group (Figure 4–17B). In assessed samples we also detected 
16αOHE1, 17αE2 and an unknown oestrogen metabolite, albeit the levels of these 
metabolites were considerably lower than both parental hormones. The amount of 17βE2 
metabolised to 16αOHE1 was higher in the cell line derived from female patient compared 
to female control cell line (Figure 4–18A). Treatment with treprostinil did not affect the 
formation of 16αOHE1 compared to control treatment group across the cell lines used in 
these experiments. Interestingly, the formation of 16αOHE1 was higher in female patient 
cell line treated with 17βE2 compared to male patient cell line (Figure 4–18A). Conversion 
of 17βE2 to 17αE2 was only observed in cell lines derived from female patient and male 
control subjects, specifically in treprostinil treatment groups (Figure 4–18B). 
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Interestingly we also observed the formation of an unknown oestrogen metabolite (Figure 
4–19), which could not be identified based on the retention time of the 15 unlabelled 
oestrogen metabolites used to determine the retention time using UV detection system. 
Nonetheless, due to the position of the 14C within the 17βE2, we were satisfied labelled 
oestrogen was metabolised to this uncharacterised metabolite, whose formation was 
significantly enhanced when cells were co-treated with treprostinil and 17βE2 for 48 hours 
(TE48) compared to control treatment in female patient cell line. Representative 
chromatograms are shown in Figure 4–20 to Figure 4–23. 
The effects of treprostinil treatment on oestrogen metabolic profile are shown in Figure 4–
24. In female control cell line, the oestrogen metabolites present in the analysed media 
samples, indicated the enzymatic activity of 17βHSD type 2 and cytochrome P450 oestrogen 
metabolising enzymes, while there was no evidence of COMT activity (Figure 4–17 and 
Figure 4–18). In female patient, male control and patient cells, however, the present 
metabolites indicated that 17βHSD type 2 was more active compared to control cell line 
(Figure 4–24). Pre-treatment with treprostinil in male patient cells may result in increased 
activity of 17βHSD type 2, indicating the used prostacyclin analogue might affect the 
expression of this enzyme, while it does not affect the enzymes’ activity (Figure 4–17B). 
The presence of 16αOHE1 further indicated the presence and enzymatic activity of 
cytochrome P450 oestrogen metabolising enzymes, especially CYP1B1, whilst the 
formation of 17αE2 also showed that hPASMCs can convert the original substrate to this 
isomer. It is not clear, though, whether this was a spontaneous reaction, or a specific 
isomerase enzyme was required. The presence of an unknown metabolite implied that 17βE2 
is the substrate of an oestrogen metabolising enzyme, whose end products we have not yet 
included in our research of oestrogen metabolism in in vitro model. In order to draw sound 
conclusions regarding the effect of treprostinil on oestrogen metabolism, these experiments 
would require to be repeated in more cell lines in order to increase the N number and allow 
statistical evaluation of the results. However, some of the preliminary results corroborate 
previous observations that prostacyclin analogues might affect oestrogen metabolism, 
specifically the 17βHSD expression (Corton et al., 1997;Davis et al., 1994), leading to 
altered production of enzymes’ metabolites. Whether this occurs trough activation of PPARs 
still remains to be investigated. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with either treprostinil (1μM) l 
or vehicle (0.005% ethanol (v/v)) for 24 hours, prior to addition of 50nM 14C4-17βE2, and treprostinil (1μM) or vehicle (0.005% ethanol) for further 48 hours. The spend 
media were collected and analysed using HPLC with scintillation counter. N=1 per group, repeated 3 times over three different passages. Data is expressed as mean±SEM.  
Figure 4–17: Treprostinil increases metabolism of 17β-oestradiol in human pulmonary arterial smooth muscle cells derived from female controls. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with either treprostinil (1μM) l 
or vehicle (0.005% ethanol (v/v)) for 24 hours, prior to addition of 50nM 14C4-17βE2, and treprostinil (1μM) or vehicle (0.005% ethanol) for further 48 hours. The spend 
media were collected and analysed using HPLC with scintillation counter. N=1 per group, repeated 3 times over three different passages. Data is expressed as mean±SEM.  
Figure 4–18: In human pulmonary artery smooth muscle cell line derived from male control subjects, treprostinil increases the formation of 17αE2 
isoform. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with either treprostinil (1μM) l 
or vehicle (0.005% ethanol (v/v)) for 24 hours, prior to addition of 50nM 14C4-17βE2, and treprostinil (1μM) or vehicle (0.005% ethanol) for further 48 hours. The spend 
media were collected and analysed using HPLC with scintillation counter. N=1 per group, repeated 3 times. Data is expressed as mean±SEM. 
 
Figure 4–19: In human pulmonary artery smooth muscle cells from female patient, treprostinil increases the formation of an unknown oestrogen 
metabolite. 
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A) Chromatogram of oestrogen metabolites formed when female control hPASMCs were stimulated 
with 14C4-17βE2 for 48 hours. B) Chromatogram of oestrogen metabolites formed when female 
control cell lines were pre-treated with 1µM treprostinil 24 hours prior to stimulation with 50nM 
14C4-17βE2 and 1µM treprostinil. C) Chromatogram of oestrogen metabolism in female control cell 
lines co-stimulated with 50nM 14C4-17βE2 and 1µM treprostinil for 48 hours.  
Figure 4–20: Representative high-performance liquid chromatography chromatograms 
for female control pulmonary artery smooth muscle cells (84MP). 
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A) Chromatogram of oestrogen metabolites formed when female PAH patient hPASMCs were 
stimulated with 14C4-17βE2 for 48 hours. B) Chromatogram of oestrogen metabolites formed when 
female control cell lines were pre-treated with 1µM treprostinil 24 hours prior to stimulation with 
50nM 14C4-17βE2 and 1µM treprostinil. C) Chromatogram of oestrogen metabolism in female 
control cell lines co-stimulated with 50nM 14C4-17βE2 and 1µM treprostinil for 48 hours.  
Figure 4–21: Representative high-performance liquid chromatography chromatograms 
for female patient pulmonary artery smooth muscle cells (35MP). 
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A) Chromatogram of oestrogen metabolites formed when male control hPASMCs were stimulated 
with 14C4-17βE2 for 48 hours. B) Chromatogram of oestrogen metabolites formed when female 
control cell lines were pre-treated with 1µM treprostinil 24 hours prior to stimulation with 50nM 
14C4-17βE2 and 1µM treprostinil. C) Chromatogram of oestrogen metabolism in female control cell 
lines co-stimulated with 50nM 14C4-17βE2 and 1µM treprostinil for 48 hours.  
Figure 4–22: Representative high-performance liquid chromatography chromatograms 
for male control pulmonary artery smooth muscle cells (34MP). 
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A) Chromatogram of oestrogen metabolites formed when male PAH patient hPASMCs were 
stimulated with 14C4-17βE2 for 48 hours. B) Chromatogram of oestrogen metabolites formed when 
female control cell lines were pre-treated with 1µM treprostinil 24 hours prior to stimulation with 
50nM 14C4-17βE2 and 1µM treprostinil. C) Chromatogram of oestrogen metabolism in female 
control cell lines co-stimulated with 50nM 14C4-17βE2 and 1µM treprostinil for 48 hours. 
Figure 4–23: Representative high-performance liquid chromatography chromatograms 
for male patient pulmonary artery smooth muscle cells (67MP). 
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Female and male, control and patient PASMCs were incubated with 14C4-17βE2 (50nM) for 48 hours in 1% (oestrogen-free) CSS PRF DMEM. Samples were extracted 
by solid phase extraction using Oasis® HLB cartridges and analysed by HPLC/flux method with UV and radiolabelled detection. N=1 cell line per group, repeated two 
or three times. 
Figure 4–24: Oestrogen metabolic profile in pulmonary artery smooth muscle cells stimulated with treprostinil. 
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4.2.8.2 2,4,3’,5’-Tetramethoxystilbene did not Alter Oestrogen 
Metabolism in Female Human Pulmonary Artery Smooth Muscle 
Cells 
TMS, a potent inhibitor of the CYP1B1 oestrogen-metabolising enzyme, has been shown to 
attenuate the development of experimental PH phenotype in female SERT+ mice and mice 
exposed to cHx (Johansen, 2014). It also improved the overall survival in male rats 
exhibiting monocrotaline-induced PH, although it did not improve the haemodynamic 
parameters and vascular remodelling (Johansen, 2014). The beneficial effects of CYP1B1 
inhibition may be mediated through anti-proliferative effects observed in vitro, where TMS 
reduced 17βE2-induced proliferation in hPASMCs (White et al., 2012). High local 
concentrations of oestrogens due to local synthesis (Mair et al., 2014) and metabolism 
(Johansen, 2014) was shown to potentially contribute to potent pathogenic environment, 
stimulating proliferation of VSMCs, and leading to muscularisation of small PAs. 
Considering the robust evidence of the detrimental role of CYP1B1 in the pathogenesis of 
PAH (Austin et al., 2009; White et al., 2012), we wished to assess the effects of its inhibition 
in vitro on oestrogen metabolism in female cell lines. 
We showed that female control and patient cell lines metabolise 17βE2 differently (Figure 
4–25A), with larger quantities of E1 produced in female patient cells compared to control 
cells (Figure 4–25B). Moreover, in accordance with previous studies, 16αOHE1 was only 
detected in female patient cells (Figure 4–27A). Its production in female patient cells 
stimulated with 17βE2 was higher compared to control cell line. We also observed the 
formation of 16αOHE2 and 2OHE1 in female control and patient cell lines, respectively 
(Figure 4–26A and Figure 4–27B). Treatment with TMS did not affect the overall oestrogen 
metabolism in control and patient cell lines, respectively, although a small decrease in the 
production of 16αOHE1 was observed (Figure 4–27A). Similarly, the production of 
16αOHE2 in female control cells was decreased as well, albeit this was not significant 
(Figure 4–27B). Stimulation of female patient cell line with TMS also resulted in the 
formation of two unknown oestrogen metabolites (Figure 4–26 B, C).  
252 
 
 
HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with 2,4,3',5'-tetramethoxystilbene 
(TMS, 100nM) 30 minutes prior to addition of 50nM 14C4-17βE2. The spent media samples were collected after 48 hours and analysed using HPLC with scintillation 
counter. N=1 per group, repeated 3 times. Data is expressed as mean±SEM. 
Figure 4–25: Treatment of human pulmonary arteries from female control subjects and clinical patients with 2,4,3',5'-tetramethoxystilbene (TMS) 
does not alter oestrogen metabolism. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–
24 hours. Cells were then stimulated with 2,4,3',5'-tetramethoxystilbene (TMS, 100nM) 30 minutes 
prior to addition of 50nM 14C4-17βE2. The spent media samples were collected after 48 hours and 
analysed using HPLC with scintillation counter. N=1 per group, repeated 3 times. Data is expressed 
as mean±SEM. 
Figure 4–26: In human pulmonary artery smooth muscle cell line derived from female 
patient subject, treatment with 2,4,3',5'-tetramethoxystilbene (TMS) results in the 
formation of two unknown metabolites. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with 2,4,3',5'-tetramethoxystilbene 
(TMS, 100nM) 30 minutes prior to addition of 50nM 14C4-17βE2. The spent media samples were collected after 48 hours and analysed using HPLC with scintillation 
counter. N=1 per group, repeated 3 times, Two-Way ANOVA, followed by Tukey’s multiple comparison post-hoc test. Data is expressed as mean±SEM.
Figure 4–27: 2,4,3',5'-Tetramethoxystilbene (TMS) does not affect the metabolism of 17β-oestradiol to 16α-hydroxyoestrogens. 
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Chromatograms shown above depict oestrogen metabolites in female control and patient cell lines 
treated with 50nM 14C4-17βE2 (A, C) and 2,4,3',5'-tetramethoxystilbene (TMS, 100nM), a potent 
cytochrome CYP1B1 inhibitor, in the presence of 14C4-17βE2 (B, D).  
Figure 4–28: Representative high-performance liquid chromatography chromatograms 
for female control and patient pulmonary artery smooth muscle cells (80MP, 38MP). 
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 Expression of 17β-Hydroxysteroid Dehydrogenase 
Type 2 is Increased in Unstimulated Male Patient 
Pulmonary Arterial Smooth Muscle Cells 
17βHSD type 2 is the oxidoreductase catalysing the interconversion of 17βE2 to E1, with 
equally high catalytic activity for the interconversion of testosterone to androstenedione 
(Labrie et al., 1997), and is therefore generally considered to mediate anti-oestrogenic and 
anti-androgenic effects. 17βHSD type 2 is widely expressed in the peripheral tissues, 
including the lung and liver (Miettinen et al., 1996), as well as in oestrogen-target tissues, 
indicating its main metabolic role might be associated with the conversion of sex hormones 
to biologically less potent hormones. Previously, it was reported that exposure to cHx results 
in increased expression of 17βHSD type 1 enzyme, which catalyses the interconversion of 
the E1 to 17βE2 (Johansen, 2014), indicating that increased conversion of less biologically 
potent oestrogens to more biologically potent hormones, might be associated with 
dysregulated oestrogen metabolism observed in PAH. We assessed the expression levels of 
17βHSD type 2 in PASMCs of both sexes, derived from control and PAH patient subjects 
to determine whether there is a difference in the expression associated with sex. At gene 
expression level, we observed no difference in the expression of 17βHSD type 2 between 
the groups (Figure 4–29A), indicating the expression level of this enzyme might not be 
affected by sex or disease. 
Furthermore, at protein level, a trend of increased expression of 17βHSD type 2 in 
unstimulated human PASMCs derived from male subjects exhibiting clinical PAH 
phenotype compared to cells derived from control male subjects and female subjects 
exhibiting PAH phenotype, respectively was observed (Figure 4–29B). Although the results 
from immunoblotting should be considered with caution due to the quality of the blot, the 
results indicate that the protein expression might be affected on the level of microRNA or 
its degradation pathway, considering the expression at gene level was not altered across 
groups, our observations. 
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Figure 4–29: Expression of 17β-hydroxysteroid dehydrogenase type 2 is increased in unstimulated male human pulmonary artery smooth muscle 
cells derive from patients with pulmonary arterial hypertension. 
HPASMCs were grown to reach approximately 80% confluence in 10% FBS DMEM media. PASMCs were then washed with ice-cold PBS and protein samples were 
collected and prepared as previously described. (A) The expression of 17βHSD type 1 was assessed by Taqman quantitative Real Time-PCR. Results were normalised 
to β-2-microglobulin. N=3–6 per group in triplicate, One-way ANOVA followed by Tukey’s post-hoc test. Data is expressed as 𝑅𝑄 ±
𝑅𝑄𝑚𝑎𝑥
𝑅𝑄𝑚𝑖𝑛
, where RQ=Relative 
quantification. (B) The level of 17βHSD type 1 protein expression was addressed using immunoblotting. N=3‒4 per group in duplicate, ****p<0.0001, One-way 
ANOVA followed by Tukey’s post-hoc test. Data is expressed as fold change to Control group±SEM. The representative immunoblotting image is shown in (C). 
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 Hypothesis-Free Metabolomic Screen in Female 
Pulmonary Artery Smooth Muscle Cells Stimulated 
with 17β-Oestradiol 
When conducting HPLC/flux analyses of oestrogen metabolism in vitro we have been 
confronted with the presence of oestrogen metabolites that were previously not identified. 
Due to the position of radioactive label within the parental hormone, however, we were 
convinced the observed compounds were oestrogen metabolites, although we were unable 
to correlate them with the retention times of 15 most frequent metabolites. 
To the best of author’s knowledge, a metabolomic screen using an in vitro model of 
hPASMCs has not yet been carried out. Our aim was, therefore, to conduct a hypothesis-free 
metabolomic screen in female control and patient cell lines, treated with 17βE2 or vehicle, 
as described in Chapter 2.6.1. Sample preparation and analysis were performed at 
Strathclyde University, Glasgow with the support of Dr David Watson and Muhammad 
Abbas. Our aim was to identify any metabolites that are either altered with clinical disease 
onset or with 17βE2 stimulation, an insult known to contribute to PAH pathogenesis. Any 
identified changes in the metabolome could namely potentially point towards molecular 
pathways that might be imperative in disease pathogenesis but have not yet been investigated 
in the context of PAH. The library used to carry out the metabolomic screen was constructed 
at Strathclyde University and was kindly provided by Dr Watson. 
The analysis was carried out in two modes, positive and negative, hence the results herein 
are presented in such manner as well. In positive mode, we observed that stimulation with 
17βE2 did not lead to many changes in the metabolome of female control cell lines. A 
statistically significant increase in (S)-ATPA and an unknown complex was observed, with 
more of the molecule present when cells were stimulated with 17βE2. Similar observations 
were made in negative mode, where the only significant difference in the metabolome 
between vehicle- and 17βE2-treated cells was a fatty acid 4,7-dioxo-octanoic acid (data not 
shown). Interestingly, when comparing female patient cells stimulated with vehicle and 
17βE2, more metabolites were shown to be significantly changed (Figure 4–30). A variety 
of peptides and chemical complexes were found to be altered in female patient cells 
stimulated with 50nM unlabelled 17βE2 compared to vehicle treatment. However due to 
their general character, it is difficult to establish their potential association with metabolic 
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pathways which might be affected in hPASMCs by 17βE2 stimulation (Figure 4–31). 
Interestingly, creatine, whose main physiological function is to recycle adenosine 
triphosphate (ATP), was significantly increased in female patient cells stimulated with 50nM 
unlabelled 17βE2. Moreover, the levels of glutathione were also affected by 17βE2 treatment 
in female patient cells. It therefore appears that energy metabolism and the formation of ROS 
are affected by oestrogens in female patient hPASMCs. The level of L-kynurenine, a 
catabolite of tryptophan which is the precursor of 5-HT, was also altered in female patient 
cells treated with 17βE2 (Figure 4–31), where treatment resulted in catabolite diminished 
concentration. While further catabolite products of L-kynurenine metabolism have been 
shown to possess vasoactive properties (Wang et al., 2010), the parental molecule is a known 
AhR ligand, shown to be increased in certain cancers, where it promoted tumour growth 
(Opitz et al., 2011). In negative mode, we did not observe significant changes in metabolites 
present in female patient cells stimulated with 17βE2 compared to vehicle treatment group. 
When comparing the metabolome of vehicle-treated female controls to female patients, we 
observed significantly increased levels of glutathione and decreased levels of nicotinamide 
in female patient cell lines, indicating the formation of ROS might be dysregulated (Figure 
4–32). The levels of L-carnitine and pantothenate, which are both involved in the synthesis 
and stabilisation of coenzyme A (CoA) and acetyl-CoA, respectively, were decreased with 
treatment in female control cell lines. In negative mode, we show that besides numerous 
complexes, the levels of pantothenate are slightly reduced in female patient cell lines (Figure 
4–34). Equally, using positive mode, we have established that in female patient cells 
treatment with 17βE2, results in significantly altered levels of numerous chemical 
complexes, and levels of L-carnitine compared to female patient cell lines (Figure 4–33). 
The ratio of levels indicated that L-carnitine was decreased in female patient cell lines. 
Whilst in negative mode, treatment with 17βE2 resulted in increased levels of 2-
oxoglutarate, which has an important role in oxidation reactions involving molecular 
oxygen, in female patient cell lines compared to female control cell lines (Figure 4–34). 
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Figure 4–30: Metabolomic screen of pulmonary artery smooth muscle cells from female 
patient subjects comparing vehicle-treated cells with those treated with 17β-oestradiol 
using positive mode. 
Female patient hPASMC were grown to 60-70% confluence, as previously described, and 
serum starved for 16–24 hours. Cells were then stimulated with vehicle (0.005% (v/v) EtOH 
in 1% CSS PRF DMEM) for 48 hours. The spend media were collected as previously 
described and analysed using LC-MS. N=3 per group, repeated 2–3 times, *p≤0.05, 
****p<0.0001, unpaired t-test. 
The graph presents only the selection of metabolites, which were significantly altered by treatment 
with 17β-oestradiol. 
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Figure 4–31: Metabolomic screen comparing vehicle-treated pulmonary artery smooth 
muscle cells from female control subjects to female patient subjects using positive mode. 
Female control hPASMC were grown to 60-70% confluence, as previously described, and 
serum starved for 16–24 hours. Cells were then stimulated with vehicle (0.005% (v/v) EtOH 
in 1% CSS PRF DMEM) for 48 hours. The spend media were collected as previously 
described and analysed using LC-MS. N=3 per group, repeated 2–3 times, *p≤0.05, 
****p<0.0001, unpaired t-test. 
The graph presents only the selection of metabolites, which were significantly different between 
vehicle-treated female cell lines derived from control and patient subjects.
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Figure 4–32: Metabolomic screen comparing vehicle-treated pulmonary artery smooth 
muscle cells from female control subjects to female patient subjects using positive mode 
Female control hPASMC were grown to 60-70% confluence, as previously described, and 
serum starved for 16–24 hours. Cells were then stimulated with vehicle (0.005% (v/v) EtOH 
in 1% CSS PRF DMEM) for 48 hours. The spend media were collected as previously 
described and analysed using LC-MS. N=3 per group, repeated 2–3 times, *p≤0.05, 
****p<0.0001, unpaired t-test. 
The graph presents only the selection of metabolites, which were significantly different between 
vehicle-treated female cell lines derived from control and patient subjects.  
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Female control and patient hPASMC were grown to 60-70% confluence, as previously described, 
and serum starved for 16–24 hours. Cells were then stimulated with vehicle 17βE2 (50nM) in 1% 
CSS PRF DMEM for 48 hours. The spend media were collected as previously described and analysed 
using LC-MS. N=3 per group, repeated 2–3 times, *p≤0.05, ****p<0.0001, unpaired t-test. 
The graph presents only the selection of metabolites, which were significantly different between 
vehicle-treated female cell lines derived from control and patient subjects.  
Figure 4–33: Metabolomic screen comparing vehicle-treated pulmonary artery smooth 
muscle cells from female control subjects to female patient subjects using negative mode. 
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Female control and patient hPASMC were grown to 60-70% confluence, as previously described, 
and serum starved for 16–24 hours. Cells were then stimulated with vehicle 17βE2 (50nM) in 1% 
CSS PRF DMEM for 48 hours. The spend media were collected as previously described and analysed 
using LC-MS. N=3 per group, repeated 2–3 times, *p≤0.05, ****p<0.0001, unpaired t-test. 
The graph presents only the selection of metabolites in female cell lines derived from controls 
compared to patient cell lines, which were significantly altered by 17β-oestradiol.  
Figure 4–34: Metabolomic screen comparing 17β-oestradiol-treated pulmonary artery 
smooth muscle cells from female control subjects to female patient subjects using negative 
mode. 
 
R
a
ti
o
 [
N
o
n
-P
A
H
/P
A
H
]
P
h
e
n
o
l 
s
u
lf
a
te
L
-A
la
-L
-G
lu
2
-O
x
o
g
lu
ta
ra
te
N
-A
c
e
ty
l-
L
-h
is
t i
d
in
e
G
u
a
n
o
s
in
e
[M
+
H
2
C
O
3
] 
6
2
.0
0
0
4
 m
/z
 a
d
d
u
c
t  
o
f  
3
3
6
.8
1
7
7
 m
/z
A
z
e
la
ic
 a
c
id
C
o
m
p
le
x
 o
f  
1
1
5
.0
0
3
6
 a
n
d
 1
2
7
.0
5
1
3
 m
/z
0
1
2
3
265 
 
 Initial Development of Liquid Chromatography 
Tandem Mass Spectrometry Method for the Detection 
and Quantitation of Oestrogens in Spent Cell Media 
Samples 
Liquid chromatography tandem mass spectrometry (LC/MS/MS) is an analytical technique, 
providing information on structure, molecular mass and concentration of analytes present 
within a complex sample. The technique utilises separation of analytes by liquid 
chromatography or HPLC, and detection of these analytes by mass spectrometry (MS). 
Briefly, the compounds in samples are first separated by UHPLC, where the sample together 
with mobile phase is pumped through the separation column, resulting in differential elution 
of compounds, based on their interaction with stationary phase packed inside the column. 
The separated sample compounds are then immediately introduced into the mass 
spectrometer. In mass spectrometer, the sample components are firstly ionised, most often 
using the electrospray ionisation technique (ESI). Here, the sample introduce into the MS is 
dispersed by electrospray tip into a mist of highly charged droplets, having the same polarity 
as the capillary voltage, due to strong electric field applied at the tip. The charged droplets 
travel down a pressure gradient and potential gradient toward the analyser of the mass 
spectrometer. The temperature of the ESI source together with a stream of drying gas enable 
the de-solvation of charged droplets, leading to reduction of droplet size, to a critical point, 
when ions can be ejected in an electric field, resulting in the formation of analyte ions. 
Resulting emitted ions are then accelerated into the mass analyser, where the charged 
parental molecules or charged fragments of the analyte are separated in vacuum according 
to their mass-to-charge ratio by their behaviour within quadrupole analysers. The value of 
indicator quantity is then recorded by the detector, and signal is transformed into a mass 
spectrum. In tandem mass spectrometry, a precursor ion is selected based on its mass by a 
mass analyser. The selected ion then undergoes a gas-phase chemical reaction, resulting in 
the fragmentation of the ion to product ions of different masses, which are then passed to 
another mass analyser. The masses of the product ions are detected in the latter mass 
analyser, generating the mass ion spectrum. Due to the method’s numerous advantages, such 
as small sample volumes, improved specificity and sensitivity, and short analysis times, LC-
MS/MS is rapidly replacing other methods for steroid hormone analysis. Importantly, LC-
MS/MS additionally offers the identification of unknown analytes present in a sample, based 
on their molecular weight and structure, determined by fragmentation pattern of the analyte. 
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As dysregulation of oestrogen metabolism has been associated with the onset of PAH, it is 
our belief that a technique is required, which could be employed to investigate the changes 
and/or differences in the oestrogen metabolism in patients and healthy individuals. Albeit 
numerous techniques are currently available to assess the levels of individual oestrogen 
metabolites, the considerable number of oestrogen metabolites, having similar structure and 
exhibiting high tendency for oxidation, severely hinder the separation and identification of 
these compounds. UHPLC was previously successfully used to investigate oestrogen 
metabolism by several groups (Rogan et al., 2003;Johansen et al., 2014;Delvoux et al., 
2007). Nonetheless, this technique did not readily guarantee quantification of oestrogen 
metabolites, as it is partially hindered by high detection limits. Moreover, the identification 
of the metabolites when analysing complex samples might be impeded by the lack of means 
of metabolite identification. We therefore opted to develop an LC-MS/MS method to assess 
the profile of oestrogens in in vitro model of hPASMCs, which offers numerous advantages 
over other methods: i) the separation of oestrogen metabolites is not only based on liquid 
chromatography, but also the differences in metabolite molecular masses and chemical 
structures, ii) enhanced sensitivity of LC-MS/MS, achieved through the introduction of 
derivatising chemical groups, enables the detection of oestrogen metabolites on pico-molar 
level, and iii) the redundancy of radioactively labelled oestrogens introduces cost- and 
environment/health-benefits. Most often this technique has been used to investigate the 
levels of parental oestrogens (Nelson et al., 2004b), with Guo and colleagues recently 
reporting the quantification of 16αOHE1 in human sera samples (Guo et al., 2008). 
However, the LC-MS/MS approach to oestrogen metabolism analysis requires the 
compounds to ionise for them to be separated in the electrical field according to their 
molecular mass, and oestrogens, as all other steroid-based compounds, do not ionise readily. 
Although chemical derivatisation, which enhances the sensitivity of the assay, is required, it 
could potentially introduce errors into the system. 
The work presented in this chapter was done in close collaboration with Prof Ruth Andrew 
and Dr Natalie Homer at University of Edinburgh. The method development was a joint 
effort by the author and Ioannis Stasinopoulos, who has dedicated his time to establishing 
and validating the initial technique as a part of his internship research project.
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Figure 4–35: Initial liquid-chromatography tandem mass spectrometry method for the detection and quantitation of oestrogen metabolites in in vitro 
model. 
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4.2.11.1 Establishing a Method by Initial Liquid Chromatography 
Tandem Mass Spectrometry 
The initial method for quantitation of oestrogen metabolites in aqueous matrix was 
established by Ioannis Stasinopoulos, who compared available ACE LC columns, by 
Hichrom Ltd, UK, which were suitable for separation of analytes with steroid character. The 
most suitable column was selected based on the peak shape and size, and the maximal 
resolving power achieved for E1 and 17βE2, as assessed by the difference in the retention 
time for these two parental oestrogens. For the separation of oestrogens, gradient elution was 
selected, as generally longer gradient times result in larger differences in the retention times 
of metabolites, and therefore better chromatographic separation. 
The ACE Excel C18-AR column was selected for the separation of complex mixture of 
oestrogen metabolites, with gradient length (tg) of 660 seconds at 25°C, where the gradient 
was applied from to increase the organic phase (CH3CN+0.1% FA (v/v), B) from 10% to 
80%, before the system was re-equilibrated to initial 10% of organic phase. Excellent 
separation of E1, 17αE2, 17βE2, 2OHE1, 2OHE2, 4OHE1, 4OHE2, 16αOHE1 and 
16αOHE2 was achieved (Figure 4–35). The separation of methoxy metabolites, however, 
was not obtained. Considering the important impact of these metabolites in the treatment 
and prevention of the experimental PH in animal models, we deemed it necessary to alter 
the method to also be able to detect and quantify methoxyoestrogens. 
4.2.11.2 Separation of Methoxyoestrogens was Achieved by 
Replacement of High-Performance Liquid Chromatography 
Column 
Separation of methoxyoestrogens was attempted by the author by i) decreasing temperature 
(T=10°C and 15°C), ii) prolonging the gradient time to tg=23 minutes, and iii) reducing flow 
rate (0.5mL/min). None of the introduced changes in the LC-MS/MS method resulted in 
improved chromatographic separation of these metabolites. 
Separation of methoxyoestrogens was achieved only by exchange of the ACE Excel C18-
AR column for the ACE Excel C18-PFP column (Figure 4–36). Improved selectivity was 
achieved due to the presence of pentafluorophenyl (PFP) group, due to multiple mechanism 
of analyte separation. With ACE Excel C18-PFP column, the retention times of 
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methoxyoestrogens have changed. Specifically, with ACE Excel C18-AR column, the 
4MeOE1 eluted from the column after 2MeOE1, while the order of metabolite elution was 
reversed with ACE Excel C18-PFP column. Importantly, the peaks presenting 2MeOE1 and 
4MeOE1 were completely separated. Equally, the replacement of ACE Excel C18-AR 
column resulted in complete separation of the peaks corresponding to 2MeOE2 and 
4MeOE2, which previously eluted from the column simultaneously. 
4.2.11.3 Sample Matrix Affects Calibration Curves of Oestrogen 
Metabolites 
As the initial method development was done using aqueous sample matrix, we aimed to 
determine whether the relationship between the ratio of peak area of an oestrogen metabolite 
to the peak area of corresponding internal standard with concentration of that metabolite was 
linear when recovered from cell medium. The ratio of peak areas is used instead of 
metabolite peak area to account for any losses during solid-phase extraction. We prepared 
two calibration curves for each of oestrogen metabolites in either aqueous or media matrices 
in the range of 5 to 2000ng/mL, and extracted these samples as previously described 
(Chapter 2.5.2). Extracted samples were then derivatised and methylated as described in 
Chapter 2.7.3. 
While the relationship between the concentration and the ratio of oestrogen metabolites to 
the peak area of corresponding inert standard was linear in aqueous samples, the relationship 
was not linear in the media sample matrix for all steroids, with particular problems at lower 
concentrations (Figure 4–37 to Figure 4–41). Nonetheless, in the range between 500 and 
2000ng/mL, linearity was obtained for most of oestrogen metabolites in both sample 
matrices. Therefore, the quantitation of oestrogen metabolites using the LC-MS/MS method 
might be hindered, as the expected concentrations of oestrogen metabolites are expected in 
physiological concentrations, i.e. the lower part of the calibration curves.
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Figure 4–36:Liquid-chromatography tandem mass spectrometry method for the detection and quantitation of oestrogen metabolites in in vitro model, 
using ACE Excel C18-PFP column. 
271 
 
 
 
  
Figure 4–37: Calibration curves for oestrone, 17α-oestradiol and 17β-oestradiol prepared in two different sample matrices (aqueous – above and 
media – below). 
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Figure 4–38: Calibration curves for 2- 4- and 16α-hydroxyoestrone prepared in two different sample matrices (aqueous – above and media – below). 
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Figure 4–39: Calibration curves for 2- 4- and 16α-hydroxyoestradiol prepared in two different sample matrices (aqueous – above and media – 
below). 
C o n c e n tra t io n  (n g /m L )P
e
a
k
 a
r
e
a
 2
O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0
2
4
6
8
1 0
C o n c e n tra t io n  (n g /m L )P
e
a
k
 a
r
e
a
 4
O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0
2
4
6
8
1 0
C o n c e n tra t io n  (n g /m L )
P
e
a
k
 a
r
e
a
 1
6

O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0 .0
0 .2
0 .4
0 .6
C o n c e n tra t io n  (n g /m L )P
e
a
k
 a
r
e
a
 2
O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0
2
4
6
8
C o n c e n tra t io n  (n g /m L )P
e
a
k
 a
r
e
a
 4
O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0
2
4
6
8
1 0
C o n c e n tra t io n  (n g /m L )
P
e
a
k
 a
r
e
a
 1
6

O
H
E
2
/ 
 P
e
a
k
 a
r
e
a
1
3
C
-E
2
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0 .0 0
0 .0 5
0 .1 0
0 .1 5
274 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4–40: Calibration curves for 2- and 4-methoxyoestrone prepared in two different sample matrices (aqueous – above and media – below). 
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Figure 4–41: Calibration curves for 2- and 4-methoxyoestradiol prepared in two different sample matrices (aqueous – above and media – below). 
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4.2.11.4 Assessment of Wash Step for Solid-Phase Extraction of 
Oestrogen Metabolites from Media Sample Matrix 
The solid-phase extraction protocol was optimised as previously described in (Johansen, 
2014) for use with radio-HPLC. Due to the observed matrix effects of media, we wished to 
assess whether the extraction protocol may be further optimised. First, we assessed 
alternative types of solid-phase cartridges. Here we compared the HLB and MCX cartridges 
where the first cartridge is universal, exhibiting strongly hydrophilic character and can 
maintain high retention and capacity even if it dries, and the latter is a mixed-mode, strong 
cation-exchange cartridge, allowing for greater selectively of retention through manipulation 
of pH. The suitability of cartridges was assessed based on recoveries of oestrogen 
metabolites and internal standards. To recapitulate, recovery was calculated as the 
percentage of a given extracted oestrogen metabolite to unextracted metabolite. It follows 
from the equation, that the best cartridge for SPE is the one offering recoveries close to 
100%. Here we showed that although MCX cartridges might offer better recovery of some 
metabolites, the HLB cartridges exhibit better recovery of internal standards labelled with 
stable 13C isotope and most of oestrogen metabolites, when MeOH is used for elution (Figure 
4–42 and Figure 4–44). Although ACN as eluent resulted in seemingly better recoveries, we 
observed large variability with the latter eluent. The difference in the recovery of 
hydroxylated oestrogens is shown in Figure 4–43, where the recovery of these metabolites 
in HLB extraction cartridges was poorer compared to the MCX cartridges. To circumvent 
this, samples of spent media could be divided, and applied to both cartridges, although this 
would inevitably lead to lower metabolite amount per each sample. 
We then also assessed the wash steps used to wash out undesired matrix components, which 
are not bound to the cartridge. We show that the combination of a wash step with 100% H2O 
followed by a wash with 5% (v/v) MeOH in water might wash out some of the oestrogen 
metabolites present in the samples, as the recoveries, especially for more hydrophilic 
metabolites, were lower in this instance (Figure 4–44B).  
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10ng of each oestrogen metabolite was added to 10mL of 1% CSS PRF DMEM media before 
extraction. MCX and HLB cartridges were used for solid-phase extraction, and either 3mL of 
methanol (MeOH) or acetonitrile (ACN) was used to elute the oestrogens. The recovery of oestrogen 
metabolite using solid-phase extraction cartridges Oasis® HLB was calculated by determining the 
ratio of pre- to post-spiked samples. The recovery of oestrogen metabolites was calculated by 
determining the ratio of pre- to post-spiked samples. Each extraction was performed in duplicate. 
  
Figure 4–42: The combination of HLB cartridges for solid-phase extraction and methanol 
as eluent results in less variable recovery of oestrogen metabolites from cell media. 
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Unextracted Hydroxyoestrones (10ng) 
Hydroxyoestrones (10ng) extracted using MCX cartridge (MeOH) 
Hydroxyoestrones (10ng) extracted using HLB cartridge (MeOH) 
Figure 4–43: Liquid chromatography tandem mass spectrometry of unextracted 
hydroxyoestrones compared to those extracted using either HLB or MCX solid-phase 
extraction cartridges. 
279 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100ng of each oestrogen metabolite was added to 10mL of 1% CSS PRF DMEM media, either before 
(pre-spiked) or after extraction (post-spiked). The recovery of oestrogen metabolite using solid-phase 
extraction cartridges Oasis® HLB was calculated by determining the ratio of pre- to post-spiked 
samples. A) Solid-phase extraction with 5% (v/v) MeOH wash. B) Solid-phase extraction with 100% 
(v/v) H20 and 5% (v/v) MeOH wash steps. Each extraction was performed in triplicate.  
A 
B 
Figure 4–44: Recovery of hydroxy oestrogens is reduced by additional wash step with 
100% water. 
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 Oestrogen Metabolomic Profile and Quantitation 
in In Vitro Model of Pulmonary Arterial Hypertension 
4.2.12.1 Calibration Curves for Oestrogen Metabolites of Interest in 
Pulmonary Arterial Hypertension in Media Sample Matrix 
As we showed previously that the media sample matrix might affect the reaction of 
derivatisation and therefore hinder quantitation of oestrogen metabolites in spent media 
samples of naïve hPASMCs derived from control and patient subjects of both sexes, we have 
dedicated special care to construction of calibration curves. Here we show that over a wide 
concentration range of oestrogen metabolites included in these experiments, we have 
achieved satisfactory calibration curves as assessed per R-square values, which assesses the 
closeness of the data to the fitted regression curve (Figure 4–45 to Figure 4–48). Poorer fit 
of data to the linear regression curve was observed for hydroxylated oestrogens, as seen in 
Figure 4–46 and Figure 4–47. 
281 
 
  
Figure 4–45: Calibration curves for oestrone, 17α-oestradiol and 17β-oestradiol prepared in media sample matrix, and used to quantify oestrogen 
metabolites in spent media samples of naïve cell cultures of human pulmonary arterial smooth muscle cells derived from control and patient subjects 
of both sexes. 
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Figure 4–46: Calibration curves for 2-, 4- and 16α-hydroxyoestrone prepared in media sample matrix, and used to quantify oestrogen metabolites in 
spent media samples of naïve cell cultures of human pulmonary arterial smooth muscle cells derived from control and patient subjects of both sexes. 
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Figure 4–47: Calibration curves for 2-, 4- and 16α-hydroxyoestradiol prepared in media sample matrix, and used to quantify oestrogen metabolites in 
spent media samples of naïve cell cultures of human pulmonary arterial smooth muscle cells derived from control and patient subjects of both sexes. 
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Figure 4–48: Calibration curves for 2- and 4- methoxyoestrogens prepared in media sample matrix, and used to quantify oestrogen metabolites 
in spent media samples of naïve cell cultures of human pulmonary arterial smooth muscle cells derived from control and patient subjects of 
both sexes. 
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4.2.12.2 Oestrogen Metabolic Profile in In Vitro Model of Pulmonary 
Arterial Hypertension 
As the lung is a site of oestrogen synthesis and metabolism, and individual oestrogen 
metabolites have been shown to convey differential biological effects in PASMCs, we 
wished to establish a metabolic profile of oestrogens using the LC-MS/MS methodology. 
The data within this chapter is presented in two ways. Firstly, we showed the complete 
oestrogen metabolic profile in in vitro model of PAH. Next, we compared the levels of 
individual oestrogen metabolites for hPASMCs derived from control and PAH patient 
hPASMCs of both sexes, to determine whether there were significant differences in the 
amounts of these metabolites. 
According to the profile, in cells derived from female control subjects, the metabolites 
present in highest concentrations were E1, 17βE2, 17αE2, 2OHE1, 4OHE1, 2OHE2, 
4OHE2, and 4MeOE2 (Figure 4–49A). Although other metabolites are formed in these cells 
from 17βE2, their amounts were low. The results suggested in these cells oestrogen 
metabolising enzymes with high affinity for hydroxylation at positions C2 and C4 were 
present, alongside 17βHSD type 2, which converts highly active 17βE2 to less biologically 
active E1. Moreover, a significant proportion of 17βE2 was also converted to the geometrical 
isoform 17αE2, which has been in the past considered to be less biologically active. Whether 
this is a spontaneous isomerisation, or an enzyme-catalysed reaction is not clear. Considering 
the numerous extrahepatic CYP enzymes exhibits moderate or high affinity for 
hydroxylation at position C2, it is perhaps not surprising that we observed relatively high 
levels of 2OHE1. The presence of 16αOHE1 was also detected, while less of 16αOHE2 was 
present. In Chapter 1.6.1 we have summarised the catalytic affinities of CYP1A1 and 
CYP1B1 enzymes. CYP enzymes exhibit specific substrate preference, resulting in 
differential hydroxylation of E1 and 17βE2. The comparable levels of hydroxylated E1 and 
17βE2 indicated that the present CYP enzymes did not exhibit significant preference for 
their substrates. Among the protective methoxyoestrogens, 4MeOE2 was present in the 
highest amount of metabolite per μg of protein in female control hPASMCs. The observed 
amount of 4MeOE2 also indicated relatively high activity of COMT in these cells. While 
2OHE1, 4OHE1 and 2OHE2 were shown to be present, we have only measured low amounts 
of these metabolites. It is unclear why they have not been metabolised by COMT to form 
corresponding methoxyoestrogens. HPASMCs derived from female PAH patients 
metabolised 17βE2 mainly to E1, 2OHE1 and 4OHE1, with other metabolites present only 
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in moderate amounts (Figure 4–49B). Therefore, high enzymatic activity or increased 
expression of the 17βHSD type 2 was indicated. High amounts of 2OHE1 and 4OHE1 
compared to those of 2OHE2 and 4OHE2, indicated there is a shift in the expression of CYP 
enzymes, favouring E1 as their substrate. In samples from female PAH patient hPASMCs, 
the production of 16α-hydroxy metabolites was smaller than in female control cell lines. We 
have observed no significant production of protective methoxyoestrogens in samples from 
female PAH patient hPASMCs. 
In cell lines derived from male control subjects we observed the formation of E1, 2OHE1, 
4OHE1, 2OHE2 and 4OHE2. 16αOHE1 and MeOEs were also detected, while other 
metabolites were present only in minor amounts. The metabolic profile of oestrogens 
indicated high activity of 17βHSD type 2, CYP enzymes exhibiting high and moderate 
affinity for hydroxylation at position C2 and C4, with only moderate activity at position 
C16α. Moreover, considering less of 16αOHE2 was produced, the enzymes appear to favour 
hydroxylation of E1 at position C16α. The detection of all methoxyoestrogens indicated the 
activity of COMT. The oestrogen metabolism in male PAH patient hPASMCs appeared to 
be especially influenced by the enzymatic activity of 17βHSD type 2, which has also been 
confirmed in female PAH patient hPASMCs (Figure 4–50B). Interestingly, like in female 
patient hPASMCs, the isomerisation of 17βE2 to 17αE2 appeared to be a significant part of 
oestrogen metabolism in these cells (Figure 4–50B). Although, the literature on the effects 
of 17αE2 in humans is very scarce, there are reports of its pro-proliferative effects in human 
neoplasms (Papendorp et al., 1985;Hajek et al., 1997). Moreover, 17αE2 was also shown to 
increase aromatase activity in a concentration- and time-dependent manner (Hoffmann et al., 
2002). In these cells much of the 17βE2 introduced as the source for oestrogen metabolism 
has remained unmetabolized. 
For easier interpretation of oestrogen metabolite profiles in hPASMCs measured using the 
LC-MS/MS methodology for in vitro investigation of oestrogen metabolism, pie charts are 
shown in Figure 4–51.  
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Female control and patient hPASMCs were grown to 60-70% confluence, as previously described, 
and serum starved for 16–24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. The 
spent media were collected and analysed using LC-MS/MS, as previously described. N=3–5 per 
group, repeated 1–2 times. Oestrogen metabolic profile was constructed.  
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Figure 4–49: Oestrogen metabolic profile in human pulmonary arterial smooth muscle 
cells derived from females. 
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Male control and patient hPASMCs were grown to 60-70% confluence, as previously described, and 
serum starved for 16–24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. The 
spent media were collected and analysed using LC-MS/MS, as previously described. N=3–5 per 
group, repeated 1–2 times. Oestrogen metabolic profile was constructed.
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Figure 4–50: Oestrogen metabolic profile in human pulmonary arterial smooth muscle 
cells derived from males. 
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To compare the levels of oestrogen metabolites formed between different hPASMCs derived 
from control and patient subjects of both sexes, we further presented the quantified levels 
for each of the metabolites. For OHEs, currently achievable limit of detection was relatively 
high, therefore the measured amounts of these metabolites could not be deemed reliable. We 
observed that the levels of conversion of 17βE2 into E1, was increased in female and male 
patient hPASMCs, however only in female cells the increase was significant compared to 
female controls (Figure 4–52A). Furthermore, the isomerisation of 17βE2 appeared to be 
increased in patient hPASMCs of both sexes, although the increase was only statistically 
significant in female patient hPASMCs (Figure 4–52B). It is not clear whether a specific 
isomerase enzyme is required for this reaction. Interestingly, it appeared that in male patient 
hPASMCs more of the 17βE2 remained unmetabolized compared to female patient 
hPASMCs (Figure 4–52C). No statistically significant changes in the formation of OHEs 
(Figure 4–53 and Figure 4–54) and MeOEs metabolites (Figure 4–55) were detected. 
As all the results are expressed in ng of metabolite per μg of protein, we also calculated the 
amount of 17βE2 introduced as the source of oestrogen metabolism in these experiments, 
per μg of protein at 48-hour end time-point. The amount of 17βE2 used varied between 
approximately 0.11 ng/μg protein to approximately 1.1 ng/μg protein. These figures 
indicated that in certain instances significant loss of either 17βE2 or the metabolites formed 
from this source had occurred.  
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Female Non-PAH Female PAH 
Male Non-PAH Male PAH 
Figure 4–51: Oestrogen metabolite profile of pulmonary artery smooth muscle cells from controls and PAH patients of both sexes, determined using 
novel LC-MS/MS method to investigate oestrogen metabolism in vitro. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. 
The spent media were collected and analysed using LC-MS/MS, as previously described. N=3–5 per group, repeated 1–2 times, *p≤0.05, **p<0.01, One-Way ANOVA, 
followed by Tukey’s multiple comparison post-hoc test. Data is expressed as mean±SEM.  
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Figure 4–52: Comparison of oestrone, 17β-oestradiol and its 17α geometric isomer quantities in human pulmonary arterial smooth muscle cells 
determined using the novel liquid chromatography tandem mass spectrometry method. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. 
The spent media were collected and analysed using LC-MS/MS, as previously described. N=3–5 per group, repeated 1–2 times, One-Way ANOVA, followed by Tukey’s 
multiple comparison post-hoc test. Data is expressed as mean±SEM.  
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Figure 4–53: Comparison of 2-, 4- and 16α-hydroxyoestrone quantities in human pulmonary arterial smooth muscle cells determined using the novel 
liquid chromatography tandem mass spectrometry method. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. 
The spent media were collected and analysed using LC-MS/MS, as previously described. N=3–5 per group, repeated 1–2 times, One -Way ANOVA, followed by Tukey’s 
multiple comparison post-hoc test. Data is expressed as mean±SEM. 
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Figure 4–54: Comparison of 2-, 4- and 16α-hydroxyoestradiol quantities in human pulmonary arterial smooth muscle cells determined using the novel 
liquid chromatography tandem mass spectrometry method. 
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HPASMCs were grown to 60-70% confluence, as previously described, and serum starved for 16–
24 hours. Cells were then stimulated with 17βE2 (50nM) for 48 hours. The spent media were 
collected and analysed using LC-MS/MS, as previously described. N=3–5 per group, repeated 1–2 
times, *p≤0.05, **p<0.01, Two-Way ANOVA, followed by Tukey’s multiple comparison post-hoc 
test. Data is expressed as mean±SEM.  
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Figure 4–55: Comparison of 2-methoxy and 4-methoxy metabolites of oestrone and 
17β-oestradiol quantities in human pulmonary arterial smooth muscle cells determined 
using the novel liquid chromatography tandem mass spectrometry method. 
A B 
C D 
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4.3 Discussion 
The molecular mechanisms associated with the role of sex in the development of PAH 
remain largely poorly investigated and understood. It appears that the effects of sex are two-
fold. Firstly, the development of the clinical form of PAH is influenced by sex, with 
significantly higher proportion of women presenting the clinical form of the disease 
compared to men (Humbert et al., 2010a;Ling et al., 2012;Escribano-Subias et al., 2012). 
Secondly, according to survival data, women, albeit developing the disease more often, 
exhibit improved survival compared to men (Escribano-Subias et al., 2012;Humbert et al., 
2010b). Women have improved cardiac function as assessed by higher ejection fraction and 
RV function (Swift et al., 2015;Marra et al., 2016). Moreover, in CVD, the RV function 
appeared to be better preserved in women compared to men (Cleland et al., 2003), with 
documented detrimental effects of testosterone and DHEA on RV mass and volume 
(Ventetuolo et al., 2011). In PAH, the initiation of appropriate therapy does not significantly 
reduce the deterioration in RV function in men compared to matched women patients (Jacobs 
et al., 2014). 
Within the lung, oestrogen is produced and metabolised locally (Mair et al., 2014;Bieche et 
al., 2007). As numerous extrahepatic oestrogen metabolising enzymes were shown to be 
expressed within the lung, the array of metabolites that exert could be exerting their 
biological effects is considerable. Specifically, 16αOHE1 was implicated in the promotion 
of proliferation of VSMCs in PAH, while 2MeOE2 was shown to attenuate the proliferation 
of several vascular cell types (Fotsis et al., 1994;Barchiesi et al., 2006;Tsukamoto et al., 
1998;Tofovic et al., 2009;Nishigaki et al., 1995). We hypothesised that in PAH, the local 
oestrogen metabolism is altered and favours the accumulation of metabolites driving the 
disease pathogenesis, whilst less of the protective metabolites is formed. We therefore 
wished to establish oestrogen metabolic profile of VSMCs and quantify the production of 
oestrogen metabolites. Furthermore, we aimed to assess the effects of oestrogen metabolites 
on specific aspects of PAH pathogenesis. 
In human uterine artery ECs, 2OHE2, 4OHE2, 2MeOE2 and 4MeOE2 induced the 
expression of PGIS (Jobe et al., 2013). As PGIS is also widely expressed within the lung, 
we wished to assess whether oestrogen metabolites might be affecting the expression of this 
enzyme in the lung, and therefore possibly convey protective or pathogenic properties. We 
showed that in hPMECs, only 2MeOE1 and 2MeOE2 increase the expression of PGIS, 
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contrary to observations by (Jobe et al., 2013). Considering we report no changes in the gene 
expression encoding for PGIS, it is possible that MeOEs might stabilise the enzyme and 
protect it from degradation compared to other oestrogens, instead of inducing synthesis de 
novo. When assessing the effects of oestrogen metabolites on the release of PGI2, we showed 
that acute stimulation led to significantly decreased expression of 6-keto PGF1α when cells 
were treated with 16αOHE2 and 2MeOE1, indicating decreased release of its parental 
molecule PGI2. Interestingly, the release of 6-keto PGF1α in the positive control group for 
PGI2 release (20μM arachidonic acid), was like the one observed in treatment groups 
16αOHE2, 2MeOE1 and 2MeOE2. One might argue that it appears that the mentioned 
metabolites do not affect the release of PGI2 from intracellular storage. However, as all 
prostaglandins also PGI2 is produced as required in response to appropriate stimuli. 
Therefore, the observed decreased synthesis of PGI2 in response to acute treatment with 
16αOHE2, 2MeOE1 and 2MeOE2 should be further investigated. Prolonged exposure to 
oestrogen metabolites though did not result in significant changes in the release of PGI2 
levels, probably due to the selected time-points for these experiments. Furthermore, as PGIS 
is expressed not only in vascular ECs, but also in VSMCs, we assessed the effects that 
oestrogen metabolites might have on the expression of PGIS in PAs. Treatment of hPASMCs 
derived from male control subjects with pharmacological levels of 2MeOE2 resulted in 
increased expression of PGIS, whilst no effect was observed in cell lines derived from 
females. Hence, it appeared that 2MeOE2 effects on the expression of PGIS might be sex-
dependent in VSMCs. 
The protective properties of 2MeOE2 were first described in cancer research, where 
treatment with this metabolite opposed tumour progression by having antiproliferative and 
antiangiogenic activity (Sutherland et al., 2005) in numerous types of tumours, including 
lung (Huober et al., 2000). The protective effects in the lung were also described in PAH, 
where 2MeOE2 was found to prevent and attenuate the development of experimental PH 
phenotype in MCT, belomycine-induced and Su5416/Hx model (Tofovic et al., 
2009;Tofovic et al., 2008b;Tofovic and Rafikova, 2009). We therefore wanted to assess the 
antiproliferative properties of methoxyoestrogens in in vitro model of PAH and determine 
whether the protective effects are sex-dependent. We treated PASMC cell lines derived from 
control subjects of both sexes with 1nM and 100nM MeOEs. We demonstrated that 
2MeOE1, 2MeOE2 and 4MeOE2 reduce proliferation in control PASMCs of both sexes, at 
both concentrations. According to radioligand binding assays, the affinity of MeOEs for ER 
at physiological concentrations are not significant, compared to the parental hormone and 
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catechol oestrogens (Merriam et al., 1980). It is however noteworthy, that normal 
physiological concentration of 2MeOE2 is supposed to be <0.1nM. We therefore wished to 
assess whether some of the antiproliferative properties might be mediated through classical 
oestrogen signalling. Our results indicated that in male control hPASMCs, inhibition of ERα, 
ERβ and gpr30 restored proliferation, in the presence of 2MeOE2. Moreover, the 
antiproliferative properties of 4MeOE2 were only opposed by inhibition of both classical 
ER. Similar response was documented in female control PASMCs. Interestingly, 2MeOE2 
only attenuated cellular proliferation in female patient PASMCs, while it had no effect on 
male patient PASMCs. The research showing the protective activity of 2MeOE2 as 
determined by prevention and/or attenuation of experimental PH phenotype was done in 
female animals only, therefore no description of in vivo effects of 2MeOE2 in male exist. 
Treatment of hPASMCs with 2OHE2 and 4OHE2, precursors in the formation of 
antiproliferative MeOEs, led to attenuated proliferation of these cells. Herein we showed 
that both catechol oestrogens decrease serum-induced proliferation of hPASMCs. To 
establish whether the observed attenuation of proliferation is due to the metabolism of 
catechol oestrogens to methoxy metabolites, we have pre-stimulated hPASMCs with COMT 
inhibitors. Indeed, our results indicate that inhibition of the conversion of 2OHE2 into 
corresponding methoxyoestrogen, at least restores cellular proliferation. Interestingly, 
inhibition of COMT only partially restored proliferation in the presence of 4OHE2, 
indicating that 4OHE2 might confer its anti-proliferative properties through other 
mechanisms. Due to reported high binding affinity of catechol oestrogens to classical ER, 
we also explored whether these metabolites might mediate some of their effects through ER 
signalling. 2OHE2 and 4OE2 have similar affinity for both ER isoforms, which is 5–10-fold 
lower than that of the parental hormone 17β-E2 (Schutze et al., 1994). The presence of ERα 
and ERβ antagonist, or the dual ER antagonist ICI 182 780, resulted in restored proliferation 
of hPASMCs in the presence of 2OHE2, while in the presence of 4OHE2 the proliferation 
was only restored by ERα antagonist. It appears that 4OHE2 may convey its effects through 
the ERα receptors. ERα is increased in hPASMCs derived from female PAH patients, 
therefore the anti-proliferative properties of 4OHE2 might not be associated with the amount 
of the present receptor but affect cellular proliferation through a different mechanism. The 
4-OHEs were also reported to potentially activate ER (Martucci and Fishman, 1976), and 
possibly convey prolonged biological effects due to slower dissociation rates from receptors 
(Zhu and Conney, 1998;Barnea et al., 1983). 
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The BMPRII signalling pathway is intimately involved in the pathogenesis of PAH, and its 
dysregulation resulted in proliferation of PASMCs (Perez et al., 2011;Nakaoka et al., 1997) 
(Zhang et al., 2003) and apoptosis of PAECs (Teichert-Kuliszewska et al., 2006). 17βE2 
reduced BMPRII signalling, in Hx through HIF1α (Ichimori et al., 2013) and ERα signalling 
(Fessel et al., 2013). Additionally, sex appeared to be associated with differential expression 
of proteins participating in the BMPRII signalling pathway, with PASMCs from female 
control subjects exhibiting lower levels of mRNA and protein expression of BMPRII, 
Smad1, Id1 and Id3 (Mair et al., 2015). We therefore wished to assess whether different 
oestrogen metabolites might affect the expression of components of the BMPRII pathway. 
We first conducted a preliminary assessment of 13 oestrogen metabolites, showing that 
methoxyoestrogens might increase the expression of BMPRII, pSmad1/5/8(9) and Id1. We 
further showed that in male PASMCs from control subject, 2MeOE2 significantly increased 
the expression of Id1, while the increase in female PASMCs was not statistically significant. 
The alterations in the expression of other components of the BMPRII signalling pathway 
were not statistically significant due to large variation in the response between cell lines. 
Interestingly, increased expression in Id1 was observed at higher concentration of 2MeOE2, 
while we previously observed antiproliferative effects of this metabolite at lower 
concentrations. The p27/Kip1 protein is a tumour suppressor, belonging to cyclin-dependent 
kinase inhibitors (CKIs), which bind to various cyclin/cycle dependent kinase (CDK) 
complexes throughout the cell cycle and negatively regulate cells’ progression through cell 
cycle. p27/Kip1 primarily regulates CDK activity in response to extracellular signals, such 
as DNA damage, TGFβ, resulting in the formation of inhibition of cyclin E-CDK2 
complexes and phase G1 cell cycle arrest (Polyak et al., 1994;Koff et al., 1992;Kato et al., 
1994). The expression of p27/Kip1 was significantly reduced in high serum environment, 
indicating VSMCs were progressing through cell cycle and proliferating, while 
overexpression of this tumour suppressor reduced cell proliferation (Fouty et al., 2001). 
Considering vascular remodelling is essential in the pathology of PAH, the role of p27/Kip1 
in disease development might be important due to its role in the regulation of PASMCs 
proliferation. Previously, treatment of rats exposed to cHx with 17βE2 resulted in increased 
expression of p27/Kip1 animal lung tissue and cultured PASMCs (Xu et al., 2010). The 
authors summarised the mechanism by which 17βE2 might rescue the experimental PH 
phenotype in these animals might at least partially depend on increased expression of 
p27/Kip1. Moreover, the ability of 2MeOE2 to oppose the neointima formation appeared to 
at least partially depend on upregulation of p27/Kip1 expression in VSMCs (Barchiesi et al., 
2006). Here we showed that stimulation of hPASMCs derived from female control subjects 
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with 2MeOE2 elicited a concentration-dependent increase in p27/Kip1 expression, which 
might be another mechanism by which 2MeOE2 might modulate hPASMC proliferation. 
This offers the possibility that 2MeOE2 conveys its anti-proliferative properties through 
various mechanisms, which could be concentration-dependent. 
Previously, an HPLC/flux method was developed within our research group with the aim to 
trace oestrogen metabolism in in vitro model of PAH. Due to accumulating evidence 
indicating prostacyclin analogues, such as iloprost and treprostinil, used for treatment of 
PAH possess the ability to activate PPARs (Forman et al., 1997;Ali et al., 2006). Therefore, 
the protective effects of these analogues might be partly mediated through the PPAR 
signalling pathways. PPAR signalling was shown to modulate oestrogen signalling by i) 
altering the expression of ERs (Segars et al., 1993;Keller et al., 1995) or ii) binding to ERE 
and acting as competitive inhibitors (Keller et al., 1995). Activation of PPARγ results in 
reduced transcription of aromatase gene and increased protein turnover (Yanase et al., 
2001;Fan et al., 2005), while PPARα, which is constitutively expressed in the mouse lung 
(Becker et al., 2008b), increases the expression of 17βHSD type 1, leading to increased E1 
production (Corton et al., 1997;Davis et al., 1994). Interestingly, the expression of CYP1B1 
was shown to be induced through the activation of PPARα activation (Lovekamp-Swan et 
al., 2003;Murray et al., 2001). We therefore treated hPASMCs derived from control and 
patient subjects of both sexes and examined how treatment with treprostinil affects oestrogen 
metabolism in these cells. All cells were exposed to 50nM 14C4-17βE2, and cells were then 
stimulated with treprostinil (1μM): i) 24 hours prior to addition of 50nM 14C4-17βE2 (T24B), 
and ii) at the same time as 17βE2 (TE48). The experiment was designed to ascertain whether 
treprostinil affected the expression of enzymes involved in the metabolism of oestrogen or 
merely affected the enzyme’s activity. In female control cell line, preliminary results indicate 
that treprostinil increases the metabolism of oestrogen as shown by decreased amount of 
radioactively labelled 17βE still present in the samples. Moreover, in male patient cell line, 
pre-treatment with treprostinil resulted in increased production of E1, whereas co-treatment 
with treprostinil did not affect the conversion of 17βE2 to E1. Hence, we conclude that 
treprostinil affects the expression of 17βHSD type 2 expression level, which is in line with 
previous reports (Corton et al., 1997;Davis et al., 1994). Interestingly, treprostinil may only 
affect the expression of 17βHSD type 2 in male patient hPASMCs, indicting the mechanism 
behind the observed effect might be sex-dependent. A line of evidence indicates that in 
unstimulated hPASMCs, the basal expression of 17βHSD type 2 might be higher in male 
patient hPASMCs compared to female patient hPASMCs. Further investigation is merited 
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here, to establish whether the observed effects were mediated through PPAR activation and 
to ascertain whether PPAR signalling might be influenced by sex. 
CYP1B1 is overexpressed PASMCs, in experimental and clinical PAH (Johansen, 2014). Its 
role in the pathogenesis of PAH ranges from production of 16αOHE1 and 4OHE1, exhibiting 
proliferative (White et al., 2012) and genotoxic (Cavalieri et al., 2000;Cavalieri et al., 1997) 
properties, respectively, to increased formation of ROS. CYP1B1 inhibition by TMS in vivo 
reversed pulmonary haemodynamic parameters as well as vascular remodelling (White et 
al., 2012). We therefore wished to assess the effects of CYP1B1 inhibition on oestrogen 
metabolism in PASMCs derived from female control and patient subjects. Although we 
observed significant differences in the metabolism of oestrogen between control and patient 
cell lines, treatment with TMS did not significantly affect the conversion of 17βE2 into other 
metabolites. The experiments were conducted using a single time-point; however, it may be 
a warranted notion to repeat these experiments using several experimental end-points. 
During the HPLC/flux experiments used to trace the metabolism of 17βE2, we encountered 
the formation of unknown oestrogen metabolites. To possibly identify any metabolites that 
were not included in our research interests, and to correlate exposure to 17βE2 with 
dysregulation of other signalling pathways that might not yet be considered in PAH, we 
conducted a hypothesis-free metabolomic screen in female cell lines. Here we compared 
female control and patient cell lines, which were stimulated either by vehicle or 17βE2. 
Exposure of female control cell lined to 17βE2 did not affect the levels of numerous 
metabolites, whilst more metabolites were affected by 17βE2 in female patient cell lines, 
indicating energy and fatty acid metabolism might be affected alongside redox cycling. 
Indeed, exposure of hPASMCs to serotonin resulted in increased production of ROS, which 
according to the authors might cause DNA damage, and redox-sensitive proliferation (Hood 
et al., 2017). We further observed that the level of L-kynurenine, a catabolite of tryptophan 
which is the precursor of 5-HT, was also altered in female patient cells treated with 17βE2, 
where treatment resulted in catabolite diminished concentration. L-kynurenine is a known 
AhR ligand, shown to be increased in certain cancers, where it promotes tumour growth 
(Opitz et al., 2011). Here we showed that pathogenesis of PAH might be affected by 5HT in 
two-fold: i) through the formation of 5HT from its precursor tryptophan, and by ii) the 
degradation of this precursor to L- kynurenine, activating the AhR and resulting in altered 
oestrogen metabolism. The decrease in L-kynurenine levels in the 17βE2 female patient cell 
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lines might be associated with decreased turnover of tryptophan due to its increased 
conversion into 5HT. 
Investigation of oestrogen metabolism is complicated by the sheer number of metabolites, 
which are similar in chemical structure, and are therefore difficult to separate 
chromatographically. We therefore wanted to develop an LC-MS/MS methodology, with 
which we could identify and quantify each of oestrogen metabolites. Herein we provide 
qualitative oestrogen metabolic profile in control and patient hPASMC cell lines of both 
sexes, and quantitation of these metabolites. We observed statistically significant differences 
in the production of E1 and 17αE2 in female patient hPASMCs compared to female control 
hPASMCs, revealing a prominent role of 17βHSD type 2. Interestingly, in male patient 
hPASMCs, the metabolism of 17βE2 appeared to be slower compared to female patient 
hPASMCs, as assessed by the amount of the parental hormone, indicating reduced activity 
of the 17βHSD type 2, albeit the difference in the amount of E1 was not statistically 
significant. Similar observations were reported previously (Johansen, 2014). Although E1 is 
significantly less biologically active compared to 17βE2 due to lower affinity for ER, its 
production might have a significant role in PAH pathogenesis. The conversion to E1 might 
increase the pool of precursor for oestrogen metabolising enzymes, which generally do not 
distinguish between their substrates, resulting in increased production of hydroxylated 
metabolites of E1. Although these metabolites might be converted to OHEs, through the 
activity of 17βHSD type 1, the enzyme kinetic parameters are less favourable compared to 
17βHSD type 2. Moreover, the role of geometrical isomerisation of the 17βE2 to 17αE2 
might also be important in the pathogenesis of PAH, as the amount of this metabolite was 
significantly increased in female patient hPASMCs. Although previously, 17αE2 was 
considered devoid of oestrogenic effects, recent lines of evidence indicate otherwise. The 
research in the production and biological effects of the 17αE2 in the lung is therefore 
merited. 
Although the notion of an LC-MS/MS technique to quantify oestrogen metabolism in vitro 
and ascertain the effects of other environmental and endogenous insults involved in the 
development of clinical PAH on oestrogen metabolism is attractive, unfortunately, the 
transfer of the method from aqueous to media sample matrix has proven to be more difficult 
than previously warranted. Indeed, the cell media highly affected the LC-MS/MS system. 
The presence of matrix components affected the detection of metabolites despite the use of 
guard columns to remove any unwanted sample matrix constituents. It might therefore be 
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beneficial to assess how the samples might be further purified or attempt to culture cells in 
a different media, which might exert less adverse effects on the LC-MS/MS system. 
Furthermore, our results indicated that the limit of detection of certain metabolites, such as 
OHEs, needs to be addressed and improved if the LC-MS/MS method is to be used to reliably 
quantify these metabolites.  
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Chapter V 
5 General Discussion  
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5.1 General Discussion 
More than 60 years ago, the female predominance in the patient population with PAH was 
recognised. The extent of female susceptibility to develop PAH observed in recent surveys 
and registries revealed that female sex may be even more important than previously 
supposed (Humbert et al., 2006;Escribano-Subias et al., 2012;Ling et al., 2012;Badesch et 
al., 2010). Namely, the incidence of the disease in post-menopausal women is approaching 
that of men (Hoeper et al., 2013), indicating that the reducing levels of endogenous female 
sex hormones might be protective. Young female patients exhibit better pulmonary 
haemodynamics compared to age-matched men (Shapiro et al., 2012). Hence, it appears that 
albeit endogenous 17βE2 may be facilitating the pathophysiological processes associated 
with the onset of clinical PAH, 17βE2 might be protective against changes in haemodynamic 
parameters, such as mean PAP and vascular resistance. Additionally, menopause was 
reported to lessen the differences in the pulmonary haemodynamics between men and 
women (Ventetuolo et al., 2014). Despite female sex being considered the main risk factor 
for the development of clinical PAH in humans, women generally exhibit better outcome 
and survival compared to men (Shapiro et al., 2012). This could be due to a better response 
to therapy (Gabler et al., 2012) or better RV compensation (van de Veerdonk et al., 
2011;Swift et al., 2015). Hence, the understanding of the role of female sex hormones in the 
onset and progression of PAH is of utmost importance. 
Protective properties of exogenous 17βE2 were reported in the classical cHx and MCT 
experimental models of PH, where exogenously administered 17βE2 attenuated 
hemodynamic and remodelling parameters in these animals (Lahm et al., 2012;Yuan et al., 
2013). In these models female animals developed less severe experimental phenotype, 
whereas female sex was associated with the development of severe experimental phenotype 
in novel experimental models. The latter include the SERT+ and S100 Ca2+ binding protein 
A4 overexpressing mouse models, where ovariectomy protects against the onset of PH 
(Greenway et al., 2004;White et al., 2011b;White et al., 2011a;Dempsie et al., 2011). 
Locally, stimulation of hPASMCs with 17βE2 was associated with augmented proliferation 
of these cells (White et al., 2011a;White et al., 2012). Indeed, PASMCs expressed aromatase 
and can synthesise 17βE2, and the inhibition of the local synthesis of oestrogens in PAs, 
documented in (Mair et al., 2014), was shown to reduce progression of established PH 
phenotype in cHx and Su5416/Hx animal models. The study provided evidence of direct role 
of endogenous oestrogens in the pathogenesis of PAH. The presence of numerous 
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extrahepatic oestrogen metabolising enzymes indicates the lung is an important site of 
oestrogen metabolism (Bieche et al., 2007). Increased expression of CYP1B1 was 
documented in animal models, where more female animals develop experimental PH, and 
in lung sections derived from IPAH patients (White et al., 2011b;White et al., 2012). The 
detrimental role of oestrogen metabolism dysregulation in PAH was documented in (Austin 
et al., 2009), where the authors reported the association of disease penetrance in female 
BMPRII mutation carriers with the levels of urinary oestrogen metabolite, specifically 
2OHE1/2 and 16αOHE1. In female C57BL/6 mice, the administration of the latter 
metabolite resulted in increased haemodynamic and vascular remodelling parameters (White 
et al., 2012). At least partially, the observed phenotype may be associated with the pro-
proliferative effects of 16αOHE1 documented in hPASMCs (White et al., 2012). 
Interestingly, the products of O-methylation of catechol oestrogens, catalysed by COMT 
enzyme, opposed proliferation of hPASMCs, as well as lung and cardiac fibroblasts (Dubey 
et al., 1998;Tofovic et al., 2006;Tofovic et al., 2008b), and even induce apoptosis in ECs 
(Yue et al., 1997). Due to documented beneficial properties of methoxy oestrogens, 
increased activity of CYP1A1, which exhibits high affinity for hydroxylation of oestrogens 
at position C2, and COMT might be protective in cancer (Kisselev et al., 2005) and even 
PAH. The efficiency of O-methylation depends on the local concentration of catechol 
oestrogens, with evidence pointing towards inhibition of O-methylation of 4OHE2 by the 
presence of 2OHE2 (Roy et al., 1990;Zhu and Conney, 1998). Reduced removal of 4OHEs 
might be directly associated with increased production of ROS, leading to protein and DNA 
damage. Currently, no direct evidence of the effects 4OHE2 might have on O-methylation 
of 2OHE2 exists. Nonetheless, in mice, the deletion of CYP1B1 gene was associated with 
decreased production of 4-hydroxyoestrogens and increased production of 2-hydroxy and 2-
methoxyoestrogens within the lung (Peng et al., 2013a), due to inhibitory effects of 4OHE2 
on COMT expression. Previously, however, it was reported that 4OHE2 exerts differential 
effects in female and male hPASMCs (Mair et al., 2015). Namely, the metabolite decreased 
phospho-Smad1/5/8(9) and Id expression in female hPASMCs while increasing these in 
males, commensurate with a decreased proliferative effect in male hPASMCs. We showed 
that stimulation with 2OHE2 and 4OHE2 in male hPASMCs led to a reduction in serum-
induced proliferation of these cells. It is possible that the initial resistance of men to develop 
PAH might be due to the anti-proliferative effects of 2- and 4OHE2, and their respective O-
methylated metabolites. 
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The AhR regulates the expression of xenobiotic-metabolizing enzymes, including CYP450 
enzymes. The deletion of AhR is associated with i) the formation of abnormal vascular 
structures (Lahvis et al., 2000), ii) increased expression of HIF1α and VEGF (Thackaberry 
et al., 2002), and iii) inability to induce target genes such as CYP1A1, CYP1A2, and CYP1B1 
upon stimulation with selective AhR agonist (Fernandez-Salguero et al., 1995). The activity 
of AhR, however, was linked to increased thickness of vessel wall due to abnormal 
proliferation of SMCs (Sauzeau et al., 2011). Moreover, the expression of AhR was 
reportedly increased in female hPASMCs derived from PAH patients (Dean et al., 2016). 
Enhanced expression of the receptor might lead to increased ROS production, as documented 
in experimental PH animal models (Jernigan et al., 2017), due to enhanced expression of 
Phase I metabolising enzymes (Park et al., 1996). Although female sex is protective in 
classical experimental models of PH, the oestrogens apparently mediated a detrimental role 
in the Su5416/Hx model (Tofovic et al., 2012), which therefore recapitulates the human 
disease in terms of epidemiological data, as female animals develop the disease more 
frequently compared to males. Female animals exposed to Su5416/Hx insult to establish the 
experimental phenotype also developed a more severe disease compared to male animals 
according to (Tofovic et al., 2014).Therefore, we sought to examine the role of the AhR as 
a plausible key effector in the mechanism driving the onset of PAH phenotype in this animal 
model, considering the mechanism behind the experimental PH phenotype in this animal 
model is not completely understood. 
In Chapter 3 we first examined the expression level of CYP1A1, in several models of PH 
utilised within our research group, as unpublished data from microarray analysis revealed 
that this gene is significantly upregulated in Su5416/Hx model. We demonstrated that the 
expression of CYP1A1 gene could be decreased in in vitro model using hPASMCs, Smad1 
heterozygous mice and rats exposed to cHx. Our observations corroborate previous work 
showing that HIF signalling pathway reduces the expression of CYP1A1(Vorrink et al., 
2014). Recently it was demonstrated that CYP1A1 influences blood pressure regulation 
through activation of eNOS, NO bioavailability and NO-dependent vasodilation (Agbor et 
al., 2014). Hence, the decreased expression of CYP1A1 we observed might be associated 
with increased blood pressure in pulmonary circulation. Interestingly, an association 
between increased sheer stress and AhR activation was also reported in ECs (Han et al., 
2008). 
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The AhR and HIF1α signalling pathways share a common translocator protein, HIF1β 
(ARNT), which is required for receptor activation in both instances. Vorrink and colleagues 
showed that overexpression of HIF1β (ARNT) rescues the interference of Hx with AhR 
transcriptional transactivation of its target genes (Vorrink et al., 2014). In Su5416/Hx model, 
however, the expression of CYP1A1 and CYP1B1 enzymes was considerably increased, at 
gene and protein levels, respectively. Considering the reported affinity of murine AhR 
receptor isoforms for Su5416 approaches that of TCDD (Mezrich et al., 2012), we inferred 
that the mechanism of Su5416/Hx-induced experimental PH might at least partially entitle 
the activation of the AhR signalling pathway. Interestingly, increased expression of 
CYP1A1 and CYP1B1 was previously also reported in the classical MCT-induced PH 
animal model (Yuan et al., 2013). In primary human hepatocytes, pyrrolizidine alkaloids 
were shown to regulate the expression of numerous nuclear receptor or ligand-activated 
transcription factors, including PPARs and AhR, both of which regulate gene expression of 
CYP enzymes (Luckert et al., 2015). Although the effects of pyrrolizidine alkaloids and their 
metabolites in the lung have not yet been assessed in terms of their effects on the AhR 
signalling pathway, evidence suggests that increased expression and/or activity of AhR leads 
to increased expression of CYP enzymes. Sustained activity of AhR was linked to onset of 
endothelial dysfunction, hypertension and CVD (Korashy and El-Kadi, 2006;Kopf et al., 
2010). 
To further determine whether the AhR signalling pathway is activated in Su5416/Hx model 
of PH, we examined the expression of AhRR and NQO1, which are both under the 
transcriptional regulation of AhR. The expression pattern of both genes was similar to that 
observed for CYP1A1 and CYP1B1, showing that numerous target genes of AhR are induced 
in the Su5416/Hx model. It would be interesting to determine whether these genes are also 
induced in the MCT model, considering current, albeit indirect, evidence showed that 
pyrrolizidine alkaloids affect the AhR expression. We recently published our findings that 
Su5416 activates the AhR in vitro in female patient hPASMCs, resulting in the translocation 
of the receptor to the nucleus, and leading to the induction of CYP1A1 and CYP1B1, in the 
Red Journal with an encouraging positive editorial of the findings presented within the paper. 
The antagonist of the AhR attenuated the gene induction only in female hPASMCs from 
control subjects, while in patients the AhR antagonist showed no effect. The increased 
expression of AhR reported (Dean et al., 2016) might be the underlying cause for findings 
reported in this work. 
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The interaction of the HIF and AhR signalling pathways appears to be significant in the 
establishment of the experimental Su5416/Hx model, as both pathways require the 
translocator protein, HIF1β (ARNT), for full functionality of the respective receptors. We 
reported herein that the basal expression of proteins regulating the proteasome-mediated 
degradation of HIF1α, PHD2 and vHL, is significantly increased in male patient hPASMCs, 
compared to same-sex control cells. Similar observations were also made in male rats treated 
with Su5416 and exposed to cHx. Contrary, in female cells, we reported opposite trends, 
with female patient cells exhibiting lower basal expression of PHD2 and vHL compared to 
control cells. In line with these observations, exposure to cHx only increased HIF1α in 
female animals. Moreover, herein we showed that the expression of HIF1α might be higher 
in male Nx animals compared to matched female animals. Additionally, the expression of 
HIF1α did not change in Su5416/Hx male animals, while in female animals treated with both 
experimental insults, HIF1α was significantly increased. We also report the basal expression 
of HIF1α is significantly increased in female patient hPASMCs, probably due to lower 
expression of proteins regulating the receptor degradation. It appears that a sex dimorphism 
exists in response to cHx, due to sex differences in the regulation and signalling of HIF1α 
pathway. Sex differences in the response to cHx in left and right heart ventricles were 
reported, where females initially were more responsive to Hx, however in long-term, male 
animals exhibited higher levels of Hx-inducible genes (Bohuslavova et al., 2010). Whether 
the observed differences in PASMCs in exposure to cHx could be responsible for differences 
in the severity of disease phenotype and survival remains to be investigated. Equally, it is 
possible that the initial adverse response to Hx, which could be greater in females, might be 
associated with the observed dimorphism in the onset of PAH. We recently shown that in 
Hx conditions, Su5416 decreased the expression of HIF1α in nuclear and cytoplasmic 
fractions, in hPASMCs derived from female patient subjects (Dean et al., 2017). Although 
we showed that Su5416 does not have any effect on PHD2 and vHL, which are involved in 
regulation of, these experiments were conducted in Nx conditions. It would be interesting to 
repeat these experiments in Hx. Herein, we also demonstrated that in male rats exposure to 
cHx leads to diminished expression of AhR, further indicating that a complex interaction 
between both pathways exists. 
A significant hallmark of pathophysiological changes in the pulmonary circulation of 
patients with PAH, is the muscularisation of normally non-muscular small PAs. In 
experimental models of PH, the establishment of disease phenotype often relays on vascular 
injury and introduction of an insult causing hyper-proliferation of PASMCs. In the 
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Su5416/Hx model, Su5416 caused proliferation of PASMCs in Nx (Taraseviciene-Stewart 
et al., 2001). The increased muscularisation of distal small PAs in vivo, depends on the 
increased proliferation of PASMCs, although this was only described in animals which 
werem exposed to cHx (Ciuclan et al., 2011). Here it was observed that there is increased 
proliferation of hPASMCs derived from female PAH patients stimulated with Su5416 and 
Hx reported herein, which is consistent with previous reports (Ciuclan et al., 2011). Our 
observations, now published in (Dean et al., 2017), indicate that a possible synergy of 
Su5416 and Hx insults exists, through the increased expression of ARNT (HIF1β). The 
return of ARNT (HIF1β) to normal levels by the AhR antagonist, suggested the possibility 
of a synergy of the AhR and HIF signalling pathways through this coupling protein, which 
was also shown by (Vorrink et al., 2014). As ECs are also intimately involved in the 
pathogenesis of PAH, we also assessed the effects of Su5416 on PMECs, observing 
increased apoptosis. In BOECs from clinical patients, Su5416 induced cellular proliferation. 
We deduced that the initial vascular injury by apoptosis of ECs, and subsequent proliferation 
of the apoptosis-resistant population of ECs, contributes to the development of PH (Dean et 
al., 2017). 
The interaction of AhR and ER signalling needs to be investigated in the context of 
understanding the role of AhR signalling in the pathogenesis of disease with exceeding 
prevalence in females, such as PAH. The interaction of the AhR/ARNT complex with ERs 
was previously reported by (Ohtake et al., 2003). The authors showed that activated AhR 
may directly associate with unliganded ERα and ERβ, and the co-activator p300. Hence, also 
in the absence of oestrogens, the oestrogenic effects, such as induction of VEGF, c-fos and 
oestrogen-dependent cell proliferation, may be mediated through the association of 
AhR/ARNT/ER to EREs. Since exposure to cHx and 17βE2 have synergistic effects in ECs, 
resulting in increased proliferation of this cell type (Kleinman et al., 2007), it might be 
interesting to investigate whether the AhR/ARNT/ER interaction is involved in the 
synergistic effects of Su5416 and Hx on proliferation of female patient hPASMCs. To 
determine the role of AhR in the establishment of experimental PH phenotype, the 
interaction with ER should also be considered. 
The research presented in this thesis was enabled by the NC3Rs, which is dedicated to 
promoting the development of new research technologies and refinement of existing models 
and techniques to minimise the number of animals in research and improve the welfare of 
animals, whose use might not be completely avoidable. Currently, in vitro models offer the 
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advantage measuring the responses to stimulation and/or inhibition of individual molecular 
processes in real time, to determine the contribution of specific molecular processes to 
disease development (Benam et al., 2015). In Chapter 4 we sought to develop a LC-MS/MS 
technique to be used to quantify local oestrogen metabolism by hPASMCs. Although the 
circulatory levels of the parental oestrogens have been well-established, the levels of specific 
oestrogen metabolites were not addressed in the context of PAH pathogenesis. Moreover, as 
the importance of local oestrogen synthesis and metabolism were recently demonstrated and 
recognised (Mair et al., 2014;White et al., 2012), and oestrogen metabolites reportedly have 
protective and pathogenic effects in the pulmonary circulation, the quantification of local 
levels of oestrogen metabolites was warranted. We aimed to present the first quantification 
of oestrogen metabolism in hPASMCs. However, as the concentrations of some metabolites 
were below the methods’ limit of detection, the complete quantification of oestrogen 
metabolism in vitro was not reliable. Significant differences in the metabolism of parental 
oestrogen hormones were detected. Our findings indicated that in PAH the activity and/or 
expression of the 17βHSD type 2 enzyme might be increased, as the conversion of 17βE2 to 
E1 was increased. The consequences of high levels of E1 could be three-fold. Firstly, as 
numerous oestrogen-metabolising enzymes exhibit similar affinity for E1 and 17βE2, it is 
plausible that increased formation of E1 could be driving increased production of oestrone 
metabolites, such as 16αOHE1. Importantly, compared to 16αOHE2, 16αOHE1 metabolite 
has greater pro-proliferative character (White et al., 2012). Secondly, increased conversion 
of the 17βE2 to less biologically active E1, could also diminish the protective effects of 
17βE2 reported in the heart (Frump et al., 2015;Liu et al., 2014). Thirdly, the role of 17βHSD 
type 2 is not solely restricted to the conversion of 17βE2 to E1, as the enzyme can convert 
all metabolites of oestradiol to the corresponding oestrone metabolites, which are considered 
to be largely devoid of protective properties in cardiovascular cells. (Tofovic et al., 2008b). 
The importance of the 17βHSD pathway was shown to impose significant effects in the 
experimental MCT model in rats, where preventive treatment with 2MeOE1 attenuated the 
development of experimental phenotype, as well as cardiac and vascular remodelling 
(Tofovic et al., 2008b). Increased conversion of protective oestradiol metabolites to less 
active oestrone metabolites might therefore be an important aspect of oestrogen metabolism 
dysregulation in PAH. Although the expression of 17βHSD type 2 might be increased in 
hPASMCs derived from male subjects with clinical PAH phenotype, the quantitation of 
oestrogen metabolites using the novel LC-MS/MS approach, the amount of unmetabolized 
17βE2 was greater in male patient hPASMCs metabolised compared to female patient 
hPASMCs. It would be beneficial to assess the activity of 17βHSD type 2 in hPASMCs, as 
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it is possible that the presence of polymorphic variants exhibiting increased metabolic rate 
might result in observed increased formation of E1 in female patient cells. Similar 
suggestions were made regarding the expression of CYP1A1 and COMT, where the presence 
of such variants might lead to accumulation of hydroxylated oestrogen metabolites, and 
increased production of oestrogen quinones and semi-quinones (Kisselev et al., 2005). 
We also observed that geometrical isomerisation of 17βE2 to 17αE2 was increased in female 
patient cells. The geometric isomer of oestradiol was long considered to convey little 
hormonal activity. Although, the literature on the effects of 17αE2 in humans is very limited, 
there are reports of its pro-proliferative effects in human neoplasms (Papendorp et al., 1985, 
Hajek et al., 1997). In breast cancer cell lines, 17αE2 was shown to bind to ERs with high 
affinity, resulting in i) increased expression of progesterone receptor, ii) reversal of 
inhibition of cellular proliferation, and iii) increased DNA polymerase activity (Edwards and 
McGuire, 1980). Furthermore, 17αE2 may also affect aromatase activity (Hoffmann et al., 
2002). Although the authors did not provide a possible mechanism, others have suggested 
that 17αE2 may affect the levels of sex hormones by inhibiting the 5α-reductase, which 
catalyses the conversion of testosterone to the more potent dihydrotestosterone (DHT), in 
skin fibroblasts (Munster et al., 2003). The physiological function remains undetermined as 
17αE2 appeared to mediate vasorelaxation (Salas et al., 1994). It would be therefore 
interesting to assess the effects of stimulation with 17αE2 on i) aromatase activity in 
hPASMCs and ii) vasoconstriction in isolated intra-pulmonary arteries. 
Although we, in part, succeeded to quantify oestrogen metabolites produced in hPASMCs 
upon stimulation with 17βE2, we observed that the method is extremely sensitive to the 
presence of impurities present in the samples. Indeed, the analysis of numerous spent media 
samples resulted in significant decline in the sensitivity of the LC-MS/MS method, probably 
due to deterioration of column condition brought upon sample impurity. Moreover, the 
detection limit of OHEs was considerably higher than the detection limit for parental 
oestrogens or MeOEs. Hence, more work is warranted to establish ranges within which the 
method would produce reliable quantification of these metabolites. Further, it was 
considered that the composition of the cell media and serum used in these experiments might 
not be most suitable for LC-MS/MS approach, as the technique heavily relies on the use of 
sensitive LC and chemical derivatisation of oestrogen metabolites. We therefore suggest that 
if local oestrogen metabolism in vitro should be further investigated, efforts must be made 
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to try and replace the currently used cell growth media with more inert matrix or to make 
the method more robust. 
HPLC/flux analyses were used to investigate how the use of a common medicine prescribed 
for the treatment of PAH, treprostinil, affects oestrogen metabolism in hPASMCs. 
Prostacyclin analogues, which are currently used to manage moderate to severe PAH affect 
i) vasorelaxation and vasodilation of PAs (Narumiya et al., 1999, Wise, 2003), and ii) 
PASMC proliferation (Clapp et al., 2002; Yang et al., 2010). Recently it was shown that 
therapeutic effects of treprostinil might present sex bias, with females showing better anti-
proliferative response to the therapeutic compared to males (Murphy, 2017). Endogenous 
PGI2 and its stable metabolite to activate certain PPAR isoforms (Forman et al., 
1995;Nemenoff et al., 2008), directly (Forman et al., 1997) or indirectly, though the IP 
receptor (Falcetti et al., 2007). PPARs affect oestrogen metabolism by i) competitive 
inhibition of ERs (Keller et al., 1995), ii) increased degradation of ERα (Qin et al., 2003), 
iii) increased expression of 17βHSD type 1 expression (Corton et al., 1997;Davis et al., 
1994), and iv) modulation of the expression of oestrogen metabolising enzymes (Corton et 
al., 1997). Recently published evidence suggests that in human lung fibroblasts, treprostinil 
inhibits proliferation of these cells through activation of PPARβ (Ali et al., 2006). Our results 
indicate that treprostinil could affect oestrogen metabolism in male patient hPASMCs, 
through increased activity of 17βHSD type 2, indicating the used prostacyclin analogue 
might affect the expression of this enzyme. 
The unbiased metabolomic screen of female control and patient hPASMCs stimulated with 
17βE2 revealed significant changes in the levels of L-kynurenine, a catabolite of tryptophan 
which is the precursor of 5-HT, in female patient cells treated with 17βE2, where treatment 
resulted in catabolite diminished concentration. The identification of L-kynurenine in the 
context of PAH is important, as tryptophan serves as the precursor for the formation of 5-
HT, acting at the 5-HT(1B) receptor and 5-HT transporter (SERT or 5-HTT) to mediate 
constriction and proliferation of PASMCs (Maclean and Dempsie, 2010). Interestingly, the 
implication of L-kynurenine in PAH might be two-fold. Firstly, L-kynurenine metabolism 
produces molecules with vasoactive properties (Wang et al., 2010). Secondly, the parental 
molecule is a known AhR ligand (Nguyen et al., 2014). Importantly, we showed that 5-HT 
may affect the pathogenesis of PAH in two ways: directly through activation of the 5-HT1B 
receptor (MacLean, 2007;MacLean et al., 2004;Morecroft et al., 2005), and indirectly 
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through the degradation of tryptophan precursor, leading to formation of AhR ligands 
(Denison and Nagy, 2003;DiNatale et al., 2010). 
In Chapter 4 we summarised the findings of the effects of oestrogen metabolites in in vitro 
model of PAH. Protective effects of 2MeOE2 were reported in vitro, where 2MeOE2 was 
shown to attenuate the proliferation of several vascular cell types (Fotsis et al., 1994; 
Barchiesi et al., 2006; Tsukamoto et al., 1998; Tofovic et al., 2009b; Nishigaki et al., 1995), 
and in vivo, where 2MeOE2 prevented and attenuated the development of experimental PH 
phenotype in monocrotaline, bleomycin-induced and Su5416/Hx model (Tofovic et al., 
2009b; Tofovic et al., 2008b; Tofovic and Rafikova, 2009). Previously, treatment with 
17βE2 was reported to increase the expression of p27/Kip1 animals and cultured PASMCs 
exposed to Hx (Xu et al., 2010), where p27/Kip is a tumour suppressor which negatively 
regulate cells’ progression through cell cycle. Authors of (Barchiesi et al., 2006) also 
reported that the inhibition of neointima formation by 2MeOE2 depends on upregulation of 
p27/Kip1 expression in VSMCs. Our data showed that treatment with 2MeOE2 resulted in 
arrested proliferation in control hPASMCs of both sexes, whilst only female patient 
hPASMCs responded to treatment. We further showed that in female control cells, 
stimulation with 2MeOE2 may result in increased expression of p27/Kip1. As the protective 
effects of 2MeOE2 might be dependent on the effects the metabolite exerts on the regulation 
of cells’ progression through cell cycle, it might be worthy of examining the basal level of 
p27/Kip1 expression in PASMCs derived from control and patient subjects of both sexes. 
This might help to determine whether poorer survival prognosis in men could be associated 
with poorer response to protective metabolites. Additionally, in females, the protective 
character of 2MeOE2 might depend on the induction of PGIS in ECs and hPASMCs. Our 
findings indicated that in male cells, the mechanism through which 2MeOE2 might attenuate 
proliferation of male control hPASMCs might depend on the effects on BMPRII signalling 
pathway. Hence, it appears that 2MeOE2 might affect multiple pathways. Additionally, we 
have shown that the anti-proliferative effects observed for 2OHE2 are mediated through the 
formation of 2MeOE2, as inhibition of COMT enzyme reversed the inhibitory effects on 
proliferation. Partially, 2OHE2 might also activate classical ER. The inhibition of 
proliferation by 4OHE2 was found to be mediated through classical oestrogen signalling 
pathways, as inhibition of COMT had no significant effect. The enzyme was shown to favour 
2-O-methylation over 4-O-methylation, due to unfavourable position of the 4-O-hydroxyl 
substrate in the catalytic site (Männistö and Kaakkola, 1999). Although 4OHE2 was shown 
to mediate its biological effects through pathways independent of classical ER (Das et al., 
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1997), our data indicates certain effects might be mediated through activation of ERs, which 
is in accordance with reports by (Martucci and Fishman, 1976). The oestrogenic activity of 
4OHE2 through activation of ER might be prolonged due to the slow dissociation rate of the 
metabolite (Zhu and Conney, 1998; Barnea et al., 1983). The activity of COMT in the liver 
was shown to be sex-dependent, with males exhibiting higher COMT activity compared to 
females (Boudikova et al., 1990). Therefore, due to significant activity of COMT in the lung, 
the expression of this enzyme should be assessed in terms of possible differences between 
the sexes. Moreover, an assay to assess the activity of this enzyme in hPASMCs is also 
warranted. 
5.2 Limitations of the Study 
There are several aspects of limitation for the research work presented herein. Firstly, the 
pathological onset and progression of PAH is a highly complex process, involving several 
cellular types, as described in Chapter 1.2.5. Although the pathological mechanisms that 
could contribute to the onset of PAH in animal models, as well in humans, were investigated 
in SMCs and ECs, the research presented was limited by the unavailability of an established 
co-culturing or conditioning technique. Unfortunately, the use of a single cell type cell 
culture is not appropriate as the natural interactions between cell populations, which are 
present within the lung and might be important for the disease process, were not taken into 
consideration. 
Secondly, when investigating the effects of oestrogens in males and females, one should be 
aware that it is not known how the isolation of a cell type from a tissue affects the sexual 
aspect of the cells. Whether the cultures of isolated SMCs or ECs derived from a female/male 
subject retain the characteristics that they have within the intact organ within a functioning 
body is not known. Hence, in vitro research presents a valid supportive technique, however, 
only in vivo experiments might offer conclusive results when investigating the role of sex in 
PAH. 
Thirdly, the chemiluminescent technique employed to investigate the levels of protein 
expression levels presents three major disadvantages. Firstly, narrow linear signal response 
range, which differ between exposures of film and hence make it difficult to compare band 
intensities from different exposures, secondly, reciprocity failure, which may cause the faint 
and strong bands to be underrepresented on film, and thirdly parallax effects, which can 
315 
 
reduce image clarity and sharpness. Therefore, the use of a fluorescence detection-based 
system would be more appropriate to avoid the named disadvantages associated with protein 
quantitation. Additionally, the quantitation of certain proteins was hindered by the low 
expression levels in individual cell types or by the availability of a suitable monoclonal 
antibody to be employed in tissue samples. 
Fourthly, the study might have been partially limited by the selection of the housekeeping 
genes used for normalisation of RT-qPCR results. Especially, in the instances where the 
difference in the gene of interest was marginal, the variability of the housekeeper gene might 
affect the final result. Although, the variability of the housekeeper gene expression was 
assessed for each of the experiments, and was found to be acceptable, additional value would 
be added if another housekeeper gene would be employed, with documented stable 
expression. 
Lastly, the work presented herein was limited by the lack of time and access to working LC-
MS/MS equipment, in order to optimise the culture conditions, which would not hinder the 
following steps in derivatisation of oestrogen metabolites and allow us to lower the limit of 
detection. 
5.3 Concluding Remarks 
In summary, we have provided evidence for the importance of the AhR signalling pathway 
in experimental PH, showing how activation of this signalling pathway might result in initial 
vascular injury, increased VSMCs proliferation and dysregulation of oestrogen metabolism. 
We have further shown that exposure to cHx might elicit differential response depending on 
sex. Hence exposing the important question of AhR pathway interaction with HIF and ER 
signalling pathways. 
The detection of oestrogen metabolism in hPASMCs using a novel LC-MS/MS approach 
has revealed that significant differences in the metabolism of 17βE2 exist between control 
and patient hPASMCs of both sexes. The most significant finding shows altered conversion 
of 17βE2 to its enantiomer 17αE2 and E1, indicating the possible role of 17βHSD type 2 and 
dehydrogenase in PAH. Further investigation of oestrogen metabolism dysregulation is 
therefore warranted.  
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5.4 Future Perspective 
Future studies examining the interaction of AhR, hypoxia-inducible factor (HIF) and 
oestrogen signalling pathways are strongly encouraged, as evidence of synergistic effects of 
these pathways have been reported (Kleinman et al., 2007;Dean et al., 2017). The knowledge 
of how these pathways interact might be of critical importance in the understanding of the 
onset and progression of experimental and clinical PAH. 
Inhibition of AhR signalling pathway attenuated experimental PH in Sugen 5416 and chronic 
hypoxia model (Dean et al., 2017), which is currently considered as the model which most 
accurately recapitulates the essential hallmarks of PAH pathogenesis. The role of AhR 
signalling in the classical monocrotaline model should be investigated, possibly to determine 
whether the inhibition of AhR activity might be protective against disease phenotype as 
shown in (Dean et al., 2017). 
Studies of the role of 17β-hydroxysteroid dehydrogenase type 2 PAH are highly encouraged. 
Understanding the role of 17β-oestradiol to oestrone conversion may be of critical 
importance due to its role in the conversion of protective oestrogen metabolites to 
metabolites exhibiting no protective properties. A study of 17β-hydroxysteroid 
dehydrogenase type 2 inhibition might offer additional insight in the dysregulation of 
oestrogen metabolism in pulmonary arterial hypertension. 
Although promising, the novel liquid chromatography tandem mass spectrometry to quantify 
oestrogen metabolism in in vitro model of PAH using PASMCs, requires further 
optimisation in terms of eliminating the any impurities and compounds that might interfere 
with sample preparation and analysis. Moreover, method optimisation might be required for 
this novel approach to be used as a high-through put screening method to identify novel 
therapeutic targets.  
Due to significant role of endothelial cells in the pathogenesis of pulmonary arterial 
hypertension, we suggest that the expression of CYP1A1 should be addressed in blood-
outgrowth ECs of control and patient subjects. Furthermore, the effects of silencing CYP1A1 
on nitric oxide synthase and nitric oxide bioavailability in the BOECs from patients with 
PAH should also be investigated, as CYP1A1 was shown to affect NO-dependent blood 
pressure regulation through metabolism of polyunsaturated fatty acids in a CYP1A1 knock-
out mouse model (Agbor et al., 2014).  
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